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PREFACE
The World Drug Report 2014 is aimed at helping the inter-
national community to address the toll that illicit drug pro-
duction, trafficking and consumption continues to take on 
all our societies, by providing a global overview and analysis 
of developments, based on the best available data.
The report is being published at a key moment in the global 
debate on the world drug problem. A high-level review of the 
implementation of the Political Declaration and Plan of 
Action on International Cooperation towards an Integrated 
and Balanced Strategy to Counter the World Drug Problem 
was conducted in March 2014 in Vienna by the Commission 
on Narcotic Drugs, followed by a regular session of the Com-
mission. These meetings provided contributions to a special 
session of the General Assembly on the world drug problem, 
which will be held in 2016. The high-level review was more 
than a stocktaking exercise; it provided a much-needed forum 
for an open, inclusive dialogue, involving not just Govern-
ments but also the scientific community, civil society and 
young people, on the most effective ways to counter the world 
drug problem. 
Efforts to date to implement the Political Declaration and 
Plan of Action have resulted in some considerable successes, 
including sustainable reductions in illicit drug cultivation 
through alternative development initiatives and welcome 
improvements in treatment delivery. There have also undeni-
ably been serious setbacks, however, not least the surge in 
opium cultivation and production in Afghanistan, the vio-
lence associated with the illicit drug trade, and the growing 
instability of regions, including West and East Africa, that are 
already vulnerable to trafficking and to rising levels of local 
production and use of illicit drugs. 
It is clear from the discussions at the high-level review, and 
from the findings of the present report, that there are no 
simple answers to these problems. Nevertheless, the lessons 
we have learned are valuable and we have attained a shared 
understanding of a way forward. 
First and foremost, we have learned that sustainable success 
requires a balanced, cooperative, comprehensive and inte-
grated approach, addressing both supply and demand. This 
was emphasized in the Joint Ministerial Statement resulting 
from the High Level Review, in which governments reaf-
firmed the international drug conventions as the health and 
human rights-centred cornerstone of the drug control system, 
and pledged to strengthen cooperation.
A balanced approach relies on evidence-based responses, with 
a firm emphasis on public health, and includes measures 
focusing on prevention, treatment and social rehabilitation 
and integration. 
There remain serious gaps in service provision, with only one 
in six problem drug users accessing drug dependence treatment 
services each year. The new set of data on access to services 
presented in the World Drug Report this year can support 
Member States in addressing this crucial area more effectively. 
In addition, for the first time the report presents joint esti-
mates by the United Nations Office on Drugs and Crime 
(UNODC), the World Health Organization, the Joint United 
Nations Programme on HIV/AIDS (UNAIDS) and the 
World Bank on the number of people who inject drugs and 
the number of people who inject drugs and are living with 
HIV. I welcome these cooperative efforts, which are very 
much in the spirit of “One United Nations” and can help 
countries to address the discrimination that continues to 
hinder access to HIV prevention, treatment and care services, 
particularly for people who use drugs and for those in prison. 
As the chair of the UNAIDS Committee of Cosponsoring 
Organizations this year, UNODC is committed to ensuring 
evidence-informed HIV interventions for all key populations. 
We have seen that countries that have adequately invested in 
harm reduction services have lowered remarkably HIV trans-
mission among people who inject drugs. 
The World Drug Report 2014 also addresses another important 
area, namely the results achieved and the challenges the inter-
national community continues to face in controlling precur-
sors. All drugs, whether plant-based or synthetic, require 
chemicals for their manufacture or processing. An interna-
tional control system facilitating the legal trade of such chemi-
cals while avoiding their diversion must be very robust, 
particularly as we continue to see rises in the manufacture 
and trafficking of synthetic drugs, which cannot be controlled 
through traditional supply reduction approaches such as crop 
eradication. 
Changes in the international manufacture and trade of chemi-
cals present challenges. Evidence shows, however, that meas-
ures to control precursor chemicals have had a tangible impact 
in reducing their diversion for illicit manufacturing of drugs, 
and this must remain a key supply control strategy. The work 
of the International Narcotics Control Board and its coopera-
tive mechanisms is central in this regard. The international 
drug conventions entrust the Board with assessing the imple-
mentation of measures to control precursors at the interna-
tional level and supporting countries to strengthen efforts to 
prevent diversion. 
More broadly, we must continue to enhance international 
cooperation, including with respect to transparent sharing of 
data and analysis, to help us better understand the drug prob-
lem and address the many challenges, including the related 
issues of violence and insecurity. This is particularly important 
as we move towards the special session of the General Assem-
bly on the world drug problem in 2016. I hope the World 
Drug Report 2014 will serve as a tool in these efforts, provid-
ing evidence to support the international community in devis-
ing more effective policies and finding joint solutions. 
Yury Fedotov
Executive Director
United Nations Office on Drugs and Crime
Acknowledgements
The World Drug Report 2014 was prepared by the Research and Trend Analysis 
Branch, Division for Policy Analysis and Public Affairs, United Nations Office on 
Drugs and Crime, under the supervision of Jean-Luc Lemahieu, Director of the 
Division for Policy Analysis and Public Affairs, and Angela Me, Chief of the 
Research and Trend Analysis Branch.  
Core team
Research and study preparation
Philip Davis
Kamran Niaz
Thomas Pietschmann
Janie Shelton
Antoine Vella 
Graphic design and layout 
Suzanne Kunnen
Kristina Kuttnig 
Data processing and mapping support
Preethi Perera
Umidjon Rahmonberdiev
Ali Saadeddin 
Editing and coordination
Jaya Mohan
Review and comments
Valuable comments and contributions were received from Conor Crean, Natascha 
Eichinger, Martin Raithelhuber and Justice Tettey (Laboratory and Scientific 
Section) and from several colleagues from the Division for Operations, the 
Division for Treaty Affairs and the secretariat of the International Narcotics 
Control Board.
The Research and Trend Analysis Branch is also grateful for the valuable advice 
provided by the following experts: 
Michael A. Cala
Jesus Maria García Calleja
Jonathan Caulkins
Karl L. Dehne
Peter Reuter
Keith Sabin
The report also benefited from the work and expertise of many other  
UNODC staff members in Vienna and around the world.
W
O
R
L
D
 D
R
U
G
 R
E
P
O
R
T
 2
01
4
v
CONTENTS
PREFACE     iii 
EXPLANATORY NOTES  vii 
EXECUTIVE SUMMARY  ix
1. RECENT STATISTICS AND TREND ANALYSIS OF ILLICIT DRUG MARKETS
A. Extent of drug use: global overview  1
B. Health and social impact 3
C. Regional trends in drug use 13
D. Opiates: overview  21
E. Cocaine: overview  34
F. Cannabis: overview  39 
G. Amphetamine-type stimulants: overview 46
H. New psychoactive substances 51
2. PRECURSOR CONTROL
A. Introduction   55
B. What are precursor chemicals?   55
C. The potential vulnerability of the chemical industry to the diversion of precursor chemicals 56
D. Response of the inter-national community 61
E. Patterns and trends in production of, and trade and trafficking in precursor chemicals 64
F. Key precursors used in the illicit manufacture of drugs 69
G. Effect of precursor control on the supply of illicit drugs 80
H. Reactions of clandestine operators facing stronger precursor controls 87
I. Concluding remarks  93 
ANNEX I     i
Tables on drug cultivation, production and eradication and prevalence
ANNEX II     
Regional groupings   xv
GLOSSARY     xvii

W
O
R
L
D
 D
R
U
G
 R
E
P
O
R
T
 2
01
4
vii
EXPLANATORY NOTES
The following abbreviations have been used in this Report:
APAAN alpha-phenylacetoacetonitrile
ATS amphetamine-type stimulants
BMK benzyl methyl ketone
CICAD Inter-American Drug Abuse Control 
Commission (Organization of  
American States)
EMCDDA European Monitoring Centre for Drugs 
and Drug Addiction
Europol European Police Office
FAO Food and Agriculture Organization of 
the United Nations
GDP gross domestic product
INCB International Narcotics Control Board
ISIC International Standard Industrial 
Classification
INCSR International Narcotics Control 
Strategy Report, of the United States 
State Department 
 LSD lysergic acid diethylamide
MDA 3,4-methylenedioxyamphetamine 
MDMA 3,4-methylenedioxymethamphetamine 
3,4-MDP-2-P 3,4-methylenedioxyphenyl-2- 
propanone
NSDUH National Survey on Drug Use and 
Health of the Substance Abuse and 
Mental Health Services Administration 
of the Department of Health and 
Human Services of the United States  
of America
P-2-P 1-phenyl-2-propanone
PEN Online Pre-Export Notification Online
PICS Precursors Incident Communication 
System
PMK piperonyl methyl ketone
PWID people who inject drugs
UNAIDS Joint United Nations Programme on 
HIV/AIDS 
UN COMTRADE United Nations Commodity Trade 
Statistics database
UNIDO United Nations Industrial  
Development Organization
UNODC United Nations Office on Drugs  
and Crime
WHO World Health Organization
The boundaries and names shown and the designations 
used on maps do not imply official endorsement or accept-
ance by the United Nations. A dotted line represents 
approximately the line of control in Jammu and Kashmir 
agreed upon by India and Pakistan. The final status of 
Jammu and Kashmir has not yet been agreed upon by the 
parties. Disputed boundaries (China/India) are represented 
by cross hatch due to the difficulty of showing sufficient 
detail. 
The designations employed and the presentation of the 
material in this publication do not imply the expression 
of any opinion whatsoever on the part of the Secretariat 
of the United Nations concerning the legal status of any 
country, territory, city or area or of its authorities, or con-
cerning the delimitation of its frontiers or boundaries.
Countries and areas are referred to by the names that were 
in official use at the time the relevant data were 
collected.
Since there is some scientific and legal ambiguity about 
the distinctions between “drug use”, “drug misuse” and 
“drug abuse”, the neutral terms “drug use” and “drug con-
sumption” are used in this report.
The data on population used in this report are from: 
United Nations, Department of Economic and Social 
Affairs, Population Division, World Population Prospects: 
The 2012 Revision. 
References to dollars ($) are to United States dollars, unless 
otherwise stated.
When referring to drug use, all mentions of amphetamine-
type stimulants exclude “ecstasy”.
References to “tons” are to metric tons, unless otherwise 
stated.

W
O
R
L
D
 D
R
U
G
 R
E
P
O
R
T
 2
01
4
ix
EXECUTIVE SUMMARY
The World Drug Report provides an annual overview of 
the major developments in drug markets for the various 
drug categories, ranging from production to trafficking, 
including development of new routes and modalities, as 
well as consumption. Chapter 1 of the World Drug Report 
2014 provides a global overview of the latest developments 
with respect to opiates, cocaine, cannabis and ampheta-
mines (including “ecstasy”) and the health impact of drug 
use. Chapter 2 zeroes in on the control of precursor chemi-
cals used in the manufacture of illicit drugs.
On the basis of comprehensive information on supply, as 
well as the relatively limited new information on demand, 
it can be concluded that overall the global situation with 
regard to the prevalence of illicit drug use and problem 
drug use1 is generally stable, with the total global number 
of drug users increasingly commensurate with the growth 
of the world population.
That said, each region exhibits its own peculiarities with 
respect to specific drugs. Polydrug use, which is generally 
understood as the use of two or more substances at the 
same time or sequentially, remains a major concern, both 
from a public health and a drug control perspective. 
Drug use and its health and social 
consequences
Drug use continues to exact a significant toll, with valu-
able human lives and productive years of many persons 
being lost. An estimated 183,000 (range: 95,000-226,000) 
drug-related deaths were reported in 2012. That figure 
corresponds to a mortality rate of 40.0 (range: 20.8-49.3) 
deaths per million among the population aged 15-64. 
While that estimate is lower than for 2011, the reduction 
can be ascribed to the lower number of deaths reported in 
a few countries in Asia. 
Globally, it is estimated that in 2012, between 162 million 
and 324 million people, corresponding to between 3.5 per 
cent and 7.0 per cent of the world population aged 15-64, 
had used an illicit drug — mainly a substance belonging 
to the cannabis, opioid, cocaine or amphetamine-type 
stimulants group — at least once in the previous year. 
The extent of problem drug use - by regular drug users 
and those with drug use disorders or dependence - 
1 There is no standard definition of problem drug use. The definition 
may differ from country to countryand may include people who 
engage in the high-risk consumption of drugs, for example people 
who inject drugs, people who use drugs on a daily basis and/or 
people diagnosed with drug use disorders or as drug-dependent based 
on clinical criteria contained in the International Classification of 
Diseases (tenth revision) of the World Health Organization and the 
Diagnostic and Statistical Manual of Mental Disorders (fourth edi-
tion) of the American Psychiatric Association, or any similar criteria 
or definition that may be used.
remains stable at between 16 million and 39 million 
people. However, there continues to be a gap in service 
provision, as in recent years, only one in six problem drug 
users globally have had access to or received drug depend-
ence treatment services each year. 
Although the general public may perceive cannabis to be 
the least harmful illicit drug, there has been a noticeable 
increase in the number of persons seeking treatment for 
cannabis use disorders over the past decade, particularly in 
the Americas, Oceania and Europe. Nonetheless, opiates 
remained the most prevalent primary drug of abuse among 
those seeking treatment in Asia and in Europe, as did 
cocaine in the Americas.
With regard to injecting drug use, the United Nations 
Office on Drugs and Crime (UNODC), the Joint United 
Nations Programme on HIV/AIDS (UNAIDS), the World 
Bank and the World Health Organization (WHO), draw-
ing on the most recent data available, jointly estimate that 
the number of people who inject drugs is  12.7 million 
(range: 8.9 million-22.4 million). That corresponds to a 
prevalence of 0.27 per cent (range: 0.19-0.48 per cent) of 
the population aged 15-64.2 The problem is particularly 
stark in Eastern and South-Eastern Europe, where the rate 
of injecting drug use is 4.6 times higher than the global 
average. 
The sharing of used injecting equipment makes people who 
inject drugs particularly vulnerable to HIV and hepatitis C. 
It is estimated that an average of 13.1 per cent of the total 
number of people who inject drugs are living with HIV. 
UNODC, the World Bank, WHO and UNAIDS jointly 
arrived at a global estimate of the number of people who 
inject drugs living with HIV of 1.7 million persons (range: 
0.9-4.8 million). That situation is particularly pronounced 
in two regions of the world: South-West Asia and Eastern/
South-Eastern Europe, where it is estimated that the preva-
lence of HIV among people who inject drugs is 28.8 and 
23.0 per cent, respectively. More than half of the people 
who inject drugs are estimated to be living with hepatitis 
C. 
Addressing HIV among people who inject drugs, through 
the implementation of an evidence-based comprehensive 
package of nine interventions,3 as a component of what is 
2 These estimates reflect the most recent data available from different 
sources, including integrated biological and behavioural surveillance 
surveys, the improved coverage and quality of surveillance within 
countries and the increase in the number of countries reporting. 
Therefore, these estimates should be understood as an update of 
previous global estimates and not be used as a comparison for the 
purposes of trend analysis.
3 WHO, UNODC, UNAIDS Technical Guide for Countries to Set Targets 
for Universal Access to HIV Prevention, Treatment and Care for Injecting 
Drug Users: 2012 Revision (Geneva, World Health Organization, 
2012).
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also known as “harm reduction services”, is a major com-
ponent of the global response to stop the spread of HIV. 
Of them, the four most effective interventions for HIV 
prevention, treatment and care are needle and syringe pro-
grammes, opioid substitution therapy (or other evidence-
based drug dependence treatment in the case of people 
who inject non-opioid drugs), HIV testing and counsel-
ling, and antiretroviral therapy. 
The coverage of the four most effective interventions is 
greatest in Western and Central Europe, where harm 
reduction interventions have been scaled up for more than 
a decade, leading to a decline in the number of newly diag-
nosed cases of HIV among people who inject drugs and 
of AIDS-related deaths attributed to unsafe injecting drug 
use. However, recent outbreaks of HIV among people who 
inject drugs in parts of Europe demonstrate how the HIV 
epidemic situation can change very rapidly in areas where 
services and interventions are scaled down. 
It is well documented that a very high percentage of people 
who inject drugs have a history of imprisonment. Also, 
both drug use and injecting drug use are highly prevalent 
among prison populations. The lack of access to and avail-
ability of health care, especially drug dependence treatment 
and HIV prevention, treatment and care services in pris-
ons, is of major concern, since the prison population, at a 
minimum, should have access to services equivalent to 
those available to the general public. For instance, in 
Europe, the proportion of prisoners who had used an illicit 
substance during incarceration ranged from 4-56 per cent.
In Europe, the financial crisis seems to have had an impact 
on drug use modalities, with related health and social con-
sequences. While there are no comprehensive data available 
yet, two phenomena seem to have emerged in parts of 
Europe that have appeared in parallel to the financial crisis. 
First, there appears to be a shift in the pattern of drug use 
which sometimes  results in a higher risk of harm; and 
secondly, there has been a reduction in coverage of harm 
reduction services, which, according to recently published 
research, has increased the likelihood of unsafe injecting 
behaviour, thus influencing the spread of infections such 
as HIV and hepatitis C. 
Drug profiles by category
Opiates
Opiates and opioids top the list of problem drugs that 
cause the most burden of disease and drug-related deaths 
worldwide. For the third consecutive year, Afghanistan, 
which has the world’s largest opium poppy cultivation, saw 
an  increase in the area under cultivation (from 154,000 
hectares in 2012 to 209,000 hectares in 2013). In addi-
tion, Myanmar witnessed expansion in the area of opium 
poppy cultivation, although less pronounced. In 2013, the 
estimated global production of heroin rebounded to the 
levels seen in 2008 and 2011.
The global area of illicit opium cultivation in 2013 stood 
at 296,720 hectares — the largest area since 1998, when 
estimates became available. 
There is evidence that Afghan heroin is increasingly reach-
ing new markets, such as Oceania and South-East Asia, 
that had been traditionally supplied from South-East Asia. 
The long-established Balkan route seems to remain a cor-
ridor for the transit of Afghan heroin to the lucrative mar-
kets in Western and Central Europe, but its importance 
has declined due to various factors such as more effective 
law enforcement and a shrinking market in Western and 
Central Europe, as seen by the decline in opiate use and 
seizures in the subregion and the reduced level of supply 
compared with the peak levels of 2007. 
The so-called “southern route” is expanding, with heroin 
being smuggled through the area south of Afghanistan 
reaching Europe, via the Near and Middle East and Africa, 
as well as directly from Pakistan. 
An emerging phenomenon among opioid-dependent drug 
users in the United States of America is that synthetic opi-
oids are being replaced with heroin, driven by the increased 
availability of heroin in parts of the United States, and 
lesser costs to regular users to maintain their dependency. 
Further, the reformulation of one of the main prescription 
pharmaceuticals abused, OxyContin, now  makes it more 
difficult to snort or inject it. 
Following a sharp increase in 2011, global seizures of 
heroin and illicit morphine declined in 2012, while 
remaining higher than the levels of 2010 and prior years. 
The fluctuations were mainly driven by seizures in South-
West Asia and Western and Central Europe. However, in 
2012, there was an increase in heroin seizures in many 
other regions, mainly Eastern and South-Eastern Europe, 
South Asia and Oceania. Significantly, heroin seizures, and 
therefore presumably the flow of heroin, in key countries 
located along the “northern route” from Afghanistan to 
the Russian Federation, have gone down. At the same time, 
there is evidence of a significant number of small seizures 
of home made desomorphine, which is likely serving as a 
substitute for  heroin. 
The emergence of potentially more harmful behaviour, 
including the abuse of opioids such as fentanyl, has been 
noted among opioid-dependent persons in Estonia, Fin-
land and the United States. It has been observed that 
opioid users may alternate between pharmaceutical and/
or prescription opioids and heroin, depending on which 
substance is more available, accessible and cheaper in the 
market. 
Cocaine
While cocaine manufacture and trafficking have had a seri-
ous impact in the Western hemisphere, there are indica-
tions that overall global availability of cocaine has fallen. 
The estimated net area under coca bush cultivation as of 
31 December 2012 was the lowest since the beginning of 
Executive summary
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available estimates in 1990: 133,700 hectares, a decline of 
14 per cent from the estimate for 2011. 
Global cocaine seizures increased to 671 tons in 2012, 
compared with the 634 tons seized in 2011. The main 
increase in the quantities of cocaine seized were in South 
America and Western and Central Europe.
Cocaine use is still relatively concentrated in the Americas, 
Europe and Oceania, and practically all of the world’s 
cocaine is produced in three countries in South America. 
While there is no conclusive evidence with respect to the 
extent of cocaine use in Africa and Asia, expert opinion 
indicates that there may be pockets of emerging cocaine 
use in those two regions, related to the rise in trafficking 
through Africa and increased affluence in both 
continents.
The most problematic use of cocaine is in the Americas. 
In North America, cocaine use has been declining since 
2006, partly due to a sustained shortage. However, more 
recently, a slight increase in prevalence has been observed 
in the United States, as has an increase in maritime 
seizures.
In South America, cocaine consumption and trafficking 
have become more prominent, particularly in Brazil due 
to factors including its geographical location and a large 
urban population.
In Western and Central Europe, the second largest market 
after the Americas, indicators of overall supply suggest a 
possible rebound in the availability of cocaine; retail purity 
has increased in some countries with sizable consumer mar-
kets. On the other hand, they do not show an increase in 
demand. There has even been a decline in cocaine use in 
some of the countries that have had higher levels of use. 
The market has expanded in Oceania in recent years, but 
the region has a different pattern of use compared with 
other consumer markets because it has a large body of users 
(a high prevalence) who use the substance with low fre-
quency, perhaps due to the high price of cocaine.
Cannabis
Cultivation and production of cannabis herb (“marijuana”) 
remains widespread, while production of cannabis resin 
(“hashish”) remains confined to a few countries in North 
Africa, the Middle East and South-West Asia. In Afghani-
stan, despite the fact that the area under cannabis cultiva-
tion has been decreasing, the potential cannabis resin 
production in 2012 was higher than in 2011 due to the 
greater yield per hectare.
Global cannabis use seems to have decreased, essentially 
reflecting a decrease in cannabis use estimates reported by 
a number of countries in Western and Central Europe. 
However, in the United States, the lower perceived risk of 
cannabis use has led to an increase in its use. At the same 
time, more people using cannabis are seeking treatment 
each year.
In Europe, the market has changed over the past decade, 
with cannabis herb produced locally or regionally now 
gaining ground over cannabis resin, largely sourced from 
Morocco, which previously was the dominant cannabis 
substance in Europe, as evidenced by seizure data.
New regulatory frameworks in the States of Colorado and 
Washington in the United States and in Uruguay now 
make the recreational use of cannabis legal under some 
restrictions. The new laws also include provisions for the 
supply chain, including both licensed and personal culti-
vation. It is too early to understand the impact of these 
changes on recreational and problematic use of cannabis 
and in the broad range of areas that they may affect, includ-
ing health, criminal justice, and public revenues and expen-
ditures. It will take years of careful monitoring to 
understand the broader effects of those novel regulatory 
frameworks in order to inform future policy decisions.
Based on existing research, it can be argued that with 
declining risk perception and increased availability, use and 
youth initiation may increase. Tax revenues from retail 
cannabis sales are expected to provide public revenue. 
However, expected revenue will need to be cautiously 
weighed against the costs of prevention and health care.
Trend in main indicators of drug supply and 
drug supply reduction, 2003-2013
Source: Seizure data: annual report questionnaire supplemented 
by other official sources. 
Cultivation data: UNODC estimates based on national illicit crop 
monitoring systems supported by UNODC supplemented by other 
official data.
a Including amphetamine, “ecstasy”-type substances, methampheta-
mine, non-specified ATS, other stimulants and prescription stimulants. 
For the categories of other stimulants and prescription stimulants, sei-
zures reported by weight or volume only are included.
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Amphetamine-type stimulants
While it is difficult to quantify the global manufacture of 
amphetamine-type stimulants, the number of dismantled 
laboratories manufacturing amphetamine-type stimulants, 
which were mostly manufacturing methamphetamine, 
continued to rise. Manufacture of methamphetamine in 
North America expanded once again, with a large increase 
in the number of methamphetamine laboratories reported 
dismantled in the United States and Mexico. 
Of the total of 144 tons of amphetamine-type stimulants 
seized globally, half were seized in North America  and a 
quarter in East and South-East Asia. Large quantities of 
amphetamine seizures continue to be reported in the 
Middle East, in particular in Jordan, Saudi Arabia and the 
Syrian Arab Republic.
Central and South-West Asia are emerging as new markets, 
with low levels of methamphetamine seizures and use being 
reported by two countries in those subregions. South-West 
Asia has also emerged as a significant production area for 
methamphetamine destined for East and South-East Asia. 
Production in West and Central Africa is also emerging.
Seizures of “ecstasy” increased in 2012, with major quanti-
ties of “ecstasy” being seized in East and South-East Asia, 
followed by Europe (South-Eastern and Western and Cen-
tral Europe), which together accounted for over 80 per 
cent of global seizures of “ecstasy”.
The misuse of prescription stimulants or medications for 
attention-deficit hyperactivity disorder (ADHD) is not 
uncommon, although only a few countries report any prev-
alence of misuse among the general and youth population. 
Although misuse of prescription stimulants in other regions 
is not negligible, such abuse is reported mainly by coun-
tries in North and South America.
New psychoactive substances and  
web-based marketplaces
While the Internet continues to be used as a means of drug 
trafficking and illicit trade in precursor chemicals, use of 
the so-called “dark net” has been growing. The “dark net” 
constitutes a virtual marketplace, which is inaccessible by 
web search, and where it is difficult for law enforcement 
authorities to identify website owners and users, as their 
identities remain hidden by means of sophisticated con-
cealment methods. That makes the “dark net” a safe haven 
for buyers and sellers of illicit drugs, who trade principally 
in a digital currency (Bitcoin). 
While the overall proportion of drug transactions that take 
place in the “dark net” is unclear, the value of transactions, 
as well as the range of drugs available, appears to be grow-
ing. The dismantling of one prominent “dark net” site, the 
“Silk Road”, uncovered that the site had approximately 
$1.2 billion worth of total revenue from two to five years 
of operations. There is evidence of a niche market on the 
“dark net” for new psychoactive substancesas well as for 
high-quality cannabis, heroin, methylenedioxymetham-
phetamine (MDMA) and cocaine. 
Finally, the proliferation of new psychoactive substances 
continues to pose a challenge, with the number of new 
psychoactive substances (348 such substances in December 
2013, up from 251 in July 2012) clearly exceeding the 
number of psychoactive substances controlled at the inter-
national level (234 substances).
Drug-related crime
Crime recorded by the authorities in relation to personal 
use and trafficking of drugs assessed separately has shown 
an increase  over the period 2003-2012, in contrast to the 
general declining trend in property-related and violent 
crime. However, the proportion of drug offenders who 
were drug users with recorded offences for personal use 
has remained stable, given the increased number of users 
during that period. Worldwide, the large majority of drug 
use offences are associated with cannabis.
Crime related to drug trafficking varies depending on the 
type of drug and the supply patterns involved in different 
regions. 
The majority of persons arrested for or suspected of drug 
offences are men; the involvement of women in drug 
offences varies according to drug type, reflecting the drugs 
of preference among women. The highest percentage of 
women arrestees or suspects can be observed in relations 
to crimes involving sedatives and tranquillizers (25 per 
cent). 
Precursor control 
Most drugs, whether plant-based or synthetic, require 
chemicals to transform them into the final product. While 
chemicals are only one of the components required for the 
clandestine manufacture of plant-based drugs (heroin and 
cocaine), they constitute the essential components of illic-
itly manufactured synthetic drugs. 
Given the growing manufacture of synthetic drugs, the 
control of such chemicals, known as precursors, has 
emerged as a key supply control strategy because the tra-
ditional approaches, such as eradication of illicit crops and 
alternative development, cannot be applied to synthetic 
drugs.
There are potential vulnerabilities in the structure of and 
trends in the production of and trade in chemicals that are 
used in the illicit manufacture of drugs. The international 
community has, over the years, strenghtened a control 
system aimed at enabling the legal trade of such chemicals 
while preventing their diversion into illicit manufacture. 
Some successes have been achieved in precursor control, 
but they have prompted a range of reactions from the traf-
fickers and manufacturers of illicit drugs, which create new 
challenges for the international drug control system. 
Executive summary
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Vulnerabilities of the chemical industry  
to diversion of precursors
The chemical industry has seen strong growth rates and 
geographical shifts over the past few decades, notably the 
past two decades, when global production doubled and 
trade more than tripled. Also during that period, the bulk 
of production shifted to Asia, where the emerging chemi-
cal industry is now characterized by a sizeable cluster of 
small competing enterprises. In contrast to the past situa-
tion, when the chemical industry was dominated by large, 
vertically integrated conglomerates, these new develop-
ments have made the chemical industry potentially more 
vulnerable to the diversion of precursors. 
Moreover, with more and more chemicals being traded 
across borders, a greater number of transit countries and 
the emergence of a number of chemical brokers and other 
intermediaries, the potential avenues for diversion of pre-
cursors to the clandestine manufacture of drugs have been 
increasing.
Response by the international community
Precursor control emerged as one of the key pillars of inter-
national drug control in the United Nations Convention 
against Illicit Traffic in Narcotic Drugs and Psychotropic 
Substances of 1988. The Convention sets out specific 
measures for the manufacture and distribution of and 
international trade in a number of chemicals frequently 
used in the manufacture of drugs. These are listed under 
two categories: the more strictly controlled substances in 
Table I and the relatively less controlled substances in Table 
II. The 1988 Convention entrusts the International Nar-
cotics Control Board with the implementation of precursor 
control at the international level. 
The system has been further enhanced by means of a 
number of resolutions adopted by the United Nations 
Commission on Narcotic Drugs, the Economic and Social 
Council and the General Assembly, as well as the Political 
Declaration adopted by the General Assembly at its twen-
tieth special session, in 1998, and the Political Declaration 
and Plan of Action on International Cooperation towards 
an Integrated and Balanced Strategy to Counter the World 
Drug Problem, adopted by the General Assembly in 2009, 
including their related action plans. As of December 2013, 
23 substances were under international control: 15 sub-
stances in Table I and 8 substances in Table II of the 1988 
Convention. In March 2014, the Commission on Narcotic 
Drugs decided to schedule alpha-phenylacetoacetonitrile 
(APAAN) in Table I of the Convention.
Production and trade of precursor  
chemicals
There is licit use and licit trade of precursors, and control 
includes the monitoring of the licit trade while preventing 
diversion. Through the analysis of information provided 
by countries to UNODC and international trade statistics, 
it can be concluded that over the period 2010-2012, some 
77 countries were engaged in the manufacture of precur-
sor chemicals.
 A much larger number of countries were involved in trade 
in precursors. 122 countries reported exports of precursor 
chemicals over the period 2010-2012, while 150 countries 
reported imports. The largest exports of precursors were 
reported by countries in Asia, followed by Europe and the 
Americas. If only net exporting countries of precursor 
chemicals are considered, Asian countries account for 59 
per cent of total net exports over the 2010-2012 period. 
Global exports in precursor chemicals rose at a rate similar 
to that of chemicals in general. 
The licit requirements for and applications of various pre-
cursors differ from country to country. The bulk (93 per 
cent) of the international trade in precursor chemicals, in 
terms of economic value, is of substances listed in Table II 
of the 1988 Convention. In 2012, the more strictly con-
trolled substances in Table I accounted for only 7 per cent 
of international trade in precursor chemicals, or 0.04 per 
cent of overall international trade in chemicals, and their 
export growth has been far lower than for Table II sub-
stances. The most important Table I substances, in eco-
nomic terms, are acetic anhydride, used in the manufacture 
of heroin, followed by potassium permanganate, used in 
the manufacture of cocaine, and pseudoephedrine, used 
in the manufacture of methamphetamine.
The illicit trade in precursor chemicals cannot be quanti-
fied as easily as can the licit market, but information on 
seizures can provide some partial information on trends. 
Although annual seizures of precursor chemicals fluctuate 
greatly, the overall trend for Table I precursors seems to 
show an increase over the last two decades. By contrast, 
seizures of Table II substances, although fluctuating, have 
been following a stable trend overall. The regional distri-
bution of seizures of precursors in Table I and Table II 
shows a concentration in the Americas, followed, depend-
ing on the time frame examined, by Europe or, in more 
recent years, Asia.
Impact of precursor control on drug 
supply 
Measures employed to control precursor chemicals have 
had a tangible impact on reducing the diversion of chemi-
cals to the illicit manufacture of drugs, as could be observed 
through various methods of analysis:
a) Increased volume of chemicals saved from diversion. The 
number of shipments stopped before being diverted 
increased sharply, and seizures of Table I precursors 
rose 12-fold from the period 1990-1992 to the period 
2010-2012, the former period being the initial years 
of international precursor control. This may point to 
the effectiveness of precursor control, although it is not 
conclusive proof;
b) High interception rates. Measuring seizures compared 
with the overall amount estimated to have been di-
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verted into illicit manufacture, show that about 15 per 
cent of diverted potassium permanganate (in the range 
of 10-28 per cent) and 15 per cent of diverted acetic 
anhydride (in the range of 7-22 per cent) have been in-
tercepted over the period 2007-2012. Estimated diver-
sions are equivalent to just 2 per cent of international 
trade in potassium permanganate and 0.2 per cent of 
international trade in acetic anhydride;
c) Higher volumes of precursor seizures compared with the 
volume of seizures of the substances those precursors are 
used to manufacture. Seizures of precursors of “ecstasy”, 
expressed in terms of the amount of “ecstasy” they 
could be used to manufacture (end-product equiva-
lent), were almost a fifth larger than “ecstasy” seizures 
over the period 2007-2012. Seizures of amphetamine 
and methamphetamine precursors calculated in terms 
of their end-product equivalents were more than twice 
as high as amphetamine and methamphetamine sei-
zures over the same period; 
d) Reduced availability of drugs due to precursor control. 
Three examples can be cited in which precursor con-
trol appears to have reduced the supply of precursors 
and led to a consequent reduction in the availability 
of the drug. The first is the shrinking of the market 
for lysergic acid diethylamide (LSD), which could be 
at least partly attributed to improved control of LSD 
precursors. The shrinking of that market is reflected 
in the 75 per cent decline in use of LSD among high 
school students in the United States over the period 
1996-2013, which is highly correlated to the decreased 
availability of the substance. The second example is the 
decline in “ecstasy” use in many countries, associated 
with a lower purity of the substance, connected with 
the limited availability of that drug’s main precursor in 
the period 2007-2010. Thirdly, the improved control 
of precursors of methaqualone seems to have led to a 
decline in its availability and thus also its use over the 
past two decades;
e)  Prices in the illicit market. While the price of acetic an-
hydride in the licit market fluctuated between $1 and 
$1.50 per litre in recent years, the price of illicit acetic 
anhydride in Afghanistan rose over the years, at times 
reaching peaks of some $430 per litre (2011), up from 
$8 in 2002. The price rises can be linked to improve-
ments in precursor control. They also had an impact on 
the cost of heroin production. The proportion of acetic 
anhydride in total production costs of heroin in Af-
ghanistan rose from 2 per cent in 2002 to 26 per cent 
in 2010 before falling to some 20 per cent in 2013. 
New strategies by operators of drug  
laboratories 
Improved precursor controls at the global level have 
prompted clandestine operators of illegal laboratories to 
develop a number of counter-strategies. Those strategies 
include:
 • the use of more sophisticated ways to obtain precursor 
chemicals
 • the use of transit countries with weak control systems
 • the emergence of organized criminal groups specialized 
in the supply of precursor chemicals
 • the creation of front companies to conceal illegal 
imports
 • the domestic diversion and subsequent smuggling of 
precursor chemicals to final destinations in order to 
bypass the international control system
 • the use of the Internet
 • the misuse of pharmaceutical preparations (notably 
preparations containing ephedrine or pseudoephedrine) 
and,
 • the emergence of non-scheduled precursor chemicals, 
including various pre-precursors that can be easily con-
verted into the required precursors.
Thus, new pre-precursors for the manufacture of amphet-
amine-type stimulants have emerged in recent years, 
including APAAN, various esters of phenylacetic acid, 
3,4-methylenedioxyphenyl-2-propanone, methyl glycidate 
and methylamine. Some of those substances, which are 
controlled only in a limited number of countries, have 
become major substitutes for the precursor chemicals used 
in the past and are now seized in greater quantities than 
are the internationally controlled precursors of ampheta-
mine-type stimulants. 
Another counter-strategy is the manufacture of new psy-
choactive substances that can be manufactured with chemi-
cals not under international control. 
All of these strategies used by clandestine manufacturers 
create a new set of challenges for the international precur-
sor control system. At the same time, they reflect the fact 
that precursor control does have an impact. There are 
already some instruments available at the international 
level to deal with the emerging problems — use of the 
“know-your customer” principle, the limited international 
special surveillance list, the Pre-Export Notifications 
(PEN) Online and the Precursors Incident Communica-
tion System (PICS) — but they are yet to be implemented 
in a number of countries. Their universal and effective 
implementation would be a step forward in meeting these 
challenges.
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11RECENT STATISTICS AND TREND ANALYSIS  OF THE ILLICIT DRUG MARKET
A. EXTENT OF DRUG USE:  
GLOBAL OVERVIEW
Globally, it is estimated that in 2012, some 243 million 
people (range: 162 million-324 million) corresponding to 
some 5.2 per cent (range: 3.5-7.0 per cent) of the world 
population aged 15-64 had used an illicit drug — mainly 
a substance belonging to the cannabis, opioid, cocaine or 
amphetamine-type stimulant (ATS) group — at least once 
in the previous year. Although the extent of illicit drug use 
among men and women varies from country to country 
and in terms of the substances used, generally, men are two 
to three times more likely than women to have used an 
illicit substance.1 While there are varying regional trends 
in the extent of illicit drug use, overall global prevalence 
of drug use is considered to be stable. Similarly, the extent 
of problem drug use, by regular drug users and those with 
drug use disorders or dependence, also remains stable, at 
about 27 million people (range: 16 million-39 million). 
With respect to the different groups of substances, there 
has been an increase in opioid and cannabis use since 2009, 
whereas the use of opiates, cocaine and ATS (excluding 
“ecstasy”) has either remained stable or followed a decreas-
ing trend. However, not all countries conduct national 
surveys on drug use, and most countries that do so conduct 
them only periodically, once every three to five years. 
1 This is based on the prevalence rates of any drug use among males and 
females reported to the United Nations Office on Drugs and Crime 
(UNODC) by Member States through the annual report question-
naire.
Therefore, rather than looking at the year-to-year change, 
it is more meaningful to take a longer-term perspective. 
Also, year-on-year changes in a country’s prevalence rate 
have only a slight impact on a region’s overall prevalence 
unless they occur in a country with a large population. For 
2012 data, updated prevalence estimates are available for 
33 countries, mostly countries of Western and Central 
Europe and North America, representing nearly 12 per 
Fig. 1. Global trends in drug use, 2006-2012
Source: Estimates based on the UNODC annual report questionnaire.
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Fig. 2. Trends in the prevalence of use of  
different drugs, 2009-2012
Source: Estimates based on the UNODC annual report question-
naire.
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1. RECENT STATISTICS AND TREND ANALYSIS OF THE ILLICIT DRUG MARKET2
cent of the global population aged 15-64. Therefore, the 
trends and global annual estimates of overall drug use and 
of different substances reflect only the changes in or revi-
sion of the estimates for those countries and regions.
Drug use and gender
Nearly all drug use surveys indicate that men are more 
likely than women to use drugs such as opiates and can-
nabis. However the gender gap shrinks when data on the 
misuse of pharmaceuticals are considered. In five recently 
surveyed countries (Australia, United States of America, 
Spain, Urban Afghanistan, and Pakistan), the illicit use of 
drugs is more common among men than women, but the 
non-medical use of pharmaceutical drugs is nearly equiva-
lent, if not higher among women (see figure 3). Taking 
together the combined estimates of those five surveys, the 
illicit use of pharmaceuticals is notably different for the 
two sexes, as nearly half the women with past-year drug 
use had used pharmaceuticals, compared with only one 
third of men. 
Table 1. Global estimates of users of different drugs, 2012
Source: Estimates based on the UNODC annual report questionnaire.
Number of users (millions of users) Prevalence (percentage)
Best estimate Low High Best estimate Low High
Cannabis 177.63 125.30 227.27 3.8 2.7 4.9
Opioids 33.04 28.63 38.16 0.7 0.6 0.8
Opiates 16.37 12.80 20.23 0.35 0.28 0.43
Cocaine 17.24 13.99 20.92 0.37 0.30 0.45
ATS 34.40 13.94 54.81 0.7 0.3 1.2
“Ecstasy” 18.75 9.4 28.24 0.4 0.2 0.6
Polydrug use
Polydrug use is the use of two or more substances at the 
same time or sequentially;1 it is a common occurrence 
among both recreational and regular drug users2,3 in all 
regions. 
There are three distinct patterns of polydrug use:
One pattern is different substances being taken together to 
have a cumulative or complementary effect.4,5 This pat-
tern is commonly seen among cannabis and cocaine users, 
who may use the drug in combination with alcohol; other 
combinations are the use of heroin in combination with 
benzodiazepines,6 alcohol or other opioids (methadone, 
oxycodone, etc.) and the use of cocaine in combination 
with other stimulants. 
A second pattern is the use of a drug to offset the adverse 
effects of another drug, e.g., cocaine and heroin use 
(“speedball”), or cocaine use with other opioids,7 although 
in the latter case, there is also a complementary effect.
1 World Health Organization, Lexicon of Alcohol and Drug Terms 
(Geneva, 1994).
2 World Drug Report 2011 (United Nations publication, Sales No. 
E.11.X.10).
3 European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA), “Polydrug use: patterns and responses”, Selected 
issue 2009 (Lisbon, November 2009).
4 Ibid.
5 Annabel Boys, John Marsden and John Strand, “Understanding rea-
sons for drug use amongst young people: a functional perspective”, 
Health Education Research, vol. 16, No. 4 (2001), pp. 457-469.
6 Markus Backmund and others, “Co-consumption of benzodiaz-
epines in heroin users, methadone-substituted and codeine-substi-
tuted patients”, Journal of Addictive Diseases, vol. 24, No. 4 (2005).
A third pattern is observed when a drug is gradually replac-
ing or being substituted by another drug due to changes in 
price or availability or because the drug is in fashion. 
Common examples are heroin being substituted by oxyco-
done, desomorphine or other opioids, as observed in vari-
ous regions, or “ecstasy” being substituted by mephedrone 
or some other new psychoactive substance.
Various studies have documented the extent of polydrug 
use. In a study conducted in 14 European countries in 
2006, 60 per cent of cocaine users were polydrug users, of 
which 42 per cent used alcohol, 28 per cent used cannabis 
and 16 per cent used heroin.8 In another study, in the 
South-Eastern United States, 48.7 per cent of treatment 
admissions were for polydrug use, with alcohol, cocaine 
and cannabis being the most common substances.9 The 
main risks and consequences of polydrug use, for both 
recreational and high-risk drug users, continue to be the 
severe health consequences due to the increased toxicity, 
overdose and death. From a policy perspective, it is impor-
tant to understand the patterns of polydrug use because 
such use invalidates the established profile and characteri-
zation of the user of a specific, single drug.
7 Francesco Leri, Julie Bruneau and Jane Stewart, “Understanding 
polydrug use: review of heroin and cocaine co-use”, Addiction, vol. 
98, No. 1 (January 2003), pp. 7-22.
8 EMCDDA, Annual Report 2009: The State of the Drug Problem in 
Europe (Lisbon, November 2009), p. 42.
9 S. Kedia and others, “Mono versus polydrug abuse among publicly 
funded clients”, Substance Abuse Treatment, Prevention and Policy, 
vol. 2, 2:33 (8 November 2007).
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3B. Health and social impact
B. HEALTH AND SOCIAL IMPACT 
Problematic drug use as reflected in  
the demand for treatment
The need for treatment for drug use disorders and depend-
ence reflects a problematic level of consumption. There-
fore, analysing drug types that contribute to the demand 
for treatment can provide information on the drugs that 
have the highest negative impact on health in each region. 
Treatment for cannabis use is very evident in Africa, 
throughout the Americas and in Oceania. Although the 
general public may perceive cannabis to be the least harm-
ful illicit drug, between 2003 and 2012 the proportion of 
total treatment admissions for cannabis increased in West-
ern and Central Europe (from 19 per cent to 25 per cent), 
Eastern and South-Eastern Europe (from 8 per cent to 15 
per cent), Latin America and the Caribbean (from 24 per 
cent to 40 per cent) and Oceania (from 30 per cent to 46 
per cent). Opioids dominate the demand for treatment in 
Eastern and South-Eastern Europe and Asia. Cocaine is a 
major contributor to the demand for treatment in the 
Americas, in particular in Latin America and the Carib-
bean. ATS use is responsible for sizeable proportions of 
treatment demand in Asia and Oceania.
Globally, it is estimated that approximately one in six prob-
lem drug users2 accesses treatment each year. However, 
2 There is no standard definition of problem drug use. The definition 
differs from country to country and may include people who engage 
there are large regional disparities, with approximately 1 
in 18 problem drug users receiving treatment in Africa 
(primarily for cannabis use), compared with one in five 
problem drug users receiving treatment in Western and 
Central Europe, one in four in Oceania, and one in three 
in North America. 
Drug-related deaths
Drug-related death3 is the most extreme form of harm that 
can result from drug use. The United Nations Office on 
Drugs and Crime (UNODC) estimates that there were 
183,000 (range: 95,000-226,000) drug-related deaths in 
2012, corresponding to a mortality rate of 40.0 (range: 
20.8-49.3) deaths per million persons aged 15-64.4
The current estimate of the total number of drug-related 
deaths is a downward revision from the value published in 
the World Drug Report 2013. However, this should not be 
interpreted as a decline in the global number of drug-
related deaths. That revision was predominantly the result 
of the updated estimates from only a few countries (Iran 
(Islamic Republic of ), Kazakhstan and Uzbekistan), which 
mostly affected the regional total for Asia and, conse-
quently, the global number of drug-related deaths.
Drug overdose is the primary contributor to the global 
number of drug-related deaths, and opioids (heroin and 
the non-medical use of prescription opioids) are the main 
drug type implicated in those deaths. Risk factors for over-
dose include the availability and purity of opioids; reduced 
tolerance due to a recent period of abstinence such as due 
to treatment, incarceration or self-imposed abstinence; lack 
of treatment for opioid dependence; and polydrug use, 
especially involving benzodiazepines and the use of 
alcohol.5
Deaths from opioid overdose are preventable not only by 
reducing opioid dependency or restricting supply but also 
by reversing the effects of opioids after an overdose has 
occurred. Naloxone, a pure opioid antagonist, is a medica-
tion recommended by the World Health Organization 
in the high-risk consumption of drugs, for example, people who inject 
drugs, people who use drugs on a daily basis and/or people diagnosed 
with drug use disorders or as drug-dependent based on clinical cri-
teria contained in the International Classification of Diseases (10th 
revision) of the World Health Organization and the Diagnostic and 
Statistical Manual of Mental Disorders (4th ed.) of the American 
Psychiatric Association, or any similar criteria or definition that may 
be used.
3 The definition of drug-related deaths varies among Member States 
but includes all or some of the following: fatal drug overdoses, deaths 
due to HIV acquired through injecting drug use, suicide, and unin-
tentional deaths and trauma, due to drug use.
4 Because of the very limited reporting of data from countries in Africa, 
an alternative source is used: Louisa Degenhardt and others, “Illicit 
drug use”, in Comparative Quantification of Health Risks: Global and 
Regional Burden of Disease Attributable to Selected Major Risk Factors, 
vol. 1, M. Ezzati and others, eds. (Geneva, World Health Organiza-
tion, 2004).
5 Discussion paper UNODC/WHO 2013, “Opioid overdose: prevent-
ing and reducing opioid overdose mortality”, United Nations, June 
2013.
Fig. 3. Estimated proportions of pharmaceuti-
cal and non-pharmaceutical illicit drug 
use in the past-year, by gender
Source: UNODC annual report questionnaire, Afghanistan 
National Urban Household Drug Use Survey, 2012, 2010 National 
Drug Strategy Household Survey Report (Australia), Drug use in 
Pakistan, 2012, Substance Abuse Mental Health Survey 2012, 
Encuesta Sobre Alcohol Y Drogas en Población General En España 
(EDADES) 2012.
Note: Estimated proportions of non-medical use of pharmaceuticals are 
based on best available estimates and may not reflect all classes of phar-
maceutical substances which are known to be abused.
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(WHO) that can be administered to immediately reverse 
the effects of an opioid overdose. It is highly effective and 
safe and has no significant side effects and no potential for 
misuse.6
A number of countries have implemented community-
based programmes that make naloxone more readily avail-
able to appropriately trained opioid users, their peers and 
family members. In the United States, for example, there 
were 188 local opioid overdose prevention programmes 
distributing naloxone in 2010, and between 1996 and 
2010, those programmes reported 10,171 opioid overdose 
reversals through use of naloxone.7
6 Ibid.
7 Centers for Disease Control and Prevention, “Community-based 
Preventing non-fatal overdose cases 
A major health consequence of high-risk drug use — 
especially among regular opioid users and people who 
inject drugs — that remains largely underreported is the 
occurrence of non-fatal overdose cases.8 Various studies 
conducted among opioid users and people who inject drugs 
have reported that the large majority of opioid users had 
survived an overdose episode in their lifetime (ranging 
between 30 and 83 per cent, as reported in different 
opioid overdose prevention programs providing naloxone: United 
States, 2010”, Morbidity and Mortality Weekly Report, vol. 61, No. 6 
(17 February 2012), pp. 101-105.
8 Discussion paper UNODC/WHO 2013, “Opioid overdose: prevent-
ing and reducing opioid overdose mortality” (United Nations, June 
2013).
Fig. 4. Changes in the primary drug of concern among people in treatment, by region, 2003-2012
Source: UNODC annual report questionnaire, national government reports.
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Table 2. Estimated number of drug-related deaths and mortality rates per million persons aged  
15-64 years, 2012
Source: UNODC annual report questionnaire; Inter-American Drug Abuse Control Commission; Louisa Degenhardt and others, “Illicit drug 
use”, in Comparative Quantification of Health Risks: Global and Regional Burden of Disease Attributable to Selected Major Risk  
Factors, vol. 1, chap. 13, M. Ezzati and others, eds. (Geneva, World Health Organization, 2004).
Note: Data for Africa have been adjusted to reflect the 2012 population. The wide range in the estimates for Asia reflects the low level of reporting 
from countries in the region. The best estimate for Asia is placed towards the upper end of the reported range because a small number of highly  
populated countries reported a relatively high mortality rate, which produces a high regional average.
Two dots (..) indicate insufficient data. Also see footnote 4.
Region
Number of drug-related deaths Mortality rate per million                  aged 15-64
% of population 
of countries 
where mortality 
data is available
Best  
estimate
Lower 
estimate
Upper 
estimate
Best  
estimate
Lower 
estimate
Upper 
estimate
Africa  36,800  17,500  56,200 61.9 29.4 94.3 ..
North America  44,600  44,600  44,600 142.1 142.1 142.1 100
Latin America and the Caribbean  4,900  4,000  7,300 15.1 12.6 22.7 80
Asia  78,600  11,400  99,600 27.7 4.0 35.0 9
Western and Central Europe  7,500  7,500  7,500 23.2 23.2 23.2 100
Eastern and South-Eastern Europe  8,700  8,700  8,700 37.9 37.9 37.9 100
Oceania  1,900  1,600  1,900 77.5 65.3 78.5 75
Global  183,100  95,500  225,900 40.0 20.8 49.3
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studies9). Additionally, it is estimated that in Europe, there 
are 20-25 non-fatal overdose cases to each drug-induced 
death.10 Non-fatal overdose can significantly contribute 
to morbidity, including cerebral hypoxia, pulmonary 
oedema, pneumonia and cardiac arrhythmia, which may 
result in prolonged hospitalization, brain damage and 
disabilities.11
Most overdose cases occur when substances — opioids, for 
example — are mixed with other sedating substances, par-
ticularly alcohol and benzodiazepines (see the box on poly-
drug use). It may also occur when a person has had a short 
period of abstinence (e.g., after incarceration or having 
gone through a short-term episode of detoxification), 
resulting in lowered tolerance, and misjudges the dose.
People who inject drugs, health  
implications and prevention and  
treatment services
Unsafe injecting drug use can have very serious health 
implications due to the high risks of the transmission of 
blood-borne infections such as HIV, as well as hepatitis B 
and hepatitis C, contracted by sharing of contaminated 
injecting equipment. The Joint United Nations Pro-
gramme on HIV/AIDS (UNAIDS) reports that the 
number of new cases of HIV among people who inject 
drugs (PWID) remains high, constituting up to 40 per 
cent of new infections in some countries and resulting in 
a major public health challenge.12 A recent study on the 
global burden of disease from drug dependence estimated 
that in 2010, 1,980,000 years of life were lost in conjunc-
tion with unsafe injecting drug use, through premature 
death as a consequence of HIV infection, and a further 
494,000 years of life were lost worldwide due to hepatitis 
C infection.13
9 B. Sergeev and others, “Prevalence and circumstances of opiate over-
dose among injection drug users in the Russian Federation”, as cited 
in P. Coffin, S. Sherman and M. Curtis, “Underestimated and over-
looked: a global review of drug overdose and overdose prevention”, 
in Global State of Harm Reduction 2010: Key Issues for Broadening 
the Response, C. Cook, ed. (London, International Harm Reduction 
Association, 2010); K. E. Tobin and C. A. Latkin, “The relationship 
between depressive symptoms and nonfatal overdose among a sample 
of drug users in Baltimore, Maryland”, Journal of Urban Health, vol. 
80, No. 2 (2003), pp. 220-229; P. O. Coffin and others, “Identifying 
injection drug users at risk of nonfatal overdose”, Academic Emergency 
Medicine, vol. 14, No. 7 (July 2007), pp. 616-623; S. Darke, J. Ross 
and W. Hall, “Overdose among heroin users in Sydney, Australia: I. 
Prevalence and correlates of non-fatal overdose”, Addiction, vol. 91, 
No. 3 (1996), pp. 405-411; B. Powis and others, “Self-reported over-
dose among injecting drug users in London: extent and nature of the 
problem”, Addiction, vol. 94, No. 4 (1999), pp. 471-478.
10 EMCDDA, Annual Report 2010 (Lisbon, 2010).
11 M. Warner-Smith, S. Darke and C. Day, “Morbidity associated with 
non-fatal heroin overdose”, Addiction, vol. 97, No. 8 (2002), pp. 963-
967.
12 UNAIDS, Global Report: UNAIDS Report on the Global AIDS Epi-
demic 2013 (Geneva, 2013).
13 L. Degenhardt and others, “Global burden of disease attributable 
to illicit drug use and dependence: findings from the Global Burden 
of Disease Study 2010”, The Lancet, vol. 382, No. 9904 (29 August 
2013), pp. 1564-1574.
Knowledge regarding the behaviour and health of people 
who use drugs, in particular among people who inject 
drugs, has expanded over the past decade. There has been 
a considerable effort over the past 10 years to conduct bio-
logical and behavioural surveillance studies specifically 
designed to measure hard-to-reach and hidden key popu-
lations (such as people who inject drugs) in order to esti-
mate the size of those populations and the prevalence of 
infectious diseases, particularly HIV and hepatitis C, 
among them. 
While the number of integrated biological and behavioural 
surveys carried out to date is not precisely known, it has 
been estimated that over the past 10 years (from 2003 to 
2013) between 125 and 200 behavioural surveillance sur-
veys and integrated biological and behavioural surveys 
(which include serological tests for HIV and, in some cases, 
for hepatitis C and syphilis) have been carried out in over 
50 countries.14 
Current estimates are based on the information available 
on the prevalence of injecting drug use in 89 countries 
(compared with 83 countries in the World Drug Report 
2013), representing 83 per cent of the global population 
aged 15-64, and the prevalence of HIV among people who 
inject drugs in 111 countries (compared with 106 coun-
tries in the World Drug Report 2013), representing 92 per 
cent of the estimated global number of people who inject 
drugs. This represents an improvement in data coverage 
compared with what was available previously at the time 
of the published estimates of the former Reference Group 
to the United Nations on HIV and Injecting Drug Use in 
2008, for which the estimate of injecting drug use preva-
lence was based on data from 61 countries. The estimated 
prevalence of HIV among people who inject drugs was 
based on data from 84 countries.
In calculating the 2012 estimates, UNODC, UNAIDS, 
WHO and the World Bank joined forces and reached out 
to a broad group of experts from academia,15 regional, 
international and civil society organizations to ensure that 
the scientific approach to the methodology was used and 
to access the greatest number of data sets available world-
wide on the subject. A combination of methodological 
differences and factors related to data quality makes it a 
challenging task to reliably assess global and regional 
change and trends in the epidemic of injecting drug use 
and HIV among people who inject drugs. 
People who inject drugs
The joint UNODC/WHO/UNAIDS/World Bank global 
estimate for 2012 of the number of people who had recently 
injected drugs was 12.7 million (range: 8.9 million-22.4 
14 E. de Buhr, “Assessment of integrated biological and behavioural 
surveys (IBBS) for key populations”, draft report dated 28 October 
2013.
15 Including all former members of the Reference Group to the United 
Nations on HIV and Injecting Drug Use.
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million), corresponding to a prevalence of 0.27 per cent 
(range: 0.19-0.48 per cent) of the population aged 15-64. 
There are, however, large regional variations in terms of 
data coverage and quality.
The current estimate represents a slight downward revision 
in the global number of people who inject drugs from the 
estimate published in the World Drug Report 2013. How-
ever, this should not be interpreted as an actual decline in 
the number of people who inject drugs worldwide but 
rather as a revision of the estimate, following the first joint 
UNODC/WHO/UNAIDS/World Bank data and meth-
odology review and independent expert consultations con-
ducted at the end of 2013. This led to an updating of 
national estimates on people who inject drugs for 23 coun-
tries, including highly populated countries such as China 
and Indonesia.
By far the highest prevalence of injecting drug use, with a 
rate 4.6 times the global average, is found in Eastern/
South-Eastern Europe, where 1.26 per cent of the popula-
tion aged 15-64 are estimated to have recently injected 
drugs. Within that subregion, notably high rates of inject-
ing drug use are observed for the Russian Federation (2.29 
per cent), the Republic of Moldova (1.23 per cent), Belarus 
(1.11 per cent) and Ukraine (0.88-1.22 per cent). 
In terms of the actual numbers of people who inject drugs, 
three countries (Russian Federation, China and the United 
States) combined account for 46 per cent of the global 
total. 
HIV among people who inject drugs
UNAIDS reports that for the 49 countries for which data 
are available, the prevalence of HIV among people who 
inject drugs is at least 22 times higher than among the 
general population and, in 11 countries, is at least 50 times 
higher.16
The joint UNODC/WHO/UNAIDS/World Bank global 
estimate for 2012 of the number of people who inject 
drugs living with HIV is 1.7 million (range: 0.9 million-4.8 
million), corresponding to an average prevalence of HIV 
among people who inject drugs of 13.1 per cent. 
There are great challenges in collecting data on people who 
inject drugs. They are often hard to reach and difficult to 
sample. Surveys among people who inject drugs might 
capture only people currently injecting drugs, and the 
global estimate of people who inject drugs living with HIV 
may not fully represent the number of people who have a 
lifetime history of injecting drug use and are living with 
HIV but who are not currently injecting drugs.
The current estimate of the prevalence of HIV among 
people who inject drugs has been revised upwards from 
the estimate in the World Drug Report 2013. However, 
since the estimated total number of people who inject 
drugs has been revised downward, the estimated global 
number of people who inject drugs living with HIV 
16 UNAIDS, Global Report: UNAIDS Report on the Global AIDS Epi-
demic 2012 (Geneva, 2012).
Table 3. Estimated number and prevalence (percentage) of people who inject drugs among the  
general population aged 15-64 years, 2012
Source: UNODC annual report questionnaire, progress reports of UNAIDS on the global AIDS response (various years), the former Refer-
ence Group to the United Nations on HIV and Injecting Drug Use, estimates based on UNODC data, and national government reports.
Region Subregion
People who inject drugs
Estimated Number Prevalence (percentage)
Low Best High Low Best High
Africa 300,000 1,020,000 6,240,000 0.05 0.17 1.05
America 2,470,000 3,130,000 3,910,000 0.39 0.49 0.61
North America 1,770,000 2,060,000 2,360,000 0.56 0.66 0.75
Latin America and the  
Caribbean 700,000 1,070,000 1,540,000 0.22 0.33 0.48
Asia 3,480,000 4,650,000 6,190,000 0.12 0.16 0.22
Central Asia and  
Transcaucasia 360,000 410,000 470,000 0.67 0.76 0.87
East and South-East Asia 2,450,000 3,260,000 4,420,000 0.16 0.21 0.28
South-West Asia 390,000 650,000 920,000 0.22 0.37 0.51
Near and Middle East 30,000 70,000 130,000 0.03 0.08 0.13
South Asia 250,000 250,000 260,000 0.03 0.03 0.03
Europe 2,530,000 3,760,000 5,850,000 0.46 0.68 1.06
Eastern and South-Eastern 
Europe 1,800,000 2,900,000 4,750,000 0.78 1.26 2.07
Western and Central 
Europe 740,000 870,000 1,100,000 0.23 0.27 0.34
Oceania 120,000 130,000 160,000 0.49 0.53 0.66
Global 8,910,000 12,690,000 22,350,000 0.19 0.27 0.48
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remains essentially the same. Importantly, the new estimate 
reflects the results of the first joint UNODC/WHO/
UNAIDS/World Bank data and methodology review and 
independent expert consultations conducted at the end of 
2013, which led to updated national estimates for 36 coun-
tries, including the three countries with large populations 
(China, the Russian Federation and the United States).
Two regions stand out as having a very high prevalence of 
HIV among people who inject drugs. In South-West Asia, 
it is estimated that 28.8 per cent of people who inject drugs 
are living with HIV, predominantly reflecting the high 
prevalence of HIV among people who inject drugs in Paki-
stan. In Eastern/South-Eastern Europe, an estimated 23.0 
per cent of people who inject drugs are thought to be living 
with HIV, primarily reflecting the high prevalence observed 
in both the Russian Federation (range: 18.4-30.7 per cent) 
and Ukraine (21.5 per cent).
In terms of the actual number of people who inject drugs 
living with HIV, four countries combined (China, Paki-
stan, the Russian Federation and the United States) account 
for 62 per cent of the global total. 
An examination of the numbers of new cases of HIV diag-
nosed each year among people who inject drugs provides 
insight into changes in the epidemic over time and progress 
towards achieving the target set in the Political Declaration 
on HIV and AIDS adopted by the General Assembly in 
2011 of reducing HIV transmission among people who 
inject drugs by 50 per cent by 2015.17 Although the 
changes in the numbers of newly diagnosed cases may 
reflect improved surveillance, they also reflect changes in 
the transmission of HIV within that most-at-risk group. 
In several European countries18 with a high occurrence of 
newly diagnosed cases (incidence) of HIV among people 
who inject drugs, there was a noticeable peak in the 
number of new cases between 1999 and 2003, indicating 
that the epidemic in the region was greatest in those years 
and subsequently declined. That development is visible 
also in the sharp decline in the number of deaths from 
AIDS attributed to unsafe injecting drug use that occurred 
in later years in the western part of the WHO European 
region,19 with the number of deaths declining from 1,358 
in 2006 to 179 in 201220. During that time period, the 
contribution of unsafe injecting drug use to total AIDS-
related deaths in that region declined from 43 per cent to 
25 per cent. The decline in newly diagnosed HIV cases 
and AIDS-related deaths among people who inject drugs 
are consistent with the scaling-up of the provision of harm 
reduction services, a decline in the prevalence of injecting 
17 Political Declaration on HIV and AIDS: Intensifying Our Efforts 
to Eliminate HIV and AIDS (General Assembly resolution 65/277, 
annex).
18 Countries of Western and Central Europe and Eastern and South-
Eastern Europe.
19 For the list of countries of the European region as defined by WHO 
for the purposes of its work, see www.euro.who.int/en/countries.
20 European Centre for Disease Prevention and Control/WHO Regional 
Office for Europe. HIV/AIDS surveillance in Europe 2012.
Table 4. Estimated number and prevalence (percentage) of HIV among people who inject drugs, 
2012
Source: UNODC annual report questionnaire; progress reports of UNAIDS on the global AIDS response (various years), the former  
Reference Group to the United Nations on HIV and Injecting Drug Use, estimates based on UNODC data, and national government 
reports.
Region Subregion
HIV among people who inject drugs
Estimated number Prevalence 
Best estimate (percentage)Low Best High
Africa 24,000 123,000 2,006,000 12.1
America 197,000 267,000 421,000 8.6
North America 148,000 189,000 254,000 9.2
Latin America and the  
Caribbean 49,000 79,000 167,000 7.4
Asia 331,000 556,000 966,000 12.0
Central Asia and  
Transcaucasia 26,000 31,000 41,000 7.7
East and South-East Asia 196,000 312,000 596,000 9.6
South-West Asia 88,000 188,000 298,000 28.8
Near and Middle East 1,000 3,000 8,000 3.8
South Asia 20,000 21,000 22,000 8.4
Europe 364,000 719,000 1,434,000 19.1
Eastern and South-Eastern 
Europe 320,000 667,000 1,368,000 23.0
Western and Central 
Europe 44,000 52,000 66,000 6.0
Oceania 1,000 1,000 2,000 1.0
Global 917,000 1,667,000 4,828,000 13.1
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and a change in the behaviour of people who inject drugs, 
with less frequent injecting and safer injecting practices 
being observed in many Western European countries.21
There are some exceptions to the general downward trend 
in the number of new HIV cases among people who inject 
drugs in Europe, which demonstrate how the situation 
with regard to the HIV epidemic can change very rapidly. 
Greece (Athens) and Romania recently experienced sig-
nificant increases in HIV cases among people who inject 
drugs. Those outbreaks were related to the increased fre-
quency of injecting associated with a changing pattern of 
injecting, from heroin to cocaine in Greece and to amphet-
amines in Romania, and an increase in the sharing of nee-
dles and syringes.22,23 The European Monitoring Centre 
for Drugs and Drug Addiction (EMCDDA) notes a tem-
poral association between those outbreaks and the low 
levels of harm reduction services in Greece (compared with 
international standards) and Romania.24
Eastern/South-Eastern Europe has very high prevalence 
rates and numbers of people who inject drugs and people 
who inject drugs and are also living with HIV, predomi-
nantly reflecting the situation in the Russian Federation 
and Ukraine. In those two countries, the number of people 
who inject drugs who are newly diagnosed with HIV each 
year continues to be higher than in other countries of the 
region. According to the Russian Federal Research and 
Methodological Centre for Prevention and Control of 
AIDS, the proportion of newly diagnosed cases of HIV 
attributed to injecting drug use was 58.7 per cent in 2009 
and 57.0 per cent in 2013. In Ukraine, the number of 
newly diagnosed cases of HIV among people who inject 
drugs is levelling off at about 6,000-7,000 new cases annu-
ally. In Central Asia, a region with a high prevalence of 
injecting drug use, several countries with a high occurrence 
of newly diagnosed cases (incidence) of HIV among people 
who inject drugs have seen the incidence continue to rise 
over the past decade.25 Very high levels of risky injecting 
behaviour are reported in the region and, although some 
progress has been made in the scaling-up of HIV preven-
tion, treatment and care services for people who inject 
drugs, many obstacles still remain.26
21 L. Wiessing and others, “Trends in HIV and hepatitis C virus infec-
tions among injecting drug users in Europe, 2005 to 2010”, Eurosur-
veillance, vol. 16, No. 48 (2011).
22 EMCDDA, “HIV outbreak among injecting drug users in Greece” 
(Lisbon, November 2012).
23 EMCDDA, “HIV/AIDS among injecting drug users in Romania: 
report of a recent outbreak and initial response policies” (Lisbon, 
2012).
24 EMCDDA and European Centre for Disease Prevention and Con-
trol, “Joint EMCDDA and ECDC rapid risk assessment. HIV in 
injecting drug users in the EU/EEA, following a reported increase of 
cases in Greece and Romania” (Lisbon, January 2012).
25 The initial peak in reported HIV incidence in Central Asia in the 
early 2000s is also in part related to the increase or initiation of HIV 
testing among people who inject drugs.
26 Claire Thorne and others, “Central Asia: hotspot in the worldwide 
HIV epidemic”, Lancet Infectious Diseases, vol. 10, No. 7 (July 2010), 
Fig. 5. Countries with a high occurrence of 
newly diagnosed cases (incidence) of 
HIV among people who inject drugs in 
Europe and Central Asia, 1993-2011
Source: EMCDDA Statistical Bulletin 2013; European Centre for 
Disease Prevention and Control/World Health Organization, table 
INF-104; Federal Scientific and Methodological Center for Preven-
tion and Control of AIDS, Russian Federation; Republican AIDS 
Center, Ministry of Health, Tajikistan.
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South-West Asia has the highest prevalence of HIV among 
people who inject drugs, with Pakistan contributing the 
most to that prevalence rate, as that country has a large 
number of people who inject drugs and a very high preva-
lence of HIV among people who inject drugs (37 per cent). 
In Pakistan, a recent cohort study27 conducted in three 
drop-in centres in Karachi followed 636 HIV-negative 
people who injected drugs over a period of two years 
(between 2009 and 2011). Even though all of those par-
ticipating in the study were attending basic risk reduction 
programmes, the HIV incidence rate among them was 
12.4 per 100 person-years. At the end of the 24-month 
study period, 24.9 per cent of the participants were HIV-
positive. The authors reported that underfunding compro-
mised the quality and quantity of outreach services and 
the full implementation of harm reduction programmes. 
The greatest risk factor for HIV infection was found to be 
the sharing of syringes, for which the risk of infection was 
2.3 times higher than for those who did not share inject-
ing equipment. The authors concluded that the absence 
of opioid substitution therapy and inadequate needle and 
syringe programme coverage undermined the success of 
the HIV harm reduction programmes studied. Other 
countries of South-West Asia might have similarly high 
levels of HIV incidence among people who inject drugs, 
but there is a lack of available data.
pp. 479-488.
27 R. N. Samo and others, “High HIV incidence among persons who 
inject drugs in Pakistan: greater risk with needle sharing and injecting 
frequently among the homeless”, PLOS ONE (16 December 2013).
Hepatitis among people who inject drugs
Hepatitis B and C can lead to liver disease such as cirrho-
sis, liver cancer and death. Hepatitis C is highly prevalent 
among people who inject drugs and is transmitted through 
the sharing of contaminated injecting equipment even 
more easily than is HIV. The first year of injecting is the 
time of greatest risk for hepatitis C infection from sharing 
needles and syringes.28,29 The joint UNODC/WHO/
UNAIDS/World Bank global estimate for 2012 of the 
percentage of people who inject drugs who are living with 
hepatitis C is 52.0 per cent, corresponding to 6.6 million 
people aged 15-64. For 2012, the global estimate of the 
percentage of people who inject drugs living with hepatitis 
B is 6.7 per cent, corresponding to 850,000 people aged 
15-64.
Coverage of services for the prevention 
and treatment of HIV among people who 
inject drugs
Addressing HIV among people who inject drugs is a major 
component of the global response to the spread of HIV. A 
comprehensive package of nine evidence-based interven-
tions, as a component of what are also known as “harm 
reduction” services, for the prevention, treatment and care 
of HIV among people who inject drugs, as outlined in the 
28 P. Vickerman, M. Hickman and A. Judd, “Modelling the impact on 
hepatitis C transmission of reducing syringe sharing: London case 
study”, International Journal of Epidemiology, vol. 36, No. 2 (2007), 
pp. 396-405.
29 A. J. Sutton and others, “Modelling the force of infection for hepa-
titis B, hepatitis C, and HIV in injecting drug users in England and 
Wales”, BMC Infectious Diseases (2006).
Table 5. Overview of the level of provision of harm reduction services
Source: UNODC annual report questionnaire, UNAIDS.
Note: The table provides the classification and level of service provision for HIV testing and counselling, needle and syringe programmes, opioid substi-
tution therapy and antiretroviral therapy among people who inject drugs and those among them living with HIV, according to the Technical Guide; the 
percentage of countries reporting low, medium or high coverage for those services; and the global average level of service provision.
a Based predominantly on behavioural survey data.
Classification of coverage targets
Low Medium High
Less than From - To More than
40% 40 - 75% 75%
20% 20 - 60% 60%
100 100 - 200 200
20% 20 - 40% 40%
25% 25 - 75% 75%
Response at the global level
Countries reporting low, 
medium or high coverage  
(percentage)
Number 
of  
countries 
reporting
Global 
median 
value
Low Medium High
Percentage of people who inject 
drugs who were tested for HIV in 
the last 12 months and who know  
the results
31% 29% 40% 83 36%a
Percentage of all people who inject 
drugs who were reached by a 
needle and syringe programme over 
the last 12 months
49% 25% 26% 85
Number of needles-syringes distrib-
uted per person who injects drugs 
per year
62% 20% 18% 55 74
Percentage of opioid-dependent 
people who inject drugs on opioid 
substitution therapy
35% 32% 33% 79
Percentage of all HIV positive people 
who inject drugs receiving antiretro-
viral therapy at a specified date
32% 31% 37% 74
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Note: The boundaries and names shown and the designations used on this map do not imply official endorsement or acceptance by the United Nations.
Dashed lines represent undetermined boundaries. Dotted line represents approximately the Line of Control in Jammu and Kashmir agreed upon by India and Pakistan. The final status of Jammu and Kashmir has not yet been agreed upon by the parties.
The final boundary between the Republic of Sudan and the Republic of South Sudan has not yet been determined.
Opioid substitution therapy
G high
G medium
G low
Antiretroviral therapy
high
medium
low
no ART services
Needle and syringe programmes
high
medium
low
Service exists, but coverage not known
no NSP services
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
WHO, UNODC, UNAIDS Technical Guide30 (referred to 
hereafter as the Technical Guide) has been widely endorsed 
by high-level political bodies including the General Assem-
bly, the Economic and Social Council, the Commission 
on Narcotic Drugs and the Programme Coordinating 
Board of UNAIDS. In addition, donor agencies, including 
the Global Fund to Fight AIDS, Tuberculosis and Malaria 
(GFATM) and the United States President’s Emergency 
Plan for AIDS Relief (PEPFAR) have committed to using 
that framework. 
In order of priority, the four most important interventions 
are needle and syringe programmes, opioid substitution 
therapy, HIV testing and counselling, and antiretroviral 
therapy.31
National estimates of the level of service coverage in the 
community (the extent to which people who inject drugs 
30 WHO, UNODC, UNAIDS Technical Guide for Countries to Set Targets 
for Universal Access to HIV Prevention, Treatment and Care for Injecting 
Drug Users: 2012 Revision (Geneva, WHO, 2012).
31 Ibid.
actually receive the intervention) and the distribution of 
needles and syringes are presented using a classification of 
“low”, “medium” or “high” as defined according to the 
targets set in the Technical Guide.
In most countries, the extent of services provided to people 
who inject drugs falls below the lower-level targets pre-
sented in the Technical Guide. However, global estimates 
mask important regional variations.
The coverage of services is highest in Western and Central 
Europe, with 50-60 per cent of reporting countries indi-
cating that a high proportion of people who inject drugs 
are accessing needle and syringe programmes, opioid sub-
stitution therapy, HIV testing and counselling and antiret-
roviral therapy services. In Eastern/South-Eastern Europe, 
despite the increase in service availability in some countries, 
access to needle and syringe programmes in particular 
remains low. In North America, none of the countries 
report a high level of access of people who inject drugs 
to any of the services, with needle and syringe programmes 
consistently reaching only a low proportion of people 
who inject drugs. In Latin America (no countries from the 
Map 1. Service coverage for people who inject drugs and those among them living with HIV,  
classified according to the Technical Guide
Source: UNODC annual report questionnaire, UNAIDS and the former Reference Group to the United Nations on HIV and Injecting Drug 
Use.
Note: In reporting on the level of service coverage via the annual report questionnaire, Member States have the option of categorizing the level of  
service coverage as “not applicable”. That response has been interpreted as meaning that there is no service coverage. For some countries the level of 
service coverage for needle and syringe programmes is not known, but the service is known to exist in that country. However, the scale of provision of 
needle and syringe programmes in those cases can vary substantially.
The boundaries shown on this map do not imply official endorsement or acceptance by the United Nations. Dashed lines represent undetermined 
boundaries. Dotted line represents approximately the Line of Control in Jammu and Kashmir agreed upon by India and Pakistan. The final status  
of Jammu and Kashmir has not yet been agreed upon by the parties. The final boundary between the Sudan and South Sudan has not yet been  
determined.
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Caribbean reported information), the two overall most 
important interventions (needle and syringe programmes 
and opioid substitution therapy) are generally reaching 
only low numbers of people who inject drugs. It should be 
noted that in Latin American countries, the prevalence of 
use of opiates is very low and therefore, in reporting by 
countries, opioid substitution therapy would not be indi-
cated as relevant. Also six of the seven Latin American 
countries reporting through the annual report question-
naire indicated that needle and syringe programmes were 
“not applicable”, reflecting that the practice of injecting 
drugs is at a low level. In Central Asia and Transcaucasia, 
a region with a high prevalence of injecting drug use, only 
two countries indicate a high level of HIV testing and 
counselling, and access to needle and syringe programmes, 
and overall low levels of access to opioid substitution ther-
apy. In East and South-East Asia, a region with a large 
number of people who inject drugs and, among them, a 
significant number of people living with HIV, 50 per cent 
of the countries reporting indicate a high level of HIV test-
ing and counselling among people who inject drugs. How-
ever, needle and syringe programmes are not reaching many 
people who inject drugs in many countries in the region. 
South-West Asia has the highest prevalence of HIV among 
people who inject drugs, but no country in the region 
reported a high level of coverage for any of the services.
In the 16 countries32 that have the highest prevalence of 
people who inject drugs and the highest prevalence of HIV 
32 Belarus, Canada, Georgia, Indonesia, Kazakhstan, Latvia, Malaysia, 
Myanmar, Pakistan, Republic of Moldova, Russian Federation, Spain, 
Tajikistan, Thailand, Ukraine and United States. Other countries 
which have higher prevalence rates may not be included in this list 
due to lack of reporting of service provision data.
among people who inject drugs — which account for 45 
per cent of the global number of people who inject drugs 
and 66 per cent of the global number of people who inject 
drugs living with HIV — a generally low level of service 
provision can be noted, particularly with regard to needle 
and syringe programmes and opioid substitution 
therapy.
Drug use among prisoners and  
implications for health
It is estimated that worldwide, on any single day, there are 
more than 10.2 million people held in prisons (including 
pretrial detention), with the numbers growing in every 
continent.33 However, prison population rates differ con-
siderably from region to region and between different parts 
of the same continent.34 Many of those held are incarcer-
ated for offences related to the use, possession or supply 
of drugs.
Drug use and injecting drug use are both highly prevalent 
among prison populations, often more so than among the 
general population. EMCDDA reports that the propor-
tion of prisoners who had used an illicit substance during 
incarceration in individual countries in Europe (mostly 
Western and Central Europe) ranged from 4 to 56 per 
33 Roy Walmsley, “World Prison Population List” 10th ed. (London, 
International Centre for Prison Studies).
34 The World Prison Population List (10th ed.) indicates that the median 
prison population rate per 100,000 for West African countries is 46; 
Southern African countries: 205; North American countries: United 
States: 716, Canada: 118; South American countries: 202; Caribbean 
countries: 376; South/Central Asian countries (mainly the Indian 
subcontinent): 62, East Asian countries: 160; Western European 
countries: 98; countries spanning Europe and Asia (e.g., Russian 
Federation and Turkey): 225; and Oceania: 151.
Fig. 6. Levels of service provision for countries with the highest prevalence rates (among those  
reporting on service provision) of injecting drug use and HIV among people who inject drugs
Source: UNODC annual report questionnaire, UNAIDS.
Note: In reporting on the level of service coverage via the annual report questionnaire, Member States have the option of categorizing the level of  
service coverage as “not applicable”. That response has been interpreted as meaning that there is no service coverage. 16 countries have been 
assessed for this figure.
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cent, with 11 countries reporting levels of 20 per cent or 
higher. Further, countries reported proportions of prison-
ers who had injected drugs while incarcerated ranging from 
0.7 to 31 per cent, with seven countries reporting rates of 
injecting drug use of 7 per cent or higher.35
35 EMCDDA, Statistical Bulletin 2013. Tables DUP-3 and DUP-4.
Several studies document that a very high percentage 
(56-90 per cent) of people who inject drugs report a his-
tory of imprisonment since starting injecting.36 An over-
view of HIV in prisons in all regions identified rates of 
infection many times higher than among the general popu-
36 WHO, UNODC and UNAIDS, Effectiveness of Interventions to 
Address HIV in Prisons, Evidence for Action Technical Papers (Geneva, 
WHO, 2007).
Global Burden of Disease Study 2010: Estimating the burden of disease 
from drug dependence
Illicit drug use can have a profoundly negative effect on a person’s health. It can lead to premature death, such as in the 
case of overdose, but can also severely curtail the quality of life through disability (any short-term or long-term health 
loss), such as from liver disease, or infection with HIV and hepatitis B and C as a result of sharing contaminated needles 
and syringes.1
These effects can be quantified in an indicator called “disability-adjusted life year” (DALY), which encompasses both the 
years of potential life lost due to premature death (YLL) and the years of life lived with disability (YLD). A recent study 
published by Degenhardt and others (2013)2 produced global estimates of disability-adjusted life years for illicit drug 
dependence3, and drug use as a risk factor for other health outcomes (schizophrenia from cannabis use, hepatitis and 
HIV from injecting drug use, and drug dependence as a risk factor for suicide).
The findings of that study reveal that in 2010, drug dependence on illicit drugs was responsible for 3.6 million years of 
life lost through premature death and 16.4 million years of life lived with disability globally. Combined, this is equal to 
20 million years of disability-adjusted life years (representing 0.8 per cent of global all-cause disability-adjusted life years), 
an increase from 13.1 million years estimated for 1990. Opioid dependence contributed most to the burden of disease, 
being responsible for 55 per cent of years of life lost due to premature death and 44 per cent of years of life lost through 
disability. The increase in the global burden of disease from cannabis, amphetamine and cocaine dependence between 
1990 and 2010 is essentially attributable to population growth, but this is not the case for opioid dependence. The 
burden of disease from opioid dependence increased by 74 per cent between 1990 and 2010, with 42 per cent of that 
increase attributable to an increase in the prevalence of opioid dependence. According to UNODC data, the prevalence 
of opioid use has been increasing globally over the past five years as a consequence of the increased misuse of prescription 
opioids, whereas the prevalence of opiate (heroin and opium) use has been stable at the global level and declining in some 
regions such as Europe. A total of 43,000 deaths were attributed to opioid dependence in 2010, which suggests that life 
expectancy was typically cut short by 46 years in each of those cases of death. The global burden of disease attributed to 
cannabis dependency is higher than that for cocaine. Although cocaine use is associated with greater harm, the far higher 
number of cannabis-dependent users results in the greater global burden of disease overall. Broadly speaking, males 
contribute two thirds of the number of years of life lost and years lived with disability for all drug types. Disability-
adjusted life years rose sharply between the ages of 15-24, reaching a peak in the relatively young 20-30 age group, 
consistently across all drug types. Illicit drug use was estimated to be the cause of 0.8 per cent of disability-adjusted life 
years worldwide in 2010 (ranking as the 19th leading risk factor). In comparison, tobacco smoking was the cause of an 
estimated 6.3 per cent of global disability-adjusted life years, and alcohol the cause of an estimated 3.9 per cent. However, 
for drug use, disability-adjusted life years reach a peak among users aged 20-30 years, and among that age group it con-
tributes a higher proportion to the burden of disease.
The burden of disease from acquiring HIV through injecting drug use was estimated to be 2.1 million years in 2010, of 
which 2.0 million were from years of life lost through premature death. The burden of disease from hepatitis C acquired 
through injecting drug use is also high and was estimated to be responsible for 494,000 years of life lost in 2010 through 
premature death.
1 WHO, Neuroscience of psychoactive substance use and dependence (Geneva, 2004).
2 L. Degenhardt and others, “Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease 
Study 2010”.
3 Defined as the presence of three or more indicators of dependence for at least a month within the previous year. These indicators consist of a 
strong desire to take the substance, impaired control over use, a withdrawal syndrome on ceasing or reducing use, tolerance to the effects of the 
drug, the need for larger doses to achieve the desired psychological effect, a disproportionate amount of time spent by the user obtaining, using 
and recovering from drug use, and persistence of drug taking despite the problems that occur.
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lation.37 A study that compiled information on HIV preva-
lence in prisons for 75 low-income and middle-income 
countries found rates greater than 10 per cent in 20 of 
those countries.38 The situation is of particular concern in 
37 Ibid.
38 K. Dolan and others, “HIV in prison in low-income and middle-
income countries, The Lancet Infectious Diseases, vol.7; No. 1 (2007), 
pp. 32-41.
women’s prisons. Although there are fewer women in 
prison, both drug use and HIV infection are more preva-
lent among women in prison than among imprisoned 
men.39
Although the availability of data is limited, there is a high 
level of illicit substance use in prisons, in particular the 
regular use of opioids40. Injecting drugs is also a common 
practice. This is of concern because the prison environment 
is one in which there are limited prevention and treatment 
options for dealing with drug dependence and its associ-
ated health consequences.
The lack of access to and availability of health care, espe-
cially drug dependence treatment and HIV prevention and 
care services, in prisons is of major concern, since the 
prison population, at a minimum, should have access to 
these services to an extent equivalent to those available to 
the community outside. 
C. REGIONAL TRENDS IN DRUG USE
Africa
Reliable and comprehensive information on the drug situ-
ation in Africa is not available. The limited data available 
suggest, however, that cannabis use, notably in West and 
Central Africa (about 12.4 per cent) is probably higher 
than the global average (3.8 per cent). The prevalence of 
use of other substances — except for cocaine, which 
remains at the global average — is low overall in Africa. A 
recent survey conducted in Cabo Verde in 201241 found 
39 UNODC/UNAIDS, “Women and HIV in prison settings”.
40 For details see annex on drug use in prisons.
41 National inquiry on the prevalence of psychoactive substance abuse 
Fig. 7. Prevalence of drug use, injecting drug 
use and HIV infection among prisoners
Source: UNODC annual report questionnaire, EMCDDA and 
national government reports.
Note: Data are available for only a limited number of countries, mostly 
from Western and Central Europe. The countries included in each cat-
egory vary.
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that 7.6 per cent of the population had used an illicit sub-
stance at least once in their lifetime, 2.7 per cent had used 
an illicit substance in the past year and 1.6 per cent in the 
past 30 days. Cannabis was the most popular drug (2.4 
per cent reporting use in the past year) followed by cocaine 
(0.2 per cent annual prevalence). The survey also reported 
common use of a “cocktail” containing crack cocaine and 
cannabis. ATS use, although at low levels (0.1 per cent 
lifetime prevalence), seems to be emerging.
In Nigeria, the expert perception is that there has been a 
large increase in the use of cannabis, with some increase 
in the use of ATS.42 According to the national survey on 
alcohol and drug use in Nigeria conducted in 2009, aside 
from alcohol, the non-medical use of tranquillizers had the 
highest annual prevalence (5.5 per cent) among the popu-
lation aged 15-64 years. The misuse of prescription opioids 
was also reported to be high and more prevalent than the 
use of heroin (3.6 per cent annual prevalence of other opi-
oids, and 2.2 per cent annual prevalence of heroin). 
High levels of use of other substances were also reported, 
with annual prevalence as follows: cannabis, 2.6 per cent; 
amphetamine, 1 per cent; methamphetamine, 1.6 per cent; 
“ecstasy”, 1.7 per cent; cocaine, 1.6 per cent; and crack, 2 
per cent. The prevalence in the last year of people inject-
ing drugs was reported as 1.9 per cent.43
In South Africa, expert perception is that there is some 
increase in the use of heroin and methamphetamine and 
some decrease in the use of crack cocaine (with use of other 
drugs being stable).44 Treatment facilities report that can-
nabis remains the most common illicit substance used, 
particularly among young people. Almost half of the admis-
sions at specialist treatment centres were primarily related 
to cannabis use disorders. Polydrug use appears to be a 
common phenomenon among drug users in treatment.45
Americas
With the exception of opiate use, use of all other groups 
of substances (cannabis, opioids, cocaine, ATS and 
“ecstasy”) remains at levels higher than the global average 
in the region. 
North America
In the United States, past-year illicit drug use by persons 
aged 12 years or older reached the highest level in the past 
among the general population, conducted by the Ministry of Jus-
tice of Cabo Verde, published in April 2013, in collaboration with 
UNODC.
42 UNODC, annual report questionnaire replies submitted by Nigeria 
for 2012.
43  Federal Neuropsychiatric Hospital, Aro, Substance Abuse in Perspec-
tive in Nigeria 2009: National Survey on Alcohol and Drug Use in 
Nigeria 2012, Nigeria.
44 UNODC, annual report questionnaire replies submitted by South 
Africa for 2012.
45 Siphokazi Dada and others, “Alcohol and drug abuse trends”, update, 
June 2013 (Cape Town, South Africa, South African Community 
Epidemiology Network on Drug Use, 2013).
10 years, increasing from 14.9 per cent in 2011 to 16.0 
per cent in 2012. That overall increase in drug use, led 
mainly by the increase in cannabis use, is considered to be 
linked with lower risk perceptions of cannabis use, espe-
cially among young people.46 The use of cannabis rose 
from 11.5 per cent to 12.1 per cent and the non-medical 
use of psychotherapeutic drugs, particularly prescription 
opioids, rose from 5.7 per cent to 6.4 per cent after declin-
ing in 2011. In 2012, use of cocaine also increased slightly 
among the adult population but remained stable or 
declined among youth.47 In 2012, drug use was reported 
to be the highest among those in their late teens or twen-
ties, while drug use among older adults, e.g., among those 
in their fifties, was also increasing, partly due to the ageing 
cohort of “baby boomers”, whose levels of drug use have 
been higher than those of previous cohorts.48 
However, past-year use of any illicit substance declined 
from 19.0 per cent in 2011 to 17.9 per cent in 2012 among 
the youth population aged 12-17 years, reaching the lowest 
level in the previous 10 years. From 2011 to 2012, past-
year and past-month use of almost all drug types declined 
46 United States, Department of Health and Human Services, Sub-
stance Abuse and Mental Health Services Administration, Center for 
Behavioral Health Statistics and Quality, The NSDUH Report: Trends 
in Adolescent Substance Use and Perception of Risk from Substance Use 
(Rockville, Maryland, 2013).
47 United States, Department of Health and Human Services, Substance 
Abuse and Mental Health Services Administration, Results from the 
2012 National Survey on Drug Use and Health: Detailed Tables (Rock-
ville, Maryland, 2013), table 7.2B.
48 Ibid., Summary of National Findings, NSDUH Series H-46, HHS 
Publication No. SMA 13-4795 (Rockville, Maryland, 2013).
Fig. 8. Prevalence of drug use in the United 
States, 2002-2012
Source: Substance Abuse and Mental Health Services Administra-
tion, Results from the 2012 National Survey on Drug Use and 
Health: Summary of National Findings, NSDUH Series H-46, HHS 
Publication No. (SMA) 13-4795. Rockville, MD: Substance Abuse 
and Mental Health Services Administration, 2013.
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or remained stable among the 12-17 years age group.49
In the United States, the increasing non-medical use of 
pain relievers (prescription opioids) is also reflected in the 
continuing increase in the percentage of treatment admis-
sions for opiates other than heroin,50 which now surpass 
treatment admissions for cocaine and methampheta-
mine.51 The number of deaths resulting from prescription 
painkiller overdose also continues to rise, especially among 
women.52 However, increases in heroin-related overdose 
deaths in the United States have also been reported (see 
“The interplay between illicit and pharmaceutical opioid 
use”). In addition, medical emergencies related to the non-
medical use of pharmaceuticals increased 132 per cent over 
the period 2004-2011, with the number of medical emer-
gencies involving opiates and/or opioids rising 183 per 
cent.53
In Canada, however, past-year use of cannabis in 2012 
among the population aged 15 years or older remained 
unchanged from the previous year, while there was an 
increase in cannabis use among those aged 25 years or 
older: from 6.7 per cent in 2011 to 8.4 per cent in 2012. 
Past-year use of other illicit substances was estimated at 
about 1 per cent, and no changes were observed in the 
prevalence of those substances in the short term (2011-
2012) or the long term (2004-2012).54
Latin America and the Caribbean
In South and Central America and the Caribbean, use of 
cocaine remains high, especially in South America, where 
cocaine use is currently at levels comparable to high-prev-
alence regions. With the exception of ATS, the use of other 
illicit substances remains low in the subregion.
According to a recent survey conducted among university 
students in the four Andean countries, the annual preva-
lence of cannabis use ranged between 15.2 per cent in 
Colombia and 3.6 per cent in the Plurinational State of 
Bolivia. Cocaine use was high in Colombia (2.2 per cent) 
compared with 1.1 per cent in Ecuador, 0.5 per cent in 
49 Ibid., Detailed Tables, tables 7.5B and 7.6B.
50 The category “opiates other than heroin” includes non-prescription 
methadone, buprenorphine, codeine, hydrocodone, hydromorphone, 
meperidine, morphine, opium, oxycodone, pentazocine, propoxy-
phene, tramadol and any other drug with morphine-like effects.
51 United States, Department of Health and Human Services, Sub-
stance Abuse and Mental Health Services Administration, Center 
for Behavioral Health Statistics and Quality, Treatment Episode Data 
Set (TEDS): 2001-2011. National Admissions to Substance Abuse 
Treatment Services, BHSIS Series S-65, HHS Publication No. SMA 
13-4772 (Rockville, Maryland, 2013).
52 Centers for Disease Control and Prevention, “Prescription painkiller 
overdoses: a growing epidemic, especially among women”, 3 July 
2013.
53 United States, Department of Health and Human Services, Substance 
Abuse and Mental Health Services Administration, Drug Abuse Warn-
ing Network, 2011: National Estimates of Drug-Related Emergency 
Department Visits, DAWN Series D-39, HHS Publication No. SMA 
13-4760 (Rockville, Maryland, 2013).
54 Health Canada, Canadian Alcohol and Drug Use Monitoring Survey: 
summary of results for 2012; available from www.hc-sc.gc.ca.
Peru, and 0.3 per cent in the Plurinational State of Bolivia. 
ATS prevalence was reported at 0.9 per cent in Colombia, 
0.7 per cent in Ecuador and 0.5 per cent in Peru. Com-
paring the trends between 2009 and 2012, among students 
in the four countries there has been an overall increase in 
cannabis use (from 4.8 per cent in 2009 to 7.9 per cent in 
2012), a small increase in the use of ATS and stable trends 
with regard to cocaine use. A major finding of the survey 
was the high prevalence of use of lysergic acid diethylamide 
(LSD) among university students, which increased from 
0.2 per cent in 2009 to 0.95 per cent in 2012.55 LSD use 
was reported as being particularly high among students in 
Colombia.56
Asia
Reliable prevalence estimates are available for only a few 
countries in Asia. Those data suggest that consumption of 
illicit drugs is at levels similar to or below the global aver-
age. Tentative estimates suggest that cannabis is the most 
common illicit substance, with an annual prevalence of 
use of 1.9 per cent among those aged 15-64 years, followed 
by ATS (excluding “ecstasy”) at 0.7 per cent, “ecstasy” at 
0.4 per cent, opiates at 0.35 per cent and cocaine at 0.05 
per cent. As reported by experts, the use of methampheta-
mine continues to rise in most countries in East and South-
East Asia, with accompanying seizures of methamphetamine 
in pill and crystalline forms reaching record levels in 2012. 
“Ecstasy” use seems to be staging a comeback, while use 
of new psychoactive substances is on the rise.57
In the absence of reliable survey data, national experts have 
indicated that in East and South-East Asia, the use of ATS 
has both increased and diversified. ATS have been ranked 
among the three drug types most used in countries in the 
subregion since 2009. 
Methamphetamine pills are predominantly used in coun-
tries such as Cambodia, the Lao People’s Democratic 
Republic, Myanmar, Thailand and Viet Nam, whereas 
crystalline methamphetamine is the primary drug of con-
cern in Brunei Darussalam, Cambodia, Indonesia, Japan, 
the Philippines and the Republic of Korea.58 There has 
also been a resurgence in the “ecstasy” market, with 
increased use in 2012 being reported by experts in a 
number of countries following a decline for several years. 
55 Comunidad Andina, II Estudio Epidemiológico Andino sobre Consumo 
de Drogas en la Población Universitaria, Informe Regional 2012 (Lima, 
2013).
56 The Colombian forensic experts of the Attorney General’s Office ana-
lysed samples of substances sold as LSD, following a reported increase 
in its use and unusual health effects reported by users. The results 
from samples obtained in three major cities of Colombia revealed 
that substances sold as LSD did not contain such substance but rather 
the synthetic phenethylamines 25B-NBOMe and 25C-NBOMe 
(reported in UNODC, Global SMART Update 2013, vol. 10, Sep-
tember 2013).
57 UNODC, Global SMART Update 2013, Patterns and Trends of 
Amphetamine-Type Stimulants and Other Drugs: Challenges for Asia 
and the Pacific (Vienna, November 2013).
58 Ibid.
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“Ecstasy” seizures more than tripled in 2012 compared 
with the previous year. The new psychoactive substances 
market is also growing rapidly in the subregion. Ketamine 
use has been long-standing in the region. Its use is consid-
ered to be stabilizing, while kratom continues to be used 
as a traditional stimulant in Malaysia, Myanmar and Thai-
land. The use of synthetic cannabinoids has also been 
reported in China, Indonesia, Japan, the Republic of Korea 
and Singapore.59
Experts from China report a stable situation with regard 
to the consumption of cannabis, cocaine, and tranquilliz-
ers and sedatives. However, the number of registered drug 
users continued to increase. Opioid use remains high in 
China, with 1.272 million opioid users registered by the 
end of 2012, compared with 1.18 million in 2011.60 The 
proportion of heroin users among registered drug users 
(59 per cent of users) decreased in 2012, as the number of 
registered synthetic drug users increased more than heroin 
users, especially because, as reported by the experts, there 
has been a large increase in the use of methamphetamine.61 
Moreover, recent estimates of people who inject drugs — 
primarily heroin — are lower than previous estimates. The 
estimated prevalence of people who inject drugs in China, 
at 0.19 per cent in 2012, is less than the estimate of 0.25 
per cent for 2005.62
59 Ibid.
60 China, National Narcotics Control Commission, Annual Report on 
Drug Control in China 2013 (Beijing, 2013).
61 UNODC, annual report questionnaire replies submitted by China for 
2012.
62 China National Centre for AIDS/STD Control and Prevention, 2012.
Compared with East and South-East Asia, South-West and 
Central Asia are marked by high prevalence of opiate use, 
with an accompanying high prevalence of people who 
inject drugs and who are living with HIV: 28.8 per cent 
in South-West Asia and 7.7 per cent in Central Asia. The 
prevalence of opiate use in Afghanistan, Iran (Islamic 
Republic of ) and Pakistan is among the highest globally 
(average of 1.5 per cent of the adult population in the three 
countries), whereas it is 0.8 per cent in Central Asia — 
twice the global average.
Europe
In Europe, cannabis is by far the most commonly con-
sumed illicit substance, with an estimated 24 million past-
year users (4.3 per cent of those aged 15-64), followed by 
cocaine with 3.7 million past-year users (0.7 per cent of 
those aged 15-64). The use of opioids and opiates is com-
parable to global average levels. ATS (excluding “ecstasy”) 
are consumed at a level little below the global average, but 
the use of “ecstasy” is higher, with an annual prevalence of 
0.5 per cent compared with the global average of 0.4 per 
cent. Illicit drug consumption patterns are quite different 
between the two subregions in Europe. The use of cannabis 
and cocaine is much higher in Western and Central 
Europe, whereas the consumption of opioids and opiates 
is much higher in Eastern and South-Eastern Europe.
Western and Central Europe
In Western and Central Europe, although cannabis use 
remains high (5.7 per cent annual prevalence), there is 
evidence of trends of decreasing use, especially in countries 
with long and established cannabis use.63 The recent 
household surveys in Poland and Italy show substantially 
lower prevalence of cannabis use than previously reported, 
which can also be ascribed to methodological differences 
in those two most recent surveys.64 There is also an 
increasing diversity in the types of cannabis products 
available, especially high-potency herbal cannabis and the 
synthetic cannabis-like products that are emerging in the 
subregion.65
Cocaine consumption in Western and Central Europe 
remains high, at 1 per cent of the adult population. How-
ever, countries with high levels of use, e.g., Denmark, Italy, 
Spain and the United Kingdom of Great Britain and 
Northern Ireland, report a declining trend in cocaine use 
as well as in treatment demand.66
The past-year use of opioids, mainly heroin, is estimated 
as 0.4 per cent of the population aged 15-64. However, in 
Western and Central Europe, other opioids such as 
buprenorphine, fentanyl and methadone are available in 
the illicit markets, with reports that heroin has been 
63 EMCDDA, European Drug Report: Trends and Developments 2013.
64 Use of cannabis in Italy was reported as 14.6 per cent in 2009 and 4 
per cent in 2011, while in Poland cannabis use was reported as 9.6 
per cent in 2010 and 3.8 per cent in 2012.
65 EMCDDA, European Drug Report: Trends and Developments 2013.
66 Ibid.
Fig. 9. Trends in registered drug users and 
proportion of registered drug users by 
drug type in China, 2000 - 2012 
Source:Information provided by China in the UNODC annual 
report questionnaire and the annual reports on drug control in 
China published by the Office of the National Narcotics Control 
Commission. 
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17C. Regional trends in drug use
replaced with fentanyl and buprenorphine in some coun-
tries.67 Overall, most countries in the subregion report 
declining trends in the use of heroin. The number of heroin 
users entering treatment for the first time has also been 
declining, resulting in an ageing cohort of heroin users 
currently in treatment. Injecting heroin, a common prac-
tice, has also been declining. Coupled with other interven-
tions, this is likely to have contributed to the decline in 
the number of new HIV infections among heroin users 
who inject drugs.68
Amphetamine and “ecstasy” remain the most commonly 
used synthetic stimulants in the subregion, with an annual 
prevalence of use of 0.6 per cent and 0.5 per cent of the 
adult population respectively. Injecting amphetamine con-
tinues to be seen as common among chronic drug-use 
populations. While amphetamine use has been stabilizing 
in parts of the subregion, there are concerns that it is being 
displaced by methamphetamine, given the increasing avail-
ability of methamphetamine in some markets.69
Eastern and South-Eastern Europe
The main concern in Eastern and South-Eastern Europe 
is the high level of consumption of opioids, notably opi-
ates, with annual prevalence rates of 1.2 per cent and 0.8 
per cent, respectively. “Ecstasy” use is also above global 
average levels, with an annual prevalence of 0.6 per cent. 
The subregion is also marked by having one of the highest 
prevalence rates of people who inject drugs, as well as a 
high prevalence of people who inject drugs living with 
HIV. In two countries with high rates of opiate consump-
tion, Belarus and Ukraine, experts perceive a significant 
increase in the use of opiates, with Belarus also reporting 
67 Ibid.
68 Ibid.
69 Ibid.
a significant increase in the use of opium. Heroin use is 
reported as stable in Ukraine, and there is an increase in 
the use of ATS in the country.70
The Russian Federation has the highest prevalence of 
opiate use in the subregion. However, heroin use is report-
edly being replaced by cheaper and more readily available 
prescription or over-the-counter preparations containing 
opioids.71 The use of ATS, synthetic opioids and synthetic 
cannabinoids is also perceived to be increasing, particularly 
among the youth population.72
Oceania
Drug use information in Oceania is limited to Australia 
and New Zealand. No new data are available for 2012. 
The region has high levels of use of most substances: can-
nabis, 10.8 per cent; synthetic opioids, 3.0 per cent; 
cocaine, 1.5 per cent; ATS, 2.1 per cent; and “ecstasy”, 2.9 
per cent. 
In Australia, expert opinion points to an increase in the 
consumption of cannabis, cocaine, hallucinogens, and sol-
vents and inhalants, but a decline in the use of “ecstasy”. 
There is a wide range of drug analogues and new psycho-
active substances that are currently available in the Austral-
ian illicit drug market.73
In New Zealand, experts have reported that there has been 
an increase in the use of heroin, pharmaceutical opioids, 
prescription stimulants and synthetic cannabinoids. There 
has also been a diversification of new drugs available in a 
wide variety of forms: a range of synthetic drugs sold under 
the broad product name “ecstasy”, a large number of new 
synthetic cannabinoids and new analogues of existing con-
trolled drugs and so-called “research chemicals”.74
Drug use and the financial crisis in Europe
The global financial crisis had, and continues to have, sig-
nificant effects on joblessness and income inequality, as 
well as physical and mental well-being.75,76,77,78 Although 
70 UNODC, annual report questionnaire, replies submitted by Belarus 
and Ukraine for 2012.
71 UNODC, annual report questionnaire, replies submitted by the Rus-
sian Federation for 2012.
72 Ibid.
73 UNODC, annual report questionnaire, replies submitted by Australia 
for 2012.
74 UNODC, annual report questionnaire, replies submitted by New 
Zealand.
75 WHO, “Summary: Health, health systems and economic crisis in 
Europe, impact and policy implications” (Geneva, 2013).
76 Alexander Kentikelenis and others, “Health effects of financial crisis: 
omens of a Greek tragedy”, The Lancet, vol. 378, No. 9801 (October 
2011), pp. 1457-1458.
77 Shu-Sen Chang and others, “Impact of the 2008 global economic 
crisis on suicide: time trend study in 54 countries”, BMJ, vol. 17, No. 
347 (September 2013).
78 Margalida Gili and others, “The mental health risks of economic 
crisis in Spain: evidence from primary care centres, 2006 and 2010”, 
European Journal of Public Health, vol. 23, No. 1 (February 2013), pp. 
103-108.
Fig. 10. Trends in drug use in England and 
Wales, 2003/04-2012/13
Source: United Kingdom, Home Office, “Drug misuse: findings 
from the 2012/13 Crime Survey for England and Wales” (London, 
July 2013).
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European economies are recovering,79 reductions in health 
services related to austerity measures have been observed, 
with 15 out of 19 countries in Europe reporting cuts to 
drug-related budgets ranging between 2 and 44 per cent.80 
79 European Commission, European Economic Forecast: Winter 2014 
(Brussels, 2014).
80 Claudia Costa Storti and others, “Economic recession, drug use and 
public health”, International Journal of Drug Policy, vol. 22, No. 5 
Data are not yet available to explore the comprehensive 
impact of the crisis on drug markets, but early information 
describes two phenomena that have developed in parallel 
to the crisis: first, the reduction of services provided as a 
result of decreased funding, and second, a shift from more 
expensive to cheaper drugs (see below), and increased risk 
of harm due to the use of substances that require more 
(September 2011), pp. 321-325.
The “dark net”, bitcoins and the increasing sophistication of online drug sales
The online marketplace for illicit drugs is becoming larger 
and more brazen, now capitalizing on technological 
advancements in private web transactions and virtual 
online currency to protect the identities of suppliers, con-
sumers and website administrators. Buyers and sellers are 
connecting online via “dark net” sites1 and most often, 
traffic drugs directly through the postal service. UNODC 
global seizure data indicate that over the past decade, there 
was a 300 per cent increase in cannabis seizures obtained 
through the postal service between 2000 and 2011, the 
majority of which are coming from seizures reported from 
countries in Europe and the Americas.2 
The “dark net” cannot be accessed through traditional web 
searches; it requires logging in through a web proxy, such 
as to a Tor3 network, which connects to another location 
in the network, ensuring that the Internet Protocol (IP) 
address is not visible on either side of the transaction. 
These websites do not function as stores per se but work 
in a manner similar to eBay,4 where users and buyers can 
connect and are provided a venue to manage transactions 
and track fraudulent sales. Transactions are mostly con-
ducted using the online peer-to-peer currency “bitcoin”, 
which remains in escrow, until it is transferred to the seller 
once the product is satisfactorily delivered. At the time of 
this writing, 1 bitcoin was worth $625.
Several websites such as “Black Market Reloaded”, “The 
Armory” and “The General Store”, like the now defunct 
“Silk Road” website, sell a wide variety of products using 
this method. Despite the efforts to keep the site adminis-
trators, users and sellers unknown, 2013 saw the successful 
dismantling of several of these large-scale online drug traf-
ficking operations, most notorious among them being the 
“Silk Road”, which was seized by the Federal Bureau of 
Investigation of the United States, along with $28 million 
1 The term “dark net” refers to a distribution network of users, 
obscured by encryption technology, and anonymized by hidden 
IP addresses. “Dark nets” are niches within the “deep web”, which 
includes network connected sites that are not searchable by major 
search engines.
2 UNODC, individual drug seizure database.
3 “TOR” is the acronym for “The Onion Router” and works by 
encrypting communications to relay Internet traffic through multi-
ple proxies worldwide to mask users’ locations and hide servers.
4 An online auction and shopping website in which people and busi-
nesses buy and sell a wide variety of goods and services worldwide.
in bitcoins belonging to the administrator.5
While “Silk Road” sold approximately 24,400 drug prod-
ucts, websites such as “The Armory” have taken over 
broader elements of weapons and ammunitions trafficking 
after they were no longer available on the “Silk Road”.6 In 
a research paper on the user experience of the “Silk Road”, 
an interviewee, after detailing his favourite purchases 
(good-quality cannabis, 3,4-methylenedioxymethamphet-
amine (MDMA), and 2,5-dimethoxy-4-iodophenethyl-
amine (2C-I)) stated that the “Silk Road” provided users 
with access to substances they otherwise would not have 
tried.7
While there are no reliable statistics on how many people 
are buying drugs on the Internet, the variety available and 
purchased on the “dark net” appears to be diverse and 
growing. Because purchases and sales through the “dark 
net” pose unique challenges for law enforcement and pre-
sents a niche market for high-quality drugs and new psy-
choactive substances, if the past trend continues, it has the 
potential to become a popular mode of trafficking in 
controlled substances in years to come.
5 United States, Federal Bureau of Investigation, “Manhattan U.S. 
Attorney announces seizure of additional $28 million worth of 
bitcoins belonging to Ross William Ulbricht, alleged owner and 
operator of “Silk Road” website”, press release, 2013.
6 Nicolas Christin, “Traveling the “Silk Road”: a measurement analy-
sis of a large anonymous online marketplace”, in Proceedings of the 
22nd International Conference on the World Wide Web, International 
World Wide Web Conference Steering Committee (Geneva, 2013), 
pp. 213-224.
7 M. C. Van Hout and T. Bingham, “‘Silk Road’, the virtual drug 
marketplace: a single case study of user experiences”, International 
Journal of Drug Policy, vol. 24, No. 5 (2013), pp. 385-391.
The “Silk Road” in numbersa 
Estimated number of registrants: 200,000
Total revenue from 2.5 years of operation:  
9.5 million bitcoins (approx. $1.2 billion)
Top three items for sale: “weed”, “drugs”,  
“prescriptions”
Origin of sales: 44 per cent shipped from the United 
States, 10 per cent from the United Kingdom
a Nicolas Christin, “Traveling the “Silk Road”: a measurement analysis 
of a large anonymous online marketplace”, see footnote 6. United 
States of America FBI Indictment against the alleged administrator  
of the “Silk Road” website. 
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frequent injections (see: HIV among people who inject 
drugs). While surveys on the number of problem drug 
users in many of the hardest hit countries are not yet avail-
able, experts expect the number of dependent users to 
remain stable.81
Shifting trends in patterns of drug use
In some of the countries most affected by the financial 
crisis, demand for heroin declined, as users shifted to 
cheaper drugs. For example, between 2008 and 2009 in 
Milan, Italy, decreases in cocaine and heroin, which are 
more expensive, were observed, but increases in metham-
phetamine and cannabis, which are less expensive drugs, 
were noted.82 In Romania, among people who inject drugs, 
a shift was observed, with 97 per cent interviewed in 2009 
reporting heroin as the main drug of injection and in 2012, 
most respondents (49.4 per cent) reportedly injecting ATS 
(mostly synthetic cathinones) and only 38.1 per cent 
injecting heroin.83 In Greece, increased injection of a cheap 
new stimulant-type drug called “sisa”, has been reported. 
“Sisa” can be made in a kitchen from ephedrine, hydro-
chloric acid, ethanol and car battery fluid.84 Widespread 
polydrug use also facilitated those shifts. 
81 Jonathan Caulkins, “The global recession’s effect on drug demand — 
diluted by inertia”, International Journal of Drug Policy, vol. 22, No. 
5 (September 2011), pp. 374-375.
82 Zuccato E. and others, “Changes in illicit drug consumption patterns 
in 2009 detected by wastewater analysis”, Drug Alcohol Depend, vol. 
118, Nos. 2 and 3 (November 2011), pp. 464-469.
83 Botescu Andrei and others, “HIV/AIDS among injecting drug users 
in Romania Report of a recent outbreak and initial response policies”, 
EMCDDA, 2012
Drug-related crime (drug law offences)
According to available information, during the period 
2003-2012, both the number of persons arrested/suspected 
for possession for personal use85 and the number of users 
of illicit drugs increased: the former group by 31 per cent 
and the latter by approximately one fifth. Relative to the 
total population, the rate of persons arrested for or sus-
pected of offences related to possession for personal use 
increased by 18 per cent, while the point estimate preva-
lence of drug users (as a percentage of the population in 
the 15-64 age bracket) has remained fairly stable. 
The increases in drug-related crime were also apparent in 
offences for drug trafficking,86 while other kinds of crime 
declined. Although these indicators come with a large 
degree of uncertainty, they suggest that, over the period 
2003-2012, the annual global proportion of drug users 
that was arrested for possession for personal use has fluc-
tuated between 3 and 4 per cent. This suggests that the 
increase in crime rates for possession for personal use was 
due to the increase in the total number of drug users. 
Comparing the relative importance of the various drugs 
84 EMCDDA and Greek RETOIX Focal Point, 2011 National Focal 
Report (2010 data) to the EMCDDA by the Retoix National Focal 
Point: Greece — New Development, Trends and In-Depth Information 
on Selected Issues (RETOIX, Athens 2011).
85 Drug possession for personal consumption refers to drug offences 
related to the use or the possession of drugs for personal consumption 
(see art. 3, para. 2, of the United Nations Convention against Illicit 
Traffic in Narcotic Drugs and Psychotropic Substances of 1988).
86 Drug trafficking refers to drug offences committed not in connection 
with the use or possession of drugs for personal consumption (see art. 
3, para.1, of the 1988 Convention).
Fig. 11. Comparison of growth in prevalence of illicit drug use and in per capita rate of persons  
recorded for personal drug use offences, 2003-2012
Source: UNODC estimates based on annual report questionnaire supplemented by other official sources.
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Comparison of growth in prevalence of illicit drug use and in rate per 
capita of persons recorded for personal drug use offences, 2003-2012
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Fig. 14. Share of the four major drug classes in 
drug offender records, by region and 
globally, 2012 
Source: UNODC estimates based on annual report questionnaire.
a Since a given offender can be recorded in connection with different 
drugs, the percentage of records given does not necessarily coincide 
with the percentage of offenders. In addition, offenders recorded in 
connection with other substances are not included in the graph. Hence 
the total may not add up to 100 per cent.
b Average of the five regions, weighted by the estimated number of 
offenders (for all drug types) in each region. 
in records of drug-related crime, cannabis is clearly the 
most prominent drug in cases of possession for personal 
use, followed by ATS (see figure 14).
Asia and the Americas both exhibit features which distin-
guish them from the prevalent global trend. In the Ameri-
cas, cocaine follows cannabis as the second most prominent 
drug with respect to possession related to personal use, and 
was almost at par with cannabis (in first place) with respect 
to trafficking. In other regions, opioids or ATS take second 
place for possession related to personal use.
In Asia, illicit opioids offer some competition to cannabis 
as the most prominent drugs for possession related to per-
sonal use, and illicit ATS emerge as the most prominent 
for trafficking offences. 
In Europe, illicit ATS ranked last among these four drug 
classes in terms of trafficking offences, despite being in 
second place (after cannabis) in terms of personal drug use 
offences.
An analysis of the gender make-up of persons recorded for 
drug-related offences indicates that the population appre-
hended for using controlled substances tends to be pre-
dominantly male, in keeping with the picture that emerges 
from drug use data. The same is true for trafficking. For 
all drug classes and with respect to both possession for 
personal use and trafficking offences (separately), less than 
Fig. 12. Global trend in crime rates per  
population for selected  types of crime, 
2003-2012
Source: UNODC estimates based on United Nations Survey of 
Crime Trends and Operations of Criminal Justice Systems, UNODC 
Homicide Statistics, annual report questionnaire and European 
Monitoring Centre for Drugs and Drug Addiction.
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Fig. 13. Female offenders among persons  
recorded for drug-related offences, by 
drug class and type of offence, 2012
Source: UNODC estimates based on annual report questionnaire.
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one quarter of offenders were female. However, that pro-
portion of female offenders varied significantly for the vari-
ous drug classes, with the category of sedatives and 
tranquillizers standing out as the one with relatively high 
proportions of females, for both possession for personal 
use and trafficking offences. This conforms with drug use 
data for women.
The proportion of female offenders tended to be higher 
for trafficking offences than for possession related to per-
sonal use, but typically only marginally so, and still far 
below 50 per cent. Moreover, the relative importance 
(ranking) of each drug class, in terms of frequency of 
offending by females, was quite similar for trafficking and 
drug-use offences. 
D. OPIATES: OVERVIEW
Cultivation and production
The global area under illicit opium poppy cultivation in 
2013 was 296,720 hectares (ha), the highest level since 
1998 when estimates became available. An increase in cul-
tivation was seen in both Afghanistan and Myanmar. The 
main increase was observed in Afghanistan, where the area 
of opium poppy cultivation increased 36 per cent, from 
154,000 ha in 2012 to 209,000 ha in 2013. The main area 
of cultivation in Afghanistan was in nine provinces in the 
southern and western part of the country, while the major 
increase was observed in Helmand and Kandahar.87 In 
Myanmar, the increase in the area of cultivation was not 
as pronounced as in Afghanistan.
In South-East Asia, the total area under cultivation in the 
Lao People’s Democratic Republic in 2013 was estimated 
87 UNODC and Ministry of Counter Narcotics of Afghanistan, 
“Afghanistan opium survey 2013: summary findings”, November 
2013.
as 3,900 ha (range: 1,900-5,800 ha). However, the 2013 
estimates are not comparable with the estimates of 2012 
due to the varying methodology in the use of high-resolu-
tion satellite images and time of conducting the helicopter 
survey.88 Myanmar continued the trend of increasing cul-
tivation that began after 2006.89 (See tables in annex I for 
details on opium poppy cultivation and production in the 
different countries and regions).
The potential production of opium in 2013 is estimated 
at 6,883 tons, which is a return to the levels observed in 
2011 and 2008. The opium production in Afghanistan 
accounts for 80 per cent of the global opium production 
(5,500 tons). The potential production of heroin (of 
unknown purity) has also increased to 560 tons, comparable 
to 2008 estimates of 600 tons (see figure 16).
Seizures
Globally, seizures of heroin and illicit morphine went down 
19 per cent in 2012. The main declines in opiate seizures 
were reported in South-West Asia and Western and Central 
Europe, where seizures declined by 29 per cent and 19 per 
cent, respectively (from 117 tons in 2011 to 82 tons in 
2012 in South-West Asia, and from 6 tons in 2011 to 4.85 
tons in 2012 in Western and Central Europe). A substan-
tial increase in heroin seizures, however, was reported in 
Eastern and South-Eastern Europe (15.98 tons in 2012 
compared with 9.88 tons in 2011), mainly as a result of 
increased quantities reported seized in Turkey. Heroin sei-
zures also increased substantially in Australia and New 
Zealand (1.09 tons in 2012 compared with 0.61 tons in 
2011) and in South Asia (1.3 tons in 2012 compared with 
0.723 tons reported in 2011). In North America, heroin 
seizures declined by 58 per cent in Mexico but increased 
88 UNODC, Southeast Asia Opium Survey 2013 (Bangkok, 2013).
89 Ibid.
Fig. 15. Opium poppy cultivation and eradication in Afghanistan, 1997-2013 
Source: 1997-2002: UNODC; since 2003: National Illicit Crop Monitoring System supported by UNODC.
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in the United States, to 5.5 tons in 2012, compared with 
4.8 tons in 2011. However, overall heroin seizures in North 
America have remained stable over the previous year. 
Extent of use
Past-year use of opioids, including heroin and prescription 
painkillers, is estimated at between 28.6 and 38 million 
people globally. Compared to the global average prevalence 
of 0.7 per cent, opioid use remains high in North America 
and Oceania, with prevalence rates of 4.3 per cent and 3 
per cent respectively. While opioid use has increased glob-
ally over the past year, the main increase has been observed 
in the United States. Although recent and reliable estimates 
are not available from Asia and Africa, many experts from 
countries in those regions also perceive an increase in 
opioid use. The use of opiates (heroin and opium), how-
ever, remained stable globally, with 12.8 million to 20.2 
million past-year users. Opiate use at levels much higher 
than the global average of 0.4 per cent remain in South-
West Asia (1.21 per cent), Eastern and South-Eastern 
Europe (0.82 per cent) and in Central Asia and Transcau-
casia (0.81 per cent).
Opiates: market analysis
In comparison with other plant-based drugs, the global 
market for illicit opiates is perhaps the most complex. In 
contrast to cannabis, illicit cultivation and production 
feeding the illicit opiate market are limited to certain coun-
tries and regions. Consequently, illicit opiates are neces-
sarily trafficked across large distances and through multiple 
countries in order to meet demand. In contrast to coca 
bush, illicit cultivation of opium poppy occurs on a sig-
nificant scale in at least three geographically distinct areas 
— South-West Asia, South-East Asia and Latin America. 
Fig. 16. Global potential opium production, 1998-2013
Source: 1997-2002: UNODC; since 2003: National Illicit Crop Monitoring System supported by UNODC.
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Fig. 17. Seizures of heroin and illicit morphine, in selected countries and by region, 2003-2012
Source: UNODC data from annual report questionnaire and other official sources.
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Moreover the historical delineations whereby the supply 
of illicit opiates in a given consumer market could be 
assumed to originate in one of those source regions — 
rather than from several — have blurred, with trafficking 
routes diversifying accordingly. Moreover, demand for 
illicit opiates is widespread and cannot be assumed to be 
concentrated in certain regions. These layers of production 
and consumption are intertwined. For instance, opium is 
consumed as is and further used to manufacture morphine, 
which is then used in the manufacture of heroin. Further-
more, opiates and other opioids, chemically and pharma-
cologically very similar, are also widely available and used 
as licit pharmaceutical products, resulting in an interplay 
that may involve diversion from licit to illicit markets at 
various stages of the supply chain.
Long-term assessment
In spite of the apparent complexity and the fluctuations 
in key supply indicators, a long-term perspective (taking 
1991 as a starting point) reveals some elements of stability 
in the underlying fundamental indicators at a global level. 
As of the early 1990s, opium poppy was predominantly 
cultivated in South-East Asia; following a significant 
decline in that region, cultivation in Afghanistan increased 
significantly (reaching a record level in 2013), and cultiva-
tion returned to an increasing trend, as of 2007, in Myan-
mar. Global cultivation reached a low around 2005 and in 
2013, returned for the first time to a level comparable to 
the high level of 1991 (even exceeding it by a small 
margin). However, owing to the typically higher yields in 
South-West Asia (disregarding transitory year-on-year fluc-
tuations attributable to environmental factors), the overall 
trend over the period 1991-2013 was one of increasing 
production of opium poppy, even if the sharp increase in 
Afghanistan in 2013 is excluded. 
Over the same period, seizures of illicit opiates worldwide 
(aggregated by assuming a conversion factor of approxi-
mately 10 kg of opium per 1 kg of heroin) increased quite 
steadily. This increase has a significant impact on global 
supply of opiates. UNODC estimates indicate that the 
ratio (sometimes referred to as the “interception rate”) of 
seizures of opiates to illicitly produced opiates present in 
the illicit market (both expressed in opium equivalents) 
increased from 4-9 per cent in 1991 to 18-30 per cent90 
in 2012. 
With respect to the demand side, the earliest UNODC 
estimates of global consumption date to the late 1990s. 
90 These calculations are approximate and are derived by assuming that 
the weighted average purity of heroin seizures worldwide (among 
which seizures at upper levels of the supply chain, in terms of weight, 
are believed to be predominant) is no less than one third of the purity 
at the point of manufacture, and that a range of 7-10 kg of opium are 
needed for 1 kg of heroin at the point of manufacture. In addition, in 
order to account for the delay between the production of opium and 
seizures of derived opiates, some of which are made after processing 
into heroin and in locations far removed from the source, a two-year 
moving average of opium production is considered as a proxy for the 
amount of opiates present in the market.
Those estimates have always been produced on the basis 
of the latest available data, using a methodology that was 
being continually updated, and are therefore not strictly 
comparable. Nevertheless, they indicate a generally stable 
trend in terms of prevalence rate of annual use. However, 
since the global population has also been increasing, this 
means that there has been an increase in the number of 
users. That growth in demand appears to be weaker than 
the growth in supply. However, the growth trend in supply 
moves closer to the growth trend in demand once seizures 
are taken into account. Further, these estimations do not 
take into account any possible losses that may occur in 
times of excess production. If such losses did occur, it 
would suggest that the appropriately adjusted trend in 
supply would move even closer to the trend in demand. 
Even without that additional adjustment, and notwith-
standing the large degree of fluctuation and uncertainty 
inherent in these estimates, the available supply of opiates 
(net of seizures) per opiate user appears to have increased 
only marginally, if at all, over the period 1998-2012. 
Numerically, it would appear that the impact of opiate 
seizures by law enforcement authorities worldwide, while 
becoming more discernable in the big picture, had the effect 
of bringing the apparently strong growth in supply more 
in line with the growth in demand, which increased more 
slowly than opium production. However, it is not a fore-
gone conclusion that there is in fact a causal relationship; 
it could possibly be the outcome of supply adjusting to the 
circumstances in order to keep meeting demand. In other 
words, one possibility is that the available supply was con-
tained as a consequence of seizures, but the opposite cannot 
be excluded: that production adjusted to correct for seizures 
so as to keep supply stable. Most importantly, this picture 
is an assessment of the end result, but it is difficult to ascer-
tain, for the purposes of comparison, what would have 
happened had  the efforts of the international community 
been different. Moreover, it is important to note that the 
estimates on drug use are based on limited data and there-
fore subject to a high degree of uncertainty.
Recent trends
Although global supply and demand may be evening out 
globally in the long term, the illicit market for opiates is 
far from static, especially when shorter-term trends are 
taken into account. There is growing evidence of signifi-
cant changes in the flows of heroin out of Afghanistan, of 
heroin from Afghanistan becoming more available in con-
sumer markets other than the long-established European 
destinations, and of the interplay between the illicit and 
licit markets for opioids (including opiates).
European markets and their relationship to Afghanistan
It appears that the flow of heroin along the long-established 
Balkan route, from Afghanistan to Western and Central 
Europe via Iran (Islamic Republic of ) and Turkey, has 
declined in recent years. Various factors may have contrib-
uted to the decline in seizures along this route, including 
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the success of law enforcement authorities in key transit 
countries and a decline in demand in the destination 
market. 
Based on UNODC estimates, the number of past-year 
users of opiates in Western and Central Europe may have 
declined by almost one third between 2003 and 2012 
(from 1.6 million to 1.13 million). This is also observed 
for example, in the data from Germany, where the number 
of people arrested for the first time for heroin use fell stead-
ily between 2003 and 2012 — overall, by more than one 
half. Even so, in 2011 and 2012, there may have been a 
certain deficiency in the available supply of heroin (which 
may yet be corrected), as the purity-adjusted price of 
heroin underwent a distinct transition between 2010 and 
2011, and maintained the increased level in 2012. Indeed, 
the decline in heroin flowing on the Balkan Route appears 
to have been too sudden to be accompanied by a corre-
sponding  drop in demand. The ensuing shortfall may have 
helped trigger the development of routes serving as alter-
natives to the Balkan route — whose emergence is sug-
gested by other evidence — to supply Europe, possibly via 
the Near and Middle East and Africa, as well as directly 
from Pakistan, suggesting that the so called Southern Route 
is expanding.91
91 UNODC, The illicit drug trade through South-Eastern Europe, 
2014. 
Fig. 18. Evolution of main opiate supply and 
supply reduction indicators, 1991-2013
a The practical significance of the “interception rate” should be 
approached with caution, as this concept is ultimately an abstract ratio 
which, depending on the context, may not always be intuitive (see foot-
note 90). 
Source: UNODC estimates based on  annual report questionnaire 
and national illicit crop monitoring systems supported by UNODC, 
supplemented by other official data.
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Fig. 19. Comparison of growth rates in supply 
of and demand for illicit opiates,  
1998-2012 
Source: UNODC estimates based on  annual report questionnaire 
and national illicit crop monitoring systems supported by UNODC, 
supplemented by other official data.
Fig. 20. Global prevalence of illicit opiate use 
and supply of illicit opiates per user, 
1998-2012 
Source: UNODC estimates based on annual report questionnaire, 
national illicit crop monitoring systems supported by UNODC and 
UNPD population data, supplemented by other official data.
Note: Comparable data is not available for 1999, 2000 and 2007-2009.
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In the replies to the annual report questionnaires for the 
reporting years 2002-2011, Africa was only sporadically 
indicated as a region of provenance for heroin reaching 
Europe; in contrast, in 2012, East Africa which had previ-
ously never been identified by a European country as an 
area of provenance, was among the more prominent such 
regions in terms of number of mentions, following the 
Near and Middle East/South-West Asia (including Afghan-
istan) and South-Eastern Europe (including Turkey). 
Among East-African countries, the United Republic of 
Tanzania, which throughout the period 2010-2012 regis-
tered annual levels of seizures significantly higher than in 
previous years, appears to be the most prominent as a coun-
try of provenance, although Ethiopia, Kenya and Uganda 
were also mentioned. Italy in particular appears to be 
affected by this flow to a significant extent.
In an analysis of 120 cases in the period June 2006-Octo-
ber 2012 in which heroin was seized from air passengers 
on itineraries involving Europe,92 Pakistan was the second 
most cited country of provenance, second only to Turkey 
and followed by Kenya. While the role of Turkey as a tran-
sit country appeared to be on the decline over that time 
period, the cases involving Kenya related almost exclusively 
to the year 2012. In addition to European countries, other 
countries from Africa, including East and West Africa, as 
well as the Near and Middle East, also appeared as coun-
tries of provenance in those itineraries.
92 Data from the database on illicit drug seizures with relation to Euro-
pean airports, Germany Customs.
Fig. 21. Heroin seizure trends in key countries and regions along the Balkan and northern routes, 
compared with heroin seizure trends in Pakistan and opium production in Afghanistan,  
2003-2012
Seizure data: UNODC annual report questionnaire supplemented by other official data.
Production: National illicit crop monitoring system supported by UNODC.
a Taken as representative of the northern route.
b Taken as representative of the Balkan route.
c Possibly representative of the southern route.
Fig. 22. Heroin seizures in key locations along 
the Balkan route and prominence of 
Turkey as a transit country for heroin, 
2002-2012
Source: Seizure data: UNODC annual report questionnaire  
supplemented by other official data.
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Data on individual heroin seizure cases93 from Pakistan 
up to the first quarter of 2012 also confirm a recently 
increasing frequency of use of airports in Europe (notably 
the United Kingdom), the Near and Middle East (notably, 
in 2012, Oman and Saudi Arabia) and Bangladesh 
(although that increasing mention of Bangladesh was offset 
by decreasing mention of other countries in South Asia) 
as a destination for heroin couriers leaving Pakistan by air. 
However, consignments trafficked via passenger aircraft 
are necessarily small, and it is not clear to what extent such 
trafficking can affect the flow of heroin; these emerging 
93 UNODC IDS database.
patterns are likely most significant to the extent that they 
reflect a broader tendency to source heroin from a given 
region using maritime or land transportation. The number 
of heroin seizure cases involving sea transport reported by 
Pakistan was much more limited; however, since 2009 the 
only such cases with a known destination were predomi-
nantly of shipments being sent to West and Central Africa, 
with all others destined for Western and Central Europe.
A distinct market for heroin, also supplied for several years 
by heroin from Afghanistan, is that of Eastern Europe, 
Fig. 23. First-time arrestees for heroin use in Germany, 2003-2012
Source: Germany Bundeskriminalamt. 
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Fig. 24. Heroin retail prices in Western and Central Europe and the United States, 2003-2012
Source: For European countries, UNODC annual report questionnaire, EMCDDA, European Police Office (Europol). For the United States, 
Office of National Drug Control Policy, United States.
a For 2003 and 2004, comparable price data for the United States were unavailable.
b Purchases recorded in the System to Retrieve Information from Drug Evidence (STRIDE) database of the United States Drug Enforcement Agency.
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where the levels of opiate use are significantly higher than 
the global average. The Russian Federation remains a major 
consumer market for illicit opiates, with significant quan-
tities of heroin flowing northwards from Afghanistan via 
Central Asia. A marked increase in total heroin seizures in 
the Russian Federation and Central Asia together (repre-
sentative of that northern route) was observed between 
1998 and 2004. Since then, overall seizures declined, but 
it is plausible that the increased availability may have stim-
ulated a demand for opioids, which was met by alternative 
sources when the influx of heroin subsequently declined. 
If that is the case, it would be yet another instance of the 
interaction between the licit and illicit markets for opioids. 
In 2011 and 2012,94 in addition to seizures of heroin, the 
Russian Federation reported seizures of desomorphine — 
a substitute for heroin that can be derived relatively easily 
from pharmaceutical products — amounting to 100 kg in 
2011 and 95 kg in 2012. Although these quantities are 
small in comparison with the quantities of seized heroin, 
in terms of number of cases, in 2012 there was approxi-
mately one desomorphine seizure for every three heroin 
seizures in the Russian Federation. (For comparison, in 
2011, there had been approximately three desomorphine 
seizures for every four heroin seizures in that country.) The 
fact that the average quantity per seizure of desomorphine 
was low (8.2 g in 2012 and 3.5 g in 2011, compared with 
65 g of heroin in 2012 and 55 g in 2011) confirms that 
desomorphine is typically home-made and not usually traf-
ficked in large quantities.
Other markets and new flows through Pakistan
Approximately one fifth of illicit opiate users worldwide 
live in the subregion of the Near and Middle East/South-
West Asia, in spite of the fact that the region accounts for 
only 6 per cent of the global population aged 15-64 years. 
Although opiate use, particularly the use of opium, is not 
new in that region, it is plausible that the high levels of 
production in Afghanistan may have brought about an 
increase in the use of opiates (and, by association, possibly 
other opioids) close to this major source of illicit opium. 
In Pakistan, the annual prevalence of regular opiate use is 
estimated to have risen from 0.7 per cent in 2006 to 1.0 
per cent in 2013.95 With reference to the period 21 March 
94 UNODC, annual report questionnaire, replies submitted by the Rus-
sian Federation for 2012.
95 UNODC and Pakistan, Ministry of Narcotics Control, “Drug use in 
Pakistan, 2013: technical summary report”.
Fig. 25. Number of cases of heroin being 
seized from air passengers recorded  
in selected European airports with  
selected countries of provenance, 
2007-2012
Source: Database on illicit drug seizures with relation to European 
airports IDEAS, German Customs.
a Data for 2012 were incomplete. 
Fig. 26. Ranking of past-year use of illicit opiates by subregion, based on prevalence and number of 
users, 2012
Source: UNODC estimates based on annual report questionnaire and UNPD population data, supplemented by other official sources.
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2011-19 March 2012,96 experts in the Islamic Republic 
of Iran, a country with relatively high rates of opium use, 
perceived an increase in both opium and heroin use.
With respect to Afghanistan, a recent study97 conducted 
by the United States Government found high (in compari-
son with other countries) levels of use or exposure in the 
urban population of Afghanistan (overall and among both 
men and women), with 2.6 per cent of the urban test 
population (of all ages) testing positive for opioids (includ-
ing pharmaceutical opioids). Users of opioids in the form 
of opium and heroin were predominantly men, while 
women predominantly used codeine. Even a relatively high 
proportion of children tested positive for opioid use 
(including heroin): the study indicates that some 1.3 per 
cent of urban children were exposed to an opioid present 
in their physical environment or had been given the drug 
by an adult. 
Although the annual prevalence of use of illicit opiates in 
East and South-East Asia is estimated to be significantly 
below the global average, this subregion accounts for 
approximately one fifth of all users globally, mainly by 
virtue of the large population of China. In the past, the 
heroin market in China was supplied mainly from South-
East Asia; although Myanmar in particular continues to 
be a major source country for heroin reaching China, it 
appears that around 2006, a surplus of heroin from 
Afghanistan started to find its way to China, via Pakistan 
and other countries in South-East Asia.98 By 2007, the 
number of registered heroin users in China, which had 
declined in 2005, was on the increase, and heroin seizures 
in China followed a similar pattern, with a slight delay, 
which could be attributable to a time lag as law enforce-
ment authorities adjusted their efforts to the changing flow. 
This evidence does not immediately translate into a con-
clusion that heroin use in China is on the rise, especially 
since some of these indicators could reflect drug supply 
and demand reduction efforts rather than supply itself; 
indeed, the latest UNODC estimates suggest that annual 
prevalence of opiate use in China (in 2012) is lower than 
previously thought (0.19 per cent of the general popula-
tion aged 15-64, compared with 0.25 per cent in 2005). 
However, it seems clear that the share of heroin in the 
Chinese market originating in South-West Asia continues 
to increase, as has also been indicated by Chinese 
authorities,99 who detected 98 instances of heroin traffick-
ing from South-West Asia in 2012 and 148 cases in 
2013.100 Heroin seizures in the Chinese province of 
Yunnan (bordering Myanmar), continued to increase, 
reaching 5.4 tons in 2012, constituting 74 per cent of the 
96 Solar Hijri calendar year 1390.
97 United States, Department of State, Afghanistan National Urban Drug 
Use Survey (ANUDUS) (December 2012).
98 World Drug Report 2011, pp. 73 and 74 and fig. 42.
99 China, National Narcotics Control Commission, 2013 Annual Report 
on Drug Control in China (Beijing, 2013).
100 Ibid., 2014 Annual Report on Drug Control in China (Beijing, 2014).
total for China for that year. It is likely that these quanti-
ties originate in Myanmar, in line with the increasing trend 
in opium poppy cultivation in this country in recent years.
More broadly, South-West Asia (or countries therein) has 
recently been mentioned as a source of heroin with increas-
ing frequency by countries in South-East Asia, including 
Indonesia and Malaysia, both of which have registered 
increasing heroin seizures since 2006. Malaysia in particu-
lar has a significant market for heroin, with a relatively 
high level of heroin use (although declining according to 
expert perception101), and an increasing inflow of heroin, 
trafficked via sea and air cargo, facilitated by groups with 
ties to Pakistan (possibly in collusion with West African 
groups active mainly in Malaysia in the trafficking of meth-
amphetamine and cocaine) and intended for both the local 
market and for onward trafficking.102 
Nevertheless, the main source for heroin in Malaysia likely 
continues to be Myanmar.103 In addition to heroin, it 
appears that the use of morphine is, or at least was in 2010, 
widespread in Malaysia; moreover, in recent years, authori-
ties have dismantled a number of clandestine laboratories 
processing heroin (seven in 2011), apparently producing 
a low purity end product.104,105 The fact that heroin sei-
zures in Pakistan have increased markedly since 2009, inde-
pendently of the trend in opium production in Afghanistan 
and in contrast to seizures in key countries along the 
Balkan and northern routes, suggests a major transforma-
tion in the flows out of Afghanistan, with Pakistan playing 
an important role. 
Given the extensive coastline of Pakistan on the Indian 
Ocean and that maritime channels generally provide the 
possibility of trafficking large quantities over long dis-
tances, it is likely that significant quantities of heroin are 
trafficked by sea out of Iran (Islamic Republic of ) and 
Pakistan. Seizures by the Pakistan Anti-Narcotics Force 
(one of several law enforcement agencies in Pakistan) at 
seaports reached almost 1.2 tons in 2013, more than 
double the annual amounts throughout the period 2010-
2012.106 Reports of individual seizure cases also corrobo-
101 UNODC, Patterns and Trends of Amphetamine-Type Stimulants and 
Other Drugs: Challenges for Asia and the Pacific (November 2013).
102 Ibid.
103 Malaysia assessed the proportion of seized heroin originating in 
Myanmar at 80 per cent in 2010. For the reporting year 2011, 
Malaysia mentioned the Lao People’s Democratic Republic, Myanmar 
and Pakistan as the main countries of provenance. Over the period 
2010-2012, Myanmar nationals accounted for the largest number of 
foreign nationals arrested for drug-related offences in Malaysia. See 
also UNODC, Patterns and Trends of Amphetamine-Type Stimulants, 
p. 92.
104 UNODC, Patterns and Trends of Amphetamine-Type Stimulants 
(November 2013).
105 Country report submitted by Malaysia to the Thirty-seventh Meeting 
of Heads of National Drug Law Enforcement Agencies, Asia and the 
Pacific.
106 Pakistan Anti-Narcotics Force “Heroin and precursors trafficking 
through southern route”, presentation made at the UNODC work-
shop on Afghan opiate trafficking through the southern route, held 
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rate those maritime patterns of heroin trafficking. Based 
on a limited number of officially reported seizures of heroin 
consignments known to have been trafficked by sea, the 
proportion of total weight seized in cases for which Paki-
stan was mentioned as a country of provenance (including 
seizures made by authorities of Pakistan) rose sharply to a 
record level in 2009 and since then, has remained higher 
than in any prior year. In terms of the number of seizures, 
the increase was more gradual, but the proportion also 
climbed to record levels in 2010 and 2011. Further infor-
mation from national law enforcement agencies107 and 
international forces on specific, particularly significant sei-
zures in the Indian Ocean, as well as in seaports and coastal 
regions in Africa, reinforces the evidence that heroin is 
being transferred for maritime conveyance on the southern 
coast of Iran (Islamic Republic of ) and Pakistan. Labora-
tory analysis of several large heroin seizures (at least five 
seizures in excess of 100 kg each) in 2012 and 2013 made 
by the Combined Maritime Forces108 in international 
waters have confirmed that Afghanistan is the country of 
origin for the heroin trafficked in those cases.109
on 24 and 25 March 2014.
107 Presentations by the Drug Control Commission of the United 
Republic of Tanzania on heroin trafficking in the country and by 
the National Drug Law Enforcement Agency of Nigeria on “heroin 
trafficking: Nigeria’s experience”, made at the UNODC workshop on 
Afghan opiate trafficking, March 2014.
108 Combined Maritime Forces is a multinational naval partnership that 
operates in international waters, encompassing some of the world’s 
most important shipping lanes in the Indian Ocean and adjoining 
bodies of water.
109 Presentation by the Combined Maritime Forces on counter-narcotics 
operations in the Indian Ocean, made at the UNODC workshop on 
India, with almost 18 per cent of the world’s population 
in the 15-64 age bracket, is exposed to illicit opiates origi-
nating in both South-East Asia and South-West Asia. 
According to Indian authorities (i.e. country report sub-
mitted by India to Thirty-seventh Meeting of Heads of 
National Drug Law Enforcement Agencies, Asia and the 
Pacific, and the reply submitted by India in response to 
the 2011 UNODC annual report questionnaire) heroin 
from South-West Asia reaches India across the India-Paki-
stan border and tends to be trafficked onward to destina-
tions such as Europe, the United States and South-East 
Asia. These destinations are presumably more lucrative 
markets than India, given the relatively low price of heroin 
in India (reported to be the equivalent of $8.6-$13 per 
gram, as of 2011, compared with a range of $100-$400 
per gram of heroin from South-West Asia in the United 
States and an average price, taken from 17 countries in 
Western and Central Europe and weighted by population, 
of $72, both in the same year). The share of heroin of 
South-West Asian origin as a proportion of total heroin 
seizures in India in 2011 was assessed at 45 per cent, while 
most of the remainder (54 per cent) originated in India 
itself (according to information submitted by India in the 
annual report questionnaire). 
Moreover, Indian authorities also indicate illicit cultivation 
of opium poppy in some pockets within India, suspected 
diversion of opium from licit cultivation and manufacture 
of “brown sugar” (also referred to as “low-quality heroin”) 
Afghan opiate trafficking, March 2014.
Fig. 27. Indicators of heroin use and supply  in China, compared with selected indicators of opiate 
supply in South-West Asia, 2002-2012
Source: UNODC annual report questionnaire, National illicit crop monitoring system in Afghanistan supported by UNODC, UNODC IDS 
database, Office of the National Narcotics Control Commission of China (annual reports).
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Access to pain medication 
As stated in the International Narcotics Control Board (INCB) annual report for 2009, “One of the fundamental objec-
tives of the international drug control treaties is to ensure the availability of narcotic drugs and psychotropic substances 
for medical and scientific purposes and to promote the rational use of narcotics drugs and psychotropic substances”.
While opioids are essential in the management of pain experienced by millions of people who might be suffering from 
late-stage cancers, AIDS, surgical procedures and other debilitating diseases and conditions,1 they are also susceptible to 
abuse.2 This means that countries face the challenging task of balancing two public health needs: ensuring the availabil-
ity of these controlled substances for medical purposes and preventing their misuse and diversion. 
Many countries have expressed concern about misuse, and available data show a high prevalence of misuse of prescription 
opioids in some countries. This includes the high-income countries,3 such as Australia, Canada and the United States 
that have high per capita consumption of opioids for medical purposes, and even lower-middle-income countries such 
as Nigeria and Pakistan, which have the lowest per capita consumption of opioids for medical purposes.4 That suggests 
that the dynamics of misuse of prescription opioids does not necessarily follow making opioids accessible or available for 
medical purposes.5
As a response to potential or real misuse of these medicines, many countries, contrary to the provisions of the drug 
control conventions, have laws and regulations that are unduly restrictive or burdensome,6 resulting in a situation where 
a large part of the population does not have access to most of the opioid medications commonly used for the treatment 
of pain and dependence syndrome.7
Globally, in 2011, the opioid consumption for medical purposes in morphine equivalence (ME) per person was 61.66 
milligrams (mg) per person.8,9 This comprises six main opioids: fentanyl, hydromorphone, methadone, morphine, oxy-
codone and pethidine. However, there is a great disparity among levels of consumption and accessibility of pain medica-
tions. The high-income countries, which comprise 17 per cent of the global population, account for 92 per cent of the 
medical morphine consumed, whereas more than half of the countries that reported to INCB in 2011 had consumption 
levels of less than 1 mg of morphine per person.
Comparison of per capita opioid consumption in morphine equivalence among lowest and highest 
consumption countries, 2011
Source: Pain and Policy Studies Group, University of Wisconsin-Madison. 
A survey conducted by INCB in 2011 found that the laws and regulations in place for control of pain medications in 
many countries were unduly restrictive or burdensome and were perceived to be a significant limitation on availability. 
Other impediments to accessibility to pain medication included insufficient training of health-care professionals in the 
recognition and management of pain, and economic and procurement impediments such as deficiencies in drug supply 
management due to low financial resources or low priority given to health care, among other areas.
1 WHO, Ensuring Balance in National Policies on Controlled Substances: Guidance for Availability and Accessibility of Controlled Medicines (Geneva, 
2011).
2 UNODC, discussion paper based on a scientific workshop, entitled “ Ensuring availability of controlled medications for the relief of pain and 
preventing diversion and abuse: striking the right balance to achieve the optimal public health” (Vienna, 2011).
3 Based on the World Bank classification of income levels and development.
4 The annual prevalence of misuse of prescription opioids is as follows: Australia, 3.1 per cent; Canada, 1 per cent; Nigeria, 3.6 per cent; Pakistan, 
1.5 per cent; and United States, 5.2 per cent.
5 B. Fischer and others, “Non-medical use of prescription opioids and prescription opioid related harms: why so markedly higher in North America 
compared to the rest of the world?” Addiction, vol. 109, No. 2 (February 2014), pp. 177-181, and the related debate.
6 Report of the International Narcotics Control Board on the availability of internationally controlled drugs: ensuring adequate access for medical and 
scientific purposes (United Nations publication, Sales No. E.11.XI.7), para. 131.
7 UNODC, discussion paper entitled “Ensuring availability of controlled medications for the relief of pain”.
8 INCB data on global per capita opioid consumption, 2011.
9 Pain and Policy Studies Group, “Global opioid global consumption, 2011” (University of Wisconsin-Madison), available at www.painpolicy.wisc.
edu/2011-global-regional-and-national-opioid-consumption-statistics-now-available.
Lowest consumption countries 
(mg per capita of morphine equivalence)
Highest consumption countries 
(mg per capita of morphine equivalence)
Nigeria 0.0141 Canada 812.1855
Myanmar 0.0152 United States 749.7859
Pakistan 0.0184 Denmark 483.1678
Australia 427.1240
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by indigenous groups.110, 111 Thus, it appears that the 
consumer market in India is mainly supplied by heroin of 
domestic origin, quite plausibly derived from a minor pro-
portion of licitly produced opium diverted into the illicit 
market. 
Moreover, heroin originating in India also reaches other 
countries in South Asia, such as Bangladesh and Sri Lanka, 
although the flow to Sri Lanka has reportedly declined,112 
and both those countries have long indicated South-West 
Asia as being among the sources for heroin reaching their 
territory.113
In Africa, aside from its increasing role as a transit area,114 
the number of past-year users of opiates is estimated at 
between 0.92 million and 2.29 million. That broad range 
is a consequence of the paucity of data from African coun-
tries, which also extends to data from law enforcement 
authorities. The estimated annual prevalence of heroin use 
in West and Central Africa is above the global average, 
those subregions being long associated with small-scale 
trafficking by air, notably through Nigeria.115 Based on 
the latest available responses to the annual report question-
naire, South Africa is also believed to be a major consumer 
market, deriving its heroin supply from South-West Asia 
via East Africa and the Near and Middle East. 
In Oceania, the annual prevalence of opiate use is relatively 
low. However, the annual prevalence of opioid use in Oce-
ania is estimated to be more than four times the global 
average. According to Australian authorities,116 in 2011 
and in the first six months of 2012, approximately one half 
of heroin samples from seizures analysed by the Australian 
Federal Police were of South-West Asian origin. 
According to the United States, in 2012, the availability 
of heroin continued to increase in that country, likely due 
to high levels of heroin production in Mexico and Mexican 
110 Country Report by India to the Thirty-seventh Meeting of Heads 
of National Drug Law Enforcement Agencies, Asia and the Pacific, 
Bangkok 21-24 October 2013.
111 Country Report by India to the Thirty-sixth Meeting of Heads of 
National Drug Law Enforcement Agencies, Asia and the Pacific, 
Bangkok 30 October – 2 November 2012.
112 Country Report by India to the Thirty-seventh Meeting of Heads 
of National Drug Law Enforcement Agencies, Asia and the Pacific, 
Bangkok 21-24 October 2013.
113 UNODC, annual report questionnaire, replies submitted by Bangla-
desh, India and Sri Lanka; and country report submitted by India to 
the Thirty-seventh Meeting of Heads of National Drug Law Enforce-
ment Agencies, Asia and the Pacific.
114 See UNODC, World Drug Report 2013, pp. 33-35.
115 Each year of the period 2002-2012, Nigeria consistently ranked 
between eighth and twelfth among all countries mentioned in the 
annual report questionnaire as countries of provenance of trafficked 
heroin. Over the period 2000-2011, Pakistan reported 681 heroin 
consignments trafficked by air with Nigeria as a destination; expressed 
as a percentage of all such seizure cases with a known destination 
other than Pakistan, this number peaked at 51 per cent in 2004 and 
declined to 3 per cent by 2011. Nigeria assessed the percentage of 
heroin on its territory that had been trafficked by air in 2004 to be 
90 per cent; in 2012, the corresponding proportion was 25 per cent 
for inbound seizures and 70 per cent for outbound seizures.
116 Australian Crime Commission, Illicit Drug Data Report 2011-12.
traffickers expanding into “white heroin” markets.117 Some 
metropolitan areas in the United States experienced an 
increase in heroin overdose deaths. Apart from heroin orig-
inating in Latin America, heroin from South-West Asia 
may be reaching the North American market in larger 
quantities. Canada, which continues to identify Pakistan 
and India as being among the prominent countries of prov-
enance for heroin reaching its market, mentioned an 
increase in the number of heroin seizures from couriers on 
commercial airlines in the latter part of 2012 and in early 
2013, and reported that this could be due to a resurgence 
in the use of heroin across Canada, as well as possible 
export to other countries, such as the United States.118 
However, the United States has not reported a significant 
flow of heroin from Canada. India and the United States 
both indicated that there was a flow of heroin from India 
to the United States; it is plausible that the flow of heroin 
reaching North America from India, while probably still 
small in relation to the size of the North American con-
sumer market, is of South-West Asian origin (as discussed 
above). 
In Latin America, despite illicit cultivation of opium poppy 
in some countries and the manufacture of heroin in 
Colombia and Mexico, destined mainly for the United 
States, the prevalence of opiate use is relatively low. South 
America, Central America and the Caribbean collectively 
accounted for less than 3 per cent of global seizures of 
heroin in 2012. 
The interplay between illicit and  
pharmaceutical opioid use
At the heart of opioid addiction is the powerful rewarding 
effect that occurs when the active compound binds to the 
-opioid receptor, triggering a cascade of intense pleasur-
able responses related to the brain dopamine release. Users 
describe an initial rush followed by feelings of warmth, 
pleasure and sedation.119 Once regular use is established, 
vulnerable individuals develop an uncontrollable compul-
sive behaviour that is the main characteristic of opioid 
dependence, seeking to obtain the substance in spite of 
any negative consequence. 
The rewarding effect is progressively modulated by toler-
ance until a point at which people using the opioid no 
longer obtain a reward but are aiming to re-establish a 
“normal” mood. The entire reward system is hijacked by 
the opioid substance, with motivational reactions no longer 
being driven by normal life rewards or salient stimuli but 
by the opioid. Once established, that mechanism is stable 
and persistent because it is related to significant changes 
in the expression of the genes of the brain cells. 
117 UNODC, annual report questionnaire, replies submitted by the 
United States for 2012.
118 UNODC, annual report questionnaire, replies submitted by Canada 
for 2012.
119 EMCDDA, Drug profiles, heroin. Available from www.emcdda.
europa.eu.
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The use of multiple opioids is common among dependent 
users, who may choose one or the other depending on fac-
tors such as the local accessibility, availability and price of 
the opioids.
In the United States, where over 5 million people abused 
prescription pain relievers in 2010,120 those with the most 
severe dependency on pharmaceutical opioids were found 
to be 7.8 times more likely to have used heroin in the past 
year.121 In 2012, people in the United States who had ever 
used heroin were almost five times more likely to have used 
pain relievers, for other than medical purposes, than people 
in the general population, and about one third had mis-
used OxyContin, a commercial brand of oxycodone. Con-
versely, among people who had ever used OxyContin, 
almost one quarter had also used heroin.122 Another study 
compared admissions rates for overdoses from prescription 
opioids and heroin between the years 1993 and 2009 and 
found that overdose from one strongly predicted an over-
dose from the other — evidence that the markets of heroin 
120 United States, Department of Health and Human Services, National 
Institute on Drug Abuse, “Topics in Brief: Prescription Drug Abuse” 
(December 2011), available at www.drugabuse.gov/publications/
topics-in-brief/prescription-drug-abuse.
121 C. M. Jones, “Heroin use and heroin use risk behaviors among non-
medical users of prescription opioid pain relievers — United States, 
2002-2004 and 2008-2010”, Drug and Alcohol Dependence, vol. 132, 
Nos. 1 and 2 (September 2013), pp. 95-100.
122 UNODC estimates based on data from the National Survey on Drug 
Use and Health of the Substance Abuse and Mental Health Services 
Administration and extracted from the Substance Abuse and Mental 
Health Data Archive, hosted by the Inter-university Consortium for 
Political and Social Research at the University of Michigan.
and prescription opioids are strongly interconnected.123
In the United States, the shift in the opioid market towards 
heroin is also evidenced by high availability and lower 
prices of heroin. Also, fluctuations in the heroin market, 
reflected in the price of heroin since 2007, appear to have 
compensated for the use of other opioids, notably Oxy-
Contin, with the price of heroin correlating strongly with 
the past-month use of OxyContin (see figure 28). 
In line with these findings, according to the United States 
Drug Enforcement Agency, law enforcement officials 
nationwide have noted prescription opioid abusers switch-
ing to heroin because it was cheaper and/or more easily 
obtained than prescription drugs. Given the variable levels 
of heroin purity, the replacement of heroin with prescrip-
tion opioids is also fraught with risks of overdose. In several 
places in the United States, heroin overdoses have increased 
substantially. For example, in Minneapolis-Saint Paul, 
overdoses tripled in the span of one year, rising from 16 
overdoses in 2010 to 46 overdoses in 2011.124
These changes in the heroin market have been concurrent 
with national measures to control the misuse of prescrip-
tion drugs. In 2010, OxyContin was modified to make it 
a controlled-release formulation so that it could no longer 
123 G. J. Unick and others, “Intertwined epidemics: national demo-
graphic trends in hospitalizations for heroin-and opioid-related over-
doses, 1993-2009”, PLOS ONE, vol. 8, No. 2 (2013).
124 United States, Department of Justice, Drug Enforcement Adminis-
tration, “National Drug Threat Assessment Summary” (November 
2013).
Fig. 28. Price of heroin and past-month prevalence of use of OxyContin and heroin in the United 
States, January 2006-December 2012
Source: Office of National Drug Control Policy, US Government and data from National Surveys on Drug Use and Health (NSDUH) of the 
Substance Abuse and Mental Health Services Administration and extracted from SAMHDA (Substance Abuse and Mental Health Data 
Archive) hosted by the Inter-university Consortium for Political and Social Research at the University of Michigan.
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be crushed and snorted or injected. Tangible impacts of 
these measures can also be seen in a study over the transi-
tion period (2009-2011), during which OxyContin users 
were found to be switching to other opioids, including 
heroin. A United States-based study of 2,566 patients 
undergoing treatment for opioid dependence before and 
after the formulation change found that it had led to a 
decrease in OxyContin misuse among the clients (from 
35.6 per cent to 12.8 per cent), but as a replacement, fen-
tanyl and hydromorphone use went up and heroin use had 
doubled.125
In contrast, the declining availability of heroin in parts of 
Europe appears to have resulted in an increase in the use 
of prescription opioids. In Estonia, over the past decade, 
injecting drug users have switched from home-made opi-
ates and heroin to illicitly manufactured fentanyl and 
amphetamine:126 in 2012, 87.5 per cent of the clients in 
treatment listed fentanyl as their primary drug.127 Also, 
125 Cicero T. J., Ellis M. S. and Surratt H. L., “Effect of abuse-deterrent 
formulation of OxyContin”, New England Journal of Medicine, vol. 
367 (2012), pp. 187-189.
126 EMCDDA, “Fentanyl in Europe: EMCDDA trendspotter study” 
(Lisbon, November 2012).
127 Information provided by Estonia in the annual report questionnaire 
(2012).
between 2011 and 2012, there was a 38 per cent increase 
in overdose deaths in Estonia, 80 per cent of which were 
related to fentanyl and its derivatives.128 INCB now 
reports that fentanyl and buprenorphine have displaced 
heroin in Estonia and Finland.129 Similarly, in the Russian 
Federation, decreased availability of heroin led to its partial 
replacement with local and readily available substances 
such as acetylated opium and desomorphine, a home-made 
preparation made from over-the-counter medicines con-
taining codeine.130
A similar trend can be observed in Australia and New Zea-
land. In 2001, the heroin market in Australia underwent a 
supply drop and a consequent change in consumption 
patterns,131 in which most indicators of heroin use declined 
and some consumers resorted to prescription opioids as a 
substitute. In particular, use of oxycodone increased signifi-
cantly, displacing morphine in some cases.132 A comparison 
of price data for heroin and oxycodone in Queensland, 
Australia, in 2011 and 2012 shows that a tablet containing 
60 mg of oxycodone cost 20-30 Australian dollars, while 
an equivalent amount of heroin at retail prices would have 
cost 40-50 Australian dollars.133 Price data from New Zea-
land suggest that domestically produced “home bake” — a 
locally produced substance made from a chemical process 
involving prescription painkillers — remains a cheaper 
alternative to costly imported heroin.134
These trends in the overlap of heroin and prescription 
opioid use can be observed in other regions for which 
128 EMCDDA, “Drugnet Europe 85” (January-March 2014).
129 Report of the International Narcotics Control Board for 2012 (E/
INCB/2012/1).
130 World Drug Report 2013.
131 Amanda Roxburgh and others, Trends in Drug Use and Related Harms 
in Australia, 2001 to 2013 (Sydney, National Drug and Alcohol 
Research Centre, University of New South Wales, 2013).
132 Assessment based on data on morphine and oxycodone injection 
surveyed in the Australian Illicit Drug Reporting System, presented 
in Trends in Drug Use and Related Harms in Australia, 2001 to 2013, 
p. 69. Similar trends also emerge from data — which cannot be dif-
ferentiated into appropriate prescribing use and non-medical use — 
on medical prescriptions of these substances. See Amanda Roxburgh 
and others, “Prescription of opioid analgesics and related harms in 
Australia”, Medical Journal of Australia, vol. 195, No. 5 (2011), pp. 
280-284.
133 This comparison is based on a price of 100 Australian dollars for a 
quarter of a gram of heroin in Queensland, taking into account a 
purity in Queensland of 18.1 per cent (median) at the retail level (for 
quantities not larger than 2 g), and a potency for heroin of 2.67-3.33 
times that of oxycodone. Under those assumptions, 0.25 g of heroin 
would be equivalent to 121-151 mg of pure oxycodone, which is 
higher than the relevant purchase unit for oxycodone (60 mg, net 
of bulking agents). The comparison does not correct for the “bulk 
discount” possibly arising from this discrepancy, but such a correc-
tion (if it could be quantified) would render the price of heroin even 
higher relative to oxycodone. Price and purity data from the Austral-
ian Crime Commission, Illicit Drug Data Report 2011-12.
134 New Zealand reported a price of 1,000 New Zealand dollars per gram 
(approximately 807 United States dollars, using 2012 exchange rates) 
of imported heroin during the reporting years 2011 and 2012, which 
was double the per-unit price of “homebake” (50 New Zealand dol-
lars per 100 mg), despite the greater size of the purchase unit of the 
former.
Fig. 29. Correlation of heroin use versus  
OxyContin use in the United States, 
past-month prevalence among  
population aged 12 or older, 2006-2012
Source: UNODC estimates based on data from National Surveys 
on Drug Use and Health (NSDUH) of the Substance Abuse and 
Mental Health Services Administration and extracted from 
SAMHDA (Substance Abuse and Mental Health Data Archive) 
hosted by the Inter-university Consortium for Political and Social 
Research at the University of Michigan.
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limited data are available. In Afghanistan, a survey in urban 
households showed that over half the women surveyed who 
reported opioid use (64 per cent) were combining heroin 
and/or opium with pharmaceutical painkillers, and 9 per 
cent of opioid-using women used only a prescription 
opioid.135 In recent years, the misuse of tramadol (a lower 
potency opioid) has also been reported.136 in parts of 
Africa, the Middle East and Asia. 
What is clear is that the people who are dependent on 
opioids will move between the different opioids, inter-
changing one for another, all the while increasing their 
risks of serious health consequences. However, in the pres-
ence of accessible and evidence-based treatment, the situ-
ation can be prevented, while supply reduction efforts 
alone are likely to induce a balloon effect where one con-
trolled substance is replaced by another. 
E. COCAINE: OVERVIEW
Cultivation and production
Coca bush cultivation, which remains limited to Plurina-
tional State of Bolivia, Colombia and Peru, continued to 
decline in 2012 with the net area under coca bush cultiva-
tion on 31 December 2012 totalled 133,700 ha, a decline 
of 14 per cent from the previous year’s estimates and the 
lowest levels since the beginning of available estimates in 
1990. That decline was driven mainly by a 25 per cent 
decline in coca bush cultivation in Colombia, from an 
estimated 64,000 ha in 2011 to 48,000 ha in 2012. How-
ever, those figures refer to the net area under coca cultiva-
tion on 31 December of the year given. In 2012, the 
Colombian Government manually eradicated 34,486 ha 
of cultivation and conducted aerial spraying of 100,549 
ha. The addition of geographical data available on the pres-
ence of coca bush cultivation shows that 135,000 ha had 
been under cultivation at some point during 2012.137 The 
greatest reduction in coca bush cultivation in Colombia 
took place in the departments of Nariño, Putumayo, 
Guaviare and Cauca.138 The decline in coca bush cultiva-
tion observed in the Plurinational State of Bolivia contin-
ued in 2012 (25,300 ha in 2012 compared with 27,200 
ha in 2011) and in Peru, where it declined to 60,400 ha 
from 62,500 ha in 2011. As a result, the estimated global 
production of cocaine has also declined. In Colombia, the 
potential production of pure cocaine was estimated at 309 
tons, the lowest level since 1996. (For details see tables on 
coca bush cultivation and production estimates in annex.)
135 United States, Department of State, Bureau for International Narcot-
ics and Law Enforcement, Demand Reduction Program Research 
Brief, “Afghanistan National Urban Drug Use Survey” (December 
2012).
136 World Drug Report 2013 and Report of the International Narcotics 
Board Control for 2012 (E/INCB/2012/1).
137 UNODC, Government of Colombia, Colombia: Coca cultivation 
survey 2012 (June 2013).
138 Ibid.
Seizures
Globally, cocaine seizures have slightly increased over the 
past year, going up to 671 tons in 2012, compared with 
634 tons in 2011, driven largely by increased seizures in 
South America139 (418 tons in 2012 compared with 362 
tons in 2011) and in Western and Central Europe, another 
major cocaine market, where seizures increased from 63 
tons in 2011 to 71.2 tons in 2012.
139 However, there remains the possibility of double-counting of quanti-
ties of cocaine seized, considering that there are joint operations con-
ducted by national agencies together with agencies of other countries.
Fig. 30. Coca bush cultivation 2003-2012
Source: Bolivia: 2002: CICAD and US Department of State, 
INCSR. Since 2003: National Illicit Crop Monitoring System sup-
ported by UNODC. Colombia: National Illicit Crop Monitoring 
System supported by UNODC. Peru: National Illicit Crop Monitor-
ing System supported by UNODC.
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Fig. 31. Seizures of cocaine worldwide and in 
selected countries, 2003-2012
Source: UNODC annual report questionnaire and other official 
sources.
Note: Includes seizures of cocaine salts, coca paste, cocaine base and 
crack cocaine.
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Extent of use
Cocaine use remained stable over 2012, with 14 million-21 
million estimated past-year users globally (0.4 per cent 
annual prevalence). Cocaine use remained high in North 
and South America (1.8 per cent and 1.2 per cent annual 
prevalence rates, respectively), Oceania (1.5 per cent) and 
Western and Central Europe (1 per cent). While there has 
been an increase in cocaine use in North America (between 
2011 and 2012) due to a number of factors explained 
below, prevalence of cocaine use in Western and Central 
Europe declined from an estimated 1.3 per cent in 2010 
to 1.0 per cent in 2012. 
Cocaine: market analysis
Overall, the latest supply indicators suggest that the global 
availability of cocaine has fallen in the medium term. How-
ever, in 2012, there were signs of a levelling-off or even a 
possible rebound in some markets. In addition, given that 
cocaine use is still relatively concentrated in certain mar-
kets, there is a certain degree of uncertainty with respect 
to the extent of the phenomenon in Africa and Asia.
Global cultivation of coca bush is estimated to have fallen 
by approximately one quarter between 2007 and 2012. 
However, it is not clear whether the gradual decline 
brought about a shortage in meeting global demand or 
represented a return to equilibrium following a surplus 
around 2007. Indeed, the total area under cultivation, 
which had been quite stable in the period 2003-2006, at 
153,000-157,000 ha, returned to that range in 2010 and 
2011. The further decline in 2012 brought the total area 
of cultivation down to its lowest level since the beginning 
of available estimates (1990). However, the significance of 
that recent decline is tempered by the improvements in 
the efficiency of the cocaine manufacture process that are 
believed to have taken place over the long term.
Numerous indicators show that the cocaine market in the 
United States experienced a significant drop in cocaine 
availability, beginning around 2006, resulting in sustained 
decreased levels of availability and use. The average cocaine 
purity (wholesale, retail and overall) as recorded in the 
System to Retrieve Information from Drug Evidence 
(STRIDE) database of the United States Drug Enforce-
ment Agency, seizures by the United States Coast Guard 
and United States authorities along the United States-Mex-
ico border, prevalence of past-month and past-year cocaine 
use among the general population, the percentage of the 
workforce testing positive for cocaine based on urinalysis 
testing, among other indicators, all exhibit turning points 
in 2005 or 2006. 
Cocaine reaching the United States is believed to originate 
to a large extent in Colombia and to enter the country via 
Mexico.140 On the basis of the assessment of the Drug 
140 In its reply to the relevant question in the annual report question-
naire, the United States assessed that 95 per cent of cocaine seized 
Enforcement Administration of the United States, it 
appears that, in addition to the decrease in levels of manu-
facture of cocaine, law enforcement efforts that hindered 
the activities of Colombian traffickers may have contrib-
uted to the reduced availability in the United States, as 
well as a possibly self-perpetuating cycle of shortages of 
cocaine and violent conflicts between competing drug traf-
ficking organizations in Mexico.141 In addition, the 
marked decline in coca bush cultivation in Colombia in 
particular may also have contributed to the shortage of 
cocaine in North America. Cultivation of coca bush in 
Colombia halved between 2007 and 2012.
In the United States, the trend in some of the cocaine 
market indicators changed in 2011 and 2012: cocaine sei-
zures rose from 89 tons in 2010 to 106 tons in 2011, and 
the estimated prevalence of past-year cocaine use in the 
population aged 12 years or older rose from 1.5 per cent 
in 2012 originated in Colombia. In terms of the last country from 
which cocaine entered the United States, Mexico and the countries 
of Central America collectively accounted for 96 per cent of seizures 
made in the United States.
141 United States, Department of Justice, Drug Enforcement Adminis-
tration, National Drug Threat Assessment Summary 2013 (November 
2013).
Fig. 32. Indicators of the cocaine market in  
the United States, 2002-2012, indexed 
relative to 2006
Source: Office of National Drug Control Policy, US Government.
Note: Values in 2006 indicated in brackets.
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in 2011 to 1.8 per cent in 2012, following a steady decline 
between 2006 and 2011.
The general behaviour of the cocaine market in the United 
States from 2006 onward appears to be that of a tight 
market where use patterns were constrained by, and thus 
to a certain extent followed, the available supply.142 In 
142 From around 2005 onward, seizures at sea appear to correlate well 
with the prevalence of cocaine use, suggesting that maritime seizures 
reported by the United States reflect cocaine availability reasonably 
particular, the apparent rebound in cocaine use in 2012 
may be associated with a slight comeback in cocaine avail-
ability towards late 2011. However, in 2013 seizures 
returned to a declining trend, suggesting that was only a 
transitory aberration. Moreover, the increase in past-year 
use in 2012 appears to have been driven by the consump-
tion patterns of older users, including past users returning 
to the habit, rather than a predisposition of younger people 
at risk of initiating cocaine use; indeed, the number of 
first-time users actually declined in 2012, while the trend 
in past-year use was increasing only in the older age 
categories. 
South America, long the source of the world’s cocaine 
supply, has seen an increase in terms of consumption of 
cocaine (including crack). The number of past-year cocaine 
users in South America was estimated at almost 2 million 
in the period 2004-2005 and 3.35 million in 2012. A sig-
well (significantly better than seizures at the south-west border). 
When a time lag of one year from the supply indicator (seizures) to 
the demand indicator (prevalence) is introduced (comparing seizures 
in the period 2004-2011 to prevalence in the period 2005-2012, 
rather than using the period 2004-2011), the correlation coefficient 
improves from 0.89 to 0.96.
Fig. 33. Annual prevalence of cocaine use and 
cocaine seizures in the United States, 
2001-2013
Source: Office of National Drug Control Policy (US Government), 
Substance Abuse and Mental Health Services Administration.
a Prevalence data for 2013 were unavailable.
Fig. 34. Year-on-year changes in past-year 
cocaine use and first-time use in the 
United States, by age bracket, 2012 
versus 2011
Source: Substance Abuse and Mental Health Services Administra-
tion, United States.
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Fig. 35. Cocaine retail prices in the United 
States and Western and Central  
Europe, 2003-2012
Source: For European countries, UNODC annual report question-
naires, EMCDDA and Europol; for the United States, estimates 
based on the 2013 National Drug Control Strategy Data Supple-
ment, Office of National Drug Control Policy, United States.
a For 2012, comparable price data for the United States were unavail-
able.
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nificant component of cocaine use in South America is the 
smoking of various forms of cocaine, including crack as 
well as other crude forms of cocaine base.
Brazil contains approximately one half of the population 
of South America; it is a country that is vulnerable to both 
cocaine trafficking, due to its geography (which makes it 
a convenient staging area for cocaine trafficked to Europe), 
as well as to cocaine consumption, due to its large urban 
population. The last official estimate of annual prevalence 
of cocaine use in Brazil based on a general population 
survey dates to 2005. A more recent survey143 among col-
lege students in Brazilian state capitals estimated the annual 
prevalence of use of cocaine powder among college stu-
dents (of all ages) at 3 per cent in 2009. 
In Western and Central Europe, supply indicators overall 
suggest a possible rebound in availability of cocaine. Fol-
lowing a clear decline from the peak of 2006, cocaine sei-
zures reached a low in 2009 at 53 tons and climbed back 
to 71 tons by 2012. The increase in 2012 was, however, 
concentrated in a few important transit countries, notably 
Belgium, Spain and, to a lesser extent, Portugal, while 
major consumer countries such as France, Germany and 
Italy registered decreases. However, the retail purity of 
cocaine increased in some countries with sizeable consumer 
markets, such as France, Germany and the United King-
dom. Consequently, on the basis of data from 14 countries 
in Western and Central Europe with relatively good avail-
ability of both price and purity data, the estimated 
weighted average of the purity-adjusted retail price in West-
143 Brazil, National Drug Policy Secretariat (SENAD), First Nationwide 
Survey on the Use of Alcohol, Tobacco and Other Drugs among College 
Students in the 27 Brazilian State Capitals (Brasilia, 2010).
ern and Central Europe fell significantly, with the equiva-
lent (constant across countries) purity returning to its 
highest level since 2005. 
On the demand side, the data currently available do not 
indicate any changes in the recent overall decreasing trend 
in cocaine use in Western and Central Europe; that indi-
cation, however, is inconclusive, given that data on use are 
usually updated less frequently and less promptly than 
supply indicators such as seizures, prices and purity, and 
that changes in use may follow changes in availability with 
a short time lag. The apparent increasing availability in 
Europe (if confirmed to be real), could possibly be driven 
by an increasing supply originating in Peru,144 and if the 
trend in use continues to diverge from the trend in avail-
ability, it would raise the question of whether a portion of 
the cocaine entering Europe is possibly destined for emerg-
ing markets outside the established markets in Western 
and Central Europe.
One such possible destination could be Oceania, where 
the market has expanded in recent years and where prices 
are higher than in Western and Central Europe. Cocaine 
seizures in Oceania reached a record of 1.9 tons in 2010, 
and remained high in 2012, at 1.6 tons. In particular, past-
144 The small decline in coca bush cultivation in Peru registered in 2012 
was probably too recent to have an impact on indicators in Europe in 
2012. As of 2011, cultivation in Peru had increased for six consecutive 
years (by 34 per cent), while in Colombia it stood at approximately 
one third less than the peak level of 2007, and in the Plurinational 
State of Bolivia, where the cultivation area continued to be signifi-
cantly lower than both Colombia and Peru, it fell to the lowest level 
since 2005. An increase in cocaine originating in Peru is also borne 
out by data from Australia (see figure 38 and relevant discussion). See 
also Cocaine Smuggling in 2011, produced for the United States Office 
on National Drug Control Policy.
Fig. 36. Reported retail purities of cocaine salts in Western and Central Europe, 2011 and 2012 
(typical purity and ranges)
Source: UNODC annual report questionnaire and other official data.
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Fig. 37. Annual prevalence of cocaine use 
(2012) versus cocaine retail prices, 
nominal and adjusted by purchasing 
power parity (unadjusted for purity), by 
region, 2011-2012
Source: UNODC estimates based on World Bank Purchasing Power 
Parities and annual report questionnaire, supplemented by other 
official sources
a Price data for Africa were available from a very limited number of 
countries.
b An international dollar would buy in the region concerned a compara-
ble amount of goods and services a United States Dollar would buy in 
the United States.
tralia (including possibly through Europe) although, as of 
mid-2012, Colombia remained foremost among the three 
producer countries. 
In Eastern Europe, seizures of cocaine continue to be lim-
ited. Aside from Latin America, countries in Eastern 
Europe exclusively cited European countries as transit 
countries for cocaine reaching their territory in 2010-2012. 
It is likely that the Baltic region serves as an entry point 
for cocaine entering the Russian Federation.146 Limited 
quantities of cocaine may also reach Central and Eastern 
Europe from the south, via countries in Eastern and South-
Eastern Europe, including countries traditionally associ-
ated with the Balkan route for heroin entering Europe.147
The extent of drug trafficking and consumption in Africa 
is hard to assess. Although seizures in the subregion of West 
and Central Africa remained below 3 tons in 2012 (includ-
ing 2.2 tons seized in Cabo Verde alone), cocaine traffick-
ing via West Africa to Europe is believed to be continuing. 
In 2012, Algeria in particular registered a spike in cocaine 
seizures, reporting that cocaine transited through countries 
in West and Central Africa prior to seizure, and identify-
ing trafficking by air as the main mode of transportation. 
Some of the cocaine may also be diverted to other destina-
146 Finland, Latvia and Lithuania all identified the Russian Federation as 
being among the destinations of cocaine seized on their territory at 
least once over the reporting years 2010-2012.
147 This is suggested by a combined analysis of replies to the annual 
report questionnaire submitted by Albania, Austria, Belarus, Bulgaria, 
Hungary, Poland, Romania, Serbia, Turkey and Ukraine. See also the 
World Drug Report 2013, pp. 44-45.
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Fig. 38. Origin of coca leaf used to produce  
cocaine as a proportion of analysed 
seizures made by the Australian  
Federal Police, by number and by total 
weight  of seizures, 2007-2012 
Source: Australian Crime Commission.
a January-June only.
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year use of cocaine among the general population aged 14 
years or older in Australia rose from 1.6 per cent in 2007 
to 2.1 per cent in 2010, although the average frequency of 
consumption appears to be low,145 possibly due to the high 
prices. Indeed, this is corroborated by the fact that Oceania 
is something of an exception among the major consumer 
markets, in that both the price and the prevalence are rela-
tively high, while the retail price would be expected to have 
an inverse relationship to the levels of use, especially when 
adjusted for purchasing power parity (all other factors 
being equal).
In terms of the number of cocaine seizure cases in 2012, 
categorized by country of departure, Australia ranked the 
Netherlands first and Germany second. It is likely that the 
majority of those seizures were of small consignments; in 
terms of weight, and with reference to a slightly different 
reporting period (July 2011-June 2012), the most promi-
nent European country was the United Kingdom (in fifth 
place). Moreover, it appears that Peru has increased in 
importance as a country of origin of cocaine reaching Aus-
145 Amanda Roxburgh and others, Trends in Drug Use and Related Harms 
in Australia, 2001 to 2013, p. 108.
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39F. Cannabis: overview
tions, possibly including Asia; it is also likely that there is 
a link with South Africa.148
The estimated prevalence of cocaine use in South Africa 
rose from 0.78 per cent of the general population in the 
15-64 age bracket in 2008 to 1.02 per cent in 2011, con-
firming the continued existence of a sizeable and appar-
ently expanding consumer market for cocaine. Owing to 
the paucity of supply-side data, it was not possible to com-
plete the picture of the situation in that country.
Seizures of cocaine in East Africa, while still small on a 
global scale, have also increased in recent years, notably in 
the United Republic of Tanzania.
The extent of cocaine use in Asia has always been limited, 
and the most recent available evidence does not give reason 
to change that assessment. Nevertheless, cocaine has made 
its first inroads in this continent, and as pockets of con-
sumption, trafficking and trade in cocaine emerge, factors 
including affluence149 appear to play a role in determining 
which countries are affected first. In 2012, the largest 
aggregate quantities of cocaine seizures in Asia were those 
seized in Hong Kong, China, followed by the United Arab 
Emirates and Israel (in that order). The United Arab Emir-
ates, a prominent stopover point for air passenger traffic, 
has been identified as a transit country by a disparate group 
of countries with a small, possibly emerging market for 
cocaine, including countries in Asia and Africa. Israel and 
148 Nigeria identified South Africa as being among the countries of prov-
enance for seized cocaine every year from 2009 to 2012. However, 
among individual cocaine seizures made in West and Central Africa 
since 2006, a small number (14) of cocaine consignments (including 
9 seized by Nigeria) were seized on their way to South Africa, but 
none were seized entering the region from South Africa.
149 See also the World Drug Report 2013, p. 40.
Lebanon appear to be destination countries for cocaine, 
with Jordan and the Syrian Arab Republic serving as transit 
countries.150 Annual seizures in China and India were 
below 100 kg in 2011; more significant, relative to the size 
of the population, were the quantities (each in excess of 
25 kg) seized in Japan, Saudi Arabia and Thailand in 2011.
F. CANNABIS: OVERVIEW
Cultivation and production
Cannabis cultivation remains widespread in most regions, 
ranging from personal cultivation to large-scale farm and 
indoor warehouse operations, thus making it difficult to 
estimate the global levels of cannabis cultivation and pro-
duction. While cannabis herb is grown in almost every 
country in the world,151 the production of cannabis resin 
is confined to only a few countries in North Africa, the 
Middle East and South-West Asia. In Afghanistan, on the 
basis of available cultivation and production estimates, in 
2012, the total area under cultivation of cannabis was 
10,000 ha, down from 12,000 ha in 2011. But potential 
resin production, due to higher yields per hectare, was 
estimated at 1,400 tons in 2012, compared with 1,300 
tons in 2011. The decline in the price of cannabis resin in 
Afghanistan between December 2011 and December 2012 
supports the assumption of a possible increase in availabil-
ity over that period.152
150 UNODC annual report questionnaire and other official data.
151 World Drug Report 2013.
152 UNODC and Afghanistan, Ministry of Counter-Narcotics, “Afghani-
stan opium price monitoring monthly report” (December 2012).
Fig. 39. Cocaine consumption and purity- 
adjusted price in Western and Central 
Europe, weighted by population of 
countries, 2003-2012
Source: UNODC annual report questionnaire.
Note: Prevalence figures displayed as moving average.
Fig. 40. Cocaine prevalence and purity- 
adjusted price, United States,   
2003-2012
Source: UNODC annual report questionnaire, and Substance 
Abuse and Mental Health Services Administration and price data 
from the System to Retrieve Information from Drug Evidence 
(STRIDE) database of the United States Drug Enforcement Agency.
Note: Prevalence figures displayed as moving average
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Among countries reporting in 2012 through the annual 
report questionnaire, Italy, the United States and Ukraine 
reported eradication of a large number of plants and cul-
tivation sites. 
Seizures
Global cannabis herb seizures in 2012 were reported at 
5,350 tons, down from the 6,260 tons reported in 2011. 
With the exception of the Caribbean and Europe, seizures 
have declined slightly in most regions. The largest quanti-
ties of cannabis herb were seized in North America, which 
accounts for over 64 per cent of seizures worldwide. 
In contrast to cannabis herb, cannabis resin seizures 
increased in 2012, with 1,269 tons seized, compared with 
1,058 tons in 2011. Resin seizures increased significantly 
in Afghanistan, from 62 tons in 2011 to 160 tons in 2012, 
and in North Africa (mainly due to increases reported in 
Algeria (rising from 53 tons to 157 tons) and, to a lesser 
extent, in Morocco (rising from 126 tons to 137 tons). 
Spain accounts for 26 per cent of global cannabis resin 
seizures; although seizures in that country declined slightly 
from 2011 (356 tons) to 2012 (326 tons).
Based on an analysis of supply indicators for cannabis herb 
at the retail level (see annex for details), availability remains 
high in the Americas and appears to be growing in the 
subregion of Western and Central Europe and in South-
Eastern Europe. Despite reports of falling seizures, con-
sumer access to marijuana herb is likely increasing in North 
America, Oceania, Western and Central Europe and 
South-Eastern Europe. When retail prices are adjusted by 
taking into account purchasing power in order to compare 
prices worldwide, cannabis herb is found to be relatively 
inexpensive in North America, cheapest in Africa and 
South Asia (India and Sri Lanka) and most expensive in 
East and South-East Asia.
As for eradication of outdoor sites and plants, the United 
States reported a major decrease in sites eradicated (6,470 
sites eradicated in 2012 compared with 23,622 sites in 
Fig. 41. Production of cannabis resin in  
Afghanistan and seizures in neigh-
bouring countries, 2009-2012
Source: Afghanistan cannabis surveys (published by UNODC) and 
UNODC annual report questionnaires.
Fig. 42. Seizures of cannabis resin worldwide 
and in selected countries, 2003-2012
Source: UNODC annual report questionnaire.
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2011), but it is not known to what extent the decrease was 
due to declining law enforcement activity in that area or 
to increasing licit cultivation due to the new cannabis laws 
in the States of Colorado and Washington. The other coun-
tries reporting high numbers of cannabis plants and cul-
tivation sites eradicated are given in the table below.
Extent of use
In 2012, between 125 million and 227 million people were 
estimated to have used cannabis, corresponding to between 
2.7 and 4.9 per cent of the population aged 15-64 years. 
West and Central Africa, North America, Oceania and, to 
a lesser extent, Western and Central Europe remain the 
regions with prevalence rates considerably higher than the 
global average. Over the past five years in North America, 
the largest cannabis herb market, prevalence rates have 
followed an upward trend in the United States153 but 
declined in Canada between 2008 and 2011, increasing 
again between 2011 and 2012.154 Although recent epide-
miological data from Asia are not available, experts from 
nearly half of the countries in Asia consider cannabis use 
to be increasing in the region.
Cannabis: market analysis
Lower perceived risk and increased harm in consumer 
markets
Worldwide, the cannabis market (herb and resin) contin-
ues to expand, with almost two thirds of reporting coun-
tries ranking cannabis as the primary substance of abuse.155 
In major consumer markets, treatment enrolment and hos-
pitalizations related to cannabis use have been increasing. 
In the United States, between 2006 and 2010, there was 
153 United States, Department of Health and Human Services, Substance 
Abuse and Mental Health Services Administration , “Monitoring the 
Future Surveys”.
154 Health Canada, 2012 Canadian Alcohol and Drug Use Monitoring 
Survey (Ottawa, 2013).
155 UNODC, annual report questionnaire for 2012.
a 59 per cent increase in cannabis-related emergency 
department visits156 and a 14 per cent increase in cannabis-
related treatment admissions.157,158 Additionally, accord-
ing to the Potency Monitoring Project of the University 
of Mississippi, levels of tetrahydrocannabinol (THC) in 
seized or eradicated cannabis herb crops in the United 
States increased from 8.7 per cent in 2007 to 11.9 per cent 
in 2011. Because of the relationship between increased 
potency and dependence, that trend may be contributing 
to the increased risk of drug use disorders and 
dependence.159 
156 United States, Department of Justice, Drug Enforcement Adminis-
tration, National Drug Threat Assessment Summary 2013 (November 
2013), p. 12.
157 Data from Treatment Episode Data set as reported in the 2013 
National Drug Threat Assessment Summary.
158 United States, Drug Enforcement Administration, National Drug 
Threat Assessment Summary 2013, p. 12.
159 Ibid.
Table 6. Countries reporting eradication of cannabis plants and sites, 2012
Source: UNODC annual report questionnaire and government data.
Country (in order of area eradicated) Eradication (outdoors) Eradication (indoors)
Plants Sites Plants Sites
Italy 4,114,911 1,318 United States 302,377 2,596
United States 3,631,582 6,470 Switzerland 83,450  
Ukraine 2,200,000 New Zealand 21,202 783
Tajikistan 2,180,121 Chile 18,526 1,377
Philippines 1,224,738 188 Australia 17,668 322
Costa Rica 965,320 129 Italy 7,706 458
Brazil 616,133 5 Latvia 3,796 4
Indonesia 341,395 Slovakia 2,927 
Chile 216,902 291
Republic of Moldova 152,961
New Zealand 119,059
Fig. 44. Lifetime, past-year, and past-month use 
of cannabis herb among people 12 years 
and older, United States, 2008-2012
Source: Substance Abuse and Mental Health Services Administra-
tion survey of the United States.
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Increase in supply of cannabis herb in South-Eastern 
Europe and Central Asia
With respect to supply measures, although global seizures 
have declined 24 per cent (from 7,049 tons in 2010 to 
5,351 tons in 2012), the market for cannabis herb has 
become more diversified, with the largest percentage 
increases in seized herb noted in markets where cannabis 
resin had previously been predominant throughout West-
ern, Central and South-Eastern Europe. Concomitant with 
the seizure increases, prices of cannabis herb have increased 
significantly in South-Eastern Europe and Central Asia. 
Since 2009, cannabis prices in Turkey have increased the 
most among all countries reporting worldwide. Increases 
in herb price were also noted in the region, in Azerbaijan, 
Kazakhstan, Kyrgyzstan, Greece and Uzbekistan.
Overall, cannabis resin seizures have increased for the third 
straight year, with decreases in the Americas and Europe 
and increases in Africa and Asia. Further, the price of resin 
has also increased in Kazakhstan, Kyrgyzstan and Pakistan, 
a regional phenomenon potentially related to higher levels 
of regional interdictions, which is likely resulting in supply 
shortfalls at the consumer level. 
Seizures of cannabis herb now equivalent to cannabis 
resin in the European markets
There continues to be evidence that cannabis resin is 
decreasing in popularity in Europe. Whereas cannabis resin 
had previously dominated the market, now there are nearly 
equivalent levels of resin and herb seizures, implying a 
continuing shift away from imported resin coming mainly 
from Morocco to more locally or regionally produced can-
nabis herb. Unfortunately, drug use surveys typically do 
not distinguish between cannabis resin and herb; therefore 
this cannot be corroborated by drug use data.
Price declines in North America together with higher 
potency levels
Regarding the cannabis herb market in countries with regu-
Fig. 45. Trends in lifetime use among school 
children, United States, 2008-2013 
Source: Monitoring the Future Survey, United States.
Fig. 46. Average price per gram of cannabis 
herb self-reported by users, by level  
of quality, United States, 2010-2013
Source: PriceOfWeed.com.
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Fig. 47. Change in inflation-adjusted retail 
price, from the biennium 2009-2010  
to the biennium 2011-2012, weighted 
average (percentage)
Source: UNODC annual report questionnaire.
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The phenomenon of increased harm is not unique to one 
specific region. Nearly two thirds of those enrolled in drug 
treatment in Africa listed cannabis as their primary drug 
of use, and in Brazil, increasing dependence among can-
nabis users has been reported.160 In a recent national 
survey in Pakistan, three in four past-year cannabis users 
(mostly users of cannabis resin), were found to be depend-
ent.161 However, among key informants, the herbal form 
of cannabis (consumed in a traditional drink called 
“bhang”) was ranked as the tenth most harmful drug, 
whereas resin was ranked as the second most harmful.162
160 Data from the Brazilian National Alcohol and Drugs Survey (BNADS 
II), Cannabis use in Brazil, 2012.
161 UNODC and Pakistan, Drug use in Pakistan, 2013.
162 Ibid.
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latory changes such as the United States and Uruguay, 
changes in rates of interdiction and in prices are expected. 
Between 2009 and 2012 in the United States, the price of 
cannabis herb declined 12 per cent163 after adjustment for 
inflation. According to self-reported information on pur-
chases reported to the PriceOfWeed website, since 2010, 
the price, adjusted for quality, has fallen only 6 per cent, 
but the price of high-quality cannabis herb has fallen 20 
per cent, and the price of medium-quality cannabis herb 
has risen 40 per cent. Overall, the prices of various quali-
ties of cannabis herb have converged, implying that the 
price of cannabis herb in the United States has become less 
variable, indicating more retail market integration.164
Changing cannabis policy in the Americas
Recent policy changes to cannabis regulation in Uru-
guay165 and in the states of Washington166 and Colo-
rado167 in the United States168 now make the authorized 
production, distribution and consumption of marijuana 
legal,169 under some conditions, such as purchasing age. 
The International Narcotics Control Board has expressed 
concern that “a number of States that are parties to the 
163 UNODC, annual report questionnaire.
164 Price data retrieved on self-reported price, quality and location infor-
mation for the United States, submitted to the PriceOfWeed.com 
website.
165 Uruguay, Law No. 19.172. In Uruguay, prior to passing of the new 
law legislation already exempted from punishment the possession of a 
“reasonable quantity” (of any drug) intended exclusively for personal 
use. The new legislation now permits cannabis cultivation, produc-
tion and sale for recreational use.
166 United States, State of Washington, Initiative Measure No. 502. 
Available at http://lcb.wa.gov/publications/Marijuana/I-502/i502.
pdf.
167 Data from Amendment 64: Use and Regulation of Marijuana 
(United States, Constitution of the State of Colorado, art. XVIII, 
sect. 16). Available at www.fcgov.com/mmj/pdf/amendment64.pdf.
168 The United States federal Controlled Substances Act continues to 
prohibit cannabis production, trafficking and possession. 
169 For non-medical and non-scientific uses.
1961 Convention are considering legislative proposals 
intended to regulate the use of cannabis for purposes other 
than medical and scientific ones” and it urged “all Govern-
ments and the international community to carefully con-
sider the negative impact of such developments.” In the 
Board’s opinion “the likely increase in the abuse of cannabis 
will lead to an increase in related public health costs”.170
Although in those three jurisdictions, the purchase, pos-
session and consumption of cannabis are now legal, the 
details, design and implementation of the new laws vary 
significantly. For example, in Uruguay users must register 
in a database to monitor cumulative purchases (maximum 
40 g per month),171 but in the State of Colorado, pur-
chases of up to 1 oz (28 g) are allowed per outlet, with no 
central registry of cumulative purchases per buyer nor any 
limit on the amount that can be purchased each month.172 
Because of these and other notable differences in each law, 
there is unlikely to be one uniform impact of these policy 
changes, but rather measurable distinct changes reflecting 
the contexts of each jurisdiction. 
The impact of the new legislation could differ substantially 
from current cases of depenalization, decriminalization or 
“medical” cannabis laws by allowing the establishment of 
a licit supply chain, including large-scale licensing for pro-
duction, personal cultivation and retail commercializa-
tion173 of the market. While it is not yet clear how the 
market will change, the commercialization of cannabis may 
also significantly affect drug-use behaviours. Commerciali-
zation implies motivated selling, which can lead to directed 
advertisements that promote and encourage consumption. 
170 Report of the International Narcotics Control Board for 2013 (E/
INCB/2013/1).
171 Uruguay, Law No. 19.172. 
172 United States, State of Colorado, Amendment 64, sect. 5, part 2. 
173 In the states of Colorado and Washington, for-profit businesses can 
enter the market and use any means that are within the law to pro-
mote production, consumption and profits.
Fig. 48. Trends in seizures of cannabis resin and herb, Europe, 2003-2012
Source: UNODC annual report questionnaire
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For instance, in the case of tobacco companies, advertising 
was directed to attract new users, which resulted in effec-
tive marketing to youth.174 
Because laws of this kind have never before been enacted 
or implemented in a national or state jurisdiction, no pre-
vious case studies are available to predict what changes 
should be expected. Thus, monitoring and evaluation will 
provide critical data for policymakers. For this reason, it 
is important that the impacts of this legislation are meas-
ured against a number of factors, ranging from the impact 
on health and criminal justice (effects on the individual as 
well as institutions and society) to the balance of public 
revenues against costs and to other social impacts.
At this time, countries and states surrounding Uruguay, 
Colorado and Washington have not adopted similar regu-
latory or legislative measures. In consideration of this, addi-
tional outcomes that need to be monitored include drug 
tourism, cross-border leakage and access and availability 
to youth in neighbouring jurisdictions.
Health
While research has not conclusively established the impact 
of more lenient laws on cannabis consumption, an increase 
in prevalence of cannabis use from recreational use sales is 
expected, although it is also possible that the primary effect 
– particularly in the first decade or so – may differ from 
longer-term impacts. Expert analyses predict that the legali-
zation of cannabis will most likely reduce production costs 
substantially,175 which would in turn be expected to put 
downward pressure on prices over time, although whether 
lower prices materialize in the first few years or only in the 
longer term is unknown. Since cannabis consumption 
responds to prices, the lower price will probably lead to 
higher consumption.176 It is estimated that for each 10 
per cent drop in price, there will be an approximately 3 
per cent increase in the total number of users177 and a 3-5 
per cent increase in youth initiation.178 
Initiation and use among youth and young adults is of 
particular concern due to the established increased risk of 
harm, such as other drug use and dependent drug use,179 
174 United States, Center for Public Health and Tobacco Policy, “Cause 
and effect: tobacco marketing increases youth tobacco use - findings 
of the 2012 Surgeon General’s report (Boston, 2012). Available at 
www.tobaccopolicycenter.org/documents/SGR%20NY%205-25-12.
pdf.
175 Researchers estimate that the pre-tax retail price will decline by more 
than 80 per cent, but the eventual consumer price will depend on 
the tax-structure. See Beau Kilmer and others, Altered State? Assessing 
How Marijuana Legalization in California could Influence Marijuana 
Consumption and Public Budgets (Santa Monica, California, RAND 
Corporation, Drug Policy Research Center, 2010).
176 J. P. Caulkins and others, “Design considerations for legalizing can-
nabis: lessons inspired by analysis of California’s Proposition 19”, 
Addiction, vol. 107, No. 5 (2011), pp. 865-871.
177 Beau Kilmer and others, Altered State? 
178 Rosalie Liccardo Pacula, “Examining the impact of marijuana legaliza-
tion on marijuana consumption: insights from the economics litera-
ture” (RAND Corporation, Working Papers, July 2010).
179 Research by the United States Substance Abuse and Mental Health 
a risk of heavy dependence, lung problems, memory 
impairment, psychosocial development problems and 
mental health problems, and poorer cognitive performance 
associated with early initiation and persistent use between 
the early teenage years and adulthood.180, 181 For youth 
and young adults, more permissive cannabis regulations 
correlate with decreases in the perceived risk of use,182 and 
lowered risk perception has been found to predict increases 
in use.183  
Although it is an important metric to monitor, increases 
in prevalence of cannabis use may not provide a reliable 
Services Administration has shown initiation of marijuana use 
before the age of 15 is associated with higher risk of other drug use 
at 26 or older, and that those who tried marijuana before the age 
of 15 were six times more likely to be dependent on an illicit drug 
at 26 or older (relative to those who initiated marijuana at 21 or 
older). (See Joseph C. Gfroerer, Li-Tzy Wu and Michael A. Penne, 
Initiation of Marijuana Use: Trends, Patterns, and Implications, Sub-
stance Abuse and Mental Health Services Administration, Rockville, 
Maryland, 2002.)   
180 M. H. Meier and others, “Persistent cannabis users show neuro-
psychological decline from childhood to midlife, Proceedings of the 
National Academy of Sciences of the United States of America, vol. 
109, No. 40 (October 2012), pp. E2657-E2664.
181 A. Caspi and others, “Moderation of the effect of adolescent-onset 
cannabis use on adult psychosis by a functional polymorphism in the 
catechol-Omethyltransferase gene: longitudinal evidence of a gene X 
environment interaction”, Biological Psychiatry, vol. 57, No. 10 (15 
May 2005), pp. 1117–1127; Wayne Hall and Louisa Degenhardt, 
“Adverse health effects of non-medical cannabis use”, The Lancet, vol. 
374, No. 9698 (October 2009), pp. 1383–1391; Wayne Hall, “The 
adverse health effects of cannabis use: What are they, and what are 
their implications for policy?”, International Journal of Drug Policy, 
vol. 20, No. 6 (2009), pp. 458–466; A. D. Schweinsburg, S. A. 
Brown and S. F. Tapert, “The influence of marijuana use on neuro-
cognitive functioning in adolescents”, Current Drug Abuse Review, 
vol. 1, No. 1 (2008), pp. 99–111; D. M. Fergusson and J. M. Boden, 
“Cannabis use and later life outcomes”, Addiction, vol. 103, No. 
6 (2008), pp. 969–976 and discussion pp. 977–968; E. Gouzou-
lis-Mayfrank, “Dual diagnosis psychosis and substance use disorders: 
theoretical foundations and treatment” [article in German], Zeitschrift 
für Kinder- und Jugendpsychiatrie und Psychotherapie, vol. 36, No. 4 
(2008), pp. 245–253; J. Macleod and others,“Psychological and social 
sequelae of cannabis and other illicit drug use by young people: a 
systematic review of longitudinal, general population studies”, The 
Lancet, vol. 363, No. 9421 (2004), pp. 1579–1588; John Curtis, 
“Study suggests marijuana induces temporary schizophrenia-like 
effects”, Yale Medicine, vol. 39, No. 1 (Fall/Winter 2004); “Neuro-
toxicology: neurocognitive effects of chronic marijuana use charac-
terized”, Managed Care Weekly Digest (16 May 2005); J. McGrath 
and others, “Association between cannabis use and psychosis-related 
outcomes using sibling pair analysis in a cohort of young adults”, 
Archives of General Psychiatry, vol. 67, No. 5 (2010), pp. 440-447; L. 
Goldschmidt and others, “Prenatal marijuana exposure and intelli-
gence test performance at age 6”, Journal of the American Academy of 
Child and Adolescent Psychiatry, vol. 47, No. 3 (March 2008), pp. 254-
263; J. M. Tertrault and others,  “Effects of marijuana smoking on 
pulmonary function respiratory complications: a systematic review”, 
Archives of Internal Medicine, vol. 167, No. 3 (2007), pp. 221-228; 
BMJ-British Medical Journal, “Cannabis use doubles chances of vehi-
cle crash, review finds”, in Science Daily (10 February 2012).
182 S. Khatapoush and D. Hallfors, “Sending the wrong message: did 
medical marijuana legalization in California change attitudes about 
and use of marijuana”, Journal of Drug Issues, vol. 34, No 4 (Octo-
ber 2004), pp. 751-770.
183 See L. D. Johnston and others, Monitoring the Future National 
Survey Results on Drug Use 1975-2012:  Key Findings on Adolescent 
Drug Use (Institute for Social Research, University of Michigan, 
2012).
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estimate of the greatest impact on health, since many users 
use cannabis only occasionally. One aspect to consider is 
that there is a general, demonstrated increased potency of 
cannabis in Europe and North America,184 which may 
translate into more potent cannabis being available under 
the new laws and may lead to greater health consequences 
than in past years (although a clear link between potency 
and harm has not been conclusively established). Critical 
areas of harmful use — such as heavy185 or dependent use, 
as well as the age of initiation and sustained use — should 
also be carefully monitored. 
Looking at the health impact, it is also important to try to 
determine if there is a substitution effect whereby cannabis 
replaces other substances (such as alcohol or more harmful 
drugs such as heroin) or, conversely, a complementary 
effect whereby greater use of cannabis leads to greater use 
of other substances. After drug law reforms in Portugal 
that decriminalized drug possession for personal use in 
2001, referrals186 for cannabis increased from 47 per cent 
of referrals in 2001 to 65 per cent in 2005, but referrals 
for heroin decreased from 33 per cent to 15 per cent, and 
cocaine remained stable at 4-6 per cent.187 One study in 
the United States found that while cannabis-related hos-
pital admissions went up after the decriminalization of 
cannabis in the period 1975-1978, admissions for other 
drugs went down.188  
Criminal justice
Criminal justice procedures related to possession for per-
sonal consumption are likely to decrease significantly in 
the context of the new laws, whereas control of other can-
nabis-related activities, such as cultivation, sale and distri-
bution, will continue to require routine monitoring owing 
to explicit limitations set forth in the legislation.
The different ways countries have implemented the inter-
national drug control conventions determines the extent 
to which an individual will encounter the criminal justice 
system for drug possession for personal use, and penalties 
can range from a warning to more severe consequences, 
such as incarceration. In countries with depenalization189 
184 E. L. Sevigny and others, “The effects of medical marijuana laws 
on potency”, International Journal of Drug Policy, vol. 25, No. 2 (18 
January 2014), pp. 308-319.
185 Heavy use is defined as daily or near daily use.
186 Panel of three people known as the “commission for the dissuasion 
of drug addiction” (Comissões para a Dissuasão da Toxicodependên-
cia).
187 Caitlin Hughes and Alex Stevens, “The effects of decriminalization 
of drug use in Portugal”, Briefing Paper 14 (Beckley Foundation 
Drug Policy Programme, December 2007). Available at http://kar.
kent.ac.uk.
188 Karyn Model, “The effect of marijuana decriminalisation on hos-
pital emergency room drug episodes: 1975-1978”, Journal of the 
American Statistical Association, vol. 88, No. 423 (September 1993), 
pp. 737-747.
189 Depenalization refers to any policy that reduces penalties, quan-
titatively (amount of penalty) or qualitatively (type of penalty), 
associated with possession or use of cannabis for non-medical or 
non-scientific purposes, but there are variations from country to 
of possession for personal use, penalties are reduced or 
eliminated, but there remains a criminal justice encounter 
whereby the individual would still face some consequences 
or rehabilitation. The new legal status of the possession of 
cannabis in Uruguay and the states of Colorado and Wash-
ington means that no such mechanism is provided for. 
Over the past decade, across 45 countries, the number of 
people who have been in contact with the authorities (sus-
pected or arrested ) for personal drug use and possession 
offences has increased by one third (see the section on 
drug-related crime (drug law offences)).190 Among these 
encounters with authorities, cannabis is involved in the 
majority of cases in every region of the world. There are 
no data that can show how many of those apprehended 
were ultimately prosecuted, convicted and incarcerated. 
To estimate the overall criminal justice impact of increas-
ingly permissive laws on cannabis is not an easy task. Laws 
regarding cannabis possession affect both the broader insti-
tutional criminal justice system and the individual. For 
example, a research study in Australia compared, in one 
area, a group of individuals that received criminal convic-
tions for cannabis offences with a second group of indi-
viduals who had been given only infringement notices; 
those convicted were far more likely to experience adverse 
employment consequences, recidivism, relationship prob-
lems and accommodation difficulties attributed to their 
offence.191,192 
Although it has been mentioned as a rationale for policy 
change in several cases, the expected impact on the broader 
criminal networks of drug cartels is unknown. Because so 
much of cannabis cultivation is local,193 drug cartels oper-
ating in other illicit activities and other drug markets (e.g., 
cocaine, heroin and methamphetamine) would likely be 
only modestly affected after cannabis legalization. (Given 
their population sizes, Uruguay and the states of Colorado 
and Washington constitute a very small cannabis market). 
Although little research is available on the topic, experts 
estimate cartel losses of nearly $3 billion from the initia-
tives that passed in Colorado and Washington — with 
20-30 per cent cuts in profits.194 However, in another 
analysis of the potential impact of cannabis legalization in 
country in the respective laws and how they are enforced. Decrim-
inalization implies a change in the nature of the consequences of 
possession or use, from criminal penalties to administrative or civil 
penalties or to no penalties.
190 In the United States, approximately 750,000 people are arrested each 
year for cannabis possession. A similar order of magnitude in the 
number of arrests is seen in the European Union, with nearly 800,000 
arrested for cannabis-related drug offences in 2011. 
191 S. Lenton and others, “Laws applying to minor cannabis offences in 
Australia and their evaluation”, International Journal of Drug Policy, 
vol. 10, No. 4 (1999), pp. 299-303. 
192 Robin Room and others, Cannabis Policy Moving Beyond Stalemate 
(Oxford University Press, 2010). 
193 UNODC, World Drug Report 2011.
194 Alejandro Hope and Eduardo Clark, “Si los vecinos legalizan: reporte 
técnico”, Instituto Mexicano para la Competitividad (October 2012). 
Available at www.imco.org.mx.
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the state of California on Mexican drug trafficking organi-
zations, researchers concluded that legal changes in one 
state (in this case, California) would not be enough to 
greatly diminish the market for Mexican cannabis, but if 
prices dropped significantly nationwide as a result of the 
spillover to other states, cartel revenue could be affected 
substantially in the long term. The authors could not une-
quivocally predict a decline in drug-related violence in 
Mexico as a result of cannabis legalization, as there was no 
basis for comparison.195
Economic costs and benefits
Tax revenues from retail cannabis sales may provide sig-
nificant revenue, although there is uncertainty concerning 
how much can be raised. In the ballot initiative of Colo-
rado, it was stipulated that tax revenues from the sale of 
cannabis were to be used to provide $40 million for school 
construction. Based on assumptions about the size of the 
market, it was estimated that the ballot measure would 
bring in as much as $130.1 million in revenue over the 
period 2014-2015.196 Legalization may also increase 
income and social security tax revenues by shifting labour 
from criminal to legal and taxed activities.   
However, in Uruguay and the states of Washington and 
Colorado, significant costs will also be incurred through 
the establishment of programmes to deter cannabis abuse 
and regulate the new industry. Based on assumptions 
regarding the size of the consumer market, it is unclear 
how legalization will affect public budgets in the short or 
long term, but expected revenue will need to be cautiously 
balanced against the costs of prevention and health care. 
In addition to the impact on health, criminal justice and 
the economy, a series of other effects such as consequences 
related to security, health care, family problems, low per-
formance, absenteeism, car and workplace accidents and 
insurance could create significant costs for the state. It is 
also important to note that legalization does not eliminate 
trafficking in that drug. Although decriminalized, its use 
and personal possession will be restricted by age. Therefore, 
the gaps that traffickers can exploit, although reduced, will 
remain. 
The collection of reliable data both before and after these 
policy changes will support the evaluation of the health, 
criminal justice and economic consequences of the new 
regulatory frameworks. Further, careful study of the effects 
on local and transnational organized crime networks will 
allow evidence-based decisions to inform policy in this area 
at the national and regional levels. The impact of this 
legislation can be evaluated only if it is appropriately 
measured through reliable data-gathering and regular 
monitoring efforts.
195 Beau Kilmer and others, Reducing Drug Trafficking Revenues and 
Violence in Mexico, Would Legalizing Marijuana in California Help? 
(Rand Corporation, 2010), e-book.
196 See “The fiscal impact of Amendment 64 on state revenues” (Colo-
rado, Colorado State University, 24 April 2013).
G. AMPHETAMINE-TYPE  
STIMULANTS: OVERVIEW
Production, trafficking and  
consumption
While it is difficult to quantify the global production of 
ATS, the number of ATS-manufacturing laboratories that 
were dismantled increased from 12,571 (12,567 ATS labs 
in addition to four labs producing ATS in conjunction 
with non-ATS substances)  in 2011 to 14,322 in 2012 — 
nearly all of these (96 per cent) were manufacturing meth-
amphetamine. In North America, methamphetamine 
manufacturing has expanded again. In 2012, a large 
increase in methamphetamine laboratories seized was 
reported by the United States (12,857 in 2012 from 
11,116) and Mexico (259 from 159). A significant increase 
in the number of amphetamine laboratories dismantled in 
2012 was reported by the United States (from 57 to 84) 
and the Russian Federation (from 27 to 38). 
For the second year, ATS seizures reached an all-time high 
of 144 tons, up 15 per cent from 2011, due in large part 
to increases in methamphetamine seizures. Over the past 
five years, methamphetamine seizures have almost quad-
rupled, from 24 tons in 2008 to 114 tons in 2012. Of the 
total of 144 tons of ATS seized globally in 2012, approxi-
mately half were seized in North America alone and 
approximately a quarter in East and South-East Asia. Large 
quantities of amphetamine seizures continue to be reported 
in the Middle East, in particular by Jordan, Saudi Arabia 
and the Syrian Arab Republic. 
Seizures of “ecstasy” have resurged after the drop in 2011. 
Major quantities of “ecstasy” were seized in East and South-
East Asia, followed by Europe (South-Eastern Europe and 
Western and Central Europe). All three regions account 
for nearly three quarters of global “ecstasy” seizures. 
Amphetamine-type-stimulants: 
market analysis
Diversification and expansion of the global  
methamphetamine trade
In 2012, methamphetamine accounted for the majority of 
ATS seizures (80 per cent), approximately 114 tons of the 
total 144 tons of ATS seized worldwide. Nearly two thirds 
(64 per cent) of global methamphetamine seizures occurred 
in North America, and one third in East and South-East 
Asia. Although Mexico, the United States, China, Thailand 
and Iran (Islamic Republic of ), in that order, continue to 
report the highest amounts of methamphetamine seized 
worldwide, there is evidence that methamphetamine traf-
ficking is becoming more global in nature, with noteable 
increases from 2011 to 2012 observed in West and Central 
Africa (from 45 kg to 598 kg) and Oceania (from 457 kg 
to 2,283 kg). Growing methamphetamine markets have 
also been observed in Central Asia and Transcaucasia, as 
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Fig. 49. Global seizures of amphetamine-type stimulants, 2003-2012
Source: UNODC annual report questionnaire and other official sources.
Note: Total ATS includes amphetamine, “ecstasy”-type substances, methamphetamine, non-specified ATS, other stimulants and prescription stimulants.
seizures reported increased from less than a kilogram in 
2008 to 76 kg in 2012. 
In addition, methamphetamine markets grew in South-
West Asia, with recent detection of methamphetamine use 
in Pakistan.197
In North America, methamphetamine manufacturing has 
expanded again in recent years as evidenced by significant 
increases in drug and precursor seizures,198 with large-scale 
production in Mexico. Over the past five years, the amount 
of methamphetamine seized in Mexico increased from 341 
kg in 2008 to the equivalent of 44 tons in 2012 (aggregat-
197 UNODC and Pakistan, Drug use in Pakistan, 2013.
198 Precursors and Chemicals Frequently Used in the Illicit Manufacture of 
Narcotic Drugs and Psychotropic Substances: Report of the International 
Narcotics Control Board for 2012 on the Implementation of Article 12 of 
the United Nations Convention against Illicit Traffic in Narcotic Drugs 
and Psychotropic Substances of 1988 (E/INCB/2012/3).
ing seizures reported by weight and by volume). The 
United States continues to seize large quantities, 29 tons 
in 2012, up from 9.5 tons in 2008. According to the 
United States Drug Enforcement Agency, approximately 
half of the seizures in the United States occur at the United 
States-Mexico border.199 After several disruptions to the 
availability of precursors and the manufacturing processes 
in Mexico in 2005 and 2007, methamphetamine purity 
in the United States continued to increase, reaching 93 per 
cent in the second quarter  of 2012. Although the purity 
of methamphetamine is high, the potency likely decreased 
following restrictions on precursor access in Mexico (see 
the box “Does supply control work? Methamphetamine 
purity and potency following precursor regulations in 
North America”).
199 United States, Drug Enforcement Administration, “National Drug 
Threat Assessment Summary” (November 2013).
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Seizures of methamphetamine have been surging in East 
and South-East Asia and Oceania. Between 2011 and 
2012, approximately 70 per cent (12 of 17 countries) of 
the reporting countries in the region noted an increase in 
seizures of methamphetamine. Although China and Thai-
land regularly seize the largest amounts, those numbers 
increased only marginally in relative terms from 2011 to 
2012, while the quantity of methamphetamine seized in 
Australia increased over 400 per cent, from 426 kg to 2,268 
kg. Major increases were observed in countries that regu-
larly report smaller numbers of seizures, such as Brunei 
Darussalam, Cambodia, Singapore and Viet Nam. After a 
drop in seizures in 2010, Myanmar reported seizures of 2 
tons compared with 33 kg in 2011.200
Emergence of methamphetamine in South-West and 
Central Asia
Central Asia is emerging as an ATS market, reporting 253 
kg of ATS seizures, 183 kg of which were reported by 
Kazakhstan. For the first time, in 2012, Tajikistan reported 
200 UNODC annual report questionnaire and other official sources.
Does supply control work? 
Methamphetamine purity and potency following precursor regulations in North America
Methamphetamine production is dynamic, with multiple processes capable of producing the same end product. The two 
most common methods are (a) phenylacetic acid > 1-phenyl-2-propanone (P-2-P) > methamphetamine or (b) pseu-
doephedrine/ephedrine > methamphetamine. P-2-P production methods result in a less potent form of methampheta-
mine because of the contamination of the potent d-isomer with the less potent l-isomer, known as a racemic mixture. 
In the United States, in the early 1990s, methamphetamine was produced using ephedrine, which was restricted by the 
United States ephedrine single ingredient product regulation in 1995, resulting in a drop from nearly 80 per cent purity 
to approximately 20 per cent. In the following years, the purity increased during the subsequent two years and dropped 
in 1998, after the adoption of further pseudoephedrine/ephedrine product regulations. After early 1999, despite several 
precursor regulations in the United States and Canada, the purity continued to increase until 2005, when Mexico initi-
ated precursor control programmes. Subsequently, purity again dropped, climbing briefly and then dropping again after 
the arrest of a large supplier to Mexico.1 Since 2007, the purity has increased, now reaching 93 per cent. However, 
according to researchers, this high-purity methamphetamine is less potent because it is a racemic mixture. Because the 
lower potency is associated with less dependence, authors conclude the supply of harmful methamphetamine has in fact, 
decreased.2
1 J. K. Cunningham, L. M. Liu and R. Callaghan, “Impact of US and Canadian precursor regulation on methamphetamine purity in the United 
States”, Addiction, vol. 104, No. 3 (March 2009), pp. 441-453.
2 J. K. Cunningham and others, “Mexico’s precursor chemical controls: emergence of a less potent types of methamphetamine in the United States”. 
Drug and Alcohol Dependence, vol. 129, Nos. 1 and 2, (April 2013), pp. 125-136.
Price and purity of methamphetamine in the United States, 2005-2012
Source: Data from the System to Retrieve Information from Drug Evidence (STRIDE) database of the United States Drug Enforcement 
Agency.
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49G. Amphetamine-type stimulantss: overview
remained stable in 2010 and 2011, but increased in 2012. 
Within the different regions, while there is a reported 
decrease in ATS use in Western and Central Europe, the 
estimates for North America indicate an increase in ATS 
use. In the United States, treatment admissions for meth-
amphetamine use were down, and the past-year prevalence 
has remained stable for the past three years. However, the 
prevalence of other types of stimulants (amphetamines) 
has increased (see figure 56), leading to an increase in over-
all ATS prevalence from 1.8 per cent in 2011 to 2.1 per 
cent in 2012. The positive rates of urinanalysis for amphet-
amine and methamphetamine among the United States 
workforce, however, nearly tripled in 2012, reaching the 
highest levels since 1997.204 An increase in prevalence was 
reported in Mexico, from 0.02 per cent in 2008 to 0.12 
per cent in 2011.While new estimates of ATS use in Asia 
and Africa are not available, experts from most of the coun-
tries in these regions consider ATS use on the rise. Oceania 
204 United States, Quest Diagnostics, “Drug Testing Index”, (Madison, 
New Jersey, November 2013). 
seizures of 63 kg of methamphetamine and 21,740 tablets 
of “ecstasy”. The methamphetamine seized in Tajikistan 
was from one incident in which customs officials inter-
cepted a large amount shipped from the Islamic Republic 
of Iran destined for South-East Asia (Malaysia).201
In Pakistan, methamphetamine use was detected for the 
first time in a national survey, which estimated that approx-
imately 19,000 people (0.02 percent of the population 
aged 15-64) had used the drug in the past year.202 That 
marks an emergence of the substance in the area, which 
had been undetected in prior drug use surveys. According 
to reports made to INCB203, in the region there have also 
been increases in seizures of ephedrine, a precursor of 
methamphetamine. In 2011, India reported over 6 tons 
of ephedrine seizures, and Iran (Islamic Republic of ) 
reported 3.8 tons.
Amphetamine
Amphetamine continues to dominate the market in the 
Near and Middle East/South-West Asia, with over 12 tons 
seized in 2012, representing more than half of global sei-
zures (56 per cent). In the region, the largest seizure totals 
are those of Saudi Arabia, Jordan and the Syrian Arab 
Republic, in that order.
In neighbouring Turkey, a shift towards “ecstasy” and 
methamphetamine trafficking has taken place in recent 
years, with amphetamine trafficking moving to other 
markets.
Extent of amphetamine-type stimulant and “ecstasy” use
ATS, excluding “ecstasy”, constitute the second most com-
monly used group of illicit substances worldwide, with 
13.9 million to 54.8 million estimated users. ATS use 
201 Central Asian Regional Information and Coordination Centre 
(CARICC) Information Bulletin No. 114, 11 June 2012.
202 UNODC and Pakistan, Drug use in Pakistan, 2013.
203 International Narcotics Control Board annual report 2012 and previ-
ous reports.
Fig. 52. Ephedrine seizures in India and Iran  
(Islamic Republic of), 2010-2011
Source: International Narcotics Control Board annual report 2013
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Source: UNODC annual report questionnaire.
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(2.1 per cent) Central America and North America (1.3 
per cent and 1.4 per cent respectively) are the regions with 
prevalence rates higher than the global average, while the 
rates in West and Central Africa and Asia remain compa-
rable to the global rates of ATS use. 
“Ecstasy”
With between 9.4 million and 28.2 million estimated past-
year users in 2012, its use declined globally in the period 
2010-2012, mainly in Western and Central Europe. Nev-
ertheless, Oceania (2.9 per cent), North America (0.9 per 
cent) and Europe (0.5 per cent) remain regions with preva-
lence rates higher than the global average of 0.4 per cent.
Misuse of prescription stimulants 
The misuse of prescription stimulants or medications for 
attention deficit hyperactivity disorder is not uncommon, 
although only a few countries report prevalence of misuse 
among the general and youth population. With the excep-
tion of Indonesia, all countries reporting misuse of pre-
scription stimulants are from South and North America. 
This, however, does not preclude that misuse of prescrip-
tion stimulants is not common in the other countries or 
regions. Rather, the detection of such misuse in some coun-
tries may be related to better monitoring. The prevalence 
of misuse of prescription stimulants varies considerably 
among the few countries reporting, ranging from 3.28 per 
cent among the general population in El Salvador to 0.1 
per cent in Argentina. With the exception of El Salvador, 
Indonesia and Costa Rica, the misuse of prescription stim-
ulants is higher among men. In El Salvador, the prevalence 
is 3.7 per cent among women compared with 2.78 per cent 
among men. 
Compared with rates for the general population, countries 
report a higher level of misuse of prescription stimulants 
among the youth population (mostly those 15-16 years 
old). In Costa Rica, compared with the annual prevalence 
of misuse of prescription stimulants of 1.3 per cent, the 
rate is nearly 4 times higher among the youth population. 
A similar pattern of higher rates of misuse of prescription 
stimulants is seen in the other countries, with the excep-
tion of El Salvador, where the prevalence is quite low 
among youth, 0.2 per cent, compared with 3.28 per cent 
among the adult population.
Increase in ketamine and mephedrone treatment 
admissions in the United Kingdom
In the United Kingdom, there has been a decrease in preva-
lence of ketamine and mephedrone use in England and 
Wales among both the adult population (aged 16-59) and 
young adults (aged 16-24).201,206 However, there has been 
an increase in the number of people seeking treatment for 
ketamine and mephedrone over the past six years. Although 
users of ketamine and mephedrone account for only 10 
per cent of young people in specialist services and 2 per 
cent of adults in treatment, there are clear signs of an 
increase in treatment demand for drug use disorders related 
to club drugs such as ketamine and mephedrone in the 
United Kingdom. While “ecstasy” remains the most 
common club drug reported in treatment demand, the 
number of ketamine and mephedrone users seeking treat-
ment has risen between 2005/06 and 2010/11.207
205 The annual prevalence of mephedrone declined from 1.1 per cent 
in 2011/12 to 0.5 per cent in 2012/13 in the adult population and 
from 3.3 per cent to 1.6 per cent among young adults, while ketamine 
annual prevalence has declined from 0.6 per cent to 0.4 per cent in 
the adult population and from 1.8 per cent to 0.8 per cent among 
young adults over the same period.
206 United Kingdom, Home Office, “Drug misuse: findings from the 
2012/13 Crime Survey for England and Wales” (London, July 2013).
207 United Kingdom, National Treatment Agency for Substance Misuse, 
Fig. 55. Seizures of amphetamine-type  
stimulants in Central America, South 
America and the Caribbean (2008-2012)
Source: UNODC annual report questionnaire.
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51H. New psychoactive substances
H. NEW PSYCHOACTIVE  
SUBSTANCES 
Update208
Of 103 countries for which information on new psycho-
active substances was available as of December 2013, 94 
countries reported the emergence of such substances on 
their markets, up from 70 out of a total of 80 countries as 
of July 2012. This increase was due to reports of the emer-
gence of new psychoactive substances in countries in 
Club drugs: emerging trends and risks (London, November 2012).
208 This is an update from the World Drug Report 2013, which contains 
a detailed chapter on new psychoactive substances.
Europe (9 additional countries), Asia (7 additional coun-
tries) and Africa (8 additional countries).
New psychoactive substances are now found in most of 
Europe and North America, as well as Oceania, Asia and 
South America and in a number of African countries. The 
use of new psychoactive substances is thus emerging as a 
truly global phenomenon. The largest increases in the 
spread of those substances between July 2012 and Decem-
ber 2013 were reported in Europe (9 additional countries), 
Asia (7 additional countries) and Africa (6 additional 
countries).
The number of new psychoactive substances on the global 
market more than doubled over the period 2009-2013. By 
December 2013, the number of such substances reported 
to UNODC reached 348,209 up from 251 such substances 
209 Early warning advisory on new psychoactive substances, UNODC. 
Fig. 57. Annual prevalence of misuse of prescription stimulants 
Source: UNODC annual report questionnaire; data of countries varies from 2005 to 2012.
Fig. 58. Misuse of prescription stimulants 
among youth aged 15-16 years,  
2008-2011*
Source: UNODC annual report questionnaire.
Note: survey period varies by country. 
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as of July 2012,210 and 166 substances in 2009 (see figure 
60). Thus, by now, the number of new psychoactive sub-
stances clearly exceeds the number of psychoactive sub-
stances controlled at the international level (234 substances: 
119 controlled under the 1961 Single Convention on Nar-
cotic Drugs and 115 under the 1971 Convention on Psy-
chotropic Substances).
The overall increase over the period August 2012-Decem-
ber 2013 was mostly due to new synthetic cannabinoids 
(50 per cent of newly identified new psychoactive sub-
stances) followed by new phenethylamines (17 per cent), 
other substances (14 per cent) and new synthetic cathi-
nones (8 per cent) (see figure 61).
Progress has been made in some areas. In the United States, 
where national controls on some new psychoactive sub-
This information is based on information submitted by Member 
States through surveys and submissions to UNODC from laboratories 
participating in the international collaborative exercises programme.
210 UNODC, The Challenge of New Psychoactive Substances (Vienna, 
March 2013).
stances were introduced,211 prevalence of the use of syn-
thetic cannabinoids and of “bath salts” (synthetic 
cathinones) declined by some 30 percent among high 
school students. Annual prevalence of synthetic cannabi-
noid use fell from 11.4 per cent in 2011 to 7.9 per cent in 
2013 and prevalence of use of “bath salts” declined from 
1.3 per cent in 2012 to 0.9 per cent in 2013 among twelfth 
grade students.212 In England and Wales, annual preva-
lence of mephedrone, a synthetic cathinone, fell by more 
than 60 per cent, from 4.4 per cent among those aged 
211 In 2011, mephedrone, methylenedioxypyrovalerone (MDPV) and 
five synthetic cannabinoids were placed under temporary control 
(United States, Drug Enforcement Administration, “Schedules of 
controlled substances: temporary placement of three synthetic cathi-
nones into Schedule I”, Final order, 21 CFR Part 1308, Docket 
No. DEA-357). In 2012, these substances, along with 26 synthetic 
cannabinoids were placed permanently under control within the 
Controlled Substance Act (as amended by the Synthetic Drug Abuse 
Prevention Act of 2012).
212 National Institute on Drug Abuse, United States, Monitoring the 
Future Survey (December 2013). Available at http://monitoringth-
efuture.org/data/13data.html#2013data-drugs.
Are amphetamine-type stimulants substituting cocaine in the  
United States?
In the United States, cocaine use has declined but use of 
amphetamines group substances is on the rise. According 
to Quest Diagnostics, on the basis of urinanalysis, the 
number of positives for amphetamine as a metabolite 
(including, therefore, cases of methamphetamine use, in 
addition to prescription use and illicit use of ampheta-
mine) among the general workforce in 2012 were the 
highest since 1997, and positive drug tests for prescription 
medications such as Adderall more than doubled between 
1992 and 2012.1 Survey data reported over this period for 
the general population aged 12 or older also indicate a 
doubling in the past-month use of Adderall, stable use of 
methamphetamine, and declining use of cocaine since 
2007. Taken together, these data indicate that the increase 
in positive amphetamine tests in the general workforce is 
likely attributable to prescription amphetamine as opposed 
to methamphetamine. Indeed, subtracting methampheta-
mine positives from the total for all positive tests classified 
as “amphetamines” shows a distinct transition in 2007, 
when the decline in cocaine began, with the growth rate 
over the period 2007-2012 being four times that rate over 
the period 2002-2006. It would appear that the positivity 
rate for amphetamine now exceeds the historic level 
reached by the rate for cocaine in the United States in the 
period 2000-2006. This evidence, although not conclu-
sive, points to the possibility that amphetamines are being 
used as a substitute for cocaine.
1 United States, Quest Diagnostics, “Drug Testing Index”, (Madison, New Jersey, November 2013). Available at www.questdiagnostics.com/home/
physicians/health-trends/drug-testing.
Positive urinanalysis tests for amphetamine-
type stimulants among the United States 
workforce, 2000-2012
Source: Quest Diagnostics and United States Office on National 
Drug Control Policy
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53H. New psychoactive substances
16-24 years in 2010/11 to 1.6 per cent in 2012/13.213 
While no clear link has yet been established, Government 
activities aimed at raising awareness among drug users 
about the health risks associated with new psychoactive 
substances214 and the introduction of national controls215 
took place in the same period. Prevalence of use of keta-
mine, which is also controlled, fell from 2.1 to 0.8 per cent 
over the same period.216
213 United Kingdom, Home Office, “Drug misuse: findings from the 
2012/13 Crime Survey for England and Wales”.
214 For example, through the Internet website “Talk to Frank” website 
(www.talktofrank.com) and the Welsh Emerging Drugs and Identifi-
cation of Novel Substances project (www.wedinos.org).
215 In 2010, mephedrone was initially placed under control as a class B 
drug in the United Kingdom Misuse of Drugs Act (1971).
216 United Kingdom, Home Office, “Drug misuse: findings from the 
2012/13 Crime Survey for England and Wales”.
Fig. 60. Number of newly identified new  
psychoactive substances at the  
global level, 2009-December 2013  
(cumulative)
Source: UNODC, World Drug Report 2013 and UNODC early 
warning advisory on new psychoactive substances.
Note: The 2012 figures refer to information received by July 2012. For 
some substances reported in 2013, the reference period may have been 
August-December 2012.
Fig. 61. New psychoactive substances  
reported to UNODC by December 2013
Source: UNODC early warning advisory on new psychoactive sub-
stances, based on information submitted by Member States and 
submissions to UNODC from laboratories participating in the 
international collaborative exercises for national drug test labora-
tories.
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552PRECURSOR CONTROL
A. INTRODUCTION
A number of strategies have been developed by Member 
States and the international community over the years to 
address the world drug problem in a comprehensive way, 
including demand reduction programmes (prevention, 
treatment), supply reduction interventions (drug interdic-
tion, dismantlement of drug trafficking organizations, 
alternative development programmes, eradication) and 
efforts to control illicit financial flows. A further key inter-
vention in supply reduction has gained importance since 
the adoption of the United Nations Convention against 
Illicit Traffic in Narcotic Drugs and Psychotropic Sub-
stances of 1988: the control of precursor chemicals, that 
is, the control of chemicals used to manufacture plant-
based and synthetic drugs. As early as the 1990s, the 
Chemical Action Task Force pointed out that “the procure-
ment of chemicals necessary to manufacture drugs is one 
of the few points where ... drug trafficking intersects with 
legitimate commerce. Regulation of legitimate commerce 
to deny traffickers the chemicals they need is one of our 
most valuable tools in the battle against drug criminals.”1 
This has become even more relevant over time, as a grow-
ing proportion of the illicit drugs found on the market 
nowadays are synthetic drugs for which traditional supply-
control measures applied to plant-based substances, such 
as alternative development or eradication, cannot be used. 
Progress has been made with regard to precursor control.2 
Such progress has been strengthened through resolutions 
of the Economic and Social Council and the Commission 
on Narcotic Drugs, as well as the Political Declaration 
adopted by the General Assembly at its twentieth special 
session, in 1998, and the Political Declaration on Interna-
tional Cooperation towards an Integrated and Balanced 
Strategy to Counter the World Drug Problem, adopted by 
the Assembly in 2009, and their related action plans and 
the work done by the International Narcotics Control 
Board in assisting Member States in monitoring licit trade 
and preventing diversion.3 
Nonetheless, chemicals are still available for the illicit man-
ufacture of drugs. Precursor control is a complex area 
involving a large number of substances which have wide-
1 Chemical Action Task Force, Status Report for the 1992 Economic 
Summit (Washington, D.C., June 1992), p. 11.
2 Progress made in precursor control was highlighted in the March 
2014 joint ministerial statement of the high-level review by the 
Commission on Narcotic Drugs on the implementation by Member 
States of the Political Declaration and Plan of Action on International 
Cooperation towards an Integrated and Balanced Strategy to Counter 
the World Drug Problem.
3 The International Narcotics Control Board is given the prime respon-
sibility for precursor control at the international level under article 12 
of the 1988 Convention.
spread legitimate uses and which can be easily substituted. 
It involves many players and multiple links between the 
licit and illicit sectors. 
The present chapter will start with a review of the evolu-
tion of licit production and trade in chemicals, the degree 
of international interdependence and the development of 
the regulatory framework. It will then analyse the effect of 
precursor control on the supply of illicit drugs and new 
challenges, such as the growing role of the Internet, the 
emergence of substitute precursors, pre-precursors and new 
psychoactive substances, to which the current controls at 
the international level do not apply. The pages ahead will 
present an analysis of the various aspects of precursor con-
trol, covering both the licit and the illicit side of this sector 
while keeping an underlying focus on drug control. 
B. WHAT ARE PRECURSOR  
CHEMICALS? 
The term “precursor chemicals” broadly refers to chemicals 
that are employed in the manufacture of drugs. From a 
scientific point of view “precursor chemicals” are defined 
as the chemical substances that become incorporated, at 
the molecular level, into a narcotic drug or psychotropic 
substance during the manufacturing process.4 They can 
be distinguished from other chemicals used in the manu-
facturing process, such as “reagents” and “solvents”.5
This scientific distinction does not entail legal conse-
quences, however. Article 12 of the 1988 Convention, the 
legal basis for precursor control at the international level, 
does not make any such distinction and speaks only of 
“substances frequently used in the illicit manufacture of 
narcotic drugs or psychotropic substances”. 
In the Political Declaration adopted by the General Assem-
bly at its twentieth special session, in June 1998, and the 
related measures to enhance international cooperation to 
counter the world drug problem,6 the term “precursors” 
was broadened to encompass all chemicals that are con-
trolled under the 1988 Convention.
4 United Nations, Commentary on the United Nations Convention 
against Illicit Traffic in Narcotic Drugs and Psychotropic Substances 1988 
(New York, 1998).
5 “Reagents” are chemicals that react with, or take part in the reaction 
of another substance during the manufacture of a drug. They do not 
become part of the molecular structure of the end product. “Solvents” 
are liquid chemical substances used to dissolve or disperse one or more 
substances. They do not “react” with other substances and are not 
incorporated into the molecular structure of the end product. They 
are typically used to purify the end product.
6 General Assembly resolutions S-20/4 A-E.
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C. THE POTENTIAL VULNERABILITY 
OF THE CHEMICAL INDUSTRY 
TO THE DIVERSION OF  
PRECURSOR CHEMICALS 
1. Trends and patterns in the  
production of chemicals 
Over the past century, the chemical industry has been one 
of the main economic growth sectors, and it continues to 
grow strongly, both in volume and in geographical terms, 
involving an ever larger number of players. Asia has become 
the new centre for manufacture, and the increasing number 
of intermediaries provides greater opportunities for 
diversion.
The total number of “establishments” in the chemical 
sector rose worldwide from approximately 61,000 in 1981 
to 67,000 in 1990, 83,000 in 2000 and close to 97,000 
in 2010.7 This reflects an expansion of the production base 
of chemicals and thus potentially expands the possibilities 
for the diversion of chemicals. This is exacerbated by a 
growing number of “chemical operators” who are also 
involved in the trade of such substances.8
Data from the United Nations Industrial Development 
Organization (UNIDO) suggest that chemicals are now 
being manufactured in most countries.9 Of the 148 Gov-
ernments that reported manufacturing output data to 
UNIDO over the 1990-2010 period, 142 also declared 
production of chemicals.
The rapid expansion of the chemical sector can also be 
observed in terms of output. The production output of 
the chemical industry, expressed in constant United States 
dollars, almost doubled between 1990 and 2010, and rose 
more than fourfold between 1960 and 2010 to approxi-
mately $3,800 billion (see figure 1). 
The “value added”10 of the global chemical industry, which 
can be directly compared with the notion of gross domestic 
product (GDP), shows an increase in constant 2010 dol-
7 UNODC estimates, based on data contained in the 2013 edition of 
the UNIDO INDSTAT 2 database at the two-digit level of Interna-
tional Standard Industrial Classification (ISIC) Revision 3.
8 International Narcotics Control Board, Precursors and Chemicals 
Frequently Used in the Illicit Manufacture of Narcotic Drugs and Psy-
chotropic Substances: 2012 (New York, 2013), paras. 45-49.
9 Information from the INDSTAT 2 database, which has entries 
regarding the chemical industry of 158 countries and areas over the 
1963-2010 period. Data are missing mainly from a few island coun-
tries and, in recent years, from countries affected by serious conflict 
in Africa.
10 The value added of the manufacture of chemicals is defined as the 
sum of gross output less the value of intermediate inputs used in 
the production for industries classified under International Standard 
Industrial Classification (ISIC) major division 3 by UNIDO as 
chemical industries. This comprises ISIC groups 351 (manufacture 
of industrial chemicals) and 352 (manufacture of other chemical 
products). The ISIC groups 353 (petroleum refineries), 354 (miscel-
laneous products of petroleum and coal), 355 (rubber products) and 
356 (plastic products) are not included.
lars from $620 billion in 1990 to about $1,110 billion in 
2010.11 This growth was larger than the growth of the 
entire manufacturing sector and global GDP (see figure 
2). As a result, the proportion represented by the chemical 
sector in the overall value added of manufacturing increased 
from less than 11 per cent in 1990 to close to 13 per cent 
by 2010. Expressed as a percentage of global GDP, the 
value added of the chemical industry accounts for about 
2 per cent, which is comparable to the value added of agri-
culture, which accounts for 3 per cent of global GDP. . 
The observed stronger growth of output (5.8 per cent 
annually during the 2000-2010 period) as compared with 
value added12 (3.5 per cent) in the chemical industry (see 
figure 3) suggests a trend of companies redefining their 
core products and spinning off non-core production and 
services to new companies. This can be explained by a 
reduced vertical integration of the chemical industry, 
mainly as a consequence of the emergence of new produc-
tion sites in developing countries. One side effect of this 
has been increased intra-industry trade in chemicals 
between continents, which increases the risk of diversion 
of chemicals used in the clandestine manufacture of drugs. 
While the chemical sector has been growing over the past 
few decades, it is still characterized by some geographical 
concentration and by significant shifts in production, 
11 The data presented here are UNODC estimates based on country 
data provided by the World Bank (for the value added of manufac-
turing in United States dollars) and by the UNIDO INDSTAT 2 
database (for the proportion of the manufacturing sector comprised 
by the chemical sector), as reported by the World Bank. For missing 
years within a time series for a particular country, an interpolation was 
applied. For missing data at the beginning or end of a time series, the 
assumption was made that results remained unchanged from the first 
(or last) reporting year. 
12 The concepts of value added and output are different economic 
measures of overall production. Value added measures the value of 
the final product regardless of the number of companies involved in 
the intermediate production steps, while output measures the value 
of the products produced during all production steps. Countries with 
higher levels of output and similar levels of value added may reflect 
an overall lower degree of vertical integration.
Fig. 1. Output of the global chemical industry, 
1963-2010 
Source: UNODC estimates based on UNIDO INDSTAT 2 database.
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Fig. 4. Regional distribution of the value added of the chemical industry, 1990-2010
Source: UNODC estimates based on World Bank indicators on “Manufacturing, value added (in constant 2005 dollars) and “Chemicals 
(percentage of value added in manufacturing) (accessed in August 2013 at http://data.worldbank.org/indicator).
which has implications for precursor control. Traditionally, 
most chemicals have been produced in Europe and in 
North America (United States of America, Germany, 
France and the United Kingdom of Great Britain and 
Northern Ireland) and — after World War II — the former 
Union of Soviet Socialist Republics. Initially, only one 
Asian country — Japan — was included among major 
chemical producers. 
Over the past few decades, however, a number of countries 
in Asia (notably in East, South and South-East Asia) have 
gained market share at the expense of North America and 
Europe (see figure 4). By 2010, Asia accounted for 35 per 
cent of the global value added of manufacture of chemicals, 
up from 21 per cent in 1990. China advanced from gen-
erating the eighth-largest value added of chemicals in 1990 
Fig. 2. Average annual growth of the  
value added of the global economy, 
manu facturing and the chemical  
industry
Source: UNODC estimates based on World Bank indicators on 
“Manufacturing, value added (in constant 2005 dollars)” and 
“Chemicals (percentage of value added in manufacturing)” 
(accessed in August 2013 at http://data.worldbank.org/indicator).
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Fig. 3. Average annual growth of the output 
and the value added for the chemical 
industry
Source: UNODC estimates based on the UNIDO INDSTAT 2 data-
base and World Bank indicators (http://data.worldbank.org/indica-
tor).
3.3
5.8
2.4
3.5
0.0
1.0
2.0
3.0
4.0
5.0
6.0
7.0
1990-2010 2000-2010
Pe
rc
en
ta
g
e
Output Value added
42
32
9
35
32
3
21
19
2 1 1
37
30
7
27
24
2
35
30
5
1 1
0
5
10
15
20
25
30
35
40
45
A
ll 
A
m
er
ic
as
N
o
rt
h 
A
m
er
ic
a
Re
st
 o
f 
A
m
er
ic
as
A
ll 
Eu
ro
pe
W
es
te
rn
/C
en
tr
al
 E
ur
op
e
Re
st
 o
f 
Eu
ro
pe
A
ll 
A
si
a
Ea
st
 &
 S
ou
th
-E
as
t 
A
si
a
Re
st
 o
f 
A
si
a -
A
ll 
A
fr
ic
a - -
A
ll 
O
ce
an
ia
Americas Europe Asia Africa Oceania
Pe
rc
en
ta
g
e
1990
2000
2010
2. PRECURSOR CONTROL58
to second place (following the United States and ahead of 
Japan) in 2010. India progressed from fourteenth place in 
1990 to fifth place by 2010, following Germany and ahead 
of Brazil and Mexico.
An analysis of long-term output trends for the chemical 
sector reveals similar patterns (see figure 5). Above-average 
growth rates were reported in particular in Asia, notably 
in East, South and South-East Asia, and output growth 
accelerated further during the 2000-2010 period. By 2010, 
China reported the world’s largest chemical industry 
output, ahead of the United States, Japan, Germany, 
France, Brazil, the Republic of Korea, Italy, India, the 
Netherlands, the United Kingdom, the Russian Federation 
and Switzerland (in that order).13 The production output 
of these 13 countries accounted for more than three quar-
ters (78 per cent) of the global output of the chemical 
industry. 
The importance of Asia’s chemical industry as measured 
in terms of output (44 per cent, see figure 6) exceeds its 
importance in terms of value added (35 per cent, see figure 
4). The opposite is true for the Americas and Europe. This 
suggests that chemical mass products are increasingly being 
produced in Asia, while there is still a concentration of 
some value-added intensive production of chemicals in 
North America and in Western and Central Europe. 
Data on the sales of the chemical industry for 2011 (€2,744 
billion, or $3,822 billion) suggest that by that year 52 per 
cent of global turnover was credited to companies in Asia 
(see figure 7). Taken together, Asia, Europe and North 
America accounted for 92.5 per cent of world chemical 
sales in 2011.14 The largest sales were reported by compa-
13 This ranking is based on UNIDO data for 2010 or the latest year 
available (adjusted for inflation).
14 Companies and Markets, “Global Chemicals Market” (11 July 2013). 
Available from www.companiesandmarkets.com.
nies in China (27 per cent), followed by the European 
Union (20 per cent), the United States (15 per cent) and 
Japan (6 per cent). The single largest European producer 
was Germany (5.7 per cent of global sales). The largest 
producer in Latin America was Brazil (3.2 per cent), 
although its sales still lagged behind Asia’s third largest 
producer, the Republic of Korea (4.3 per cent). Other 
important producers included France (3.0 per cent of 
global sales), Taiwan Province of China (2.2 per cent),15 
the Russian Federation (2.1 per cent) and the Netherlands 
(1.9 per cent).16
All of these production shifts have potential implications 
for the control of precursor chemicals. A chemical industry 
concentrated among big companies facilitates the control 
of chemicals that can be diverted for the illicit manufacture 
of drugs, while a more scattered production system 
increases the number of trade lines and, ultimately, the risk 
of diversion. Control systems were initially developed 
mostly in North America and in Europe, where the chemi-
cal industry was dominated by large, vertically integrated 
companies. This facilitated national controls, including 
through voluntary cooperation with the authorities. The 
emerging chemical industry in Asia, in contrast, is charac-
15 Despite its sizable chemical industry, Taiwan Province of China does 
not participate in international precursor control. The International 
Narcotics Control Board encouraged the Government of China to 
work with Taiwan Province of China to devise practical ways and 
means of addressing the issue, notably in the areas of pre-export noti-
fications, suspicious shipments and diversions of precursors involving 
Taiwan Province of China (see Precursors Report, 2013, para. 33).
16 European Chemical Industry Council, “Chemicals sales by country: 
top 30” (2012). Available from www.cefic.org.
Fig. 5. Average annual growth in the output  
of the chemical industry, globally and 
by region
Source: UNODC estimates based on the UNIDO INDSTAT 2 data-
base.
Fig. 6. Regional distribution of output of the 
chemical industry, 2010
Source: UNODC estimates based on the UNIDO INDSTAT 2 data-
base.
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terized by a much greater number of smaller enterprises,17 
thus posing a bigger challenge to the authorities.
2. Trends and patterns in  
international trade in chemicals 
Growth in international trade in chemicals outstripped 
growth in the global production of chemicals. While 
output doubled between 1990 and 2010, chemical exports, 
expressed in constant 2012 United States dollars, grew to 
more than three-and-a-half times the size (see figure 8).
This pattern became even more pronounced during the 
2000-2010 period (see figure 9). 
As a consequence, global chemical exports rose from rep-
resenting 25 per cent of the global output of the chemical 
industry in 1990 to 33 per cent in 2000 and 43 per cent 
in 2010. With ever more chemicals being traded among 
an increasing number of countries, the possibility of diver-
sion of chemicals has increased. 
The chemical industry is widely seen as one of the most 
globalized of all manufacturing industries, and this glo-
balization is still in progress,18 facilitated by reduced 
import duties as a consequence of several rounds of the 
General Agreement on Tariffs and Trade and the subse-
17 The average output per “establishment” of the chemical industry 
during the 2007-2009 period amounted to $81 million in the Neth-
erlands, $64 million in Belgium and $59 million in Germany. This 
was more than three times the average output per establishment in 
China ($18 million), more than eight times the average output per 
establishment in India ($7 million), 15 times the average in Hong 
Kong, China, or Viet Nam ($4 million) and more than 40 times the 
average in Thailand ($1.25 million in 2006) (INDSTAT 2 database).
18 MBendi Information Services, “World chemicals: global chemical 
industry overview”. Available from www.mbendi.com.
quent work of the World Trade Organization. Although 
the value added generated by the chemical industry 
accounted for “just” 1.9 per cent of global GDP in 2010, 
the proportion that chemicals comprise of global exports 
is almost six times as high — and rising (see figure 10). 
The relationship between the production and trade of 
chemicals is not linear. Countries with high levels of pro-
duction are not always the biggest exporters of chemicals, 
and almost a quarter of countries have larger chemical 
exports than domestic production.19 A more linear cor-
19 This applies to 34 out of 146 countries and areas for which both 
export and domestic production data were available. Adding countries 
and areas which exported chemicals but did not report production of 
chemicals, the overall proportion of countries and areas where exports 
exceeded domestic production would rise to above 40 per cent (80 out 
of 192).
Fig. 7. Regional distribution of sales of  
the chemical industry, 2011
Note: NAFTA means North American Free Trade Agreement countries. 
EU-27 means the States Members of the European Union as of 2011.
Sources: European Chemical Industry Council Chemdata Interna-
tional, “World chemicals sales: geographic breakdown” and 
OANDA (for conversion of euros into United States dollars). 
1024
244
164
553
751
143
655
209
79
0
200
400
600
800
1,000
1,200
1,400
1,600
1,800
2,000
Asia Europe Americas Rest of the
world
B
ill
io
n
s 
o
f 
d
o
lla
rs
China Japan
Republic of Korea Rest of Asia
EU-27 Rest of Europe
NAFTA Latin America
Rest of the world
Fig. 8. Global exports of the chemical 
industry, 1990-2012
Source: UNODC estimates based on the United Nations Commod-
ity Trade Statistics database (UN COMTRADE), Standard Interna-
tional Trade Classification Revision 3.
0
500
1,000
1,500
2,000
19
90
19
92
19
94
19
96
19
98
20
00
20
02
20
04
20
06
20
08
20
10
20
12
B
ill
io
n
s 
o
f 
d
o
lla
rs
in current US dollars
in constant 2012 US dollars
Fig. 9. Average annual growth in chemical 
exports, output and value added of the 
chemical industry (in constant dollars)
Source: UNODC estimates based on World Bank indicators, IND-
STAT 2 and UN COMTRADE.
2.4
3.3
6.1
3.5
5.8
8.7
0
2
4
6
8
10
Value added Output Exports
Pe
rc
en
ta
g
e
1990-2010 2000-2010
2. PRECURSOR CONTROL60
relation is observed between the levels of exports and 
imports of chemicals (see figure 11), which underlines the 
importance of re-exports20 and the fact that trade flows 
are not always directly from producing to consuming coun-
20 Data on 127 countries and areas for the year 2012 show a correlation 
coefficient of r = 0.93 between imports and exports.
tries, but instead involve an increasing number of brokers 
and other intermediaries in the supply chain. Not only 
does this provide more opportunities for diversion, it 
makes the effective application of the “know your cus-
tomer” principle21 more difficult to achieve. 
D. RESPONSE OF THE INTER-
NATIONAL COMMUNITY 
The idea of controlling precursors as one of the strategies 
for controlling the overall manufacture of drugs and thus 
their consumption (for non-medical purposes) dates back 
to the early 1930s. It was only in the late 1980s, however, 
that an effective international precursor control system was 
devised. That system was further strengthened over the 
following decades. 
1. Conventions concluded under the 
auspices of the League of Nations 
The basic idea of precursor control was already present in 
the Convention for Limiting the Manufacture and Regu-
lating the Distribution of Narcotic Drugs of 1931, which 
had provisions for the international control of a limited 
number of “convertible substances”,22 i.e. substances that 
could be converted into a product capable of producing 
addiction.23
21 The “know your customer” principle, for those who manufacture or 
market chemicals, is set out in the Political Declaration adopted by 
the General Assembly at its twentieth special session and the meas-
ures to enhance international cooperation to counter the world drug 
problem (General Assembly resolutions S-20/4 A-E).
22 Any product obtained from any of the phenanthrene alkaloids of 
opium or from the ecgonine alkaloids of the coca leaf.
23 Article 11 of the 1931 Convention made it clear that no manufacture 
or trade in such products should be allowed “unless and until it has 
been ascertained to the satisfaction of the Government concerned that 
the product in question is of medical or scientific value”.
Fig. 10. Proportion of the chemical industry in 
global GDP and of chemical exports in 
global merchandise exports 
Source: UNODC estimates based on World Bank indicators and 
UN COMTRADE.
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Fig. 11. International trade in chemicals, 2012 or latest year available (30 largest exporting countries 
and territories) 
Source: UN COMTRADE. 
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Another reference to the need for precursor control can be 
found in the Convention for the Suppression of the Illicit 
Traffic in Dangerous Drugs of 1936. That Convention 
introduced an obligation to seize such precursors and con-
tained penal provisions for the manufacture, conversion, 
extraction and preparation of drugs,24 which also had an 
impact on the handling of precursor chemicals. Both Con-
ventions were superseded by the Single Convention on 
Narcotic Drugs of 1961. 
2. Single Convention on Narcotic 
Drugs of 1961 
A general reference to precursor control, asking for the 
“supervision”25 of such substances, is also found in the 
Single Convention on Narcotic Drugs of 1961 as amended 
by the 1972 Protocol, which is still in force today. In addi-
tion, it allowed substances “convertible into a drug” to be 
scheduled.26 The 1961 Convention also obliged parties to 
seize precursor chemicals and to introduce penal provisions 
for the illegal manufacture, extraction and preparation of 
such drugs.27
24 In article 2 of the 1936 Convention, each of the High Contract-
ing Parties agreed “to make the necessary legislative provisions for 
severely punishing, particularly by imprisonment or other penalties 
of deprivation of liberty … the manufacture, conversion, extraction, 
preparation … of narcotic drugs, contrary to the provisions of the … 
conventions”. Article 10 of the Convention states that “any narcotic 
drugs as well as any substances and instruments intended for the 
commission of any of the offences referred to in article 2 shall be 
liable to seizure and confiscation”. This was the first international 
obligation relating to precursor control. Nonetheless, the practical 
importance of this obligation remained limited, as only 13 countries 
(Belgium, Brazil, Canada, China, Colombia, Egypt, France, Greece, 
Guatemala, Haiti, India, Romania and Turkey) signed and ratified the 
Convention (Thomas Pietschmann, “A century of international drug 
control”, Bulletin on Narcotics, vol. LIX, Nos. 1 and 2 (2007).
25 Article 2, paragraph 8, of the 1961 Convention states that “the Parties 
shall use their best endeavours to apply to substances which do not fall 
under this Convention, but which may be used in the illicit manu-
facture of drugs, such measures of supervision as may be practicable”. 
This definition of a “substance” was left very broad on purpose, as the 
authors admitted that they could not foresee what kind of substances 
would be employed in the illicit manufacture of drugs in the future. 
Article 2 is important because it lays down a general obligation for 
the control of precursors used in the manufacture of narcotic drugs. 
In the discussion of the plenipotentiary conference that adopted the 
1961 Convention, acetic anhydride, used in the conversion of mor-
phine into heroin, was explicitly mentioned as a substance to which 
paragraph 8 would apply (Commentary on the Single Convention on 
Narcotic Drugs, 1961 (New York, 1962)).
26 Article 3, paragraph 3 (iii), of the 1961 Convention enables the scope 
of controlled substances to be extended to any substance “convertible 
into a drug”. Thus, one finds ecgonine, an alkaloid of the of coca 
plant which itself is not addictive but which can be converted into 
cocaine, in Schedule I of the 1961 Convention.
27 The specific provisions for precursor control of the 1936 Convention 
entered the 1961 Convention in article 37: “Any drug, substances 
and equipment used in or intended for the commission of any of the 
offences, referred to in article 36, shall be liable to seizure and confis-
cation.” Article 36 states that each Party shall “adopt such measures as 
will ensure that … production, manufacture, extraction, preparation 
… of drugs contrary to the provisions of this Convention … shall be 
punishable offences when committed intentionally”.
3. Convention on Psychotropic  
Substances of 1971
The requirements relating to the introduction of precursor 
control were broadened in the Convention on Psychotropic 
Substances of 1971 to include chemicals used in the manu-
facture of psychotropic substances.28 Precursors were thus 
in principle under international control, with provisions 
for such substances to be seized and confiscated. There was 
a general obligation for taking “measures of supervision” 
regarding such substances, though much was left to the 
discretion of Member States. Thus, only a few countries 
introduced a comprehensive control regime. Moreover, the 
1971 Convention did not include a provision for the 
scheduling of specific substances that were convertible into 
a psychotropic substance.29 This changed only with the 
1988 Convention. 
4. United Nations Convention 
against Illicit Traffic in Narcotic 
Drugs and Psychotropic  
Substances of 1988
(a) The basic control system 
The United Nations Convention against Illicit Traffic in 
Narcotic Drugs and Psychotropic Substances of 1988 
enjoys nearly universal adherence30. 
The basic idea of the Convention is to regulate the trade 
of a number of chemicals which can be used for the manu-
facture of drugs by allowing their trade for licit purposes 
and prevent their diversion for illicit manufacture of drugs. 
The 1988 Convention establishes a legal basis for the con-
trol of precursors and calls for the establishment of an 
appropriate administrative framework, working mecha-
nism and standard operating procedures to prevent the 
diversion of such substances. There are hundreds of chemi-
cals that are or could be used in the manufacture of illicit 
drugs. Of those, a total of 23 chemicals were internation-
ally controlled under the 1988 Convention as of January 
2014: 15 substances under the stricter rules foreseen for 
substances in Table I (for which pre-export notifications 
are foreseen) and 8 under the less stringent rules for sub-
stances in Table II.31 This list is regularly updated. The 
28 Article 2 states that “the Parties shall use their best endeavours to 
apply to substances which do not fall under this Convention, but 
which may be used in the illicit manufacture of psychotropic sub-
stances, such measures of supervision as may be practicable”. Sub-
sequently, article 22 also follows closely the wording of the Single 
Convention, laying down in its paragraph 3 that “any psychotropic 
substance or other substance, as well as any equipment, used in or 
intended for the commission of any of the offences referred to … shall 
be liable to seizure and confiscation”.
29 Thus lysergic acid, for instance, which is easily convertible into lyser-
gic acid diethylamide (LSD), could not be scheduled under the 1971 
Convention.
30 The Convention has been ratified by or acceded to by 187 countries 
and areas (plus the European Union).
31 Substances listed in Table I are specifically required in the manufac-
ture of narcotic drugs or psychotropic substances. Substances listed in 
Table II are mostly solvents, cleaning agents and chemical reagents.
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total number of controlled chemical substances in Table I 
and II nearly doubled from 12 in 1988 to 23 by 2013. The 
increase over the past two decades has been most notice-
able for substances in Table I, rising from 6 in 1988 to 16 
following the decision of the Commission on Narcotic 
Drugs in March 2014 to add alpha-phenylacetoacetonitrile 
(APAAN) to Table I. 
Paragraph 1 of article 3 of the 1988 Convention requires 
parties to establish as criminal offences the manufacture, 
transport and distribution of the listed precursor chemicals 
in the knowledge that they are to be used in or for the ille-
gal cultivation, production or manufacture of drugs.
As in the 1961 and 1971 Conventions, the 1988 Conven-
tion requires States parties to take appropriate measures to 
prevent the diversion of precursor chemicals.32 
Article 12 lays down more specific control measures for 
the manufacture and distribution (e.g. licensing, preven-
tion of the accumulation of large stocks)33 and interna-
32 Article 12, paragraph 1, contains a general statement that “the Parties 
shall take the measures they deem appropriate to prevent diversion 
of substances in Table I and Table II used for the purpose of illicit 
manufacture of narcotic drugs or psychotropic substances, and shall 
cooperate with one another to this end”.
33 Article 12, paragraph 8 (a), states that “the Parties shall take the 
measures they deem appropriate to monitor the manufacture and 
distribution of substances in Table I and Table II which are carried 
out within their territory”. Paragraph 8 (b) proposes the following 
concrete measures that parties may take to that end: 
 (i) Control all persons and enterprises engaged in the manufacture 
and distribution of such substances; 
 (ii) Control under licence the establishment and premises in which 
such manufacture or distribution may take place; 
 (iii) Require that licensees obtain a permit for conducting the afore-
said operations; 
 (iv) Prevent the accumulation of such substances in the possession of 
manufacturers and distributors, in excess of the quantities required for 
tional trade in precursor chemicals (e.g. notification of 
suspicious shipments, seizures, proper labelling and docu-
mentation, establishment of a comprehensive monitoring 
system,34 including pre-export notifications for substances 
in Table I)35 while guaranteeing Member States a high 
degree of confidentiality36 and limiting controls (e.g. exclu-
sion of pharmaceutical preparations from controls).37
(b) Role of the International Narcotics  
Control Board
The 1988 Convention also clarified the roles of the vari-
ous actors. The primary role of precursor control lies with 
the individual Member States;38 the International Narcot-
ics Control Board was given the prime responsibility for 
precursor control at the international level. 
The Board is responsible, along with States parties, for 
recommending to the Commission on Narcotic Drugs the 
scheduling or rescheduling of chemical substances to be 
controlled at the international level. While the World 
Health Organization (WHO) plays a key role in the sched-
uling of narcotic drugs and psychotropic substances under 
the 1961 and 1971 Conventions, the Board was given this 
role for precursor chemicals.39 It also collects statistics 
relating to precursors, reports on progress made in precur-
the normal conduct of business and the prevailing market conditions.
34 Article 12, paragraph 9, lists the following measures that each party 
shall take with regard to international trade in substances in Table I 
and Table II: 
 (a) Establish and maintain a system to monitor international trade in 
such substances in order to facilitate the identification of suspicious 
transactions;
 (b) Provide for the seizure of any such substance if there is sufficient 
evidence that it is for use in the illicit manufacture of a narcotic drug 
or psychotropic substance; 
 (c) Notify, as soon as possible, the competent authorities and services 
of the parties concerned if there is reason to believe that the import, 
export or transit of such a substance is destined for the illicit manu-
facture of narcotic drugs or psychotropic substances;
 (d) Require that imports and exports be properly labelled and docu-
mented;
 (e) Ensure that documents referred to in subparagraph (d) above are 
maintained for a period of not less than two years and may be made 
available for inspection by the competent authorities.
35 Article 12, paragraph 10, contains the core principle of international 
precursor control: the obligation of an exporting country, if asked by 
an importing country, to issue a “pre-export notification” for sub-
stances listed in Table I. This then entails some form of a clearance 
or permission to be granted from the competent authorities of the 
importing country. Importing countries can adopt stricter measures 
and request a pre-export notification not only for substances in Table 
I but also for some or all of the substances in Table II. A number of 
countries have made use of this provision.
36 See article 12, paragraph 11.
37 Article 12, paragraph 14, for example, excludes pharmaceutical prepa-
rations from precursor controls if such substances cannot be easily 
used in the manufacture of drugs: “The provisions of this article shall 
not apply to pharmaceutical preparations, nor to other preparations 
containing substances in Table I or Table II that are compounded in 
such a way that such substances cannot be easily used or recovered by 
readily applicable means”.
38 In the case of States members of the European Union, the prime 
responsibility is with the European Union, not the individual member 
States.
39 See article 12, paragraphs 2-7.
Substances controlled under the 
1988 Convention (as of January 
2014)
Table I Table II
Acetic anhydride Acetone
N-acetylanthranilic acid Anthranilic acid
Ephedrine Ethyl ether
Ergometrine Hydrochloric acid
Ergotamine Methyl ethyl ketone
Isosafrole Piperidine
Lysergic acid Sulphuric acid
3,4-Methylenedioxyphenyl-
2-propanone 
Toluene
Norephedrine
Phenylacetic acid
1-Phenyl-2-propanone
Piperonal
Potassium permanganate
Pseudoephedrine
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sor control40 and reports annually to the Commission on 
the implementation of article 12.41
Moreover, the Board has been given a special role in moni-
toring the implementation of precursor control measures 
by Member States in accordance with the requirements of 
the 1988 Convention.42 The potential sanctions of the 
Board are limited, however, to bringing an issue to the 
attention of the parties, the Economic and Social Council 
and the Commission on Narcotic Drugs; it is then up to 
these bodies to deal with the issue. This is in contrast to 
the broader powers given to the Board (e.g. recommend-
ing an “import ban”) in cases of non-compliance with the 
other drug conventions.43
In addition to collecting data and preparing reports to alert 
policymakers about new trends, the Board also engages in 
operational activities. It assists Member States in conduct-
ing joint law enforcement operations under the banner of 
Project Cohesion (with regard to chemicals used in the 
manufacture of plant-based drugs) and Project Prism (with 
regard to chemicals used in the manufacture of synthetic 
drugs) to detect unlawful precursor shipments. In response 
to various action plans and resolutions, the Board estab-
lished and maintains a limited international special surveil-
lance list of non-scheduled substances for the identification 
of substitute chemicals used in the illicit manufacture of 
drugs.44 It has also issued the Guidelines for a Voluntary 
Code of Practice for the Chemical Industry, and established 
the Pre-Export Notification Online (PEN Online) system, 
as well as the Precursors Incident Communication System 
(PICS), a secure online tool to enhance real-time commu-
nication and information sharing between national 
authorities.45
5. Resolutions passed by the  
General Assembly, the Economic 
and Social Council and the  
Commission on Narcotic Drugs
Following the adoption of the 1988 Convention, a total 
of 36 resolutions relevant to precursor control were passed 
by the General Assembly, the Economic and Social Council 
and the Commission on Narcotic Drugs during the 1991-
2013 period. While some of those resolutions were geared 
towards simply raising awareness, others were very focused, 
dealing with specific aspects of precursor control.46
40 Ibid., para. 12.
41 Ibid., para. 13.
42 Article 22 sets forth action that the Board may take if it has reason 
to believe that the aims of the Convention in matters related to its 
competence are not being met.
43 See article 14, paragraph 2, of the 1961 Convention and article 19, 
para. 2, of the 1971 Convention.
44 That list contained more than 50 substances in 2012.
45 For more information, see http://incb.org/incb/en/precursors/precur-
sors/tools_and_kits.html.
46 Topics addressed included the following: controls for non-scheduled 
substances, the Precursors Incident Communication System, the 
6. Political Declaration and Action 
Plan adopted by the General 
Assembly at its twentieth special 
session
Precursor control received a new impetus from the Politi-
cal Declaration adopted by the General Assembly at its 
twentieth special session, in 1998,47 and the related meas-
ures to enhance international cooperation to counter the 
world drug problem,48 which contained separate resolu-
tions on the Action Plan against Illicit Manufacture, Traf-
ficking and Abuse of Amphetamine-type Stimulants and 
their Precursors and on the control of precursors. 
In its resolution S-20/4 B, on control of precursors, the 
General Assembly asked Member States to implement 
many of the proposals made under the 1988 Convention. 
Member States were requested to adopt and implement 
the “proposals” of article 12 of the 1988 Convention, 
including the establishment of a system of control and 
licensing of the enterprises and persons engaged in the 
manufacture and distribution of substances listed in Tables 
I and II of the 1988 Convention. Similarly, exporting 
States were requested to issue pre-export notifications for 
substances in Table I to the competent authorities in 
importing countries (irrespective of whether an importing 
country had requested such a notification). In addition, 
information exchange (from data on licit manufacture to 
imports and exports) was highlighted as being crucial for 
precursor control, as was strengthened cooperation with 
associations of the chemical trade and industry which 
could be achieved by issuing guidelines and/or a code of 
conduct.49
Most importantly, the principle of “know your customer”50 
was introduced at the international level. It obliges the 
seller of precursor chemicals to investigate the credentials 
of the purchaser and, if in doubt, to involve the authorities. 
strengthening of monitoring and control systems at the points of 
entry of precursors (airports, ports, customs ports), the real-time 
exchange of information, backtracking investigations, the promotion 
of participation in Project Prism and Project Cohesion, chemical 
profiling, training in precursor control, the provision to International 
Narcotics Control Board of annual estimates of legitimate require-
ments for precursors of amphetamine-type stimulants, trafficking 
via the Internet, the development of joint actions with the national 
chemical industry, the promotion of a voluntary code of conduct 
for the chemical industry, the smuggling of precursors to and within 
Afghanistan, use of the Pre-Export Notification Online system for 
precursors and pharmaceutical preparations containing ephedrine 
and pseudoephedrine, treatment of safrole-rich oils, ephedra, PMK 
(=3,4-methylenedioxyphenyl-2-propanone (3,4-MDP-2-P)), nore-
phedrine and potassium permanganate. A comprehensive summary of 
the resolutions relevant to precursor control is available from http://
incb.org/incb/en/precursors/resolutions.html.
47 General Assembly resolution S-20/2.
48 General Assembly resolutions S-20/4 A-E.
49 See General Assembly resolution S-20/4 B, paras. 4, 7 (a) (i) and 9 
(b).
50 Ibid., para. 9 (c). In addition, the “know your customer” principle is 
found in several resolutions of the Economic and Social Council and 
the Commission on Narcotic Drugs.
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In addition, the document highlighted the challenges aris-
ing from the use of “substitute chemicals”. In that context, 
it proposed to prepare a limited international special sur-
veillance list of substances currently not in Tables I and II 
of the 1988 Convention. This was subsequently imple-
mented by the Board. Moreover, States were asked to apply 
monitoring measures, in cooperation with the chemical 
industry, so as to prevent the diversion of substances 
included on the special surveillance list. In addition, States 
were asked to “consider punishing, as a criminal offence 
… the diversion of non-scheduled chemical substances 
with the knowledge that they are intended for use in the 
illicit manufacture of narcotic drugs or psychotropic 
substances”.51
7. Political Declaration and Plan of 
Action of 2009
Precursor control also played a role in the 2009 Political 
Declaration and Plan of Action on International Coopera-
tion towards an Integrated and Balanced Strategy to Coun-
ter the World Drug Problem. The Plan of Action 
underlined the need for “a global approach in order to … 
prevent the diversion of synthetic drugs and their precur-
sors into illicit channels in all manufacturing, transit and 
consumer countries” and, in the Political Declaration, 
States Members of the United Nations decided to establish 
2019 as a target date for States “to eliminate or reduce sig-
nificantly … the diversion of and illicit trafficking in 
precursors”.52
The 2009 Plan of Action shows how the precursor market 
had changed over time. It recognized that pharmaceutical 
preparations and chemicals not under international control 
were being substituted for controlled precursors.53 To 
respond to these new challenges, the Plan of Action invited 
Member States to expand the use of pre-export notifica-
tions to non-scheduled substances and pharmaceutical 
preparations. Furthermore, Member States were asked to 
“develop systems (for example, shared online recording 
systems) to prevent precursor chemicals from being 
diverted into illicit channels from community 
pharmacies”.54
While acknowledging that regulatory controls helped to 
prevent the diversion of precursor chemicals from inter-
51 General Assembly resolution S-20/4 B, para. 14 (b).
52 See Official Records of the Economic and Social Council, 2009, Supple-
ment No. 8 (E/2009/28), chap. I, sect. C, Plan of Action, para. 33; 
and Political Declaration, para. 36.
53 Ibid., Plan of Action, paras. 35 and 39. While the 1988 Conven-
tion excluded pharmaceutical preparations from the control efforts 
(para. 14), the 2009 Plan of Action, as a consequence of the changed 
situation, stated in its paragraph 36 (c) that Member States should 
“strengthen controls, including through the Pre-Export Notifica-
tion Online system, where required, for the import and export of 
preparations containing precursor chemicals, such as ephedrine and 
pseudoephedrine, which could be used in the manufacture of amphet-
amine-type stimulants”.
54 Ibid., paras. 41 (k) and (r).
national trade, the Plan of Action identified the new prob-
lem of precursors being diverted “from domestic 
distribution channels” in countries where they were manu-
factured or imported.55
Responding to this new challenge, the Plan of Action asked 
Member States to “increase efforts, beyond international 
trade controls, to prevent the diversion of precursors, and 
pharmaceutical preparations containing the precursors 
ephedrine and pseudoephedrine, from domestic channels 
to be smuggled across borders.”56
Another new element is the invitation to Member States 
to “consider ‘marking’ certain chemical shipments for pos-
sible future use if scientific advances ensure the appropriate 
use of such tools, taking into account the potential burden 
this would place on authorities and industry”.57
E. PATTERNS AND TRENDS IN  
PRODUCTION OF, AND TRADE 
AND TRAFFICKING IN  
PRECURSOR CHEMICALS 
1. Licit activities 
(a) Production and trade patterns of  
substances in Table I and Table II 
Detailed information on global production of all 23 chemi-
cals under international control is not available. There is, 
however, some information on the geographical spread of 
the licit manufacture of precursor chemicals, suggesting 
that such production is a global phenomenon. 
Twenty Governments officially reported production of 
substances in Table I during the 2010-2012 period. Com-
bining this information with trade statistics (Governments 
reporting more exports than imports of Table I precursor 
chemicals during the 2010-2012 period) suggests that pro-
duction of Table I precursors is probably taking place in 
47 countries and areas. The manufacture of Table I and 
Table II precursors may occur in 77 countries and areas, 
representing about half of the 163 countries and areas for 
which information is available (see map 1).58 The com-
55 Ibid., para. 39.
56 Ibid., para. 41 (s).
57 Ibid., para. 41 (u). That provision has not been widely used so far. 
While that could represent a major leap forward in strengthening and 
improving backtracking investigations, there are concerns about the 
costs involved and its actual value added. In addition, the “marking” 
involved in the provision could be potentially problematic if applied 
to chemicals used in the manufacture of pharmaceutical products, 
entailing expensive litigation if patients claim that such pharmaceuti-
cals have been contaminated.
58 Twenty Governments reported licit manufacture of any of the 15 
Table I precursor chemicals during the 2010-2012 period, out of 
a total of 104 Governments reporting to UNODC in part I of the 
annual reports questionnaire. According to UN COMTRADE, 73 
countries exported Table I precursor chemicals during the 2010-2012 
period, i.e. almost half of the countries contained in that database. 
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bined population of the area concerned accounts for about 
77 per cent of the world’s population. 
The largest proportion of licit exports of the 23 interna-
tionally controlled chemical precursors during the 2010-
2012 period were from countries in Asia (41 per cent of 
the total in value terms), followed by countries in Europe 
and the Americas (see table 1). 
The largest proportion of such exports in Asia during that 
period were made by the Republic of Korea, followed by 
Japan, Singapore, Thailand, China and India. The largest 
exporter in Europe was Belgium, followed by Germany, 
the Netherlands and Spain. In the Americas, the list was 
topped by the United States, followed by Canada, Mexico 
and Brazil. The main exporter in Africa was South Africa, 
followed by Zambia, Nigeria, Egypt and Kenya. The larg-
est exporter in the Oceania region was Australia, followed 
by New Zealand. The role of different countries in the licit 
trade of controlled precursors can be a function of multiple 
Thirty-eight countries reported higher exports of Table I precursors 
than imports during the 2010-2012 period. If exports exceed imports 
in a country over a period of time, local manufacture is probably 
taking place. Combining information from the annual reports ques-
tionnaire and UN COMTRADE, the number of “potential” Table I 
manufacturing countries could rise to 47. Extending the analysis to all 
substances controlled in Table I and Table II, UN COMTRADE data 
show exports of internationally controlled precursors by 122 countries 
and imports by 150 countries. If one includes countries reporting 
domestic precursor production, the potential number of countries 
involved in the manufacture of precursor chemicals rises to 77.
elements: the size of their chemical industry, the domestic 
demand for chemicals and the trade sector, which may also 
be influenced by the existence of large seaports. The cor-
relation between exports and imports of precursor chemi-
cals during the 2010-2012 period was weaker than for 
chemicals in general, suggesting that re-exports, though 
common, occurred less frequently for precursor chemicals 
than for chemicals in general.
If only the “net exports” of precursors are considered (i.e. 
the difference between precursor exports and precursor 
imports), which may be a better reflection of underlying 
production, data show an even stronger concentration of 
such “net exports” of precursors from countries in Asia (59 
per cent of the total). 
If the analysis is restricted to Table I precursor chemicals, 
the largest proportion of licit exports during the 2010-
2012 period were reported, in descending order, by Bel-
gium, China, Mexico, the United States, India, Germany, 
the Netherlands and Switzerland. Aggregated to the 
regional level, the largest proportion of exports and imports 
of substances listed in Table I were accounted for by Europe 
(44 per cent of exports and 65 per cent of imports), Asia 
(29 per cent and 18 per cent, respectively) and the Ameri-
cas (27 per cent and 14 per cent, respectively). In terms of 
net exports, Asia accounts for 50 per cent of the global 
total (mainly China, followed by India) and the Americas 
for 38 per cent (mainly Mexico, followed by the United 
Note: The boundaries and names shown and the designations used on this map do not imply official endorsement or acceptance by the United Nations.
Dashed lines represent undetermined boundaries. Dotted line represents approximately the Line of Control in Jammu and Kashmir agreed upon by India and Pakistan. 
The final status of Jammu and Kashmir has not yet been agreed upon by the parties. The final boundary between the Republic of Sudan and the Republic of South Sudan has not yet been determined.
Reported Table I precursors production 
No reported Table I precursors production 
Production of precursors unknown 
No questionnaire received
Table I and Table II precursor exports larger than imports, 2010-2012 (excluding countries reporting Table I production)
Map 1. Potential manufacture of precursor chemicals (Table I and Table II), 2010-2012
Sources: Annual r ports questionnair  of UNODC nd UN COMTRADE.
Note: The boundaries shown on this map do not imply official endorsement or acceptance by the United Nations. Dashed lines represent undetermined 
boundaries. The dotted line represents approximately the Line of Control in Jammu and Kashmir agreed upon by India and Pakistan. The final status of 
Jammu and Kashmir has not yet been agreed upon by the parties. The final boundary between the Sudan and South Sudan has not yet been determined.
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States), while Europe accounts for “just” 12 per cent, 
reflecting the fact that a significant proportion of European 
precursor chemical exports are nowadays “re-exports” of 
imported substances.
(b) Economic importance of substances 
listed in Table I and Table II 
Data from UN COMTRADE indicate that precursor 
chemicals account for a very small share of the overall 
market for chemicals. Total international trade59 in pre-
cursor chemicals amounted to approximately $9 billion in 
2012,60 which is equivalent to just 0.5 per cent of total 
international trade in chemicals. 
Although there were 15 substances listed in Table I and 
only 8 in Table II, the latter substances accounted for 93 
per cent of the international trade in precursor chemicals, 
based on 2012 data (see table 2). The largest (licit) inter-
national trade amounts were reported for toluene (40 per 
cent of total exports in 2012), a chemical used as a solvent 
(paint thinner) and as an octane booster in gasoline fuels, 
although it is also used in the processing of cocaine. The 
second-largest amounts were reported for acetone (22 per 
cent), a widely used solvent and a chemical used in cocaine 
and heroin processing, followed by sulphuric acid (14 per 
cent), a chemical used in the manufacture of cocaine, and 
amphetamine-sulphate, which in the licit market is 
59 International trade is defined here, in line with the definition used 
by the Board, as the total levels of exports or imports, whichever is 
greater. Global exports should, in theory, largely equal global imports, 
except for minor differences. Owing to a lack of consistent reporting, 
however, there are important data discrepancies, i.e. some countries 
report exports, but not all of their trading partners report the cor-
responding imports, and vice versa.
60 October 2013 data from UN COMTRADE, based on HS07 clas-
sification for precursor chemicals and Standard International Trade 
Classification Revision 3 for global imports and exports of chemicals.
required, inter alia, in the production of fertilizers, deter-
gents, pharmaceuticals, insecticides, anti-freezes, explo-
sives, textiles and lubricants. 
The economic importance of international trade in sub-
stances listed in Table I is far lower. Table I precursors, 
which are under tighter control, account for only 7 per 
cent of international trade in precursors. Expressed as a 
proportion of total exports, substances in Table I comprise 
a mere 0.04 per cent of all chemicals traded at the global 
level. The most important substance in Table I is acetic 
anhydride, which is employed, inter alia, in the manufac-
ture of heroin. It accounts for global international licit 
trade of some $0.4 billion, or about 4 per cent of global 
exports in precursor chemicals. The next most important 
Table I precursors are potassium permanganate, involved 
in the manufacture of cocaine (exports of $70 million, or 
0.8 per cent of global exports of precursor chemicals) and 
pseudoephedrine ($63 million, or 0.7 per cent), which is 
used in the manufacture of methamphetamine, followed 
by piperonal ($44 million, or 0.5 per cent) part of the 
manufacture of 3,4-methylenedioxy-N-methylampheta-
mine (MDMA), commonly known as “ecstasy”. 
(c) Trends in the licit trade of Table I and 
Table II precursors 
Expressed in constant United States dollars, global exports 
of precursor chemicals rose almost fivefold during the 
1996-2012 period.61 Even accounting for inflation, such 
exports still rose threefold over this period. 
There was, however, a marked difference between Table I 
61 The subsequent analysis of international trade will be based, unless 
otherwise indicated, on information contained in UN COMTRADE. 
Those data have the advantage of being readily available and, in 
contrast to trade data submitted by Member States to the Board, not 
being subject to any confidentiality clauses.
Table 1. Regional distribution of trade in internationally controlled precursors (Table I and Table II), 
2010-2012
Source: Data from UN COMTRADE (based on HS07 classification).
Exports  
(122 countries; N = $7.8 billion per year)  
Imports  
(150 countries; N = $8.6 billion per year)
Net exporting countries  
(29 countries; N = $3.1 billion per year)
Asia, 
41%
Europe, 
40%
Americas, 
16%
Africa, 
2%
Oceania, 
0.1%
Asia, 
41%
Europe, 
36%
Americas, 
19%
Africa, 
3%
Oceania, 
1%
Asia, 
59%
Europe, 
32%
Americas, 
5%
Africa, 
3%
Oceania, 
0%
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and Table II precursors. While Table II precursor chemicals 
rose three-and-a-half times in constant dollars over the 
1996-2012 period, the increase in the more strictly con-
trolled substances in Table I amounted to 35 per cent (see 
figure 12).
 2. Trafficking in Table I and Table II 
substances 
One way to examine trafficking in precursor chemicals is 
to analyse statistics relating to seizures, although these may 
reflect variations in law enforcement efforts and changes 
in trafficking patterns. Information on seizures also pro-
vides only a partial picture of trafficking of precursors 
because law enforcement activities in this area are geared 
towards the prevention of diversion (e.g. via stopped sus-
picious shipments) and the detection of clandestine 
laboratories. 
Table 2. International trade in precursor chemicals, 2012 
Source: October 2013 data from UN COMTRADE (based on HS07 classification for precursor chemicals and Standard International Trade 
Classification Revision 3 for global chemicals imports and exports). 
Used in manufacture of
Chemical  
substance
Schedule
Licit exports 
(in millions 
of dollars)
As a  
percentage 
of global 
precursor 
exports
Licit imports 
(in millions of 
dollars)
As a  
percentage 
of global 
precursor 
imports
Cocaine Potassium  permanganate Table I 70.3 0.8 56.7 0.7
Heroin, conversion of phenylacetic 
acid to P-2-P and conversion of 
anthranilic acid to N-acetylanthranilic 
acid
Acetic anhydride Table I 361.8 4.49 415.4 4.8
Amphetamines (methamphetamine/
amphetamine) and methcathinone
Ephedrine Table I 10.0 0.1 7.5 0.1
Pseudoephedrine Table I 63.3 0.8 51.2 0.6
P-2-P Table I 2.9 0.04 2.8 0.03
Phenylacetic acid Table I 11.3 0.1 28.4 0.3
Norephedrine Table I 2.2 0.03 1.2 0.01
MDMA (“ecstasy”)
3,4-MDP-2-P Table I 0.3 0.00 0.3 0.00
Piperonal Table I 44.1 0.5 42.7 0.5
Safrole Table I 0.06 0.0 0.05 0.0
Isosafrole Table I 3.8 0.05 2.8 0.03
Lysergic acid diethylamide (LSD)
Lysergic acid Table I 0.6 0.01 0.8 0.01
Ergotamine Table I 3.6 0.04 5.7 0.07
Ergometrine Table I 0.7 0.01 1.0 0.01
Methaqualone
N-acetylanthranilic 
acid Table I 1.3 0.02 0.8 0.01
Anthranilic acid Table II 12.1 0.1 5.2 0.1
Phencyclidine Piperidine Table II 432.6 5.2 420.0 4.8
Cocaine
Toluene Table II 3,273.3 39.5 3,208.4 36.8
Methyl ethyl 
ketone Table II 711.5 8.6 768.4 8.8
Cocaine and heroin
Acetone Table II 1,794.4 21.7 1,881.0 21.6
Ethyl ether Table II 27.1 0.3 28.7 0.3
Cocaine and amphetamine sulphate Sulphuric acid Table II 1,144.9 13.8 1,455.1 16.7
Cocaine, heroin, methamphetamine, 
“ecstasy” and phencyclidine Hydrochloric acid Table II 308.0 3.7 330.1 3.8
Internationally controlled precursors 
Table I 574.0 616.0 7.1
Table II 7,703.9 8,096.7 92.9
Table I and Table II 8,280.0 8,713.9 100.0
All chemicals 1,764 429 1,764 429
Precursors as a percentage of international trade in chemicals 0.5 0.5
Fig. 12. Global exports of precursor chemicals 
in constant 2012 dollars, 1996-2012
Source: Data from UN COMTRADE (based on HS96 classification).
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2. PRECURSOR CONTROL68
Compared with seizures of all drugs, seizures of precursors 
are concentrated in a smaller number of countries and are 
the result of fewer operations. They are often the result of 
joint international operations and are characterized by the 
interception of large volumes per seizure case. A relatively 
low, though rising, number of Governments report such 
seizures. The number increased from 37 in 2002 to 61 in 
2012,62 reflecting improvements in precursor control as 
well as a greater geographical spread in the smuggling of 
precursors. The number of Governments reporting seizures 
of precursors is still, however, only half of the number 
reporting drug seizures (124 in 2012). Over the 2002-2012 
period, 96 Governments reported seizures of precursors, 
compared with 146 reporting seizures of drugs.63
Owing to the smaller number of seizures involved, seizures 
of precursors are characterized by large annual fluctuations, 
which makes trend analyses difficult to interpret and often 
rather speculative. 
The annual fluctuations have been very large for seizures 
of Table I precursors, which peaked in 2011, primarily 
reflecting a massive rise of seizures of the amphetamine-
type stimulants precursor phenylacetic acid and its deriva-
tives64 and some increases in acetic anhydride, potassium 
permanganate, ephedrine and safrole. 
62 The number of countries reporting seizures of Table I precursors 
to the Board rose from 32 in 2002 to 51 in 2012; the number of 
countries reporting seizures of Table II precursors rose from 28 to 45 
during the same time period.
63 Data from the annual reports questionnaire of UNODC.
64 The peak in 2011 occurred in the wake of the international Operation 
Phenylacetic Acid and Its Derivatives, conducted under the auspices 
of Project Prism, which deals with precursors of synthetic drugs.
Preliminary figures for 2012, in contrast, show some of 
the lowest seizure figures for substances in Table I in the 
past two decades (see figure 13). Declines were reported 
primarily for phenylacetic acid and acetic anhydride. Some 
of the decline also reflects the fact that seizure information 
is not yet available from all countries, i.e. totals may still 
rise. Seizures of potassium permanganate, several of the 
precursors of amphetamine-type stimulants and the pre-
cursors of lysergic acid diethylamide (ergotamine, lysergic 
acids) rose in 2012. 
Seizures of substances in Table II show a different pattern. 
Overall seizures of such substances peaked in 2002 and in 
2004 (see figure 14). The 2002 peak was mainly the result 
of acetone seizures, while the 2004 peak was linked to sei-
zures of hydrochloric acid. Since then, overall seizures have 
been at far lower levels. The underlying trend, except for 
the two peaks, appears to have been stable. This is in con-
trast to international licit trade in these substances, which 
has greatly increased over the past two decades. In recent 
years, seizures of substances in Table II have been domi-
nated mainly by seizures of sulphuric acid and/or acetone. 
During the 1990-2012 period, seizures of substances in 
Table II accounted in volume terms for almost 98 per cent 
of all seizures of chemicals controlled under the 1988 
Convention.
The regional distribution of seizures of substances in Table 
I and Table II shows a concentration in the Americas, fol-
lowed, depending on the time frame used, by either Europe 
or Asia. The largest overall precursor seizures in volume 
terms during the 2002-2012 period were reported by coun-
tries in North America (59 per cent of the total), followed 
by South America (12 per cent), Europe (4 per cent) and 
Fig. 13. Global seizures of substances in Table I, in tons, 1989-2012 
Note: Preliminary data for 2012; figures may increase once additional information becomes available.
Cocaine precursor: potassium permanganate
Heroin precursor: acetic anhydride 
Amphetamine-type stimulants precursors: P-2-P, phenylacetic acid, ephedrine, pseudoephedrine, norephedrine, 3,4-MDP-2-P, safrole, isosafrole and 
piperonal
Others: lysergic acid; ergometrine, ergotamine and N-acetylanthranilic acid. 
Source: International Narcotics Control Board, Precursors Report, 2013 (and previous years). 
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Asia (3 per cent). Africa accounted for 0.05 per cent and 
the Oceania region for 0.02 per cent. 
If the analysis is restricted to more recent years (2007-
2012), the largest seizures were made in South America 
(60 per cent of the total), followed by North America (17 
per cent), Asia (15 per cent, of which the bulk (13 per cent 
of the world total) were made in East and South-East Asia) 
and Europe (8 per cent). Seizures in the Oceania region 
accounted for 0.1 per cent and Africa for 0.04 per cent of 
the total. 
F. KEY PRECURSORS USED IN  
THE ILLICIT MANUFACTURE  
OF DRUGS 
1. Key chemical used in the  
manufacture of cocaine:  
potassium permanganate 
(a) Use 
Potassium permanganate has a broad range of licit applica-
tions, mostly derived from its characteristic as an oxidizing 
agent in chemical reactions. Those applications include 
use as a disinfectant for hands; for the treatment of der-
matitis, fungal infections and mouth ulcers; for fruit pres-
ervation and disinfection of vegetables; treatment of 
drinking water and wastewater; and as an oxidant and 
reagent for the synthesis of various organic compounds. 
Significant amounts are required for the synthesis of ascor-
bic acid (used for vitamin C tablets) and saccharin (an 
artificial sweetener). Solutions of potassium permanganate 
with hydrogen peroxide were used to propel rockets65 and 
are still used to propel torpedoes. 
65 Josef Köhler and others, Explosivstoffe (Wiley-VCH, July 2008).
Potassium permanganate is also used in the illicit manu-
facture of cocaine. It is employed in the processing of coca 
paste into cocaine base, and is critical for achieving a 
proper crystallization of cocaine HCl later in the process, 
and ultimately for obtaining high-quality cocaine.66
(b) International trade
Global exports of potassium permanganate (based on data 
from UN COMTRADE) amounted to 25,400 tons in 
2012, exceeding globally reported imports (17,500 tons).67 
This indicates discrepancies in the reporting of trade sta-
tistics, along with possible underreporting of imports. 
The value of global exports of potassium permanganate 
amounted to slightly more than $70 million in 2012 
(equivalent to 0.004 per cent of global chemical exports 
in 2012), up from $23 million in 1996 (see figure 15). 
During the 2007-2012 period, a total of 66 Governments 
reported exports of potassium permanganate, while 141 
Governments reported imports. Total exports amounted 
to $55.3 million per year during the period. The largest 
exporters were China (54 per cent of the total), followed 
by the United States (14 per cent), Belgium (11 per cent) 
and India (7 per cent). 
The largest importer of the substance in South America 
during that period was Brazil, with imports of about 1,000 
tons per year, more than 90 per cent of which originated 
in China. Annual licit imports into the three main cocaine-
producing countries were far lower: 45 tons for Peru, 29 
tons for Colombia and 6 tons for the Plurinational State 
of Bolivia. The potassium permanganate required (385 
66 H. L. Schlesinger, “Topics in the chemistry of cocaine”, in Bulletin on 
Narcotics, Issue 1 (1985), pp. 63-78.
67 If correctly reported, total imports and exports at the global level 
should be equal in weight terms.
Fig. 14. Global seizures of Table II substances in volume terms, 1989-2012 
Note: Preliminary data for 2012; figures may increase once additional information becomes available.
Source: International Narcotics Control Board, Precursors Report, 2013 (and previous years).
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2. PRECURSOR CONTROL70
tons per year) for the manufacture of illegal cocaine68 is 
rather large compared with an annual total of 1,500 tons 
of legal imports into South America, Central America and 
the Caribbean during the 2007-2012 period, suggesting 
that diversion from the licit market happens before it 
reaches the region and/or that it is being produced domes-
tically in clandestine laboratories in the Andean region.69
(c) Trafficking 
Following initially high seizures of potassium permanga-
nate in 1989, when the substance was placed under inter-
national control, seizures remained rather modest during 
the following decade before rising sharply in 1999 in the 
wake of Operation Purple (launched under the auspices 
of the International Narcotics Control Board in April 
1999), which focused on the tracking of potassium per-
manganate and led to a temporary shortage of the chemical 
in the Andean region. As a consequence, alternative sub-
stances were used and operators of cocaine laboratories 
(notably in Colombia) experimented with the illegal pro-
duction of potassium permanganate in clandestine labo-
ratories. Further noteworthy seizures were made during 
the 2004-2007 period as part of Operation Cohesion. Sei-
zures subsequently declined, in parallel with declines in 
global cocaine production and falling purity levels in North 
America, until 2009 and remained at lower levels before 
climbing again in 2012 (see figure 16). 
Thirty-nine Governments reported seizures of potassium 
permanganate during the 2002-2012 period, including 31 
Governments during the 2007-2012 period. Global aver-
age annual seizures of the substance totalled 65 tons during 
the 2007-2012 period, equivalent to 0.3 per cent of global 
licit exports. 
68 See calculations in subsection 1 (a) of section G below.
69 International Narcotics Control Board, Precursors Report, 2013.
South America accounted for 88 per cent of seizures, 
reflecting the use of the substance in the illegal manufac-
ture of cocaine in the Andean region, followed by Asia (9 
per cent), mostly China (8 per cent of total global seizures). 
The bulk of the seizures made by China took place in 
2012, reflecting improved control measures in that coun-
try. The International Narcotics Control Board reported 
that more than three quarters of all pre-export notifications 
for potassium permanganate in 2011 were issued by China, 
followed by the United States and India.70
The largest seizures worldwide were reported by Colombia 
(80 per cent during the 2007-2012 period), followed, in 
the Americas, by the Plurinational State of Bolivia (4 per 
cent) and Peru (2 per cent). Average annual seizures fell by 
half in Colombia during the 2007-2012 period as com-
pared with the 2002-2006 period, but more than tripled 
in Peru and rose 27-fold in the Plurinational State of Boliv-
ia.71 Those patterns reflect a decline in cocaine production 
in Colombia, as well as the growing importance of both 
the Plurinational State of Bolivia and Peru as not only 
coca-producing countries72 but also cocaine-manufactur-
ing countries.73
70 International Narcotics Control Board, Precursors Report, 2012, para. 
96.
71 Seizures of potassium permanganate in the Plurinational State of 
Bolivia surged between 2006 (104 kg) and 2011 (9,914 kg) before 
falling in 2012 (954 kg). These trends were in parallel with the 
destruction of coca base and HCl laboratories in that country, rising 
from 645 in 2000 to 2,622 in 2005, 4,074 in 2006 and 5,299 in 
2011, before falling to 4,508 in 2012. (UNODC, Estado Plurina-
cional de Bolivia: Monitoreo de Cultivos de Coca 2012 (July 2013)).
72 The average annual area under coca cultivation declined in Colom-
bia by 71 per cent between 2000 and 2012, or 18 per cent during 
the 2007-2012 period as compared with the 2002-2006 period. In 
contrast, it increased in Peru by 39 per cent during the 2000-2012 
period, or 23 per cent during the 2007-2012 period as compared 
with the 2002-2006 period, and it increased in the Plurinational 
State of Bolivia by 73 per cent between 2000 and 2012, or by 15 per 
cent during the 2007-2012 period as compared with the 2002-2006 
period. (See chapter I of this edition and previous World Drug Reports.)
73 The number of dismantled cocaine paste, base and crystallization 
laboratories rose in the Plurinational State of Bolivia from 3,093 units 
Fig. 15. Global exports of potassium  
permanganate, 1996-2012
Source: Data from UN COMTRADE.
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
19
96
19
97
19
98
19
99
20
00
20
01
20
02
20
03
20
04
20
05
20
06
20
07
20
08
20
09
20
10
20
11
20
12
M
ill
io
n
s 
o
f 
 d
o
lla
rs
 
Exports in current dollars
Exports in constant 2012 dollars
Fig. 16. Global seizures of potassium  
permanganate, 1989-2012
Source: International Narcotics Control Board, Precursors Report, 
2013 (and previous years). 
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There are indications that significant amounts of potas-
sium permanganate are produced illegally in the Andean 
region. In 2011, Colombian authorities dismantled seven 
laboratories producing the substance; in 2012, eight such 
laboratories were dismantled.74 The International Narcot-
ics Control Board cites estimates that between 60 and 80 
per cent of the potassium permanganate used in Colombia 
is obtained nowadays through illicit manufacture of the 
substance using manganese dioxide as a starting material.75 
Backtracking investigations also suggest that potassium 
permanganate has been diverted from domestic distribu-
tion channels abroad and then smuggled into the Andean 
region and/or that alternative chemicals have been used.76
Smaller amounts were also seized in Argentina, Brazil, 
Chile, Ecuador and Venezuela (Bolivarian Republic of ), 
i.e. in countries neighbouring the three main cocaine-pro-
ducing countries, during the 2007-2012 period. In 2013, 
small amounts were also found in dismantled cocaine-
processing laboratories in the Dominican Republic and 
Panama.77
2. Key chemical used in the  
manufacture of heroin: acetic 
anhydride
(a) Use
Acetic anhydride is used mainly as an acetylating and dehy-
drating agent in the chemical and pharmaceutical indus-
tries. It is a versatile reagent and is used, inter alia, in the 
production of aspirin and the conversion of cellulose to 
cellulose acetate, a substance used for photographic films, 
adhesives, synthetic fibres and as a frame material for eye-
glasses. It is also used as a wood preservative, for polishing 
metals and in the production of brake fluid, dyes and 
explosives. 
In addition, acetic anhydride is used in the manufacture 
of heroin and, to a lesser extent, in the manufacture of 
other drugs, such as methaqualone, or in the conversion 
of phenylacetic acid to P-2-P. The synthesis of heroin, also 
known as “diacetylmorphine”, is a simple one-step acetyla-
tion reaction of morphine using acetic anhydride.78 
in 2007 to 5,299 units in 2011. Similarly, the number of dismantled 
coca paste and base laboratories in Peru rose from 649 in 2007 to 
1,498 in 2011 while the number of cocaine crystallization laboratories 
there rose from 16 in 2007 to 21 in 2010 and still 19 in 2011. In 
contrast, the number of cocaine paste/base laboratories in Colombia 
declined from 3,147 in 2008 to 2,200 in 2011 while the number of 
dismantled cocaine crystallization laboratories fell in Colombia from 
296 to 200 over the same period. (UNODC, Colombia, Monitoreo de 
Cultivos de Coca 2011 and previous years; Peru, Monitoreo de Cultivos 
de Coca 2011 and previous years; and Estado Plurinacional de Bolivia, 
Monitoreo de Cultivos de Coca 2011 and previous years.)
74 Data from the annual reports questionnaire of UNODC.
75 International Narcotics Control Board, Precursors Report, 2013, para. 
97.
76 International Narcotics Control Board, Precursors Report, 2012, para. 
95.
77 International Narcotics Control Board, Precursors Report, 2013, para. 
98.
78 United Nations International Drug Control Programme, Recom-
(b) International trade
Estimates of annual licit production of acetic anhydride 
range from 1.1 million tons (2011)79 to 2.13 billion litres, 
or 2.3 million tons,80 per year. The latest estimate of the 
International Narcotics Control Board is close to 1.5 mil-
lion tons per year.81
Global exports of acetic anhydride in 2012 reached 
397,000 tons, while global imports reached 414,000 tons, 
suggesting that international trade amounts to some 28 
per cent of global production of the substance. Global licit 
exports of acetic anhydride rose, in real terms, by 80 per 
cent during the 1996-2012 period (see figure 17). This 
was less than the rise in chemical exports in general. 
During the 2007-2012 period, 118 Governments reported 
importing acetic anhydride, while 45 reported exports of 
the substance. The largest exporters in Asia were China 
and Japan; in North America, the United States and 
Mexico; and in Europe, Belgium and the Netherlands. In 
terms of “net exports”, North America predominates 
(Mexico followed by the United States). 
Officially reported licit imports into South-West Asia, 
however, were very small. There were no licit imports into 
Afghanistan. Licit imports into Pakistan fell from 149 kg 
mended Methods for Testing Opium, Morphine and Heroin (New York, 
1998), p. 7.
79 “Acetic Acid Global Market to 2020” (GBI Research, 1 Febru-
ary 2013). Available from www.companiesandmarkets.com. See 
also www.plastemart.com/Plastic-Technical-Article.asp?LiteratureI
D=1918&Paper=global-acetic-acid-market-estimated-15.5-million-
tons-2020.
80 International Narcotics Control Board, Precursors Report, 2012, box 
1. One kilogram of acetic anhydride is equivalent to 0.926 litres of 
acetic anhydride.
81 International Narcotics Control Board, Precursors Report, 2013, para. 
106.
Fig. 17. Global exports of acetic anhydride, 
1996-2012
Source: Data from UN COMTRADE (based on HS96).
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2. PRECURSOR CONTROL72
in 2008 to 14 kg in 2012, according to data from UN 
COMTRADE. That is far below the requirements of 
Afghanistan’s opiate industry. No licit acetic anhydride 
imports were reported by the Islamic Republic of Iran or 
any of the other countries bordering Afghanistan (except 
China). Yet, clandestine heroin production and seizures of 
acetic anhydride in West Asia, notably in Afghanistan, were 
substantial. This suggests that most of the acetic anhydride 
destined for the subregion originates as diversions made 
outside the subregion.82
In Asia, relatively large imports of acetic anhydride during 
the 2007-2012 period were reported by China (24,400 
tons per year), the Republic of Korea (10,600 tons), Sin-
gapore (6,700 tons), Thailand (4,000 tons) and India 
(1,200 tons). Historically, the largest importer in South-
Eastern Europe has been Turkey (1,400 tons per year), an 
important trans-shipment location for acetic anhydride 
diverted in Europe and smuggled into Afghanistan. During 
the same period in Asia, relatively large exports were 
reported by Saudi Arabia (17,100 tons per year), the 
United Arab Emirates (15,800 tons),83 China (11,400 
tons), Japan (8,200 tons), Singapore (5,700 tons) and India 
(2,300 tons).
(c) Trafficking 
Following increases in seizures of acetic anhydride in the 
1990s, and a peak reached in 2001 in the wake of the 
implementation of Operation Topaz (which started in late 
2000), seizures fell in the first few years of the new mil-
lennium, possibly as a delayed reaction to the 2001 Afghan 
opium poppy ban, before recovering as precursor control 
gained a new impetus in the wake of the introduction of 
Operation Cohesion in 2006. Even though seizures 
declined in 2012, the underlying trend seems to be upwards 
(see figure 18).
Seizures of acetic anhydride were reported by 43 Govern-
ments during the 2002-2012 period. Global annual sei-
zures during the 2007-2012 period amounted to 
approximately 131,000 litres, equivalent to just 0.03 per 
cent of global imports. 
The largest seizures were made in “West Asia”84 (34 per 
cent of the world total), mostly reflecting seizures made in 
Afghanistan (22 per cent of the world total). 
Afghanistan has no legitimate trade in or manufacture of 
acetic anhydride. Despite that fact, sizeable quantities of 
the substance are diverted each year from domestic trade 
in other countries before being smuggled into 
Afghanistan.85
82 International Narcotics Control Board, Precursors Report, 2013, paras. 
109-112.
83 This reflects huge exports of 94,749 tons of acetic anhydride in 2008, 
while no exports were reported in other years.
84 According to Board classification, West Asia includes countries in the 
Near and Middle East, Central Asia, Turkey and the Caucasus.
85 International Narcotics Control Board, Precursors Report, 2012, para. 
106.
Countries close to Afghanistan are at a particular risk of 
being targeted to obtain and traffic acetic anhydride into 
Afghanistan. “That applies particularly to China, India, 
Islamic Republic of Iran and Uzbekistan – countries that 
manufacture acetic anhydride or countries in which a sig-
nificant amount of the substance is available because of 
domestic or international trade” 86 as well as to Iraq 87. 
Two recent large seizures made in Pakistan88 and the 
Islamic Republic of Iran89 show how these countries con-
tinue to be used as transit countries for such shipments.
The next largest seizures were reported by countries in 
Europe90 (27 per cent of the total during the 2007-2012 
period). The largest, in order of size, were made in Slove-
nia, Hungary, the Russian Federation, Bulgaria and 
Slovakia. 
During the 2002-2012 period, Turkey reported regular 
seizures of acetic anhydride, typically originating in West-
ern and Central Europe.91 Overall seizures of acetic anhy-
dride in Turkey have shown a downward trend, possibly 
reflecting the declining importance of Europe as a source 
region.
86 International Narcotics Control Board, Precursors Report, 2012, para. 
112.
87 In January 2012, Iraqi authorities objected to a shipment of 32 
tons of acetic anhydride from China. (INCB, 2012 Precursors and 
chemicals frequently used in the illicit manufacture of narcotic drugs and 
psychotropic substances, New York 2013, p. 25).
88 In mid-2013, for instance, 15 tons of acetic anhydride were seized 
while transiting Pakistan on its way to Afghanistan (International 
Narcotics Control Board, Precursors Report, 2013, para. 111).
89 A recent example was a shipment of 17.8 tons of acetic anhydride 
from China via the Islamic Republic of Iran to Afghanistan, which 
was seized by the Iranian authorities in June 2013. (International 
Narcotics Control Board, Precursors Report, 2013, para. 111).
90 According to the International Narcotics Control Board classification, 
which excludes Turkey.
91 One of the largest cases involved the seizure of 17 tons of acetic 
anhydride in Turkey in December 2010 on a truck which had loaded 
the chemicals in Slovakia and was, officially, said to be transporting 
disinfectants.
Fig. 18. Global seizures of acetic anhydride, 
1989-2012
Source: International Narcotics Control Board, Precursors Report, 
2013 (and previous years).
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Seizures in North America, which accounted for 26 per 
cent of the world total during the 2007-2012 period, were 
made mainly by Mexico (15 per cent of the world total) 
and the United States (11 per cent). Such seizures were 
increasingly linked to the illicit manufacture of metham-
phetamine, and increased after 2009. 
Seizures in East and South-East Asia accounted for 11 per 
cent of the world total during the 2007-2012 period, pri-
marily reflecting seizures made in China (8 per cent of the 
world total), followed by the Republic of Korea and Japan. 
The only other country in South-East Asia reporting 
annual seizures during the 2002-2010 period was Myan-
mar, the world’s second-largest producer of opium. 
As reported by the Interational Narcotics Control Board, 
“while seizures are an important indicator of the level of 
activity of drug trafficking organizations, it is important 
to note that they are also indicators of known diversions 
that have been successful. The international precursor con-
trol system is primarily aimed at the prevention of diver-
sion. Comparative figures on stopped, suspended or 
suspicious shipments show that although seizures of acetic 
anhydride during the period 2008-2011 amounted to 
551,000 litres, nearly double that amount — 943,000 
litres — was either stopped or suspended (a total of 
761,000 litres) or identified as suspicious (182,000 litres) 
through the PEN Online system."92
3. Key methamphetamine  
precursors: ephedrine and  
pseudoephedrine
(a) Use 
Ephedrine and/or pseudoephedrine have been the key pre-
cursors used in the manufacture of methamphetamine for 
many years. In addition, they are used in the illegal manu-
facture of methcathinone, another amphetamine-type 
stimulant.
Ephedra, known as má huáng in traditional Chinese 
medicine, contains both ephedrine and pseudoephedrine. 
Its use has been documented since the Han Dynasty (206 
B.C.-220 A.D.),93 in the treatment of asthma and 
bronchitis and as a stimulant. Licit uses of ephedrine as a 
pharmaceutical product include cough medicine 
(bronchodilators), while pseudoephedrine is often used in 
nasal decongestants. In combination with promethazine, 
ephedrine is used to combat seasickness. Ephedrine is also 
found on the WHO list of essential medicines “for use in 
spinal anaesthesia during delivery, to prevent 
hypotension”.94 In addition, ephedrine preparations are 
92 International Narcotics Control Board, Precursors Report, 2012, para. 
115.
93 Woodburne Levy and Kavita Kalidas, “Use of addictive medications 
and drugs in athletics”, in Principles of Addictions and the Law: Appli-
cations in Forensic, Mental Health, and Medical Practice, Norman S. 
Miller, ed. (Academic Press, 2010), pp. 307-308.
94 World Health Organization, WHO Model List of Essential Medicines: 
sold as food supplements or pills to lose weight and reduce 
body fat. 
A total of 113 Governments reported licit requirements95 
for ephedrine to the Board, and 108 reported requirements 
for pseudoephedrine (out of a total of 153 Governments 
reporting).96 The bulk of the requirements for these sub-
stances concerned pseudoephedrine (see figure 19). The 
largest licit demand for those substances was in Asia (60 
per cent of the total), followed by the Americas (18 per 
cent), Europe (13 per cent), Africa (8 per cent) and the 
Oceania region (0.4 per cent). The single largest markets 
for ephedrine and pseudoephedrine in volume terms were 
India (18 per cent of the world total) and China (17 per 
cent), followed by the United States (13 per cent), the 
United Kingdom (4.2 per cent), the Republic of Korea 
(3.9 per cent), Switzerland (3.3 per cent), Pakistan (3.2 
per cent), Egypt (3.1 per cent), Singapore (2.9 per cent), 
Indonesia (2.7 per cent), the Islamic Republic of Iran (2.5 
per cent), the Syrian Arab Republic (2.3 per cent) and 
Nigeria (1.5 per cent).97
18th list (April 2013).
95 “Annual legitimate requirements for ephedrine and pseudoephedrine 
include quantities of those substances that may be manufactured 
domestically and/or imported into the country to provide adequate 
supplies of each chemical for estimated medical, scientific, research 
and industrial needs; licit export requirements; and establishment 
and maintenance of reserve stocks.” (International Narcotics Control 
Board, “Issues that Governments may consider when determining 
annual legitimate requirements for ephedrine and pseudoephed-
rine”. Available from www.incb.org/incb/en/precursors/precursors/
tools_and_kits.html.)
96 International Narcotics Control Board, Precursors Report, 2013, annex 
II.
97 Ibid.
Fig. 19. Licit requirements for ephedrine and 
pseudoephedrine, 2012 (or latest year 
available)
Note: Based on information from 153 Governments.
Source: International Narcotics Control Board, Precursors Report, 
2013, annex II. 
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(b) International trade
Global international trade in ephedrine and pseudoephed-
rine declined during the 1996-2012 period (see figure 20).
Global exports of ephedrine amounted to, on average, 133 
tons per year during the 2007-2012 period, or roughly 
half of reported imports (264 tons per year). That discrep-
ancy once again indicates problems with regard to report-
ing of trade statistics. 
Thirty Governments reported exports of ephedrine, while 
92 reported imports, during the 2007-2012 period. The 
largest ephedrine exports were reported by India (59 per 
cent). The largest imports were reported by the United 
States (20 per cent) and Egypt (19 per cent), followed by 
the Republic of Korea (8 per cent) and Nigeria (6 per cent). 
Global pseudoephedrine exports amounted to, on average, 
1,136 tons per year during the 2007-2012 period, exceed-
ing imports (863 tons per year). Thirty-five Governments 
reported exports of pseudoephedrine, while 96 Govern-
ments reported imports during that period. The largest 
exports were reported by India (52 per cent of the total), 
followed by Germany and China. According to the United 
States Department of State, Taiwan Province of China was 
actually the third-largest exporter worldwide of pseu-
doephedrine during the 2009-2011 period.98 The largest 
pseudoephedrine imports during the 2007-2012 period 
were recorded by the United States (25 per cent), followed 
by Egypt (8 per cent).
98 United States Department of State, Bureau of International Narcotics 
and Law Enforcement Affairs, International Narcotics Control Strategy 
Report, vol. I (March 2013), chapter on “Chemical controls”. See also 
the same report from previous years.
(c) Trafficking 
While there has been a marked upward trend in overall 
seizures of precursors used in the manufacture of metham-
phetamine and amphetamine (see figure 21), that has not 
been the case with regard to the “traditional” metham-
phetamine precursors, ephedrine and pseudoephedrine. 
Global seizures of ephedrine and pseudoephedrine peaked 
in the second half of the 1990s and again in 2004 before 
falling in subsequent years (see figure 22). 
The initial increases were in line with reports of strong 
growth in the clandestine manufacture of methampheta-
mine since the mid-1990s. The declines in recent years 
seem to reflect improved controls for these substances, 
along with the emergence of alternative precursor chemi-
cals such as phenylacetic acid and a number of chemicals 
not under international control. In addition, data show 
that the use of pharmaceutical preparations containing 
ephedrine or pseudoephedrine has increased in recent 
years.99 
Seizures of ephedrine were reported by 54 Governments 
and seizures of pseudoephedrine by 50 Governments 
during the 2002-2012 period. Total seizures of both sub-
stances amounted to, on average, 56 tons per year during 
the 2007-2012 period, equivalent to 21 per cent100 of 
global licit imports (based on UN COMTRADE data), a 
very high proportion as compared to potassium perman-
ganate or acetic anhydride, which both had ratios of clearly 
less than 1 per cent. 
The bulk of the seizures were made by countries in North 
America (43 per cent) and East and South-East Asia (22 
per cent), reflecting the concentration of global metham-
phetamine production in those two regions, followed by 
Central America (14 per cent), an emerging transit region. 
The largest seizures by individual countries during the 
2007-2012 period were reported by the United States (32 
per cent of the total), followed by China (18 per cent) and 
Mexico (11 per cent). 
East and South Asia continue to be the origins of pseu-
doephedrine and ephedrine used in illicit manufacture of 
methamphetamine in the region and in Oceania.101 Sei-
zures of ephedrine and pseudoephedrine in Mexico have 
been declining strongly following improved controls in the 
country in 2009, which prompted clandestine operators 
of methamphetamine to shift to alternative precursors. 
While Mexico is a major supplier of methamphetamine, 
the country does not seem to have clandestine facilities or 
99 International Narcotics Control Board, Precursors Report, 2013 (and 
previous years).
100 Based on international trade data collected by the International Nar-
cotics Control Board, the proportions during the 2007-2011 period 
amounted to 14 per cent for bulk ephedrine and 2 per cent for pseu-
doephedrine (Precursors report, 2012, table 1).
101 UNODC, Patterns and Trends of Amphetamine-Type Stimulants and 
Other Drugs: Challenges for Asia and the Pacific, Global SMART Pro-
gramme 2013.
Fig. 20. Global exports of ephedrine and  
pseudoephedrine, 1986-2012
Source: Data from UN COMTRADE. 
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chemical plants that synthesize or manufacture pseu-
doephedrine or ephedrine powder. Mexico dismantled 259 
methamphetamine laboratories in 2012, up from a few 
dozen a few years earlier, and it reported the world’s largest 
aggregrated amount of seizures of methamphetamine for 
the period 2010-2012. 
Most of the seizures of these precursors in East and South-
East Asia involved ephedrine (80 per cent). There was also 
a significant domestic demand for both ephedrine and 
pseudoephedrine. China alone dismantled 228 clandestine 
laboratories producing methamphetamine in 2012.102 Sig-
nificant seizures of ephedrine were also reported by Myan-
mar, another key producer of methamphetamine in the 
102 International Narcotics Control Board, Precursors Report, 2013, para. 
48.
region, followed by the Lao People’s Democratic Republic; 
Malaysia; the Philippines; Thailand; Indonesia; Japan; 
Macao, China; Hong Kong, China; Cambodia; and the 
Republic of Korea. Traditionally, most of the shipments of 
ephedrine and pseudoephedrine to countries and areas in 
the region originate within the subregion or in South Asia. 
4. Key amphetamine precursors: 
P-2-P and phenylacetic acid 
(a) Use
One of the key precursors for the manufacture of ampheta-
mine (and in recent years also of methamphetamine) is 
phenyl-2-propanone (P-2-P), or phenylacetone, also 
known as benzyl methyl ketone (BMK). This substance is 
mainly used for the manufacture of amfetamine and some 
Fig. 21. Global seizures of key amphetamines precursors, 1989-2012 
Note: Preliminary data for 2012; data for ephedrine and pseudoephedrine include pharmaceutical preparations. 
Source: International Narcotics Control Board, Precursors Report, 2013 (and previous years).
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Fig. 22. Global seizures of ephedrine and pseudoephedrine, 1989-2012 
Source: International Narcotics Control Board, Precursors Report, 2013 (and previous years).
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of its derivatives, as well as for the synthesis of another 
stimulant drug, propylhexedrine. The latter substance is 
frequently sold over-the-counter as an inhalant (e.g. Ben-
zedrex) to provide temporary relief of nasal congestion, 
and as an appetite suppressant (e.g. Obesin). 
Global licit requirements for P-2-P reported to the Board 
amount to some 65 tons per year, a modest amount com-
pared with the reported requirements for ephedrine (close 
to 400 tons) or pseudoephedrine (more than 1,700 tons). 
The bulk of the reported licit requirements for P-2-P was 
from countries in North America (96 per cent of the total), 
followed by Europe (4 per cent). Small requirements were 
also reported by Governments in Oceania, Asia, South 
America and the Caribbean.103
One of the potential precursors for P-2-P is phenylacetic 
acid, which itself is employed to treat type II hyperam-
monemia, a metabolic disturbance characterized by an 
excess of ammonia in the blood that can lead to encepha-
lopathy (a brain disorder). Moreover, phenylacetic acid is 
used in the production of penicillin G (benzylpenicillin), 
as well as in the treatment of syphilis, diphtheria, menin-
gitis, gonorrhoea, aspiration pneumonia and septic arthri-
tis. Phenylacetic acid is also used in some perfumes.
(b) International trade
Average global exports of P-2-P during the 2007-2012 
period amounted to 77 tons, while average annual imports 
amounted to 143 tons, once again indicating significant 
reporting discrepancies. Fifteen Governments reported 
exports of P-2-P during the 2007-2012 period. The largest 
exporters were France (51 per cent), followed by India (14 
per cent) and Egypt (14 per cent). 
The number of Governments reporting imports of P-2-P 
during the 2007-2012 period amounted to 52. The largest 
importers were the United States (53 per cent), followed 
by China (17 per cent), Jordan (6 per cent), Poland (5 per 
cent) and Egypt (4 per cent). In 2012, the largest import-
ers was the United States, followed by Pakistan. 
International trade in phenylacetic acid is substantially 
larger. Total exports amounted to 4,800 tons per year and 
total imports to 5,900 tons per year during the 2007-2012 
period. The largest exporter during the 2007-2012 period 
was China (75 per cent), followed by the United States (16 
per cent) and India (7 per cent). The largest importer was 
Mexico (32 per cent). A total of 32 Governments reported 
exports of phenylacetic acid, while 79 reported imports of 
phenylacetic acid during the 2007-2012 period.
Combined global exports of P-2-P and phenylacetic acid 
in 2012 remained at similar levels as in 1996 (see figure 
23). A decline of 59 per cent in exports of phenylacetic 
acid during the 2007-2012 period was linked mostly to 
lower exports by the United States, China and India, while 
103 In total, 24 countries reported licit requirements for P-2-P to the 
Board. (International Narcotics Control Board, Precursors Report, 
2013, annex II.)
lower imports were reported mainly from Mexico, the 
United Kingdom and Spain. Declines in 2012 can be 
ascribed to falling exports from China; declines in imports 
were mainly the result of improved controls in Mexico.
(c) Trafficking
The overall trend with regard to total combined seizures 
of P-2-P and phenylacetic acid appears to have been 
upwards (see figure 24). The rise in seizures until 2011 was 
primarily a result of seizures of phenylacetic acid, which is 
increasingly being used in North American methampheta-
mine production. The peak in 2011 may in part have been 
a result of the transfer of phenylacetic acid from Table II 
to Table I of the 1988 Convention in that year and thus 
of stricter monitoring and controls. Moreover, the inter-
national Operation Phenylacetic Acid and its Derivatives, 
conducted under Project Prism in 2011 by the Board, 
appears to have played an important role. 
Average annual seizures of P-2-P during the 2007-2012 
period amounted to 8.3 tons, while average annual seizures 
of phenylacetic acid reached 216.7 tons. Seizures of the 
latter were higher than those of ephedrine and pseu-
doephedrine. Global seizures of P-2-P were equivalent to 
6 per cent of global P-2-P imports, and phenylacetic acid 
seizures were equivalent to 4 per cent of global phenylacetic 
acid imports during the 2007-2012 period.104 These were 
smaller proportions than for ephedrine and pseudoephed-
rine (based on UN COMTRADE data).
Seizures of P-2-P were reported by 22 Governments and 
seizures of phenylacetic acid by 20 Governments during 
104 Based on international trade statistics collected by the Board, sei-
zures of P-2-P were equivalent to 15 per cent of international trade, 
and phenylacetic acid equivalent to 11 per cent of international 
trade during the 2007-2011 period. (International Narcotics Control 
Board, Precursors Report, 2012, table 1.)
Fig. 23. Global exports of P-2-P and  
phenylacetic acid, 1986-2012
Source: Data from UN COMTRADE.
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the 2002-2012 period, fewer than the number reporting 
seizures of ephedrine or pseudoephedrine. 
During the 2002-2012 period, 38 per cent of global P-2-P 
seizures were made in Europe, which is the main ampheta-
mine production centre, followed by East and South-East 
Asia (32 per cent) and North America (30 per cent). 
During the 2007-2012 period, most seizures were made 
in North America (50 per cent), where P-2-P has been 
used in the manufacture of methamphetamine. The larg-
est seizures were reported by Mexico (38 per cent of the 
total), followed by the Netherlands and Canada (12 per 
cent each) and Belgium and China (10 per cent each). 
In the case of phenylacetic acid, North America accounted 
for 98 per cent of total global seizures during the 2007-
2012 period. Forensic profiling of seized methampheta-
mine in the United States confirmed that nearly all 
methamphetamine is now being manufactured using phe-
nylacetic acid or other P-2-P-based methods (94 per cent 
of all samples tested in the second quarter of 2012, up 
from 69 per cent in 2010 and close to 0 per cent in 
2007).105
5. Key “ecstasy” precursors: 
3,4-MDP-2-P, safrole, isosafrole 
and piperonal
(a) Use
The “traditional” precursor for the manufacture of MDMA 
(“ecstasy”) is 3,4-methylenedioxyphenyl-2-propanone 
(3,4-MDP-2-P), also known as PMK (piperonyl methyl 
ketone) or in international trade statistics as 1-(1,3-ben-
zodioxol-5-yl)propan-2-one.106 Its licit use is limited.
105 International Narcotics Control Board, Precursors Report, 2012, para. 
76.
106 That terminology may have led to some misunderstandings, however, 
and thus resulted in erroneous classifications.
Safrole, a precursor of 3,4-MDP-2-P and MDMA 
(“ecstasy”), is produced mainly from the sassafras plants. 
According to a study in South-East Asia, the plant is found 
largely in China, Myanmar and Cambodia107. Other stud-
ies reveal that it can also be produced from a number of 
plants grown in other parts of the world, notably in the 
Americas.108 In East and South-East Asia, more than 360 
plants containing essential oils rich in safrole were identi-
fied. The most widely used plants are those of the Cin-
namomum genus109. Sassafras oil is used mainly in the 
manufacture of safrole, which is used in the manufacture 
of pesticides, insecticides and some fragrances. Safrole is 
also used for its antiseptic properties and as a pediculicide 
to treat lice. In addition, it serves as an additive in products 
such as root beer, sassafras tea or pinga com sassafras (Brazil). 
Given indications of its carcinogenic properties, however, 
safrole has been banned as a food additive in a number of 
countries, including the United States and several Euro-
pean Union countries.110 Similarly, for health reasons, the 
International Fragrance Association issued a recommenda-
tion in 1987 to prohibit or limit its use in fragrance 
ingredients. 
Isosafrole, another precursor of 3,4-MDP-2-P, is an isomer 
of safrole. Although it can be produced synthetically out 
of safrole, it is also derived from sassafras oil. It is used in 
the fragrance industry. Isosafrole is used for making soaps 
107 “Safrole-rich essential oils — risk of illicit use”, in Eastern Horizons 
(UNODC Regional Centre for East Asia and the Pacific, Summer-
Autumn 2007), pp. 9-10.
108 Sérgio Rocha and Lin Chau Ming, 1999, “Piper hispidinervum: a 
sustainable source of safrole” in Perspectives on new crops and new 
uses, J. Janick, ed. (American Society for Horticultural Science Press, 
Alexandria, VA, 1999), pp. 479-481.
109 UNODC, Amphetamines and Ecstasy: 2008 Global ATS Assessment 
(August 2008), p. 103.
110 Joint FAO-WHO Expert Committee on Food Additives, WHO Food 
Additives Series 16. Available from www.inchem.org/documents/jecfa/
jecmono/v16je22.htm.
Fig. 24. Global seizures of P-2-P and phenylacetic acid, 1989-2012 
Source: International Narcotics Control Board, Precursors Report, 2013 (and previous years).
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and perfumes, as well as in the manufacture of preserva-
tives as an antiseptic agent. It is also a key precursor for 
the manufacture of piperonal. 
Piperonal, a further precursor for 3,4-MDP-2-P and 
3,4-methylenedioxyamphetamine (MDA), is another 
organic compound commonly found in fragrances and 
flavours. Piperonal occurs in a range of plants, including 
dill, violets, black pepper and vanilla, but it is also pro-
duced by oxidation of isosafrole. Piperonal itself is some-
times used in aromatherapy.111
(b) International trade
In terms of legal trade, piperonal is nowadays by far the 
most important substance among the “ecstasy” precursor 
chemicals. Global piperonal exports increased during the 
1996-2012 period, while exports of the other chemicals 
declined after reaching a peak in 1998. The strong decline 
in exports of “ecstasy” precursors between 1998 and 2000 
was the result mainly of a fall in isosafrole exports, reflect-
ing improvements in precursor control owing to a signifi-
cant upward trend in “ecstasy” use in key markets in the 
1990s (see figure 25).
A total of 38 Governments reported exports of “ecstasy” 
precursor chemicals during the 2007-2012 period, 
amounting to, on average, $42 million per year. Imports 
were reported by 102 Governments ($45 million per year). 
The largest exporters of“ecstasy” precursor chemicals were 
China (56 per cent) and Hong Kong, China (21 per cent). 
The largest importers were Hong Kong, China (18 per 
cent) and the United States (17 per cent), followed by 
Germany (9 per cent), Spain (7 per cent), Switzerland (7 
per cent) and the United Kingdom (5 per cent). China 
was the largest net exporter during the 2007-2012 period. 
The totals primarily reflect international trade in piperonal 
of about $41 million per year. Exports of the substance 
were reported by 26 Governments; imports were reported 
by 84 Governments. 
The second most widely traded substance was isosafrole: 
18 Governments reported exports and 53 reported imports. 
They recorded annual exports of about $1 million and 
imports of $2.8 million per year during the 2007-2012 
period, again indicating some significant reporting gaps. 
Exports of 3,4-MDP-2-P amounted to about $0.3 million 
annually, while imports totalled $1.5 million per year 
during the 2007-2012 period, again indicating inconsist-
encies in reporting. There were a total of 15 Governments 
that reported exports and 46 that reported imports. 
For safrole, 15 Governments reported exports and 45 
reported imports. They recorded total exports of $0.09 
million and imports of $0.17 million per year. 
In both value and volume terms, piperonal is the most 
111 For more information, see http://micro.magnet.fsu.edu/primer/tech-
niques/polarized/gallery/pages/heliotropinsmall.html.
widely traded substance among MDMA precursors, 
according to UN COMTRADE data. Average annual 
exports during the 2007-2012 period amounted to 1,759 
tons of piperonal, 62 tons of 3,4-MDP-2-P, 25 tons of 
isosafrole and 9 tons of safrole. If all of these exports are 
transformed into 3,4-MDP-2-P equivalents (based on the 
conversion ratios of the International Narcotics Control 
Board), the aggregated figure amounts to some 1,000 tons 
per year. The bulk of these exports in volume terms is 
accounted for by piperonal (91 per cent), followed by 
3,4-MDP-2-P (6 per cent), isosafrole (2 per cent) and saf-
role (1 per cent). Calculations on the import side reveal a 
similar pattern.112
Expressed in common 3,4-MDP-2-P equivalents, Board 
statistics suggest that about two thirds of international 
trade in “ecstasy” precursors relates to piperonal, and 
almost a third to safrole and oils rich in safrole. The other 
substances, isosafrole and 3,4-MDP-2-P, account for less 
than 1 per cent of the total (see figure 26). 
Based on such figures, the overall international trade in 
(potential) “ecstasy” precursors would have amounted to, 
on average, 6,580 tons in 3,4-MDP-2-P equivalents during 
the 2007-2011 period. This is a significant discrepancy as 
it is more than six times the figure found in UN 
COMTRADE113. The differences, of course, raise ques-
112 Average annual imports of 1,726 tons of piperonal, 71 tons of isosaf-
role, 40 tons of 3,4-MDP-2-P and 18 tons of safrole during the 
2007-2011 period. This would amount to approximately 1,000 tons 
in 3,4-MDP-2-P equivalents.
113 The comparison made exaggerates the actual difference, as sassafras oil 
is not specifically reported in UN COMTRADE statistics. Neverthe-
less, excluding sassafras oil, the overall total based on International 
Narcotics Control Board statistics would have still been almost five 
times larger than shown in the UN COMTRADE statistics. This is 
mainly owing to differences in the reported trade in piperonal, which 
Fig. 25. Global exports of 3,4-MDP-2-P, safrole, 
isosafrole and piperonal, 1996-2012 
Source: Data from UN COMTRADE.
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tions as to the underlying reasons for this apparent over-
reporting or underreporting by Member States in the case 
of “ecstasy” precursors. 
(c) Trafficking 
In line with global seizures of “ecstasy”, the overall trend 
with regard to the seizure of “ecstasy” precursors was 
upwards in the 1990s, peaking in 2000 and again in 2007 
before falling sharply during the 2007-2010 period and 
remaining, despite some recovery, at lower levels until 2012 
(see figure 27). Overall seizures of “ecstasy” precursors 
amounted to some 16 tons per year during the 2002-2012 
period and were thus far lower than seizures of ampheta-
mine precursors (209 tons per year during the same 
period). 
is much larger in the Board data and more than offsets the smaller 
numbers reported by the Board in the other categories.
If total seizures during the 2002-2012 period are consid-
ered, most seizures of “ecstasy” precursors were for safrole 
(44 per cent), followed by 3,4-MDP-2-P (33 per cent), 
piperonal (23 per cent) and isosafrole (0.2 per cent). There 
have been frequent changes in the type of “ecstasy” precur-
sors used, however. In most years during the 1996-2006 
period, the “traditional” “ecstasy” precursor, 3,4-MDP-2-P, 
was the most widely seized substance. During the 2007-
2012 period, improved controls of 3,4-MDP-2-P 
prompted organized criminal groups to look for alterna-
tives, which led to the use of safrole and various safrole-
containing oils. For the same period, about 85 per cent of 
all seizures of “ecstasy” precursors turned out to be related 
to safrole, 8 per cent to piperonal and only 7 per cent to 
3,4-MDP-2-P. Less than 1 per cent were related to isosaf-
role. All of this is in sharp contrast to licit international 
trade, which is dominated by piperonal. 
Seizures of all of the “ecstasy” precursors during the 2007-
2012 period amounted to, on average, 13.5 tons or, 
expressed in 3,4-MDP-2-P equivalents (based on Board 
conversion ratios), 8.5 tons, equivalent to close to 1 per 
cent of global exports or imports of these substances.114 
This is a higher rate than for potassium permanganate or 
acetic anhydride, although a lower rate than for ampheta-
mine precursors. 
A breakdown by subregion of seizures of “ecstasy” precur-
sors during the 2007-2012 period shows that more than 
two thirds (69 per cent) of seizures were in East and South-
East Asia and a fifth of them in North America, followed 
by Oceania (6 per cent) and Europe (4 per cent). 
Safrole was seized primarily in East and South-East Asia 
(82 per cent of the total during the 2007-2012 period), 
114 The calculation shows a ratio of 0.85 per cent for the 2007-2012 
period. Based on trade statistics of the International Narcotics Con-
trol Board, the proportion amounted to 0.15 per cent during the 
2007-2011 period (see Precursors Report, 2012, table 1).
Fig. 26. International trade in potential  
“ecstasy” precursors in 3,4-MDP-2-P 
equivalents, 2007-2011 
Source: UNODC calculations based on International Narcotics 
Control Board, Precursors Report, 2012.
Piperonal
68%
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containing oils 
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0.20%
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Fig. 27. Global seizures of 3,4-MDP-2-P, safrole, isosafrole and piperonal, 1989-2012 
Source: International Narcotics Control Board, Precursors Report, 2013 (and previous years).
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followed by North America, Europe and the Oceania 
region. The largest seizures were reported by Thailand and 
Malaysia, followed by Australia, the United States, Canada 
and Cambodia. Average global seizures of safrole rose 
almost fourfold between the 1989-2006 period (3,042 
litres per year) and the 2007-2012 period (11,381 litres). 
Piperonal was seized mainly in North America (account-
ing for 95 per cent of the total during the 2007-2012 
period), followed by Europe. Global piperonal seizures 
amounted to, on average, 1.1 tons per year during the 
2007-2012 period, down from 2.9 tons per year during 
the 1989-2006 period. 
The “traditional” precursor of “ecstasy”, 3,4-MDP-2-P, was 
seized mainly in North America (60 per cent during the 
2007-2012 period) and in Oceania (35 per cent) and, to 
a lesser extent, in East and South-East Asia and Europe. 
The largest seizures were reported by Canada (60 per cent) 
and Australia (35 per cent). Global 3,4-MDP-2-P seizures 
amounted to, on average, 919 litres per year during the 
2007-2012 period, down from 5,278 litres per year during 
the 1989-2006 period. China was often identified to be 
the most common source of this substance, although 
improved controls by that country have helped to reduce 
its availability. Given the shortage of illegal 3,4-MDP-2-P, 
there are indications, according to the Board, that India 
may be emerging as a new source.115
G. EFFECT OF PRECURSOR  
CONTROL ON THE SUPPLY  
OF ILLICIT DRUGS 
The most obvious measure of the success of the precursor 
control system is the number of shipments that are stopped 
and the number of seizures made. There are, however, addi-
tional ways of measuring the effectiveness of precursor 
control, some of which are set out below.
115 International Narcotics Control Board, Precursors Report, 2013, para. 
75.
1. Interception rates of diverted 
chemicals 
Two figures are needed to estimate the interception rates 
of diverted chemicals: the amount seized and the amount 
required for the clandestine manufacture of the respective 
end product. The estimated amount of the chemicals 
required plus the amount seized gives an estimate of the 
total amount diverted. Expressing the seizures as a propor-
tion of such diversions gives the interception rate.
Given the strong yearly fluctuations in seizures, the fol-
lowing calculations cover a longer period (2007-2012) and 
have been made for two substances: potassium permanga-
nate and acetic anhydride. They reveal average interception 
rates of about 15 per cent of the chemicals diverted. 
(a) Key chemical used in the manufacture of 
cocaine: potassium permanganate 
Average annual global cocaine manufacture was an esti-
mated 966 tons (range: 835-1,097 tons) over the period 
2007-2012116. On average, some 385 tons of potassium 
permanganate (range: 167-603 tons) per year were required 
for such cocaine manufacture over this period.When sei-
zures are included, this suggests that, on average, some 450 
tons (range: 232-668 tons) of potassium permanganate 
were diverted from licit channels during the period 2007-
2012, which gives a global interception rate of diverted 
potassium permanganate of about 15 per cent (range: 
10-28 per cent) for the period 2007-2012117 (see table 3).
This is a rather high interception rate, given the small pro-
portion of diverted potassium permanganate as compared 
with the global international trade in the substance (2 per 
cent of global exports of potassium permanganate were 
diverted during the period 2007-2012) (range: 1-3 per 
cent; see table 4).
Global cocaine manufacture declined by about a quarter 
over the period 2007-2012 (range: 23-30 per cent),118 
116 Global cocaine manufacture estimates amounted to between 1,024 
and 1,064 tons for 2007, 865-1,122 tons for 2008, 842-1,110 tons 
for 2009, 788-1,060 tons for 2010, 776-1,051 tons for 2011 and 
714-973 tons for 2012 (World Drug Report data).
117 Estimates by the International Narcotics Control Board arrived at an 
interception rate of between 12 and 25 per cent for the period 2007-
2011 (International Narcotics Control Board, Precursors Report, 2012, 
para. 98).
118 World Drug Report data.
Table 3. Global interception rate of potassium permanganate for the period 2007-2012
Source: UNODC estimates based on World Drug Report data.
a Minimum: 65 tons/668 tons = 10 per cent; maximum: 65 tons/232 tons = 28 per cent.
Minimum Maximum Midpoint
Average annual global cocaine manufacture, 2007-2012 (tons) 835 1,097 966
Amount of potassium permanganate needed for the  
manufacture of 100 kg of cocaine
20 55 -
Average annual amount of potassium permanganate required  
for illicit cocaine production (tons) 167 603 385
Average annual seizures of potassium permanganate (tons) 65 65 65
Average annual amounts diverted (tons) 232 668 450
Average annual interception rate (per cent)a 10 28 15
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which suggests that diversions of potassium permanganate 
may have declined by similar proportions. Falling seizures 
of potassium permanganate over that period may also indi-
cate a reduction in diversion attempts. 
(b) Key chemical used in the manufacture  
of heroin: acetic anhydride
Global heroin manufacture was estimated at about 479 
tons per year119 during the period 2007-2012, resulting 
in requirements for some 642,000 litres (range: 479,000-
1,197,500 litres) of acetic anhydride per year for the manu-
facture of heroin.120 Including seizures,121 some 756,000 
119 The estimate of 479 tons has been calculated as the average of annual 
heroin manufacture estimates, which are derived from annual opium 
production (686 tons of heroin in 2007, 600 tons in 2008, 427 tons 
in 2009, 383 tons in 2010, 467 tons in 2011 and 311 tons in 2012). 
While the annual heroin figures derived from opium production esti-
mates may be incorrect for individual years as a result of the accumu-
lation or depletion of opium stocks in such years, over a longer period 
of time such changes in stocks, in general, do not play much of a role. 
This suggests that the 2007-2012 average may be a good estimate for 
actual average annual heroin manufacture during that period.
120 According to International Narcotics Control Board data, between 1 
and 2.5 litres of acetic anhydride are required for the manufacture of 
1 kg of heroin (midpoint estimate of 1.75 litres). However, the bulk 
of the world’s heroin is manufactured in Afghanistan and, accord-
ing to UNODC studies, the amounts of acetic anhydride used in 
Afghanistan typically range from 1 to 1.5 litres for a kilogram of 
heroin (midpoint 1.25 litres). Afghanistan accounted for 83 per cent 
of the world’s total opium production during the period 2007-2012. 
This gives a best estimate of about 1.34 litres of acetic anhydride per 
kilogram of heroin at the global level. The best estimate thus suggests 
that the heroin manufactured required some 642,000 litres of acetic 
anhydride. UNODC estimates are based on International Narcotics 
Control Board and World Drug Report data.
121 Not all seizures of acetic anhydride have been related to the manu-
facture of heroin. Acetic anhydride is also used in the conversion 
of phenylacetic acid to P-2-P, which is of particular importance in 
litres were diverted annually (range: 576,000-1,328,500) 
for use in the clandestine manufacture of heroin. That 
results in a global interception rate of about 15 per cent 
for acetic anhydride diverted for the manufacture of 
heroin122 (range: 7-22 per cent) (see table 5). 
This can be considered a rather high interception rate, 
given the extremely small proportion of acetic anhydride 
that is actually diverted as compared with the global inter-
national trade in the substance (0.2 per cent of global 
imports of acetic anhydride during the period 2007-2012 
(range: 0.14 per cent-0.33 per cent) (see table 6)).
2. Reduction in drug availability 
The present section focuses on the extent to which precur-
sor control results in a reduction in the availability of drugs. 
A reduction in the availability of drugs may be brought 
about by seizing drugs or reducing the availability of the 
raw materials used in their manufacture. It must be pointed 
out, however, that the seizure of precursor chemicals is 
only one of the strategies used to reduce the illicit supply 
of precursors. The prime objectives of precursor control 
are preventing precursor chemicals from being diverted to 
North America, where those precursors are then used to manufacture 
methamphetamine. The subsequent calculation of seizures of acetic 
anhydride was thus based on two scenarios: (a) all acetic anhydride 
seized was intended for use in the manufacture of heroin (seizures of 
131,000 litres); and (b) all acetic anhydride seized in North America 
was for use in the manufacture of methamphetamine (remaining 
acetic anhydride seizures: 97,000 litres). The actual figure is most 
likely somewhere in between the two.
122 According to International Narcotics Control Board estimates, less 
than 17 per cent of globally diverted acetic anhydride was seized each 
year during the period 2007-2011 (International Narcotics Control 
Board, Precursors Report, 2012, para. 106).
Table 4. Diversion as a proportion of international trade in potassium permanganate, 2007-2012
Source: UNODC estimates based on data from the International Narcotics Control Board, World Drug Report and UN COMTRADE.
Minimum Maximum Mid-point
Average annual amounts of potassium permanganate diverted (tons) 232 668 450
Global average annual exports of potassium permanganate (tons) 22,186 22,186 22,186
Global average annual imports of potassium permanganate (tons) 17,233 17,233 17,233
Global average annual international trade (maximum export/import) 
(tons) 
22,186 22,186 22,186
Diversion as a proportion of international trade (per cent) 1.0 3.0 2.0
Table 5. Global acetic anhydride interception rate, 2007-2012
Source: UNODC estimates based on International Narcotics Control Board and World Drug Report data. 
a Minimum: 97,000/(1,197,500+97,000) = 7 per cent; maximum: 131,000/(479,000+131,000) = 22 per cent.
Minimum Maximum Midpoint
Average annual global heroin manufacture, 2007-2012 (tons) 479 479 479
Amount of acetic anhydride needed for the manufacture of 100 
kg of heroin (litres) 100 250 134
Average annual amounts of acetic anhydride required for the 
manufacture of heroin (litres) 479,000 1,197,500 641,860
Average acetic anhydride seizures, 2007-2012 (litres) 97,000 131,000 114,000
Average annual amounts diverted for the manufacture of heroin 
(litres) 576,000 1,328,500 755,860
Average annual interception rate (per cent)a 7 22 15
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illicit channels and identifying and dismantling clandestine 
laboratories. Thus, in quantitative terms, stopped ship-
ments of suspicious chemicals are often more important 
than seizures of precursor chemicals. Nonetheless, seizures 
of precursor chemicals are quite significant when compared 
with seizures of end products. 
(a) Seizures of precursor chemicals as  
compared with seizures of drugs
Another approach to assessing reductions in the availability 
of drugs is to compare seizures of precursor chemicals with 
seizures of drugs. This provides a comparison between the 
efforts, which target the end products, with precursor con-
trol efforts. Such an analysis for the period 2007-2012 
reveals that seizures of potassium permanganate, expressed 
in terms of the amounts of cocaine that could have been 
produced with that chemical, were equivalent to about a 
third of actual cocaine seizures. The acetic anhydride sei-
zures, expressed in terms of the amounts needed for heroin 
production, were almost equivalent to the total amounts 
of heroin and morphine seized. When converted into 
“ecstasy” equivalents, the total amount of “ecstasy” precur-
sors seized over the period 2007-2012 exceeded actual 
“ecstasy” seizures by a fifth. When converted into ampheta-
mine equivalents, total seizures of amphetamine and meth-
amphetamine precursors were more than twice as high as 
actual seizures of amphetamine and methamphetamine 
(see table 7).
One of the explanations for the large amounts of amphet-
amine-type stimulant precursors seized could be that such 
precursors are often seized at the sites of clandestine labo-
ratories. The amount of precursors often exceeds the end 
products found in those laboratories. An additional expla-
nation is that the regions in which parts of the illegal pro-
duction of amphetamine-type stimulants have traditionally 
taken place have invested heavily in precursor control in 
recent years. Moreover, much of the manufacture and con-
sumption of amphetamines tends to be local or regional, 
while trade in or smuggling of precursor chemicals is often 
international and entails the crossing of borders. These 
aspects tend to facilitate the interception of precursors. 
(b) Reductions in supply of drugs possibly 
linked to precursor control 
Significant amounts of precursor chemicals have been 
intercepted in recent years. Taking precursors out of the 
market, however, may not be sufficient to yield a reduction 
in the supply of a drug. Nonetheless, in some cases, pre-
cursor control appears to have played a role in reducing 
the supply of drugs. 
(i) Lysergic acid diethylamide
Lysergic acid diethylamide (LSD) was highly popular in 
several countries in the 1960s and the 1970s. However, 
consumption has declined in most parts of the world, 
including the main consumer markets, over the past two 
decades. 
Data from England and Wales123 showed a decline in LSD 
use among 16-24 year olds from 4.5 per cent in 1996 to 
123 United Kingdom, Home Office, Drug Misuse: Findings from the 2012 
to 2013 Crime Survey for England and Wales (London, 2013).
Table 6. Estimated diversion as a proportion of international trade in acetic anhydride, 2007-2012
Source: Based on UN COMTRADE data.
Minimum Maximum Midpoint
Average annual amounts of acetic anhydride diverted for the 
manufacture of heroin (litres) 576,000 1,328,500 755,860
Global average annual international trade (imports) (litres) 405,218,382 405,218,382 405,218,382
Diversion as a proportion of international trade (per cent) 0.1 0.3 0.2
Table 7. Precursor seizures in end product equivalents versus end product seizures, based on  
averages for the period 2007-2012 
Source: UNODC data from the annual reports questionnaire; and International Narcotics Control Board, Precursors Report, 2013.
Chemical substance/
precursor(s)
Amount of drugs that could have been  
manufactured, in end product equivalents  
(in tons)
Drugs
Amount of 
drugs seized 
(street purity) 
(in tons)
Ratio of precur-
sor seizures to 
end product sei-
zures (per cent)
 Minimum Maximum Midpoint
Potassium  
permanganate 118.6 326.1 222.4 Cocaine 674.4 33
Acetic anhydride 52.28 130.6 97.4 Heroin and  morphine 103.1 95
3,4-MDP-2-P, safrole, 
isosafrole, piperonal 6.8 9.0 7.9
MDMA 
(“ecstasy”) 6.7 118
Ephedrine, pseudo-
ephedrine, norephe-
drine, P-2-P, phenylacetic 
acid
163.1 226.1 194.6
Amphetamine 
and metham-
phetamine
81.9 238
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0.4 per cent during the 2012-2013 period, a decline of 90 
per cent. A number of surveys in other countries also 
showed strong declines in LSD use.124 
Data on secondary school students in the United States125 
showed a decline of 75 per cent in the use of LSD during 
the period 1996-2013. That decline occurred alongside a 
strong decline in the reported availability of LSD in the 
country (reduction of 52 per cent during the period 1996-
2013), which seems to have been the prevailing factor in 
explaining the decline in its use (see table 8).126 Improved 
controls over LSD precursors seem to have contributed to 
the reduction in the availability of LSD. Expressed in con-
stant dollars, global exports of the main LSD precursors 
(ergotamine, ergometrine and lysergic acid) declined by 
78 per cent between 1996 and 2012, which reduced the 
potential for diversion of those chemicals.127 
(ii) Methaqualone 
There are indications that the misuse of methaqualone, a 
sedative-hypnotic drug that has similar effects to barbitu-
rates, is less widespread than it used to be. Precursor control 
appears to have played a role in that reduction. Initially 
widely used in North America, often under the brand name 
Quaalude, and in Europe (notably in the United Kingdom) 
in the late 1960s and early 1970s, it was listed as a con-
trolled substance in the 1971 Convention and was eventu-
ally withdrawn from many developed markets in the early 
1980s. Though some clandestine laboratories in Mexico 
and other countries continued underground production 
in the 1980s, improved controls of N-acetylanthranilic 
acid and anthranilic acid appear to have halted those activi-
ties since the 1990s. 
124 Annual prevalence of LSD use among young adults (aged 15-34) 
fell in Ireland from 2.9 per cent in 1998 to 0.6 per cent during the 
period 2010-2011; in Latvia from 1 per cent in 2003 to 0.1 per cent 
in 2011; and in Hungary from 1.3 per cent in 2001 to 0.3 per cent in 
2007 (European Monitoring Centre for Drugs and Drug Addiction, 
Statistical Bulletin 2013 (Lisbon, 2013)).
125 See Lloyd D. Johnston and others, Monitoring the Future National 
Survey Results on Drug Use: 1975-2013 – 2013 Overview: Key Findings 
on Adolescent Drug Use (Ann Arbor, University of Michigan, 2014).
126 The correlation between annual prevalence and perceived availability 
of LSD turned out to be very strong during the 1996-2013 period, 
amounting to r = 0.93 (statistically significant at α = 0.01). The 
decline in perceived availability was much sharper than the decline in 
the perceived risk of harm during that period (see table 8).
127 Data from UN COMTRADE.
However, methaqualone use became increasingly concen-
trated in South Africa. In the 1980s and the early 1990s, 
methaqualone, known locally as Mandrax, was the second-
most-used drug in the country (after cannabis). While it 
is still used in South Africa, there are indications that its 
usage has declined. In 2000, 33 per cent of all treatment 
related to psychoactive substances (excluding alcohol) in 
four South African towns was reported to have been related 
to Mandrax;128 this proportion fell to 19 per cent by 
2011.129 The decline in methaqualone use around the 
world is also reflected in seizures: global seizures declined 
from a peak of 54 tons in 1994 to 11 tons in 2002 and 
0.2 tons in 2012. India (47 per cent of total) and South 
Africa (45 per cent), followed by China (7 per cent), 
reported the largest seizures of methaqualone during the 
2000-2012 period.130 At the same time, global legal 
exports of the two main methaqualone precursors, N-acet-
ylanthranilic acid and anthranilic acid, fell by some 70 per 
cent between 2002 and 2012.131 
(iii) “Ecstasy”
The availability of MDMA (“ecstasy”) has declined in 
recent years, which appears to have been largely a result of 
improved precursor control at the global level, notably in 
China.132 
Reduced availability had an impact on “ecstasy” use. 
Declines in the use of “ecstasy” were reported from a 
number of countries in Europe, North America and Oce-
ania in recent years. In England and Wales, a key “ecstasy” 
market in Europe, use of the drug declined from a peak of 
6.8 per cent among 16-24 year olds during the 2001-2002 
period to 2.9 per cent during the 2012-2013 period.133 
128 Andreas Plüddemann and others, Monitoring Alcohol and Drug Abuse 
Trends in South Africa, Proceedings of SACENDU Report Back Meet-
ings: January-June 2002, Phase 12, October 2002 (Cape Town, South 
Africa, South African Community Epidemiology Network on Drug 
Use, 2002). 
129 Siphokazi Dada and others, Monitoring Alcohol and Drug Abuse 
Treatment Admissions in South Africa: August 2012, Phase 31, July to 
December 2011 (and previous years) (Cape Town, South Africa, South 
African Community Epidemiology Network on Drug Use, 2012).
130 UNODC, data from the annual report questionnaires.
131 Data from UN COMTRADE.
132 International Narcotics Control Board, Precursors Report, 2013, para. 
75.
133 Drug Misuse: Findings from the 2012 to 2013 Crime Survey for England 
and Wales.
Table 8. Annual prevalence and perceived availability and risk of using LSD among twelfth-grade 
students in the United States, 1996-2013 
Source: Lloyd D. Johnston and others, Monitoring the Future National Survey Results on Drug Use: 1975-2013.
Year
Annual 
prevalence
Perceived  
availability
Perceived risk of harm
“Fairly easy” or “very easy” 
to get LSD
Trying LSD once or twice 
constitutes a great danger
Using LSD regularly  
constitutes a great danger
1996 8.8 51.3 36.2 77.8
2013 2.2 24.5 34.9 66.8
Change (per cent) -75 -52 -4 -14
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This was not an exception: most European countries 
reported declines over the past few years and overall 
“ecstasy” consumption in countries of the European Union 
and the European Free Trade Association appears to have 
fallen by almost half among those aged 15-34 in recent 
years, based on a comparison of the pooled results of recent 
surveys for the 2007-2012 period with surveys for the 
1998-2006 period.134 General population surveys also 
indicate declines in the use of “ecstasy” in Oceania, as well 
as a sharp decline (of more than 50 per cent) in North 
America in recent years (see figure 28). 
Data from the ongoing United States study Monitoring 
the Future, undertaken by the Institute for Social Research 
at the University of Michigan, show that the annual preva-
134 European Monitoring Centre for Drugs and Drug Addiction, Statisti-
cal Bulletin 2013.
lence rate of “ecstasy” use among students in the twelfth 
grade fell by 58 per cent between 2000 and 2013. That 
went hand in hand with a decline of about 32 per cent in 
the perceived availability of “ecstasy”. While the number 
of those who considered that there was a great risk in taking 
“ecstasy” increased between 2000 and 2005, they declined 
thereafter, and the perceived availability of “ecstasy” on the 
market declined during the 2000-2013 period (see table 
9). 
There are also indications in other countries that the 
decline in the availability of MDMA has played a key role 
in the decline of “ecstasy” use. Overall exports of “ecstasy” 
precursors fell by 41 per cent between 1998 and 2012.135 
Average annual seizures of “ecstasy” precursors declined by 
135 Data from UN COMTRADE.
Fig. 28. Trends in the annual prevalence of “ecstasy” use among the adult population in selected 
countries in Oceania, Europe and North America 
Source: Australian Institute of Health and Welfare, 2010 National Drug Strategy Household Survey Report, Drug Statistics Series No. 25 
(Canberra, July 2011); United States, Department of Health and Human Services, Substance Abuse and Mental Health Services Adminis-
tration, Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-46, HHS Publica-
tion No. SMA 13-4795 (Rockville, Maryland, 2012); Drug Misuse: Findings from the 2012 to 2013 Crime Survey for England and Wales; 
and European Monitoring Centre for Drugs and Drug Addiction, Statistical Bulletin 2013. 
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Table 9. Annual prevalence and perceived availability of and risk of using “ecstasy” among  
twelfth-grade students in the United States, 2000-2013 
Source: Lloyd D. Johnston and others, Monitoring the Future National Survey Results on Drug Use: 1975-2013.
Year
Annual 
prevalence
Perceived
availability (per cent)
Perceived
risk (per cent)
“Fairly easy” or “very easy”  
to get “ecstasy”
Trying “ecstasy” once or twice  
constitutes a great danger
2000 3.6 51.4 37.9
2013 1.5 35.1 47.5
Change (per cent) -58 -32 25
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57 per cent during the 2007-2012 period compared with 
the 2000-2006 period. At the same time, average annual 
seizures of the end product, “ecstasy”, fell by 39 per cent 
over the same period and by 70 per cent between 2007 
and 2012. The proportion of MDMA found in substances 
sold as “ecstasy” also declined.136 All those data suggest 
that improvements in the control of “ecstasy” precursors 
at the global level have played a key role in reducing the 
availability of MDMA, which, in turn, has been an impor-
tant factor in the decline in “ecstasy” use. 
(c) Price: the case of acetic anhydride 
Another expected impact of precursor control should be a 
measurable increase in the prices paid by operators of clan-
destine laboratories, and hence in illicit production costs, 
as compared with the normal licit market prices. This is 
demonstrated in the case of acetic anhydride.
(i) Import and export prices 
The average global export and import prices of acetic 
anhydride,137 if traded in large quantities, amount to about 
$1 per litre, according to UN COMTRADE data. They 
did not change much during the period 2007-2012. Export 
prices in all major exporting countries fluctuate around 
that figure. Similarly, according to a market analysis by the 
International Narcotics Control Board, wholesale prices 
for acetic anhydride fluctuate around $1.50 per litre.138 
Of 46 countries for which export prices could be estab-
lished, 34 indicated an export price of less than $5 per litre 
over the 2007-2012 period. Higher export prices were 
reported by, inter alia, some countries along the Balkan 
route and countries along the “silk route”. Similarly, import 
prices exceeding $5 per litre were reported in, inter alia, 
several countries along the Balkan route and along the “silk 
route”, as well as countries in East and South-East Asia. It 
is not clear if the higher prices reflect different market 
dynamics or attempts by some intermediaries to purchase 
acetic anhydride for non-legal purposes. 
(ii) Prices paid by operators of clandestine heroin 
laboratories 
The prices paid by operators of clandestine laboratories, 
in general, tend to be far higher than those paid for acetic 
anhydride on the licit market. In Afghanistan, the world’s 
largest opium-producing and heroin-manufacturing coun-
try, average prices for acetic anhydride during the 2008-
2011 period were reported to have ranged from $300 to 
$430 per litre (see figure 29), clearly exceeding the price 
of about $1 charged by the main licit suppliers of the 
substance. 
136 UNODC, Global Smart Update 2012, vol. 7, March 2012, p. 4.
137 The export prices are calculated by dividing the global value of 
exports of acetic anhydride by global exports of the substance in 
kilograms; import prices are calculated by dividing the global value 
of imports of acetic anhydride by global imports of the substance in 
kilograms.
138 International Narcotics Control Board, Precursors Report, 2013.
(iii) Differences in prices depending on the source 
Trafficking in acetic anhydride into Afghanistan emerged 
as a lucrative business as it had limited risks compared with 
drug trafficking even though traffickers are forced to take 
the more expensive option of smuggling acetic anhydride 
from countries where it has already been diverted. During 
the 2007-2010 period, the prices in Asia of acetic anhy-
dride from illicit sources ranged from $4-$6 in the Repub-
lic of Korea, $12 in China and $60 in India to $200-$300 
in Pakistan. In Europe, they were reported to have ranged 
from $25 in Slovakia and $100 in Bulgaria to $200-$225 
in Turkey, all in 2010.139 
Nonetheless, some traders have been making extraordinar-
ily high profits. In a seizure case in 2008, an Afghan traf-
ficker admitted procuring 12 tons of acetic anhydride from 
the Republic of Korea, for which $50,000 had been 
paid.140 That equated to a purchase price of about $4 per 
litre, at a time when the average wholesale price of acetic 
anhydride in Nangarhar, Afghanistan, stood at about $300 
per litre (see figure 29). 
(iv) Differences in price linked to perceived quality 
Prices also differ significantly according to perceived qual-
ity. In total, six different quality levels of acetic anhydride 
are regularly monitored in Afghanistan. The monthly price 
monitoring data for Afghanistan in 2013 showed a range 
from $76 per litre for quality “C” acetic anhydride in 
December 2013 to $247 per litre in July 2013 for quality 
139 UNODC, The Global Afghan Opium Trade, p. 147.
140 Ibid., p. 114.
Fig. 29. Prices of acetic anhydride per litre in 
Afghanistan, in dollars, 1998-2013 
Source: UNODC, The Global Afghan Opium Trade: A Threat 
Assessment; UNODC and Afghanistan, Ministry of Counter Nar-
cotics, opium surveys; and Afghanistan drug price monitoring 
monthly reports. 
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“A” acetic anhydride.141 Differences in the price of acetic 
anhydride in Afghanistan often go hand in hand with dif-
ferences in the perceptions of the origin of the 
substance.142 
(v) Changes of price over time 
In addition, prices change significantly over time. Average 
annual prices of a litre of acetic anhydride amounted to an 
average of $24 (range: $13-$34) in Afghanistan in 1998. 
Following the ban on opium production in 2001, heroin 
manufacture also declined, as did the demand for acetic 
anhydride. As a consequence, acetic anhydride prices fell 
to a low of $8 per litre in Nangarhar in 2002. Average 
annual prices in Afghanistan as a whole increased thereafter 
to more than $430 per litre by 2011, before decreasing in 
2012 and 2013.
Price increases over the 2002-2011 period, notably between 
2007 and 2011, may be linked to improvements in pre-
cursor control. One element at the international level may 
have been the rescheduling of acetic anhydride from Table 
II to Table I of the 1988 Convention in 2001, which 
resulted in tightened international control, owing to the 
increasing use of pre-export notifications. In addition, vari-
ous international cooperation efforts, such as Project Cohe-
sion, reduced the readiness of companies to provide 
significant quantities of acetic anhydride to unknown or 
suspicious customers. In 2008, the Afghan authorities offi-
cially prohibited all imports of acetic anhydride.143 Pre-
cursor control efforts were also strengthened in Pakistan 
(which started seizing acetic anhydride 2008 onwards), the 
Islamic Republic of Iran and some other countries in the 
vicinity of Afghanistan.144 In parallel, average annual sei-
zures of acetic anhydride at the global level rose from 
46,000 litres per year during the 2004-2007 period to 
147,000 litres per year during the 2008-2010 period, and 
then to 198,000 litres in 2011, thus contributing to a 
shortage on the Afghan market. 
In 2012, however, global seizures of acetic anhydride fell 
by more than half to about 89,000 litres. At the same time, 
acetic anhydride prices in Afghanistan fell from $431 per 
litre to $230 per litre, which suggests that the availability 
may have increased. 
Some of the increases in the price of acetic anhydride 
between 2002 and 2011 may also have been linked to the 
expansion of opium production in Afghanistan, and thus 
the higher demand for acetic anhydride to convert mor-
phine into heroin. This relationship, however, is complex. 
Acetic anhydride prices in Afghanistan only partially fol-
lowed the trends of opium production. In fact, the statisti-
cal correlation between Afghan opium production and 
141 UNODC and Afghanistan, Ministry of Counter Narcotics, Afghani-
stan drug price monitoring monthly reports.
142 UNODC, The Global Afghan Opium Trade, p. 147.
143 United States Department of State, Bureau of International Narcotics 
and Law Enforcement Affairs, International Narcotics Control Strategy 
Report, vol. 1, Drug and Chemical Control (March 2009).
144 International Narcotics Control Board, Precursors Report, 2011.
acetic anhydride prices in Afghanistan during the 2002-
2013 period is weak (r = 0.17), and not statistically 
significant. 
In 2011, opium production, as well as seizures of heroin 
and morphine, increased sharply. The increase may have 
reflected an underlying growth in Afghan opiate manufac-
ture, resulting in greater demand for acetic anhydride, 
which may explain the further price rise of that substance 
in 2011.
The situation changed again in 2012, when both opium 
production and heroin seizures fell in Afghanistan. The 
apparent decline in Afghan heroin manufacture seems to 
have prompted a decline in the demand for acetic anhy-
dride. At the same time, the sharp decline in global seizures 
of acetic anhydride in 2012 may have eased the previous 
shortage of the chemical. In parallel, a worsening security 
situation facilitated the smuggling of acetic anhydride into 
the country. All of this contributed to a reduction of the 
risk premium and, thus, to lower acetic anhydride prices 
in 2012. The trend also continued in 2013, leading the 
International Narcotics Control Board to express fear that 
the supply of acetic anhydride may be rising again in 
Afghanistan.145 
(vi) Importance of the illicit acetic anhydride 
market in Afghanistan 
Based on data contained in the UNODC study The Opium 
Economy in Afghanistan: An International Problem,146 the 
overall size of the acetic anhydride market may have been 
about $5 million in 2002. The market increased drastically 
over the next few years. By 2009, the total amount of acetic 
anhydride smuggled into Afghanistan was estimated at 
between 380 and 570 tons (midpoint estimate: 475 tons). 
Prices typically ranged between $250 and $450 per litre 
at the time, which resulted in a market value of between 
$130 and $200 million in 2009 (midpoint estimate: $165 
million).147 
Based on data reported in UNODC, Afghanistan: Opium 
Survey 2013,148 demand for acetic anhydride may have 
amounted to between 525 and 735 tons in 2013 (midpoint 
estimate: 630 tons). As a result of falling prices, the overall 
acetic anhydride market in Afghanistan appears to have 
fallen to between $116 and $162 million (midpoint esti-
mate: $140 million).149 That is equivalent to about 0.7 
145 International Narcotics Control Board, Precursors Report, 2013, para. 
112.
146 UNODC, The Opium Economy in Afghanistan: An International 
Problem (New York 2003).
147 UNODC, The Global Afghan Opium Trade, p. 146.
148 UNODC and Ministry of Counter Narcotics of Afghanistan (Decem-
ber 2013).
149 In 2013, the UNODC annual opium survey estimated heroin manu-
facture in Afghanistan at between 350 and 490 tons, which would 
have resulted in a demand for acetic anhydride of between 525,000 
and 735,000 litres. Given an average price of $221 per litre according 
to this report, the acetic anhydride market in Afghanistan can be esti-
mated to have ranged from $116 to $162 million in 2013. (Estimates 
based on data from UNODC, Afghanistan: Opium Survey 2013.) 
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per cent of Afghan GDP and compares with a total (farm-
gate) value of Afghan opium production of about $950 
million in 2013.
(vii) Acetic anhydride as a cost factor in heroin 
manufacture 
The high prices of acetic anhydride in Afghanistan during 
the 2008-2011 period, which ranged from $300-$430 per 
litre, became an important cost factor for Afghan heroin 
manufacturers. 
An estimate of heroin manufacture costs in Afghanistan 
revealed that acetic anhydride accounted for a mere 2 per 
cent of the total in 2002.150 In contrast, an estimate in 
May 2010151 found overall production costs of about 
$1,600 per kilogram of brown heroin (up from less than 
$600 in 1998152). The bulk of the cost came from opium 
(73 per cent) and acetic anhydride (26 per cent). Other 
chemicals such as activated carbon (charcoal), ammonium 
chloride, calcium oxide, hydrochloride acid, acetone and 
concentrated ammonia solutions accounted for just 1 per 
cent of the total cost. 
The increase could have been even larger, but clandestine 
laboratory operators seem to have reacted to the rising 
prices of acetic anhydride by minimizing its use to about 
1 litre per kilogram of heroin, often compromising on the 
quality of the heroin manufactured. While typical purity 
for Afghan heroin destined for overseas export had 
remained at about 70 per cent (range: 50-80 per cent)153 
for years, data sent to UNODC by the Special Testing and 
Research Laboratory of the Drug Enforcement Adminis-
tration of the United States showed that the average purity 
of heroin samples seized across Afghanistan had fallen to 
37 per cent in 2007 and 32 per cent in 2008.154 The foren-
sic laboratory of the Counter Narcotics Police of Afghani-
stan confirmed that many heroin samples continued to 
have a low level of purity in the first six months of 2011.155 
In 2011, the cost of acetic anhydride as a proportion of total 
heroin manufacture costs appeared to have remained at the 
same level as in 2010 (about 26 per cent), before declining 
in 2012 and 2013 as a result of falling acetic anhydride 
prices. Based on data reported in UNODC, Afghanistan: 
Opium Survey 2013, and based on the use of 1.5 litres of 
acetic anhydride per kilogram of heroin, the proportion of 
150 UNODC, The Opium Economy in Afghanistan, p. 139.
151 UNODC, The Global Afghan Opium Trade, p. 151
152 UNODC, The Opium Economy in Afghanistan, p. 136.
153 UNODC, World Drug Report 2010, p. 138.
154 In total, 41 heroin samples were analysed in 2008 and 40 samples in 
2007. In 2007, the tested heroin samples had a purity ranging from 
less than 1 per cent to 86 per cent; in 2008 the purities ranged from 
less than 1 per cent to 91 per cent. Data suggested that the purity of 
heroin was low in the south of Afghanistan. In contrast, high purity 
levels were reported in Kabul in both 2007 and 2008 and heroin 
purity levels were also quite high in the north in 2007 and in the east 
in 2008.
155 UNODC and Afghanistan, Forensic Laboratory of the Counter 
Narcotics Police of Afghanistan, “Laboratory Information Bulletin” 
(LIB/1/2011), p. 2.
acetic anhydride in the overall production costs for heroin 
($1,500-$1,600 per kilogram) declined to some 20 per cent 
of total manufacture costs by 2013. That is, however, still 
10 times higher than in 2002 (see figure 30).
H. REACTIONS OF CLANDESTINE 
OPERATORS FACING STRONGER 
PRECURSOR CONTROLS
Improved precursor controls at the global level have 
prompted clandestine operators of illegal laboratories to 
develop a number of counterstrategies, including the use 
of more sophisticated ways to obtain precursor chemicals, 
and substitute them with non-controlled “pre-precursors” 
to manufacture the needed precursors, as well as the 
development of new psychoactive substances to which the 
current controls do not apply. While all of these 
counterstrategies constitute a challenge for the ongoing 
development of precursor control at the national, regional 
and international levels, they are at the same time an 
indication that precursor control is having an impact. 
1. More sophisticated ways to 
obtain precursor chemicals
(a) Creation of specialized groups to obtain 
precursor chemicals
One of the strategies of operators of clandestine laborato-
ries has been to hire specialists to organize the purchase of 
precursor chemicals. Such specialists are well aware of the 
actual status of the implementation of the 1988 Conven-
tion by various Governments. Moreover, they tend to be 
well connected and often can guarantee the supply of the 
chemicals. In general, chemical trafficking organizations 
have become increasingly resourceful, organized and adapt-
able in order to circumvent the growing number of control 
measures.156 
156 International Narcotics Control Board, Precursors Report, 2011, para. 
158.
Fig. 30. Estimated proportions of acetic  
anhydride in total heroin manufacture 
costs in Afghanistan, 2002-2013 
Source: Estimates based on The Opium Economy in Afghanistan: 
An International Problem; The Global Afghan Opium Trade: A 
Threat Assessment; and Afghanistan: Opium Survey 2013.
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(b) Creation of front companies
Investigations made in El Salvador and Guatemala revealed 
the set-up of front companies or the use of existing com-
panies operating in industries in which there is a well-
established licit demand for the required chemicals. While 
the competent national authorities are, in general, well 
aware of the kind of business in which the controlled 
chemicals are used, it is far more difficult for them to iden-
tify actual requirements, as it is often possible to substitute 
one chemical for another. Unless regularly monitored, or 
if no inside information from competitors or employees is 
provided, such diversions of chemicals from licit front 
companies can remain undetected for many years. None-
theless, the authorities in a number of countries have been 
successful in dismantling at least some such 
companies.157 
(c) Identification of weak links in the  
international control system 
Another strategy has been to identify weak links in the 
international control system and to use them as sources 
for the purchase of precursor chemicals. While practically 
all countries have signed and ratified the 1988 Convention 
(187 out of 193 United Nations Member States), there are 
still a number of countries that have not invoked article 
12, paragraph 10 (a), of that Convention and do not 
require pre-export notifications. 
This applies to a number of countries in Africa, as well as 
some countries in Central America, Western and Central 
Asia, South-East Asia and Oceania. Those countries are 
particularly vulnerable to being targeted as transit countries 
by precursor trafficking organizations. 
The same applies to countries that have yet to register with 
the PEN Online system — mostly countries in Africa — 
and to countries that do not participate in PICS — again 
mostly African countries, as well as some countries in 
South America, the Near and Middle East, Central Asia, 
South-East Asia and Europe. In fact, the International Nar-
cotics Control Board has in recent years identified a 
number of shipments of controlled chemicals that transited 
such countries in Africa, Central America, South America, 
the Near and Middle East, Central Asia, South-East Asia 
and the Balkan region. 
A special case is Taiwan Province of China, which has a 
highly sophisticated chemical industry, including for the 
manufacture of several precursor chemicals; however, 
owing to its status, it does not participate in international 
157 In El Salvador and Guatemala, for instance, police investigated the 
operations of more than a dozen front companies, including compa-
nies involved in pesticides, clothes and furniture, that had been set up 
to smuggle precursor chemicals in large quantities from China into 
Central America in 2011 and 2012. The clandestine labs were appar-
ently controlled by the Mexican Sinaloa cartel, and the final market 
for the methamphetamine was the United States. (Elyssa Pachico, 
“Investigations in El Salvador, Guatemala reveal thriving trade in pre-
cursor chemicals” (27 June 2012). Available from www.insightcrime.
org.)
precursor control efforts such as issuing pre-export notifi-
cations, participating in PICS and providing relevant infor-
mation on seizures and suspicious shipments to the 
International Narcotics Control Board. According to the 
United States Department of State, in 2011 Taiwan Prov-
ince of China was the third largest importer of ephedrine 
and the third largest exporter of pseudoephedrine world-
wide.158 It also trades in a number of other substances 
under international control, including acetic anhydride. 
Methamphetamine laboratories have been detected by the 
authorities. Significant seizures of precursors in recent years 
have been made by the local authorities.159 Even though 
they may act in good faith, the mere fact that significant 
quantities of such substances are traded outside the inter-
national precursor control system constitutes an inherent 
risk that such trade flows may be diverted. The Board thus 
stressed in its latest report that “the current situation rep-
resents a significant weakness in the international control 
system.”160 
(d) Identification of weaknesses at the 
national level (diversion from domestic 
sources) 
Given the ongoing improvements in the control of the 
international trade in precursor chemicals, another strategy 
has been to identify weaknesses at the national level in 
individual countries. Organized criminal groups targeting 
precursor chemicals often do not wait until the chemicals 
enter the international market and thus become subject to 
tight monitoring. Instead, they divert the chemicals in the 
original manufacturing country, or in some subsequent 
transit country that has a legitimate demand for such 
chemicals. The chemicals are then smuggled out of that 
country to the final country of destination, thus bypassing 
the international control system developed for monitoring 
the international trade in such substances.
In this regard, the organizations trafficking precursor 
chemicals use methods similar to drug trafficking organi-
zations. Their advantage, however, is that the customs and 
port authorities of most countries are not as well equipped 
to detect smuggled precursor chemicals as they are to detect 
smuggled drugs. Moreover, the penalties in most countries 
are less severe for trafficking of precursors than for drug 
trafficking, while profit margins can be very high. 
(e) Use of the Internet 
Another strategy has been to expand the supplier base by 
looking for new suppliers on the Internet. The specific 
problems related to the Internet addressed in chapter 1, in 
158 United States Department of State, Bureau for International Nar-
cotics and Law Enforcement Affairs, International Narcotics Control 
Strategy Report (March 2013).
159 Food and Drug Administration, Ministry of Health and Welfare, 
Statistics Table for Seized Narcotics Drugs and Controlled Drugs in 
Taiwan. Available from www.fda.gov.tw/EN/download.aspx.
160 International Narcotics Control Board, Precursors Report, 2013, para. 
33.
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the box titled “the ‘dark net’ bitcoins and the increasing 
sophistication of online drug sales”, apply to precursors as 
well. 
2. Use of alternative precursors
(a) Pharmaceutical preparations 
One way to circumvent the rules governing the interna-
tional trade in bulk chemicals has been to focus on phar-
maceutical preparations containing precursor chemicals.161 
Pharmaceutical preparations are largely excluded by the 
1988 Convention, which states, in article 12, paragraph 
14, “The provisions of this article shall not apply to phar-
maceutical preparations, nor to other preparations contain-
ing substances in Table I or Table II that are compounded 
in such a way that such substances cannot be easily used 
or recovered by readily applicable means”. The lack of con-
trols has, in particular, affected pharmaceutical prepara-
tions containing ephedrine and pseudoephedrine. While 
such substances contained in nasal decongestants, bron-
chodilators and various cold medicines have positive prop-
erties for persons in need, they can be misused. 
In this context, in the 2009 Political Declaration and Plan 
of Action, Member States were explicitly asked to prevent 
the diversion of such pharmaceutical preparations from 
domestic and international trade (Plan of Action, para. 41 
(s)). In the light of continuing challenges, the Commission 
on Narcotic Drugs adopted resolution 54/8 in March 
2011, in which Governments were encouraged to adopt 
regulatory frameworks to control the production, distribu-
tion and commercialization of pharmaceutical preparations 
containing ephedrine and pseudoephedrine, to utilize the 
PEN Online system and to apply similar control measures 
for such pharmaceutical preparations as for bulk precursor 
chemicals. 
Global seizures of pharmaceutical preparations containing 
ephedrine or pseudoephedrine increased from negligible 
levels in the 1990s to 5.6 tons in 2006 and 36.1 tons in 
2011 before falling again to 4.1 tons in 2012. The largest 
diversions of ephedrine and pseudoephedrine preparations 
over the period 2007-2012 were reported from North 
America (60 per cent) and East and South-East Asia (20 
per cent), the two largest methamphetamine-producing 
regions, followed by the Oceania region (10 per cent), 
Europe (4 per cent), South Asia (4 per cent), and Central 
America and the Caribbean (2 per cent); smaller amounts 
were seized in South America and West Asia.162 The 
number of Governments reporting seizures of pharmaceu-
tical preparations containing such substances amounted 
to 37 over the period 2007-2012, including 18 reporting 
161 Over the years, the operators of clandestine laboratories have identi-
fied simple means for extracting pseudoephedrine from such prepara-
tions, e.g. by dissolving the tablets in isopropyl alcohol. (UNODC, 
Patterns and Trends of Amphetamine-Type Stimulants and other Drugs: 
Asia and the Pacific, 2011, p. 43.)
162 International Narcotics Control Board, Precursors Report, 2013, annex 
VI.
seizures of ephedrine preparations and 28 reporting sei-
zures of pseudoephedrine preparations.163 About 17 per 
cent of all ephedrine and pseudoephedrine seizures over 
that period were in the form of pharmaceutical 
preparations.
Awareness of such problems rose following a number of 
operations conducted under the auspices of Project Prism 
in recent years. While in Operation Crystal Flow, con-
ducted in 2007, more than 90 per cent of the ephedrine 
and pseudoephedrine seizures were still related to bulk 
ephedrine and pseudoephedrine, that proportion fell to 
less than 75 per cent in Operation Ice Block in 2008 and 
to just a third in Operation Pila, conducted in 2009 and 
early 2010.164 
Post-operational communications issued between April 
2010 and August 2012 led to the seizure of 8.8 tons of 
ephedrine in bulk and more than 24 tons in the form of 
preparations, i.e. 73 per cent of the ephedrine and pseu-
doephedrine seized was in the form of pharmaceutical 
preparations,165 clearly indicating the rapidly growing role 
of pharmaceutical preparations as inputs for the manufac-
ture of methamphetamine. Before 2010, several of the 
stopped shipments of pseudoephedrine preparations went 
from South Asia and South-East Asia with the destination 
of Central America and Mexico, but the shipments to 
Mexico have declined following stricter controls in that 
country. 166
(b) Use of substitute chemicals and  
“pre-precursors” 
Another strategy of the operators of clandestine laborato-
ries has been to shift from substances controlled under the 
1988 Convention to non-controlled substitute chemicals 
and/or to non-controlled “pre-precursors”. Instructions on 
the use of such chemicals are also available on the 
internet. 
Examples of such substitute chemicals for the manufacture 
of amphetamine or methamphetamine are: APAAN, vari-
ous esters of phenylacetate and P-2-P bisulfite adduct (see 
figure 31). An example for the manufacture of “ecstasy” is 
3,4-MDP-2-P methyl glycidate, sometimes abbreviated as 
MMDMG or PMK-glycidate. Substances such as the 
bisulfite adduct of P-2-P and MMDMG are often also 
referred to as “masked” precursors, as their use helps crimi-
nals to conceal the normal form of precursors of amphet-
amine-type stimulants by packaging and smuggling them 
in a way that has heretofore been rather uncommon and 
thus difficult for law enforcement agencies to detect. 
163 International Narcotics Control Board, Precursors Reports, 2012 and 
2013.
164 International Narcotics Control Board, Precursors Report, 2012, figure 
XI.
165 Ibid., para. 35.
166 International Narcotics Control Board, Precursors Report, 2014 and 
previous years.
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(i) alpha-Phenylacetoacetonitrile: a precursor for 
P-2-P 
An example of the use of substitute chemicals has been the 
ever wider use of APAAN, until recently a non-controlled 
precursor that can be easily converted into P-2-P at a ratio 
of 1.4 to 1.167 It emerged as a substitute chemical for P-2-
P-based manufacture of methamphetamine in Asia and for 
P-2-P-based amphetamine laboratories in Europe, thus 
circumventing the improved controls over P-2-P. 
APAAN was originally discovered in a large-scale meth-
amphetamine manufacturing laboratory in Malaysia in 
2006, and since 2009 has been seized in various European 
countries.168 The International Narcotics Control Board 
reported that in 2011 three European countries seized 
APAAN totalling more than 3.5 tons, of which the bulk 
was seized in the Netherlands.169 For 2012, six European 
countries reported seizures totalling 17.5 tons, with the 
largest seizures reported from Belgium, the Netherlands 
and Hungary. Seizures of P-2-P, in contrast, declined in 
Europe from some 5,500 litres in 2010 to 2,700 litres in 
2011 and 800 litres in 2012,170 possibly indicating a shift 
away from P-2-P towards APAAN. 
Between April and October 2012, authorities in Belgium, 
Bulgaria, the Netherlands and Romania communicated 
17 incidents involving 13.6 tons of APAAN, all of which 
originated in China. Over the period November 
2012-November 2013, 29 incidents were communicated, 
167 International Narcotics Control Board, Precursors Report, 2013, para. 
82.
168 UNODC, Global Smart Update 2012, vol. 7, March 2012, p. 5.
169 International Narcotics Control Board, Precursors Report, 2012, para. 
88.
170 International Narcotics Control Board, Precursors Report, 2013, p. 80.
affecting Austria, Belgium, Estonia, France, Germany, 
Latvia, Luxembourg and the Netherlands, with the latter 
country accounting for almost half of all incidents.171 It 
appears that the final destination of the shipments was the 
Netherlands, while the shipments of APAAN typically 
originated in China.172 
The misuse of APAAN, however, is not just a European 
problem. In 2012, Canada informed other countries of 
the seizure of two shipments of APAAN totalling 6.7 tons. 
The two shipments originated in China.173 
The increased trafficking in APAAN has been attributed 
to its availability and low cost. As a consequence, the Inter-
national Narcotics Control Board recommended to the 
Commission on Narcotic Drugs that APAAN be included 
in Table I of the 1988 Convention.174
(ii) Esters of phenylacetic acid and other non-
scheduled precursors for the manufacture of 
amphetamines 
Ethyl phenylacetate and methyl phenylacetate 
Another example of the spread of non-controlled sub-
stances as precursor chemicals has been the use of various 
171 Ibid., para. 85.
172 Ibid., para. 84.
173 International Narcotics Control Board, Precursors Report, 2012 para. 
89.
174 The Board sent an official communication to the UN Secretary-Gen-
eral to formally initiate procedures for the scheduling of APAAN in 
March 2013. The Secretary-General invited Member States to express 
their opinion. A total of 42 Governments responded to the question-
naire, which confirmed that there was practically no legitimate use 
of that substance for industry. On the basis of those responses, the 
Board submitted a recommendation to the Commission on Narcotic 
Drugs to include APAAN in Table I of the 1988 Convention, and the 
Commission approved that proposal in March 2014.
Fig. 31. Use of non-controlled substitute chemicals in the manufacture of amphetamine-type  
stimulants 
Source: UNODC, Global Smart Update, vol. 7, March 2012, pp. 5-6.
Note: alpha-phenylacetoacetonitrile (APAAN) will be internationally controlled in 2015.
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esters of phenylacetic acid.175 While phenylacetic acid is 
a controlled substance under the 1988 Convention, this 
is not the case for its esters.176 Examples of such trafficked 
esters are ethyl phenylacetate and methyl phenylacetate. 
Both can be easily converted into phenylacetic acid. 
Significant amounts of such esters were seized as part of 
the International Narcotics Control Board’s Operation 
Phenylacetic Acid and its Derivatives, launched in March 
2011. It led to seizures of some 610 tons of derivatives of 
phenylacetic acid in ports, warehouses and laboratories in 
Latin America. Mexico alone seized 421 tons. The opera-
tion also led to important seizures in Belize, El Salvador, 
Guatemala and Nicaragua. Ethyl phenylacetate was the 
most commonly identified ester.177 Mexico seized 369 tons 
and 177,000 litres of ethyl phenylacetate in 2011 and El 
Salvador seized 157 tons. In addition, Mexico seized 
313,000 litres of methyl phenylacetate in 2011. Those 
were substantial amounts, exceeding seizures of other 
methamphetamine precursors.178 
Though there have been declines in seizures since 2011, 
they remain significant. Authorities in Mexico, where ethyl 
phenylacetate has been under control since 2009, reported 
the seizure of 72 tons and 46,000 litres in 2012179 and 
Guatemala reported the seizure of 16 tons in a warehouse 
in 2012. As in previous incidents, the chemical had origi-
nated in China. 180
Despite extensive misuse of the esters of phenylacetic acid 
for the clandestine manufacture of methamphetamine, no 
attempts have been made to schedule them at the interna-
tional level.
(iii) Phenylacetamide, benzylchloride, hypophos-
phorous acid, styrene, benzaldehyde and benzyl 
cyanide 
Even if all of the esters of phenylacetic acid were controlled, 
there would still be a large number of substitute chemicals 
available. For instance, the Mexican authorities reported 
the seizure in 2011 of a variety of other non-scheduled 
chemicals used in the manufacture of methamphetamine, 
including phenylacetamide (300 tons), benzylchloride 
(77,000 litres) and small amounts of 2-phenylethanol. Ear-
lier, the Mexican authorities had reported seizures of 
hypophosphorous acid (1,941 litres in 2009). Large 
175 UNODC, Global Smart Update 2012, vol. 7, March 2012, pp. 5-6.
176 Contrary to the substances controlled under Schedule I of the 1961 
Convention, where esters are automatically under international con-
trol.
177 International Narcotics Control Board, Precursors Report, 2011, para. 
90.
178 Average annual phenylacetic acid seizures at the global level amounted 
to some 217 tons per year over the period 2007-2012, seizures of 
ephedrine amounted to some 29 tons and seizures of pseudoephed-
rine to some 18 tons.
179 International Narcotics Control Board, Precursors Report, 2013 para. 
91.
180 International Narcotics Control Board, Precursors Report, 2013 para. 
70.
amounts of that substance were also seized in Canada (9.8 
tons). In 2012, the Australian authorities reported the sei-
zure of 11 tons of hypophosphorous acid in New South 
Wales.181 
In June 2012, the Mexican authorities dismantled a meth-
amphetamine laboratory where styrene, an industrial start-
ing material for the production of plastics (polystyrene), 
was used as a key precursor. In 2007, there was a report of 
some smaller seizures of styrene in Australia. 182
In Europe and in Asia, Governments have reported seizures 
of a number of other non-scheduled pre-precursors for 
P-2-P in recent years, including benzaldehyde and benzyl 
cyanide. Larger amounts were seized in the Philippines 
(2,400 litres), while smaller amounts of benzaldehyde (less 
than 100 kg) were seized in 2012 in Estonia, Germany, 
Hungary, Poland and the Russian Federation. In 2012, 
attempts were also made to smuggle benzyl cyanide to 
Lebanon (520 litres), together with equipment for illicit 
amphetamine manufacture.183 
(iv) Substitute chemicals for the manufacture of 
“ecstasy”: 3,4-MDP-2-P methyl glycidate 
Substitute chemicals have also emerged for the manufac-
ture of MDMA (“ecstasy”), notably following the intro-
duction of improved controls over 3,4-MDP-2-P by 
China. This led to a shortage of “ecstasy” precursors over 
the period 2007-2010. In the Netherlands, which is iden-
tified by many European countries as the source of 
“ecstasy”, the content of MDMA in products sold as 
“ecstasy” fell from some 90 per cent over the 2000-2004 
period to around 70 per cent in 2009 before recovering to 
82 per cent in 2010 and 91 per cent in 2011.184 Recent 
trends indicate a further recovery of the “ecstasy” market. 
This has been made possible by the increasing use of saf-
role-rich oils and the “discovery” of a number of non-
controlled substitute chemicals. One such chemical is 
3,4-MDP-2-P methyl glycidate, which can be easily con-
verted into 3,4-MDP-2-P. It is frequently made out of 
piperonal (a controlled “ecstasy” precursor).185 
3,4-MDP-2-P methyl glycidate was initially detected in 
Australia in 2004, following the seizure of a 44-gallon drum 
mislabelled as glycidyl methacrylate, which the authorities 
expected to be linked to MDMA production.186 In 2010 
181 International Narcotics Control Board, Precursors Report, 2013, para. 
93.
182 International Narcotics Control Board, Precursors Report, 2012, para. 
92.
183 International Narcotics Control Board, Precursors Report, 2013, para. 
92.
184 European Monitoring Centre for Drugs and Drug Addiction – Trim-
bos instituut, Report by the Reitox National Focal Point The Netherlands 
Drug Situation 2012, p. 154 (and previous years).
185 UNODC, Global Smart Update, vol. 7, March 2012, pp. 4-5.
186 M. Collins and others, “Methyl 3-[3′,4′-(methylenedioxy)phenyl]-
2-methyl glycidate: an ecstasy precursor seized in Sydney, Australia”, 
Journal of Forensic Sciences, vol. 52, No. 4 (July 2007), pp. 898-903.
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the substance was found in the Netherlands,187 together 
with instructions on how to convert it into “ecstasy”. In 
total, the Netherlands authorities seized 1.2 tons of the 
substance in 2010, including 1 ton seized in an air-freight 
shipment from China that had been mislabelled. Subse-
quently, the substance also appeared in Slovakia, Belgium, 
Poland and Estonia188 as well as in Denmark in a shipment 
that had originated in China and was destined for the Neth-
erlands.189 Over the period November 2012-November 
2013, the Netherlands authorities reported the seizure of 
only 690 grams of 3,4-MDP-2-P methyl glycidate, inter-
cepted at the Amsterdam airport in a package sent from 
China via a courier service to the Netherlands. The sub-
stance was mislabelled as methyl cellulose.190 
(v) Methylamine: a universal precursor in the 
manufacture of amphetamine-type stimulants 
Methylamine is another non-scheduled chemical that has 
emerged in recent years in the clandestine manufacture of 
amphetamine-type stimulants. When combined with 
P-2-P, it can be used for the manufacture of methampheta-
mine or, if combined with 3,4-MDP-2-P, it can produce 
“ecstasy”. 
On the basis of seizure patterns, the largest amounts of this 
chemical appear to be currently used for the manufacture 
of methamphetamine. Seizures of methylamine have been 
reported in increasing numbers since 2004, primarily by 
countries in North America, though seizures have also been 
made in Oceania, Europe and East and South-East Asia. 
Following years of seizures totalling a few hundred kilo-
grams, the amounts seized rose to 665 tons and 478,000 
litres in 2011 (see figure 32). Large-scale seizures also con-
tinued in 2012 (197 tons and 208,000 litres).191 Though 
smaller than a year earlier, they still exceeded seizures of 
“traditional” precursors of amphetamine-type stimulants 
(less than 50 tons in 2012).192 
The largest seizures of methylamine in recent years have 
been reported by Mexico, where this chemical has been 
controlled since November 2009. In 2010, Mexico 
reported seizures of 44.3 tons and 47,300 litres of 
methylamine and it accounted for more than 90 per cent 
of global seizures of this substance. The next largest seizures 
were reported by the Netherlands, followed by Canada and 
187 International Narcotics Control Board, Precursors Report, 2010, para. 
62.
188 UNODC, Global Smart Update, Volume 7, March 2012, pp. 4-5.
189 International Narcotics Control Board, Precursors Report, 2011, para. 
99.
190 International Narcotics Control Board, Precursors Report, 2013, para. 
89.
191 Ibid., para. 90.
192 Global seizures in 2012: pseudoephedrine, 25 tons; ephedrine, 7 
tons; P-2-P, 6,800 litres; phenylacetic acid, 2 tons; safrole, 2,000 
litres; piperonal, 336 kg; 3,4-MDP-2-P, 228 litres; isosafrole, 10 litres 
(International Narcotics Control Board, Precursors Report, 2013, p. 
81).
Fig. 32. Global seizures of methylamine,  
2007-2011
Source: International Narcotics Control Board, Precursors Report, 
2012, figure III.
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the United States. By mid-2011, Mexico had reported 
three seizures of methylamine at seaports, totalling more 
than 154,000 litres, originating in China.193 Large seizures 
were also reported in some countries in Central America. 
El Salvador seized almost 69 tons in two shipments in June 
2011, destined for Guatemala.194 In 2011, Mexico 
accounted for 56 per cent of global seizures of methylamine, 
followed by the United States (38 per cent).195 In 2012, 
seizures of methylamine took place again primarily in 
Mexico (197 tons and 150,000 litres), followed by 
Honduras (51,000 litres), the United States (6,929 litres) 
and Poland (403 litres).196 
3. Production of new psychoactive 
substances 
Another strategy to circumvent controls of precursor 
chemicals has been to opt for the manufacture of new 
psychoactive substances. As of end-2013, 348 such 
substances had been identified, exceeding the number of 
substances already under international control (234 in 
2013). The categories of such substances most frequently 
identified have been, in order of frequency, synthetic 
193 International Narcotics Control Board, Precursors Report, 2011, para. 
95
194 International Narcotics Control Board, Precursors Report, 2011, para. 
95.
195 International Narcotics Control Board, Precursors Report, 2012, para. 
93.
196 International Narcotics Control Board, Precursors Report, 2013, para. 
90.
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cannabinoids, phenethylamines, synthetic cathinones, 
tryptamines, various plant-based substances, piperazines, 
phencyclidines and ketamine, as well as aminoindanes.197 
Given the lack of a global control mechanism for new psy-
choactive substances, the chemicals needed to produce 
them are, in general, easy to obtain. This offers plenty of 
opportunities for operators of clandestine laboratories to 
acquire such chemicals and use them in the manufacture 
of new psychoactive substances. Nonetheless, for the time 
being, trafficking in these chemicals at the global level 
seems to be rather limited. 
I. CONCLUDING REMARKS 
The analysis of the precursor control sector highlights the 
substantial progress made over the past two decades, since 
the international community, in the 1988 Convention, 
adopted precursor control as one of its strategies to fight 
illegal drug production. While drug production has not 
been eliminated by the introduction of precursor control 
measures, there is sufficient evidence to show that precur-
sor control has had an impact on the illicit manufacture 
of some drugs. Over the period 2007-2012, about 15 per 
cent of the diverted precursor chemicals acetic anhydride 
and potassium permanganate was seized. Reductions in 
LSD use and “ecstasy” use in recent years appear to have 
been linked, inter alia, to improved precursor controls. 
The new strategies of operators of clandestine laboratories 
clearly highlight, at the same time, the challenges that pre-
cursor control will face in the future, as ever more new 
chemical substances emerge and are able to replace “tradi-
tional” precursor chemicals. 
Some of the instruments for dealing with this problem are 
already in place. In line with the request contained in the 
Political Declaration adopted by the General Assembly at 
its twentieth special session, in 1998, and its related action 
plan on precursor chemicals, a limited international special 
surveillance list of substances not in Tables I and II of the 
1988 Convention is regularly prepared and updated by the 
International Narcotics Control Board to help authorities 
to identify potential precursor shipments. The 1998 action 
plan on precursors also provided that Member States 
should apply monitoring measures, in cooperation with 
the chemical industry, to prevent the diversion of sub-
stances included on the special surveillance list, and 
Member States were asked to consider making the diver-
sion of non-scheduled chemical substances a criminal 
offence. Moreover, in the 2009 Political Declaration and 
Plan of Action, Member States were invited to expand the 
use of pre-export notifications to include non-scheduled 
substances and pharmaceutical preparations. In the 2009 
Plan of Action, Member States were also asked to increase 
efforts to prevent precursors from domestic channels from 
being smuggled across borders. 
197 UNODC, World Drug Report 2013, p. 71.
While all of these actions have been agreed on by Member 
States, they await implementation in a number of coun-
tries. The challenge is the effective and universal imple-
mentation of the international instruments. 
At the same time, it is important to note that most precur-
sor chemicals have a wide spectrum of legitimate uses. Any 
control system, whether local or international, must thus 
be aimed at effectively limiting the availability of such 
chemicals for operators of clandestine laboratories, while 
guaranteeing that licit manufacture of, trade in and use of 
such chemicals are not jeopardized. 
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ANNEX I
TABLES 
Cannabis cultivation, production and eradication, 2012
Country Cultivated 
(ha)
Eradicated 
(ha)
Harvest-
able (ha)
Production (tons) Plants eradicated Sites eradicated
Indoor Outdoors Indoors Outdoors Indoors Outdoors
Afghanistan 10,000 1,400
Albania 50 33,000 154
Australia 17,668 35,146 322 240
Azerbaijan 6 6 0 308 7,538 121
Bosnia and 
Herzegovina 2,807 3
Brazil 22 185 616,133 5
Bulgaria 6,913 42
Chile 18,526 216,902 1,377 291
Costa Rica 8 8 0 965,320 129
Italy 7,706 4,114,911 458 1,318
Latvia 3,796 101 4 3
Lebanon 3,500 800 2,700
Mexico 9,058 12,166
Morocco 52,000 5,000 47,000 760 38,000
New Zealand 21,202 119,059 783
Philippines 21 1,224,738 188
Poland 4 58,156 687 627
Tajikistan 2,180,121
Ukraine 529 2,200,000
United States 
of America 302,377 3,631,582 2,596 6,470
Cannabis
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Cocaine
 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
Bolivia  
(Plurinational 
State of)
21,600 23,600 27,700 25,400 27,500 28,900 30,500 30,900 31,000 27,200 25,300 
Colombia a 102,000 86,000 80,000 86,000 78,000 99,000 81,000 73,000 62,000 64,000 48,000 
Peru b 62,500 60,400 
Peru c 46,700 44,200 50,300 48,200 51,400 53,700 56,100 59,900 61,200 64,400 
Total 170,300 153,800 158,000 159,600 156,900 181,600 167,600 163,800 154,200 155,600 (d) 133,700
Potential production of sun-dried coca leaf, 2005-2012 (Tons)
Sources: For Bolivia (Plurinational State of): potential sun-dried coca leaf production available for cocaine manufacture is estimated by the 
national illicit crop monitoring system supported by UNODC. Source of estimates for leaf yield is UNODC for Yungas de la Paz, and 
United States Drug Enforcement Administration (DEA) for Chapare (DEA scientific studies). The estimated amount of coca leaf produced 
on 12,000 ha in the Yungas of La Paz, where coca cultivation is authorized under national law, was deducted (ranges: upper and lower 
bounds of the 95 per cent confidence interval of the estimated coca leaf yield).  For Peru: potential sun-dried coca leaf production avail-
able for cocaine manufacture is estimated by the national illicit crop monitoring system supported by UNODC. A total of 9,000 tons of 
sun-dried coca leaf production was deducted, which, according to Government sources, is the amount used for traditional purposes 
(range: upper and lower bounds of the 95 per cent confidence interval of the estimated coca leaf yield.
Note: The estimates for 2011 and 2012 are not directly comparable ; for a discussion of the different concepts, see the World Drug Report 2012, pp 
41-42. 
2005 2006 2007 2008 2009 2010 2011 2012
Bolivia 
(Plurinational 
state of)
28,200 33,200 36,400 39,400 40,100 40,900 33,500 30,400
Range
34,200-
38,300
37,300-
41,800
37,900-
42,300
 38,600-
43,100 
 31,900-
35,400 
 28,900-
31,900 
Peru 97,000 105,100 107,800 113,300 119,000 120,500 126,100 119,700 
Range
85,400-
108,600
91,000-
119,200
93,200-
122,000
97,600-
127,800
102,400-
134,200
103,000-
136,300
110,300-
142,100
103,300 
- 136,100
Global illicit cultivation of coca bush, 2002-2012 (Hectares)
Sources: For Bolivia (Plurinational State of), 2002: CICAD and United States Department of State, International Narcotics Control Strategy 
Report; since 2003: national illicit crop monitoring system supported by UNODC. For Colombia and Peru: national illicit crop monitoring 
system supported by UNODC. 
Note: An account of the different concepts for different areas and their effect on comparability was presented in the World Drug Report 2012 (pp. 
41-42). In the continuing efforts to improve comparability of estimates between countries, the estimated net area under coca bush cultivation
at the reference date of 31 December is presented for Peru in addition to the area under coca bush cultivation in Peru as seen on satellite imagery. 
The reference date of 31 December is also used for the estimated area under coca bush cultivation in Colombia. The estimates presented for the Pluri-
national State of Bolivia represent the area under coca bush cultivation as seen on satellite imagery.
a Net area on 31 December. Estimates from 2009 were adjusted for small fields, while estimates for previous years did not require that adjustment. 
b Net area on 31 December. 
c Area as interpreted from satellite imagery. 
d The global coca cultivation figure was calculated using the area as interpreted on satellite imagery  for Peru.   
ANNEX Iiv
Potential production of fresh coca leaf, 2005-2012 (Tons)
2005 2006 2007 2008 2009 2010 2011 2012
Colombia 555,400 528,300 525,300 389,600 343,600 305,300 263,800 231,700
Range 305,300-349,600 179,200-284,200
Potential production of fresh coca leaf in oven-dried equivalent, 2005-2012 (Tons)
Sources: National Illicit Crop Monitoring System supported by UNODC.
Notes: Owing to the introduction of an adjustment factor for small fields, estimates since 2010 are not directly comparable with those of previous 
years. The ranges reflect the uncertainty associated with the estimates. For Bolivia (Plurinational State of) and Peru, the ranges are based on confi-
dence intervals, and the best estimate is the midpoint between the upper and lower bounds of the range. In the case of Colombia, the range is  
estimated on the basis of the area under coca cultivation in the two previous years. The methodology  used to calculate uncertainty ranges for  
production estimates is still under development, and figures may be revised when more information becomes available.
Potential manufacture of 100% pure cocaine, 2005-2012 (Tons)
Sources: For Bolivia (Plurinational State of): Government calculations based on coca leaf yield surveys by UNODC (Yungas of La Paz) and 
United States DEA scientific studies (Chapare). For Colombia: national illicit crop monitoring system supported by UNODC and DEA scien-
tific studies. Due to the introduction of an adjustment factor for small fields, estimates since 2010 are not directly comparable with those 
of previous years. For Peru: Government calculations, based on a coca leaf to cocaine conversion ratio from DEA scientific studies. 
Notes: Owing to the ongoing review of conversion factors, no point estimate of the level of cocaine production could be provided since 2009. Because 
of uncertainty about the level of total potential cocaine manufacture and about the comparability of the estimates of the various countries, the figures 
were estimated as ranges (842-1,111 tons in 2009,  788-1,060 tons in 2010, 776-1,051 tons in 2011 and 714-973 tons in 2012). Detailed informa-
tion on the ongoing revision of conversion ratios and cocaine laboratory efficiency is available in the World Drug Report 2010 (p. 249).  Figures in ital-
ics are being reviewed. Information on estimation methodologies and definitions can be found in the section on methodology in the online version of 
this report.
2005 2006 2007 2008 2009 2010 2011 2012
  Bolivia 
 (Plurinational state of) 80 94 104 113 n.a. n.a. n.a. n.a.
Colombia 680 660 630 450 410 350 345 309
Range 350-400 240-377
Peru 260 280 290 302 n.a. n.a. n.a. n.a.
Total 1,020 1,034 1,024 865 * * * *
2005 2006 2007 2008 2009 2010 2011 2012
Colombia 164,280 154,130 154,000 116,900 103,100 91,600 79,100 69,500
Range 91,600-104,880
Reported cumulative eradication of coca bush (ha), 2005-2012)
Source: UNODC annual report questionnaire and database on estimates and long-term trend analysis (DELTA); Government of Bolivia 
(Plurinational State of), Colombia and Peru. 
Notes: Totals for Bolivia (Plurinational State of) since 2006 include voluntary and forced eradication. Totals for Peru include voluntary and forced eradication. 
Two dots (..) indicate that data are not available
2005 2006 2007 2008 2009 2010 2011 2012
Bolivia (Plurinational 
State of) manual  6,073  5,070  6,269  5,484  6,341  8,200  10,460 
 
11,044 
Colombia manual  31,980  43,051  66,805  95,634  60,544  43,690  33,727  30,486 
spraying  138,775  172,026  153,134  133,496  104,771  101,939  103,302  100,549 
Peru manual  7,605  9,153  10,188  11,102  10,091  12,239  10,290  14,235 
Ecuador manual  18  9  12  12  6  3  14  .. 
Venezuela (Bolivarian 
Republic of)
manual  40  0 0 0 0 .. .. ..
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ANNEX Ivi
Opium/Heroin
Net cultivation of opium poppy in selected countries, 1998-2013 (Hectares)
Source: For Afghanistan: 1998-2002: UNODC; 2003-2012: National Illicit Crop Monitoring System supported by UNODC. For Pakistan: 
annual report questionnaire, Government of Pakistan, United States Department of State. For the Lao People’s Democratic Republic: 
1998-1999: UNODC; 2000-2012: National Illicit Crop Monitoring System supported by UNODC. For Myanmar: 1998-2000: United States 
Department of State; 2001-2012: National Illicit Crop Monitoring System supported by UNODC. For Colombia: 1998-1999: various 
sources; From 2000: National Illicit Crop Monitoring System supported by UNODC. For 2008-2012, production was calculated based on 
regional yield figures and conversion ratios from the United States Department of State/DEA. For Mexico: estimates derived from United 
States Government surveys.
Note: Figures in italics are preliminary and may be revised when updated information becomes available. Information on estimation methodologies 
and definitions can be found in the methodology section of the online version of the present report.  
a May include areas that were eradicated after the date of the area survey.
b Owing to continuing low cultivation, figures for Viet Nam (as of 2000) and Thailand (as of 2003) were included in the category “Other countries”.
c The Government of Mexico does not validate the estimates provided by the United States, as they are not part of its official figures and it does not 
have information on the methodology used to calculate them. The Government of Mexico is in the process of implementing a monitoring system in 
collaboration with UNODC to estimate illicit cultivation and production.
d Eradication and plant seizure reports from different sources indicate that illicit opium poppy cultivation also exists in the following subregions: North 
Africa, Central Asia and Transcaucasia, Near and Middle East/South-West Asia, South Asia, East and South-East Asia, Eastern Europe, South-Eastern 
Europe, Central America and South America. Starting in 2008, a new methodology was introduced to estimate opium poppy cultivation and opium/
heroin production in those countries. The estimates are higher than the previous figures but have a similar order of magnitude. A detailed description 
of the estimation methodology is available in the online version of the present report.
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
SOUTH-WEST ASIA
 Afghanistan  90,583 82,171 7,606 74,100 80,000 131,000 104,000 165,000 193,000 157,000 123,000 123,000 131,000 154,000 209,000
 Pakistan 284 260 213 622 2,500 1,500 2,438 1,545 1,701 1,909 1,779 1,721 362 382 382
 Subtotal 90,867 82,431 7,819 74,722 82,500 132,500 106,438 166,545 194,701 158,909 124,779 124,721 131,362 154,382 209,382
SOUTH-EAST ASIA
 Lao People's 
Democratic 
Republic a
22,543 19,052 17,255 14,000 12,000 6,600 1,800 2,500 1,500 1,600 1,900 3,000 4,100 6,800 3,900
 Myanmar a 89,500 108,700 105,000 81,400 62,200 44,200 32,800 21,500 27,700 28,500 31,700 38,100 43,600 51,000 57,800
 Thailand b 702 890 820 750
 Viet Nam b 442
 Subtotal 113,187 128,642 123,075 96,150 74,200 50,800 34,600 24,000 29,200 30,100 33,600 41,100 47,700 57,800 61,700
LATIN AMERICA
 Colombia 6,500 6,500 4,300 4,153 4,026 3,950 1,950 1,023 715 394 356 341 338 313
 Mexico c 3,600 1,900 4,400 2,700 4,800 3,500 3,300 5,000 6,900 15,000 19,500 14,000 12,000
 Subtotal 10,100 8,400 8,700 6,853 8,826 7,450 5,250 6,023 7,615 15,394 19,856 14,341 12,338 12,338 12,338
OTHER
 Other  
countries d  2,050  2,479 2500 2500  3,074 5,190 5,212 4,432 4,184 8,600 7,700 10,500  16,100  11,900  13,300 
TOTAL 216,204 221,952 142,094 180,225 168,600 195,940 151,500 201,000 235,700 213,003 185,935 190,662 207,500 236,420 296,720
Tables on drug cultivation, production and eradication and prevalence
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Global potential production of oven-dry opium in selected countries, 1998-2013 (Tons)
Source: For Afghanistan: 1998-2002: UNODC; 2003-2012: National Illicit Crop Monitoring System supported by UNODC. For Pakistan: 
annual report questionnaire, Government of Pakistan, United States Department of State. For the Lao People’s Democratic Republic: 
1998-1999: UNODC; 2000-2012: National Illicit Crop Monitoring System supported by UNODC. For Myanmar: 1998-2000: United States 
Department of State; 2001-2012: National Illicit Crop Monitoring System supported by UNODC. For Colombia: 1998-1999: various 
sources; From 2000: National Illicit Crop Monitoring System supported by UNODC. For 2008-2012, production was calculated based on 
regional yield figures and conversion ratios from the United States Department of State/DEA. For Mexico: estimates derived from United 
States Government surveys.
Note: Figures in italics are preliminary and may be revised when updated information becomes available. Information on estimation methodologies 
and definitions can be found in the methodology section of the online version of the present report. The opium production estimates for Afghanistan 
for 2006-2009 were revised after data quality checks revealed an overestimation of opium yield estimates in those years. 
a Owing to continuing low cultivation, figures for Viet Nam (as of 2000) and Thailand (as of 2003) were included in the category “Other countries”.
b The Government of Mexico does not validate the estimates provided by the United States, as they are not part of its official figures and it does not 
have information on the methodology used to calculate them. The Government of Mexico is in the process of implementing a monitoring system in 
collaboration with UNODC to estimate illicit cultivation and production.
c Eradication and plant seizure reports from different sources indicate that illicit opium poppy cultivation also exists in the following subregions: North 
Africa, Central Asia and Transcaucasia, Near and Middle East/South-West Asia, South Asia, East and South-East Asia, Eastern Europe, South-Eastern 
Europe, Central America and South America. Starting in 2008, a new methodology was introduced to estimate opium poppy cultivation and opium/
heroin production in those countries. The estimates are higher than the previous figures but have a similar order of magnitude. A detailed description 
of the estimation methodology is available in the online version of the present report.
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
SOUTH-WEST ASIA
  Afghanistan 4,565 3,276  185 3,400 3,600 4,200 4,100 5,300 7,400 5,900 4,000 3,600 5,800 3,700 5,500 
  Pakistan 9 8 5 5 52 40 36 39 43 48 44 43 9 9
  Subtotal 4,574 3,284 190 3,405 3,652 4,240 4,136 5,339 7,443 5,948 4,044 3,643 5,809 3,709 5,500
SOUTH-EAST ASIA
  Lao People's  
Democratic  
Republic
 124  167  134  112  120 43 14 20 9 10 11 18  25 41 23
  Myanmar  895 1,087 1,097  828  810 370 312 315 460 410 330 580  610 690 870
  Thailand a  8  6  6  9 
  Viet Nam a 2
  Subtotal 1,029 1,260 1,237 949 930 413 326 335 469 420 341 598 635 731 893
LATIN AMERICA
  Colombia  88  88  80  52  50  49 24 13 14 10 9 8  8 8
  Mexico b 43 21 91 58 101 73 71 108 150 325 425 300 250
  Subtotal 131 109 171 110 151 122 95 121 164 335 434 308 258 258 258
OTHER
  Other  
countries c  30  38 32 56  50 75 63 16 15 139 134 181  281  208  232 
TOTAL 5,764 4,691 1,630 4,520 4,783 4,850 4,620 5,810 8,091 6,841 4,953 4,730 6,983 4,906 6,883
ANNEX Iviii
Global potential production of opium and manufacture of heroin of unknown purity, 2004-2013 (Tons)
Notes: Only for Afghanistan, the proportion of potential opium production which is not converted into heroin within the country could be estimated. For all 
other countries, for the purpose of this table, it is assumed that all opium potentially produced is converted into heroin. If the total potential opium produc-
tion in Afghanistan in 2012 were converted into heroin, the total potential heroin production in Afghanistan would be 786 tons and global production would 
be total 923 tons. The estimates for 2006 - 2009 were revised due to the revision of opium production figures for Afghanistan.
Figures in italics are preliminary and may be revised when updated information becomes available.
Reported opium poppy eradication in selected countries, 2003 to 2013 (Hectares)
Sources: UNODC annual reports questionnaire, Government reports, reports of regional bodies, and the United States International  
Narcotics Control Strategy Report 
Notes: In this table, only eradication reported in terms of area is considered. Eradication reported in terms of number of plant seizures can be found in the 
annex on seizures of the electronic version of the World Drug Report located at https://www.unodc.org/wdr/
a Although eradication took place in 2004, it was not officially reported to UNODC.
 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
Afghanistan  21,430 a  5,103  15,300  19,047  5,480  5,351  2,316  3,810  9,672  7,348 
Bangladesh  8  22 
Colombia  3,266  3,866  2,121  1,929  375  381  546  711  299  319 
Egypt  34  65  45  50  98  121  89  222  1 
Guatemala  489  720  449  536  1,345  918  1,490  590 
India  494  167  12  247  8,000  624  2,420  3,052  5,746 
Lao People’s  
Democratic Republic
 4,134  3,556  2,575  1,518  779  575  651  579  662  707  397 
Lebanon  4  67  27  8  21  4 
Mexico  20,034  15,926  21,609  16,890  11,046  13,095  14,753  15,491  16,389  15,726 
Myanmar  638  2,820  3,907  3,970  3,598  4,820  4,087  8,268  7,058  23,718 12,288 
Nepal  19  4  1  21  35 
Pakistan  4,185  5,200  391  354  614 0 105 68 1,053 592
Peru  57  98  92  88  28  23  32  21 
Thailand  767  122  110  153  220  285  201  278  208  205  264 
Ukraine  28  436 
Venezuela  
(Bolivarian Republic of)
0  87  154 0 0 0
Viet Nam 100  32  38  99  31  38  35 
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
Total potential opium production  4,850  4,620  5,810  8,091  6,841  4,953  4,730  6,983  4,906  6,883 
Potential opium not processed into heroin  1,197  1,169  1,786  3,078  2,360  1,680  1,728  3,400  1,850  2,600 
Potential opium processed into heroin  3,653  3,451  4,024  5,012  4,481  3,273  3,002  3,583  3,056  4,283 
Total potential heroin manufacture  529  472  553  686  600  427  383  476  385  560 
Tables on drug cultivation, production and eradication and prevalence
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ANNEX Ixii
Prevalence of drug use among persons held in prisons
Region Subregion Country
Year of  
estimate
Annual  
prevalence of 
any illicit drug 
use
Number of  
persons held  
in prisons
Three main drugs
America North America Canada 2011 56.72 14,141 Cannabis
Cocaine salts
Opiods
South America Argentina 2009 64.4 55,000
Ecuador 2007 33.9 15,736 Cannabis
Cocaine 
Tranquilizers
Asia Central Asia  
and Transcaucasia
Armenia 2012 ∙∙ ∙∙ Cannabis
Opioids
Pharmaceutical opioids
Kyrgyzstan 2010 15 7,000
East and  
South-East Asia
Indonesia 2010 17.04 133,252
China, Macao SAR 2012 25.6 488 Ketamine
Cannabis
Methamphetamine
Malaysia 2011 39 12,214 Heroin/morphine
"Syabu"
"Ganja"
Myanmar 2011 30 1,544 Amphetamines
Cannabis
Opiates
Near and Middle East 
/South-West Asia
Israel 2012 51.8 10,485
Lebanon 2012 ∙∙ 2,249 Cannabis
Cocaine
Heroin
Europe Eastern Europe Belarus 2011 ∙∙ 1,200 Opium
Cannabis
Tranquillizers
Russian Federation 2012 14.8 701,517 Cannabis
Cocaine
Opioids
Southeast Europe Bulgaria 2011 21.6 9,000 Heroin
Cannabis
Amphetamines
Croatia 2010 17.3 ∙∙
Romania 2011 2 29,284 Opioids
Cannabis
"Ecstasy"
Western and  
Central Europe
Belgium 2010 ∙∙ ∙∙ Amphetamine
Cannabis
Cocaine salts
Czech Republic 2012 37.7 20,000 Cannabis
"Ecstasy"-type substances
Methamphetamine
Denmark 2010 8 3,969
France 2003 ∙∙ 61,604 Cannabis
Cocaine
Opioids
Germany 2011 33 70,041 Cannabinoids
Opioids
Amphetamines
Hungary 2008 8.4 16,328 Cannabis
"Ecstasy"
Amphetamines
Italy 2012 23.84 65,701
Latvia 2011 17.7 4,588 Amphetamine
Cannabis
Sedatives and  
tranquillizers
Lithuania 2012 14.61 9,734 ATS
Opioids
Netherlands 2007 57 13,260 Cannabis
Cocaine
Heroin
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Prevalence of drug use among persons held in prisons
Region Subregion Country
Year of  
estimate
Annual  
prevalence of 
any illicit drug 
use
Number of  
persons held  
in prisons
Three main drugs
Europe Western and  
Central Europe
Poland 2007 ∙∙ 84,156 Amphetamine
Cannabis
"Ecstasy"-type substances
Slovakia 2012 17.24 10,850 Heroin
Cannabis
Methamphetamine
Slovenia 2011 21.6 4,975
Spain 2011 ∙∙ 70,472 Cannabis
Cocaine salts
Heroin
Sweden 2011 42 6,250
Oceania Oceania Australia 2012 70 29,383 Cannabis
Methamphetamine
Pharmaceutical opioids
New Zealand 2011 5.5 8,600 ATS
Cannabis
Opioids
Source: UNODC annual report questionnaire. 
Note: Two dots (∙∙) indicate that data are not available.
Morbidity among persons held in prisons
Region Subregion Country
Year of  
estimate
Hepatitis B Hepatitis C HIV Infection
Prevalence Number Prevalence Number Prevalence Number
America North America Canadaa 2008 ∙∙ ∙∙ 30.2 3,907 1.72 222
United States  
of Americab 2010 ∙∙ ∙∙ ∙∙ ∙∙ 1.46 ∙∙
South America Uruguay 2004 8.5 5.5
Asia
Central Asia and 
Transcaucasia
Kazakhstan 2012 ∙∙ ∙∙ ∙∙ ∙∙ 2.2 ∙∙
Kyrgyzstan 2010 10 ∙∙ 10 ∙∙ 15 ∙∙
Tajikistan 2011 ∙∙ 3,000 ∙∙ 3,000
East and  
South-East Asia
China, Hong 
Kong SAR 2012 ∙∙ ∙∙ ∙∙ ∙∙ 0.74 ∙∙
Indonesia 2011 ∙∙ ∙∙ ∙∙ ∙∙ 3.63 ∙∙
Indonesia 2010 ∙∙ ∙∙ 0.84 ∙∙ ∙∙ 5,106
Malaysia 2011 0.18 66 1.23 445 3.04 1,102
Europe Eastern Europe Republic of  Moldova
2011 226
Western and 
Central Europe
Belgium 2011 5.8 ∙∙ 22.4 ∙∙ 4.8 ∙∙
Czech Republic 2009 16.2 ∙∙ 41.6 ∙∙ 2.4 ∙∙
Finland 2010 ∙∙ ∙∙ 84 1,600 2 40
France 2012 ∙∙ ∙∙ 4.8 3,000 2 1,220
Germany 2011 ∙∙ ∙∙ 14.3 ∙∙ 1.2 ∙∙
Hungary 2012 1.25 35 7.01 194 0.13 3
Latvia 2012 ∙∙ ∙∙ ∙∙ ∙∙ 6 450
Lithuania 2011 ∙∙ ∙∙ ∙∙ ∙∙ 4.1 396
Luxembourg 2007 9 72 52.6 417 5.2 41
Slovakia 2012 3.82 41 36.84 395 0.47 5
Source: UNODC annual report questionnaire unless otherwise stated.
a Source: Public Health Agency of Canada
b Source: United States Department of Justice 
Note: Two dots (∙∙) indicate that data are not available.
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ANNEX II
Regional groupings
This report uses a number of regional and subregional 
designations. These are not official designations. They are 
defined as follows:
 • East Africa: Burundi, Comoros, Djibouti, Eritrea, 
Ethiopia, Kenya, Madagascar, Mauritius, Rwanda, 
Seychelles, Somalia, Uganda and United Republic of 
Tanzania. 
 • North Africa: Algeria, Egypt, Libya, Morocco, South 
Sudan, Sudan and Tunisia.
 • Southern Africa: Angola, Botswana, Lesotho, Malawi, 
Mozambique, Namibia, South Africa, Swaziland, Zam-
bia and Zimbabwe.
 • West and Central Africa: Benin, Burkina Faso, Cam-
eroon, Cabo Verde, Central African Republic, Chad, 
Congo, Côte d’Ivoire, Democratic Republic of the 
Congo, Equatorial Guinea, Gabon, Gambia, Ghana, 
Guinea, Guinea-Bissau, Liberia, Mali, Mauritania, 
Niger, Nigeria, Sao Tome and Principe, Senegal, Sierra 
Leone and Togo. 
 • Caribbean: Antigua and Barbuda, Bahamas, Barbados, 
Bermuda, Cuba, Dominica, Dominican Republic, 
Grenada, Haiti, Jamaica, Saint Kitts and Nevis, Saint 
Lucia, Saint Vincent and the Grenadines and Trinidad 
and Tobago.
 • Central America: Belize, Costa Rica, El Salvador, Gua-
temala, Honduras, Nicaragua and Panama.
 • North America: Canada, Mexico and United States of 
America. 
 • South America: Argentina, Bolivia (Plurinational State 
of ), Brazil, Chile, Colombia, Ecuador, Guyana, Para-
guay, Peru, Suriname, Uruguay and Venezuela (Bolivar-
ian Republic of ).
 • Central Asia and Transcaucasia: Armenia, Azerbaijan, 
Georgia, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmen-
istan and Uzbekistan.
 • East and South-East Asia: Brunei Darussalam, Cam-
bodia, China, Democratic People’s Republic of Korea, 
Indonesia, Japan, Lao People’s Democratic Republic, 
Malaysia, Mongolia, Myanmar, Philippines, Republic 
of Korea, Singapore, Thailand, Timor-Leste and Viet 
Nam. 
 • Near and Middle East/South-West Asia: Afghanistan, 
Bahrain, Iran (Islamic Republic of ), Iraq, Israel, Jor-
dan, Kuwait, Lebanon, Oman, Pakistan, Qatar, Saudi 
Arabia, Syrian Arab Republic, United Arab Emirates 
and Yemen. The Near and Middle East refers to a sub-
region that includes Bahrain, Israel, Jordan, Kuwait, 
Lebanon, Oman, Qatar, Saudi Arabia, the Syrian Arab 
Republic, the United Arab Emirates and Yemen.
 • South Asia: Bangladesh, Bhutan, India, Maldives, Ne-
pal and Sri Lanka. 
 • Eastern Europe: Belarus, Republic of Moldova, Russian 
Federation and Ukraine.
 • South-Eastern Europe: Albania, Bosnia and Herzego-
vina, Bulgaria, Croatia, Montenegro, Romania, Ser-
bia, the former Yugoslav Republic of Macedonia and 
Turkey.
 • Western and Central Europe: Andorra, Austria, Bel-
gium, Cyprus, Czech Republic, Denmark, Estonia, 
Finland, France, Germany, Greece, Hungary, Iceland, 
Ireland, Italy, Latvia, Liechtenstein, Lithuania, Luxem-
bourg, Malta, Monaco, Netherlands, Norway, Poland, 
Portugal, San Marino, Slovakia, Slovenia, Spain, Swe-
den, Switzerland and United Kingdom of Great Britain 
and Northern Ireland.
 • Oceania: Australia, Fiji, Kiribati, Marshall Islands, Mi-
cronesia (Federated States of ), Nauru, New Zealand, 
Palau, Papua New Guinea, Samoa, Solomon Islands, 
Tonga, Tuvalu, Vanuatu and small island territories.

W
O
R
L
D
 D
R
U
G
 R
E
P
O
R
T
 2
01
4
xvii
GLOSSARY
amphetamine-type stimulants — a group of substances com-
posed of synthetic stimulants that were placed under inter-
national control in the Convention on Psychotropic 
Substances of 1971 and are from the group of substances 
called amphetamines, which includes amphetamine, meth-
amphetamine, methcathinone and the “ecstasy”-group sub-
stances (3,4-methylenedioxymethamphetamine (MDMA) 
and its analogues)  
annual prevalence — the total number of people of a given 
age range who have used a given drug at least once in the 
past year divided by the number of people of the given age 
range 
coca paste (or coca base) — an extract of the leaves of the 
coca bush. Purification of coca paste yields cocaine (base 
and hydrochloride)  
crack cocaine — cocaine base obtained from cocaine hydro-
chloride through conversion processes to make it suitable 
for smoking
new psychoactive substances — substances of abuse, either 
in a pure form or a preparation, that are not controlled 
under the Single Convention on Narcotic Drugs of 1961 
or the 1971 Convention, but which may pose a public 
health threat. In this context, the term “new” does not 
necessarily refer to new inventions but to substances that 
have become available in recent years
opioids — a generic term applied to alkaloids from opium 
poppy, their synthetic analogues and compounds synthe-
sized in the body
opiates — a subset of opioids comprising the various prod-
ucts derived from the opium poppy plant, including 
opium, morphine and heroin
poppy straw — all parts (except the seeds) of the opium 
poppy, after mowing
problem drug users — people who engage in the high-risk 
consumption of drugs, for example people who inject 
drugs, people who use drugs on a daily basis and/or people 
diagnosed with drug use disorders or as drug-dependent 
based on clinical criteria contained in the International 
Classification of Diseases (tenth revision) of the World 
Health Organization and the Diagnostic and Statistical 
Manual of Mental Disorders (fourth edition) of the Ameri-
can Psychiatric Association, or any similar criteria or defi-
nition that may be used

